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Abstract 
The G-protein coupling specificity of D2-like dopamine receptors was investigated using 
both receptor-G protein fusions and membranes of cells in which pertussis toxin-resistant 
mutants of individual Gαi-family G proteins could be expressed in an inducible fashion.   
A range of ligands displayed agonism at the long isoform of the human dopamine D2 
receptor. However, varying degrees of efficacy were observed for individual ligands as 
monitored by their capacity to load [
35S] GTPγS onto each of Gαi1, Gαi2, Gαi3 and Gαo1. 
By contrast, S-(-)-3-(3-hydroxyphenyl)-N-propylpiperidine (S-(-)-3PPP) was a partial 
agonist when Gαo1 was the target G protein but an antagonist/inverse agonist at Gαi1, Gαi2, 
Gαi3.  In ligand binding assays dopamine identified both high and low affinity states at 
each of the dopamine D2 receptor-G protein fusion proteins and the high affinity state was 
eliminated by guanine nucleotide. S-(-)-3PPP bound to an apparent single state of the 
constructs where the D2 receptor was fused to Gαi1, Gαi2 or Gαi3.  However, it bound to 
distinct high and low affinity states of the D2 receptor-Gαo1 fusion with the high affinity 
state being eliminated by guanine nucleotide. Similarly, although dopamine identified 
guanine nucleotide-sensitive high affinity states of the D2 receptor when expression of 
pertussis toxin-resistant forms of either Gαi2 or Gαo1 was induced, S-(-)-3PPP identified a 
high affinity site only in the presence of Gαo1. These results demonstrate S-(-)-3PPP to be 
a protean agonist at the D2l receptor and may explain in vivo actions of this ligand.  
Furthermore, in agreement with previous studies, the ability of the dopamine D2l receptor 
to couple promiscuously to Gαi1-3, and Gαo1 was demonstrated.  However, despite high 
homology between dopamine D2l and D3 receptors, the G protein-coupling specificity of 
the D3 receptor has not been well characterised.  Again using both receptor-G protein 
fusions and membranes of cells in which pertussis toxin-resistant mutants of individual 
Gαi-family G proteins could be expressed in an inducible fashion, we confirmed the 
selective coupling of the D3 receptor to Gαo1.  A range of ligands displayed agonism at the    
III 
D2l receptor and the D3 receptor when coupled to Gαo1.  As a general trend, agonists, 
including dopamine, displayed a higher potency at the D3 receptor.  This perhaps reflects 
the role of D3 as an autoreceptor.  Of particular interest was the demonstration that S-(-)-
3PPP has both a higher efficacy and potency at the D3 receptor when coupled to Gαo1.    
 
The investigations into dopamine receptor-G protein coupling highlighted the utility of the 
[
35S]GTPγS binding assay as a method of directly measuring receptor catalysed nucleotide 
exchange on the α subunit of G proteins.  However, the expense associated with the use of 
radiolabels makes this assay less attractive, particularly for high-throughput screening 
programmes.  In an attempt to develop a non-radioactive assay equivalent to the [
35S] 
GTPγS assay an immunisation programme was initiated to generate antibodies selective 
against the active (GTP bound) conformation of G proteins.  4 way primary screening of 
1632 hybridomas generated from mice immunized with GTPγS-loaded Gαi1 and isolated 
using an automated robotic colony picker, identified 3 antibodies that interacted with the 
constitutively active Q
204L but neither the constitutively inactive G
203A nor wild type form 
of Gαi1. This profile extended to other closely related Gi-family G proteins but not to the 
less closely related Gαs and Gαq/Gα11 families.  Each of these antibodies was, however, 
also able to identify wild type, GDP-bound Gi- family G proteins in the presence of AlF4
- 
which mimics the presence of the terminal phosphate of GTP and hence generates an 
active conformation of the G protein.  Stimulation of cells co-expressing a wild type 
Giα subunit and the dopamine D2 receptor with the agonist ligand nor-apomorphine also 
allowed these conformation selective antibodies to bind the G protein. Such reagents allow 
the development of label- free assays for G protein-coupled receptor-mediated activation 
of Gi- family G proteins. 
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1  Introduction 
1.1  G protein-coupled receptors 
The G protein coupled receptor (GPCR) family represents the largest and most versatile 
group of cell surface receptors, which can detect a diverse array of chemical signals in a 
highly selective way.   As a family of proteins, GPCRs share common structural features 
including seven transmembrane spanning domains.  They can couple to specific guanine 
nucleotide binding proteins (G proteins) thereby transducing an extracellular signal to an 
intracellular effector, although more recently several GPCRs have been demonstrated to 
signal via G protein-independent mechanisms (Hall and Lefkowitz, 2002).   GPCRs are the 
largest superfamily of cell-surface receptors making up nearly 2% of the human genome, 
with 865 genes that have easily identifiable seven transmembrane characteristics 
(Vassilatis et al., 2003).   Approximately half of these are odorant receptors.  Of the 
remaining 360 receptors, the natural ligand has been identified for approximately 210 
receptors, leaving 150 so-called orphan GPCRs with no known ligand or function. 
 
As a family of proteins, GPCRs have the highest impact from a social, therapeutic and 
economic point of view.  Drugs active at these receptors have therapeutic actions across a 
wide range of human diseases ranging from allergic rhinitis to pain, hypertension and 
schizophrenia and it has been estimated
 that approximately 30% of all modern drugs are 
targeted at these receptors. Interestingly, however, the majority of GPCR-targeted drugs 
exert their effects on approximately only 30 GPCRs (Wise et al., 2004).  
  GPCRs are 
involved in all major disease areas such as cardiovascular, metabolic, neurodegenerative, 
psychiatric, cancer and infectious diseases (Lundstrom, 2006). It is also evident that drugs 
have still only been developed
 to affect a very small number of the GPCRs, and the 
potential
 for drug discovery within this field is enormous.
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GPCRs are thought to operate through a similar molecular mechanism.  The binding of 
extracellular ligands or light activation to GPCRs causes as yet poorly defined 
conformational changes in the receptor protein, which promotes association of the receptor 
with distinct classes of heterotrimeric G proteins.  These G proteins consist of α subunits 
bound to βγ complexes and are attached to the cytoplasmic surface of the plasma 
membrane.  Interaction of the ligand-activated receptor with the G protein triggers the 
exchange of GTP for GDP on the α subunit and results in the dissociation of the G protein 
α subunit from the βγ dimer or alternatively a conformational rearrangement between the 
two (Figure 1.1) (Bunemann et al., 2003).   These are then able to interact with distinct 
effector enzymes and ion channels thereby transmitting an extracellular signal into the cell.  
The Gα subunit has an intrinsic GTPase activity and the bound GTP is hydrolysed to GDP 
resulting in the inactivation of the Gα subunit.  Gα.GDP binds with the βγ dimer and the 
system is returned to the resting state(Milligan and Kostenis, 2006). 
 
In this chapter I will give a general overview of the diversity and structure of both GPCRs 
and their heterotrimeric G protein signalling partners.  I will summarise the current 
understanding of the structural changes occurring upon receptor-mediated G protein 
activation, focusing particularly on the structural determinants of receptor/G protein 
coupling specificity.  The final part of this chapter will focus on dopamine receptors, their 
structure and G protein coupling specificity. 
 
1.1.1  Structural features of G protein-coupled receptors 
Despite the remarkable structural diversity of the activating ligands and their amino acid 
sequences, all GPCRs are predicted to share a common three dimensional fold  consisting 
of seven transmembrane helices (TMI-TMVII) linked by alternating intracellular (ICL I - J. Robert Lane, 2007    Chapter 1  
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III) and extracellular (ECL I - III) loops (Figure 1.2A).  The extracellular receptor surface 
including the extracellular N-terminal domain, different extracellular loops, and/or the 
exofacial portions of various TM domains is known to be critically involved in ligand 
binding.  On the other hand, the intracellular surface (the intracellular loops, the 
intracellular C-terminal domain, and the cytoplasmic ends of different TM helices) is 
known to be important for G protein recognition and activation (Wess, 1998). This seven-
transmembrane domain structure was predicted by hydrophobicity analysis of the primary 
sequence of GPCRs.  This structure has been confirmed by the determination of the crystal 
structure of rhodopsin, archetypal class I GPCR (Palczewski et al., 2000) and to date the 
only solved GPCR structure (Figure 1.2B). 
The rhodopsin structure provides a useful model for the prediction of other class I receptor 
structures.  The seven transmembrane domains form α helices of different lengths with TM 
III being the longest and TMVI and VII being relatively short (Teller et al., 2001; Wess, 
1998).   The helices are organised in a counter-clockwise arrangement (Figure 1.2C-D).  
In family I  receptors the C-terminal end of TM III contains a highly conserved DRY (Asp-
Arg-Tyr) motif, that has been implicated in the receptor/G protein coupling (Wess, 1998).  
In the crystal structure of bovine rhodopsin the transmembrane domains were found to be 
distorted or kinked due to the presence of proline residues within the transmembrane 
domains (Palczewski et al., 2000).  The helices of TM I and II were found to be tilted from 
the plane of the membrane by 25º while TM III displayed a 33º tilt.  TM IV and VI were 
shown to be almost perpendicular to the membrane whilst TM V is tilted by 26º.  A highly 
conserved NPXXXY motif in TM VII was shown to be important in stabilising the inactive 
state of the receptor (Teller et al., 2001).  Interestingly the structure also resolved an 
amphipathic cytoplasmic helix located in the C-terminal domain extending from TM VII.  
This helix is tilted at 90º to the membrane and forms one of the binding sites for the Gt α-
subunit and plays a role in the regulation of Gγ binding (Ernst et al., 2000). A cysteine 
residue located in the membrane proximal C-terminal region of several GPCRs has been J. Robert Lane, 2007    Chapter 1  
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identified as a potential site for palmitoylation, the attachment of the fatty carbon chain 
palmitic acid via a thioester bond.  This serves as an anchor into the membrane, and 
effectively creates a fourth intracellular loop.  The C-terminal tail is an important site for 
receptor phosphorylation by receptor kinases following receptor activation, inducing 
receptor desensitisation (Teller et al., 2001). 
The N-terminal region of GPCRs varies considerably in length between individual 
receptors and can be important for ligand binding.  Virtually all GPCRs possess one or 
more N-linked glycosylation sites (Asn-X-Ser/Thr) where X is any amino acid except 
proline or asparagine (Wess, 1998).  For several GPCRs, prevention of receptor 
glycosylation results in reduced cell surface expression but has no effect on the function or 
pharmacology of these receptors.  Conserved cysteine residues within this region are 
thought to be important for protein folding.  The extracellular loops of rhodopsin possess 
two highly conserved cysteine residues in ECL I and the N-terminus of TM III (Cys 110 
and Cys 197, respectively) that form a disulphide bond that have  been shown to stabilise 
the receptor structure.  The mutation of analogous residues within the β2-adrenoceptor 
gives a variant with reduced ability to bind ligand and a destabilised tertiary structure. 
. 
1.1.2  Classification of G protein-coupled receptors 
GPCRs can be divided phylogentically into six classes.  Schematic representations of 
receptor monomers showing some key structural aspects of the three main families are 
shown. Family I (Figure 1.3A, also referred to as family A or the rhodopsin-like family) is 
by far the largest subgroup and contains receptors for odorants, small molecules such as 
the catecholamines and amines, some peptides and glycoprotein hormones. Receptors of 
Family I are characterized by ~20 highly conserved amino acids (some of which are 
indicated in the diagram by red circles) and a disulphide bridge that connects the first and J. Robert Lane, 2007    Chapter 1  
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second extracellular loops (ECL1 and 2).  Most of the conserved residues, including 
several conserved proline residues and a conserved DRY (aspartic acid, arginine, tyrosine) 
motif adjacent to transmembrane domain III (TM III), are located in the cytoplasmic half 
of the transmembrane domain.  Mutagenesis data suggests that these residues are required 
for protein stability and/or mediating the conformational changes that accompany receptor 
activation.   
 
Family II or family B GPCRs are characterized by a relatively long amino terminus that 
contains several cysteines, which presumably form a network of disulphide bridges. Their 
morphology is similar to some family 1 receptors, but they do not share any sequence 
homology (Figure 1.3B). For example, the family 2 receptors also contain a disulphide 
bridge that connects ECL1 and ECL2, but the palmitoylation site is missing, the conserved 
prolines are different from the conserved prolines in the family 1 receptors and the DRY 
(aspartic acid, arginine, tyrosine) motif adjacent to TM III is absent. Little is known about 
the orientation of the TM domains, but, given the divergence in amino acid sequence, it is 
probably quite dissimilar from that of rhodopsin. Ligands for family 2 GPCRs include 
hormones, such as glucagon, gonadotropin-releasing hormone and parathyroid hormone.  
 
Family III (Figure 1.3C) contains the metabotropic glutamate, the Ca
2+ sensing and the γ-
aminobutyric acid (GABA) B receptors. These receptors are characterized by a long N-
terminus and C-tail. The ligand binding domain is located in the amino terminus, which is 
often described as being like a ‘Venus fly trap’. Except for two cysteines in extracellular 
loop 1 and extracellular loop 2 that form a putative disulphide bridge, class III receptors do 
not have any of the key features that characterize class I and II receptors. A unique 
characteristic of the class III receptors is that the third intracellular loop is short and highly 
conserved. Although the structure of the amino terminus is well characterized, similar to 
the class II receptors, little is known about the orientation of the transmembrane domains. J. Robert Lane, 2007    Chapter 1  
6 
 
Of the smaller, less characterized GPCR families, family IV comprises pheromone 
receptors (VNs) associated with the Gαi/o G protein family, while family V includes the 
‘frizzled’ and the ‘smoothened’ (Smo) receptors involved in embryonic development and 
in particular in cell polarity and segmentation. Finally, the cAMP receptors have only been 
found in D.discoideum but possible expression in vertebrate has not yet been reported 
(Bockaert and Pin, 1999; Lee et al., 2003a). 
 
1.1.3  Quaternary structure of GPCRs 
GPCR homo and hetero-oligomerisation has been well described for a multitude of GPCRs 
(Milligan, 2007).  Although the work in this thesis does not investigate this area, the 
perceived importance of quaternary structure for both expression and function of GPCRs 
warrants a brief discussion in this introduction. The use of atomic force microscopy to 
visualise discs from mouse rod outer segments and the use of cryo-electron microscopy on 
2 dimensional crystals of squid rhodopsin have shown higher order organisation of these 
proteins (Davies et al., 2001; Fotiadis et al., 2003).  In images obtained by atomic force 
microscopy rhodopsin is organised within para-crystalline arrays with densely packed 
double rows of the receptor.  Models were subsequently generated that optimised the 
packing arrangements.  These models have suggested that the interactions between rows of 
dimers are provided by the contacts involving elements of TM I.  Key interactions between 
monomers are provided by contacts involving TM IV and V (Fotiadis et al., 2004).  
Similarly, although no direct biophysical evidence exists, due to lower expression levels, 
both homo-oligomersation and hetero-oligomerisation has been demonstrated for a diverse 
range of other GPCRs in a vast range of studies (Angers et al., 2002; George et al., 1998; 
Milligan, 2007).  Similarly, contacts between transmembrane domains have been shown to J. Robert Lane, 2007    Chapter 1  
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be crucial for organisation of these quaternary structures, for example cysteine cross 
linking studies in the dopamine D2 receptor highlighted residues within TM IV as being 
contact points between the dimer (Guo et al., 2005).  Dimerisation or oligomerisation has 
been implicated in a wide variety of functions or roles.  These include the formation of 
dimers/oligomers as an early step in GPCR protein folding, maturation, cell surface 
delivery and functional expression of the receptor (Milligan, 2007).   Functional 
consequences of hetero-oligomerisation include modulation of signal transduction, for 
example, the co-expression of the orexin-1 and cannabinoid CB1 receptor has been 
reported to enhance the potency of the peptide orexin-A to stimulate phosphorylation of 
the ERK 1 and 2 MAP kinases 100 fold, an effect that was blocked by the CB1 receptor 
antagonist/inverse agonist rimonabant (Ellis et al., 2006).  Perhaps most pertinent to this 
body of work is that hetero-oligomerisation can alter receptor/G protein selectivity.   For 
example, both µ-opioid and δ opioid receptors are generally considered to be highly 
selective for Gαi/o family subunits.  However, upon co-expression it was reported that 
signals insensitive to pertussis toxin were generated, and interestingly, a switch in G 
protein coupling selectivity to Gαz has been implicated (George et al., 2000). 
 
1.2  Diversity of heterotrimeric G proteins and their effectors 
Although nearly 900 heptahelical receptors have been identified, they interact with a 
relatively small number of G proteins. To date, 21 Gα subunits have been identified and 
these are encoded by 16 genes.    Heterotrimeric G proteins are typically divided into four 
main classes: Gi/o, Gs, Gq/11, and G12/13 based on sequence homology of the Gα subunits.  
Members of this family range from 39-52 kDa and share between 35% and 95% sequence 
identity (Downes and Gautam, 1999).  The Gα subunit families, subtypes, effectors and 
expression are described in Table 1.1.  The Gαs family includes several splice variants of J. Robert Lane, 2007    Chapter 1  
8 
αs, as well as αolf, which is largely expressed in olfactory epithelia.  Typically, Gαs subunits 
enhance the function of adenylate cyclase.  The cholera toxin-catalysed ADP ribosylation 
of an arginine residue leads to the constitutive activation of this family of Gα subunits.  
The Gαi/o family consists of three distinct αi species, αo, two retinal transducins (αt1 and 
αt2), an α-subunit found in the gustatory epithelium (αgust) and αz.  Downstream actions of 
α-subunits in this family include the inhibition of adenylate cyclase and the stimulation of 
K
+ channels.  Pertussis toxin-catalysed ADP ribosylation of a cysteine residue 4 amino 
acids from the c-terminus prevents functional interaction of these all α-subunits, apart from 
Gαz with the receptor.   The Gαq/11 family activate isoforms of phospholipase Cβ and 
consist of Gαq, Gα11, Gα14, and Gα16.   
In humans 6 Gβ subunits are encoded by 5 genes and 12 Gγ subunits are expressed 
(Downes and Gautam, 1999).  There is then, the potential for a substantial number of 
pairings, although a number of possible pairings have been indicated not to form, and 
tissue expression patterns may further limit the actual number of pairings in particular cells 
and tissues.  β1-β4 are highly homologous but β5 is less so, and unlike the other β subunits it 
dissociates from the γ subunit.  γ subunits are structurally more diverse compared to the β 
subunits.  βγ subunits can bind to and influence a wide variety of effectors as summarised 
in Table 1.1(Milligan and Kostenis, 2006). 
Because of the diversity of G protein subunits and downstream effector molecules, the 
pattern of physiological responses of a particular cell following stimulation of a given 
GPCR is quite complex.  The nature of the observed responses critically depends on which 
G protein heterotrimers are recognised by the receptor and which specific effector 
molecules are present in the cell or tissue.  Furthermore, the magnitude of the response will 
depend on the relative concentration of all molecules involved in the signalling pathway 
(Wess, 1998). J. Robert Lane, 2007    Chapter 1  
9 
Table 1.1: The family of mammalian heterotrimeric G protein subunits: function and 
expression 
Adapted from Milligan and Kostenis, (2006) 






Adenylyl cyclases ↑ (Gαs,s(XL),olf) 
Maxi K
+ channel ↑ (Gαs) 
Src tyrosine kinases (c-Src, Hck) ↑ (Gαs)  
Gαs: ubiquitous 
Gαolf: olfactory neurons, certain CNS ganglia; 








Adenylyl cyclase ↓ (Gαi,o,z) 
Rap1GAPII-dependent ERK/MAPkinase activation ↑ 
(Gαi) 
Ca
2+ channels ↓ (Gαi,o,z) 
K
+ channels ↑ (Gαi,o,z) 
Src tyrosine kinases (c-Src, Hck) ↑ (Gαi) 
Rap1GAP ↑ (Gαz) 
GRIN1-mediated activation of Cdc42 ↑ (Gαi,o,z) 
cGMP-PDE ↑ (Gα t) Gαgust: ? 
Gαo1–2: neurons, neuroendocrine cells, astroglia, 
heart 
Gαi1–i3: neurons and many others 
Gαz: platelets, neurons, adrenal chromaffin cells, 
neurosecretory cells 
Gαt1: rod outer segments, taste buds 
Gαt2: cone outer segments 
Gαgust: sweet and/or bitter taste buds, 







Phospholipase Cβ isoforms ↑ 
p63-RhoGEF ↑ (Gαq/11) 
Bruton's tyrosine kinase ↑ (Gαq) 
K
+ channels ↑ (Gαq) 
Gαq/11: ubiquitous 




Phospholipase D ↑ 





Leukaemia-associated RhoGEF (LARG) ↑ 
Radixin ↑ 
Protein phosphatase 5 (PP5) ↑ 







Adenylyl cyclase I ↓ 
Adenylyl cyclases II, IV, VII ↑ 
PI-3 kinases ↑ 
K
+ channels (GIRK1,2,4) ↑ 
Ca
2+ (N-, P/Q-, R-type) channels ↓ 
c-Jun N-terminal kinase (JNK) ↑ 
Src kinases ↑ 
G protein-coupled receptor kinase recruitment to 
membrane ↑ 
Protein kinase D ↑ 
β1 γ1: retinal rod cells 
β3 γ8: retinal cone cells 
β5: neurons and neuroendocrine organs 
β5(L): retina 
Most cell types express multiple β and γ subtypes
 J. Robert Lane, 2007    Chapter 1  
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1.2.1  Structural features of heterotrimeric G proteins  
Unlike GPCRs, the crystal structures of heterotrimeric G-proteins in a variety of different 
conformations have been determined, and these structures form the basis of our 
understanding of the mechanisms of G protein signalling (Coleman et al., 1994; Coleman 
and Sprang, 1998; Mixon et al., 1995; Raw et al., 1997). G α subunits contain two 
domains: a GTPase domain that is involved in the binding and hydrolysis of GTP and a 
helical domain that buries the GTP within the core of the protein (Mixon et al., 1995) 
(Figure 1.4).  The GTPase domain is homologous to that of the family of monomeric G 
proteins and is composed of a six stranded β-sheet surrounded by five α helices.  The most 
highly conserved sequences in this domain are the five loops that contain the consensus 
sequence for guanine nucleotide binding: the diphosphate-binding (P-) loop 
(GXGESGKS), the Mg
2+-binding domain (RXXTXGI and DXXG) and the guanine ring-γ-
phosphate binding motifs (NKXD and TCAT).  Comparison of the inactive (GDP bound) 
and active (GTP bound) Gαi1 crystal structures has revealed the presence of three flexible 
regions, designated switches I, II and III, which become more rigid and well ordered in the 
GTP-bound active structure (Lambright et al., 1994; Mixon et al., 1995) (Figure 1.4 C-D). 
The GTPase domain not only hydrolyses GTP but also contains sites for binding to the βγ 
dimer, GPCRs and downstream effector proteins. 
 
The helical domain has the most divergent sequence among Gα subunits and consequently 
may play a role in both receptor/G protein coupling selectivity and G protein/effector 
selectivity.  It is composed of six α-helices that form a lid over the nucleotide binding site, 
burying bound nucleotides in the core of the protein.  The helical domain has been shown 
to increase the affinity for nucleotides and increase the GTP hydrolysis activity of the Gα 
subunits (Liu et al., 1998; Remmers et al., 1999).   
 J. Robert Lane, 2007    Chapter 1  
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 In the isolated G protein crystal structures solved thus far, the N- and C- termini of Gα 
were either removed from the protein or disordered.  Consequently, less is known about the 
structure of these important regions.  However, in two separate crystal structures of the 
heterotrimeric complex, the N-terminal helix is ordered by its interaction with the β-
propeller domain of Gβ (Lambright et al., 1996; Wall et al., 1995) (Figure 1.4B).  As 
discussed later, biochemical studies suggest that these terminal regions play a key role in 
the activation process and in directing specific receptor/G protein coupling interactions.  
The N-terminus is also the site of fatty-acid modifications on Gα subunits that regulate G 
protein localisation and protein-protein interactions.  All of these proteins, except Gαt, are 
modified post-translationally with the 16-carbon fatty acid palmitate attached by a 
reversible thioester bond to cysteines near the N-terminus (Smotrys and Linder, 2004).  
Mutations that prevent palmitoylation shift the localisation of myristoylated proteins from 
the membrane to the cytoplasm (Wise and Milligan, 1997).  Members of the Gαi/o family 
are also myristoylated, with the addition of the saturated 14-carbon fatty acid myristate to 
and N-terminal glycine following removal of the initiating methionine residue.  This 
modification is irreversible (Chen, 2001).    It is thought that myristoylation has an 
important role in the structure of the N-terminal helix of Gα. In the non-myristolated 
protein, this region is disordered, but becomes ordered upon myristolation in the Gα.GDP 
complex even without the binding of the Gβγ-dimer (Medkova et al., 2002).  Furthermore 
this myristolated structure is unchanged upon binding of the Gβγ-dimer.  Myrisolation also 
affects the interaction between Gα and effectors (Preininger et al., 2003).  For Gαi 
subunits, a two-signal membrane trapping model has been suggested for anchoring of Gα 
subunits to the membrane.  In this model, myristolation is the first signal which leads to a 
transient interaction between the Gα subunit and the membrane. Palmitoylation is the 
second signal that serves to securely attach the protein to the membrane (Shahinian, 1995).    
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All six Gβ-subunits are ~ 36 kDa and share 50-90 % sequence identity and have a β-
propeller structure containing seven WD-40 repeats (Downes and Gautam, 1999) (Figure 
1.4 B-C).   Each blade of the propeller is composed of four anti-parallel β-strands, where 
one WD-40 sequence contributes the last three strands in one blade and the first strand in 
the next blade.  The final blade contributes the last three strands in one blade and the first 
strand in the next blade.  The remaining N-terminal residues adopt an α-helical 
conformation that forms a coiled coil which is essential for interaction with Gγ, an 
interaction that is essential for the proper folding of Gβ (Oldham, 2006; Sondek et al., 
1996).  Members of the Gγ family are all small proteins, between 7 and 8 kDa and share 
30-80% sequence identity (Downes and Gautam, 1999).  They are composed of two α 
helices connected by a loop.  The N-terminal helix interacts with the N-terminus of Gβ 
whilst the C-terminal binds to blades 5 and 6 (Sondek et al., 1996).  Gγ subunits undergo 
post-translational isoprenylation at their C-termini.   This increases the affinity of the Gβγ 
dimer for the membrane (Higgins and Casey, 1996).  The Gβγ dimer is a functional unit 
that is not dissociable except by denaturation.  Most β subunits can interact with most but 
not all γ subunits.  Several Gβγ dimers can interact with the same Gα isoform suggesting 
that differential expression may be an important determinant of signalling specificity 
(Clapham and Neer, 1997).  The Gβγ dimer may be a determinant of the membrane 
localisation of Gα subunits. 
 
The crystal structures of G protein heterotrimers highlight two sites of interaction between 
Gα and Gβγ (Lambright et al., 1996; Mixon et al., 1995; Wall et al., 1995).  The primary 
site is between switches I and II of Gα and residues from blades 5 and 7 of Gβ, and the 
second is an interaction between blade 1 of Gβ  and the N-terminus of Gα.  There is 
however, no evidence of a Gα:Gγ interaction surface.  Upon heterotrimer formation no 
perturbations in the structure of Gβγ were identified.  Conversely Gβγ binding significantly J. Robert Lane, 2007    Chapter 1  
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alters the conformation of Gα.   By stabilising the two flexible loops, Switches I and II, 
and by forming a salt bridge between the P-loop and Switch I Gβγ binding locks GDP into 




1.3  Structural basis of receptor-G protein interactions 
1.3.1  Conformational changes associated with receptor activation 
As described above the only receptor for which crystal structures have been defined is the 
dark (inactive) conformation of rhodopsin.  Consequently, these structures shed little light 
on the G protein coupling mechanism of GPCRs.  However, they have provided a 
framework within which to interpret other biophysical studies on the conformational 
changes associated with receptor activation.  Extensive site-directed spin-labelling (SDSL) 
studies of rhodopsin have shown that photo-activation primarily results in an outward 
movement of helix VI, thereby opening a crevice in the intracellular face of the receptor 
(Farrens et al., 1996).  This outward movement appears to be essential for G protein 
activation, as disulfide and metal-ion cross-links between helices III and VI prevent light-
stimulated nucleotide exchange in Gαt.  Similar movements have been identified upon 
activation of other receptors (Gether et al., 2002).  For example, studies of β2 adrenergic 
receptors labelled with fluorescent probes at the cytoplasmic end of TM VI provide 
evidence that agonists induce a rotation or titling movement of the cytoplasmic end of TM 
VI similar to that observed in rhodopsin (Ghanouni et al., 2001).  A key structural change 
involving the disruption of an ionic interaction between the highly conserved D(E)RY 
sequence at the cytoplasmic end of TM VI is observed upon activation of both rhodopsin 
and the β2 adrenoceptor (Yao et al., 2006).  Cysteine crosslinking studies on the M3 
muscarinic receptor provide evidence for the movement of the cytoplasmic ends of TM V J. Robert Lane, 2007    Chapter 1  
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and TM VI toward each other upon agonist activation (Ward et al., 2006).  Interestingly, 
studies using FRET have shown that partial agonists and inverse agonists impart a 
conformational change on the receptor that is distinct from that of a full agonist (Nikolaev 
et al., 2006; Vilardaga et al., 2005). 
1.3.2  The receptor-G protein interface 
The newly formed pocket in the cytoplasmic face of the receptor forms the binding site for 
the c-terminus of Gα which, as described below is the best characterised receptor contact 
site in G proteins.  Structural information about this region is lacking from crystal 
structures as this region is missing or disordered in most of them.  Experiments using 
alanine scanning mutagenesis, chimeric Gα subunits, chemical cross linking and tryptic 
proteolysis have also implicated residues in the α4/β6 loop at the C-terminus of Gα.  
Similarly, the N-terminal helix has also been shown to be involved with receptor 
interaction.    The Gβγ dimer also binds receptors and is required to stabilise the receptor-G 
protein interface, with the C-terminus of Gβ and the Gγ subunit thought to be particularly 
important (Oldham, 2006).  As described below, the intracellular loops of GPCRs are 
though to form the primary interaction surface on the receptor.  Computational techniques 
have enabled investigators to apply the extensive amount of biochemical and biophysical 
information to the high resolution structures of rhodopsin and Gαt and develop a model for 
the complex between an active rhodopsin and a GDP bound (inactive) Gαt (Ciarkowski et 
al., 2005; Fotiadis et al., 2006).  However, according to one model, the cytoplasmic surface 
of the receptor is not large enough to accommodate both the Gα C-terminus in its binding 
pocket and the Gγ C-terminus (Ciarkowski et al., 2005).  One possible resolution is that 
receptors function as dimers (Javitch, 2004; Milligan, 2007), and increasing experimental 
evidence suggests that this is the case.  Therefore, the functional complex between a 
receptor and G protein could be one receptor dimer coupling to one Gαβγ heterotrimer.   J. Robert Lane, 2007    Chapter 1  
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1.3.3  Structural basis of receptor G protein coupling selectivity 
The G protein coupling profiles of most GPCRs have been elucidated in considerable 
detail with the use of various different experimental approaches (Wess, 1998; Wong, 
2003).  When activated by the appropriate ligands, most GPCRs can recognise and activate 
only a limited set of the many structurally similar G proteins expressed in a cell 
(Gudermann et al., 1997; Milligan, 1995).  Not surprisingly, given the sequence similarity 
between Gα subunits within the same sub-family, receptors ultimately can be broadly 
classified into Gαi/o, Gαs and Gαq/11 coupled receptors.  However, it has also become clear 
that most GPCRs, although preferentially linked to a certain subfamily of G proteins, can 
also couple to other classes of G proteins, although often with reduced efficiency 
(Gudermann et al., 1997).  It should be noted that G protein coupling specificity is relative 
rather than absolute.  In most cases where sufficient data are available, it appears that 
receptors are able to interact with most or all members of their preferred G protein family, 
frequently with different efficacies (Gazi et al., 2003; Perez and Karnik, 2005; Senogles et 
al., 2004).  Because all GPCRs and all heterotrimeric G proteins are thought to share a 
similar molecular architecture, it is likely that the overall geometry of different receptor/G 
protein complexes is generally conserved.  However, the amino acids predicted to 
determine the coupling properties of a specific member of a given receptor subfamily are 
usually not well conserved among the other GPCRs that display a similar G protein 
coupling profile.  In addition, receptors from different structural classes, sharing little or no 
sequence homology, appear to couple to the same set of G proteins.  Despite this wealth of 
information concerning GPCRs and their cognate G protein partners, little is known about 
how GPCRs selectively couple to a single subtype of G protein α subunit.  This is 
particularly puzzling given that there is approaching a thousand GPCRs of diverse primary 
structures, yet there are only four subfamilies of G protein.   It is not possible, then, to J. Robert Lane, 2007    Chapter 1  
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predict the G protein coupling profile of a GPCR based on its primary sequence, unless it 
shares a very high degree of sequence homology with a receptor whose G protein coupling 
preference is already known.  However, despite the wide diversity of GPCR sequences, the 
regions within the receptor critical for receptor G protein coupling are generally conserved. 
 
The observation that purified Gαo1 subunits could be activated by the wasp venom 
mastoparan, a 14 amino acid residue peptide, suggests that G proteins can be activated by 
short amphiphilic structures (Wong, 2003).  This activation was pertussis toxin sensitive.  
Furthermore, a structure-function relationship study using a variety of synthetic peptides 
with sequences distinct from mastoparan suggests that G proteins can be activated by a 
variety of cationic and hydrophobic peptides with no obvious similarity in primary 
sequence.  The common feature of all of these activators appears to be an amphiphilic α-
helical structure with a cationic residue on one side and a hydrophobic side chain on the 
other.  This was also demonstrated for Gαs and Gαq (Bluml et al., 1994; Sukumar et al., 
1997).    Synthetic peptides based on regions of GPCRs have also been shown to activate G 
proteins, however, the receptor/G protein coupling specificity of the GPCR is not 
necessarily exhibited by the peptide (Wong, 2003).  
 
1.3.4  Receptor domains involved in G protein coupling 
 
A wide body of work has tried to isolate domains within GPCRs that are important for 
receptor/G protein coupling.  Initial studies performed on muscarinic receptors have been 
extended to many other classes of GPCRs.  Taken together, these studies have shown that 
G protein coupling specificity is determined by multiple intracellular receptor regions 
(Wess, 1998; Wong, 2003).  The most critical regions are the second intracellular loop 
(ICL 2) and the third intracellular loop (ICL 3) (Figure 1.2).  A considerable body of J. Robert Lane, 2007    Chapter 1  
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evidence suggests that these regions act in a cooperative fashion to dictate proper G protein 
recognition and efficient G protein activation   However, the membrane proximal region of 
the C-terminal tail and residues within the first intracellular loop may also modulate both 
the selectivity and efficiency of receptor/G protein interactions.  A general principle that 
has emerged from these studies is that the relative contribution of different intracellular 
receptor domains to the selectivity of G protein recognition varies among different classes 
of GPCR and even between GPCRs that are from the same subfamily.  Below I will 
summarise the vast body of work that has implicated the importance of these regions in G 
protein coupling. 
 
1.3.4.1  The second intracellular loop 
 
Studies with hybrid GPCRs have provided strong evidence that the ICL 2 represents one of 
the key regions regulating the selectivity of receptor/G protein interactions.    Several 
examples are known in which the substitution of the ICL 2 together with at least one other 
cytoplasmic receptor region, such as the ICL 3 or the C-terminal tail from a donor receptor 
into a functionally different, but structurally similar, acceptor receptor can confer on the 
resulting chimeric receptor the G protein coupling profile of the donor receptor (Wess, 
1998).  Such results have been obtained with m1 muscarinic/β1 adrenergic and 
mGluR1/mGluR3 glutamate hybrid receptors (Pin, 1994; Wong and Ross, 1994).  Other 
studies have shown that substitution of the ICL 2 alone can be sufficient to confer a new 
functional activity on a recipient receptor.  For example, replacement of the ICL 2 of the 
Gs coupled V2 vasopressin receptor with the corresponding sequence of the Gαq/11 coupled 
V1a receptor sequence yielded a receptor that gained productive coupling to Gαq/11 (Liu 
and Wess, 1996).  Similar approaches have been used on the D2 dopamine receptor and β2-J. Robert Lane, 2007    Chapter 1  
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adrenergic receptors. The substitution of the second intracellular loop of these receptors for 
that of the Gαq/11 coupled thrombin receptor results in the conference of Gαq coupling to 
the D2 dopamine and β2 adrenergic receptors, which do not usually couple to Gαq 
efficiently (Berg et al., 2001; Verrall et al., 1997).  Interestingly, a study has shown that the 
editing of 5-HT2C receptor mRNA can result in receptor isoforms that differ in their ICL 2 
sequences.  These isoforms vary considerably in their Gq coupling efficiencies.  This not 
only demonstrates that mRNA editing may represent a mechanism by which receptor/G 
protein coupling is regulated but also highlights the importance of this region in receptor/G 
protein coupling specificity (Berg et al., 2001; Burns et al., 1997). 
 
1.3.4.2  The third intracellular loop 
A vast body of evidence has implicated this region as playing a key role in receptor/G 
protein coupling specificity, but, as for the second intracellular loop, the relative 
contribution of this region to receptor/G protein coupling differs between GPCRs.  Early 
studies carried out with chimeric muscarinic and adrenergic receptors showed that the 
exchange of the i3 loop between functionally different receptors frequently leads to a 
reversal of G protein coupling profiles, but with reduced efficiency.  Furthermore, several 
of these hybrid receptors were shown to have retained coupling to G proteins normally 
activated by the recipient receptor (Wess, 1998).  Both of these findings show that whilst 
the third intracellular loop is important, other regions of the receptor must be present to 
fully account for the coupling properties of a given receptor. 
 
The third intracellular loop differs considerably in size among different classes of GPCRs 
and can contain as many as 240 (m3 muscarinic receptor) or as few as 15 amino acids (N-
formyl peptide receptor).  Deletion mutagenesis studies have shown, however, that only J. Robert Lane, 2007    Chapter 1  
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the N- and C- terminal 8-15 amino acids of the third intracellular loop appear to be critical 
for G-protein coupling (Strader et al., 1994).  Indeed, mutations in the C terminal region of 
the third intracellular loop frequently lead to constitutively active receptors (Lefkowitz, 
1993).  The structural and functional characteristics of both the N and C-terminal domains 
of the third intracellular loop have been analysed in great detail by mutagenesis studies of 
different muscarinic subtypes.  Both residues at the junction of transmemembrane region V 
and VI are thought to form amphiphilic α helices that are critical for G protein recognition 
(Altenbach et al., 1996).  According to the model proposed by Baldwin et al. the 
functionally critical receptor surfaces present at the N and C-terminal domains of 
intracellular loop three are predicted to project into the interior of the helical bundle 
(Baldwin et al., 1997).  Receptor activation is proposed to be accompanied by an outward 
movement of transmembrane domains III and VI leading to an opening of the intracellular 
receptor surface that may allow the G protein heterotrimer to access the functionally 
important residues at the third intracellular loop/ transmembranes domain junctions.  
Furthermore Hubbell et al. measured light-activated changes in rhodopsin. They employed 
internitroxide distance measurements between labelled residues at cytoplasmic ends of 
TM1 (where a nitroxide label was attached as a reference point) and TM II, and another 
labelled residue at the cytoplasmic end of TM VIII. Residues in TM II were displaced 
relative to the position of TM VIII upon light activation when compared to the position of 
the reference residue (Altenbach et al., 2001). This group used the same approach to show 
that distances between a labelled residue in TM I and TM VII increase upon light 
activation of rhodopsin, which is consistent with a 2 to 4 Å movement of TM VII away 
from TM I. Together, these studies suggest that conformational changes occur in several 
regions of rhodopsin's cytoplasmic face (Altenbach et al., 2001). 
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1.3.4.3  C-terminal tail and intracellular loop 1 
 
Relatively few studies have shown that the first intracellular loop is implicated in G protein 
coupling.  However, several studies have shown that the structural integrity of the first 
intracellular loop is critical for efficient receptor/G protein coupling.  Furthermore, the 
length of this region is highly conserved among GPCRs (Wess, 1998) indicating that it 
may play an important structural role.  Studies using chimeric receptors with the fMLP 
formyl peptide and the C5a receptor, both of which couple to Gαi/o and Gα16 subunits, 
showed that the exchange of the first intracellular loop of the fMLP peptide receptor with 
that of the C5a receptor led to a chimeric receptor that coupled to Gα16 even in the absence 
of activating ligands (Amatruda et al., 1995).  There is, then, evidence that the first 
intracellular loop can influence G protein coupling.  However, it remains to be determined 
whether this is due to direct contacts with the G protein heterotrimer or due to indirect 
conformational effects, for example, on the orientation or accessibility of other regions 
such as the third intracellular loop. 
 
Deletion mutagenesis studies have shown that most of the cytoplasmic C-terminal tail 
region except for the membrane proximal 8-16 amino acids is not required for efficient G-
protein coupling.  However, it was noted that several truncated receptors were able to 
couple to G proteins with improved efficacy or display increased basal activity (Wess, 
1998).  Moreover, biochemical studies with short synthetic peptides corresponding to C-
terminal tail sequences as well as loss of function mutagenesis studies implicate this region 
as being directly involved in G protein coupling (Merkouris et al., 1996).  Interestingly, 
truncation of the C-terminal tail of the Mel1c receptor, which couples to Gαi/o only, J. Robert Lane, 2007    Chapter 1  
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enabled the receptor to couple to Gαi/o and Gα16 (Lai et al., 2002).  Grafting this region 
onto the c-terminus of the MT1 or MT2 receptors, which couple to both Gαi/o and Gα16, 
disrupted the coupling to Gα16 but not Gαi/o.  This indicates that the C-terminal region of 
Mel1c negatively regulates the coupling to Gα16 but not Gαi/o. 
 
In summary, there is no consensus sequence predictive of Receptor/G protein coupling 
specificity but regions of importance in receptor/G protein coupling specificity, such as 
ICL 3, are conserved across many and diverse GPCRs.  It could be postulated then that it is 
the orientation and availability of these domains that determines G protein coupling 
specificity (Oldham, 2006; Wong, 2003).  Perhaps in agreement with this is the 
observation that point mutations of the LH/RH receptor (2
nd extracellular loop) (Gilchrist 
et al., 1996) and α2-adrenoceptor receptor (2
nd transmembrane domain) (Surprenant et al., 
1992) disrupt G protein coupling.  Indeed the work of Suprenant et al. is particularly 
relevant to this thesis and requires further discussion. An aspartate residue in the 2
nd 
transmembrane domain of the α2-adrenoceptor receptor  (Asp
79) that is highly conserved 
among GPCRs, was mutated to an asparagine.  In cells transfected with the mutant 
receptor, agonists inhibited adenyl cyclase and calcium currents but did not increase 
potassium currents.  It was postulated that distinct G proteins couple adrenoceptors to 
potassium and calcium currents, and that the mutant adrenoceptor was unable to achieve 
the conformation necessary to activate the G protein α subunits that mediate potassium 
channel activation(Surprenant et al., 1992).  These results can be explained by the loss of 
fidelity of G protein coupling due to a change in conformation at the intracellular region 
and suggests that the requirements for conferring G protein specificity may be subtle. 
Furthermore, these results also highlight one of the caveats of investigating G protein 
coupling using mutagenesis.  Since this result shows that a single mutation in a seemingly 
distinct region can disrupt the structure of a GPCR in such a way as to alter the G protein 
coupling profile of this receptor, it is therefore not unlikely that other mutations, for J. Robert Lane, 2007    Chapter 1  
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example within regions that are known to be involved with G protein coupling could have 
similar effects on the overall structure of that GPCR.  As a consequence it is difficult to 
distinguish between mutations that affect G protein coupling, because that particular 
residue makes direct contact with the G proteins or mutations that simply change the 
overall structure of the receptor.  In support of a model where specific receptor 
conformations may be more or less favourable for coupling to specific G proteins, different 
agonists can affect which, and to what extent, G proteins are activated by a given receptor 
(Kenakin, 2003; Perez and Karnik, 2005; Urban et al., 2006a).  
 
1.3.5  Regions of G protein α subunits predicted to interact with 
GPCRs 
 
The extreme C-terminus of Gα and, in particular, the last five residues, has been 
established as an important mediator of receptor/G protein interaction.  This consensus was 
arrived at from numerous studies using diverse methodologies (Wess, 1998).  The pertussis 
toxin catalysed ADP ribosylation of cysteine residue -4 results in the uncoupling of Gαi/o 
proteins from receptors (Milligan, 1995).    Numerous reports of mutations in this region 
that alter receptor-G protein specificity have also appeared.  In addition, several 
investigators have generated sequence-specific C-terminal peptides or antibodies targeting 
the C-terminal domain to study receptor-G protein interaction (Milligan, 1995).  Antisera 
raised against decapeptides corresponding to the C-terminal ten amino acids of Gα subunits 
have been used to study receptor-G protein interaction.  Antisera recognising Gα C-
terminal domains block receptor-G protein signalling.  Sequence-specific C-terminal 
synthetic peptides have been shown to either: stabilise the active agonist bound form of the 
receptor and therefore mimic the G protein, or serve as competitive inhibitors of receptor-
G protein interface (Gilchrist et al., 1998; Rasenick et al., 1994).  The sequence homology J. Robert Lane, 2007    Chapter 1  
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of Gα subunits is high, and consequently the overall structural similarity is also high.  This 
has allowed the construction of chimeric Gα subunits that fold appropriately and are 
functional.  It was shown that the presence of only some 3 to 5 amino acids from the 
extreme C-terminus of Gα was sufficient to determine the selectivity of receptor coupling 
(Conklin and Bourne, 1993; Kostenis et al., 1997).  This finding has allowed the generation 
of chimeric Gα subunits in which the C-terminal five amino acids of Gαs or forms of Gαi/o 
are transplanted onto the backbone of Gαq (Kostenis et al., 2005).  This allows receptors 
that normally couple to Gαs or forms of Gαi/o and those that couple to Gαq to all generate a 
[Ca
2+] output in response to agonist activation.  Consequently, a single generic assay 
suitable to detect agonist activation of many GPCRs can be developed.   This not only 
demonstrates the importance of this region for receptor-G protein coupling selectivity but 
illustrates the potential benefits that an understanding of this subject can bring. 
 
The c-terminus is not the only region directing receptor-G protein interactions.  Several Gα 
subunits possess identical or nearly identical residues within the extreme C-terminus yet 
exhibit differential coupling to receptors.  For example, within the last 11 amino acids of 
Gαi1 and Gαt, only a single residue is divergent, yet the 5-HT1B receptor fails to couple to 
Gαt but couples to Gαi1.  It was shown that two residues within the α4 helix of Gαi1 are 
critical mediators of this specificity (Bae et al., 1999).  Slessarevara et al. (2003) 
demonstrated that receptors use multiple and distinct domains on G protein α-subunits for 
selective coupling.  This study made use of Gαi1/Gαt and Gαq/Gαi1 chimeras and 
monitored their differential coupling to the A1 adenosine, 5-HT1A, 5-HT1B and muscarinic 
M2 receptors.  The findings indicate that whilst the C-terminal region of Gα subunits is 
indeed an important region for the interaction of receptor and G protein, the residues 
involved in G protein coupling differ among the receptors studied.  Domains within the N-
terminus, α4-helix, and α4-helix-α4/α6-loop of Gαi1 are involved in 5-HT and M2 
receptor interaction.  However, the relative influence of these domains and the individual J. Robert Lane, 2007    Chapter 1  
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residues involved in the receptor/ G protein interaction differ with individual receptors.  
These results suggest that coupling selectivity ultimately involves subtle and cooperative 
interactions among various domains on both the G-protein and the associated receptor 




1.3.6  Regions of G protein βγ subunits predicted to interact with 
GPCRs 
 
In addition to the structural determinants on Gα subunits, specific isoforms of Gβ and Gγ 
subunits have been shown to preferentially interact with specific receptors.  For example, 
both Gβ1γ2  and Gβ5γ2 can couple Gαq to endothelin B and M1-muscarinic receptors, but 
only Gβ1γ2  promotes endothelin B receptor binding to Gαi (Lindorfer et al., 1998). Further 
work showed that Gβ5γ2 specifically couples Gαq to receptors (Fletcher, 1998; Hou et al., 
2000).  The Gγ subunit also plays an important role in the determination of receptor G 
protein coupling specificity.  For example, the M2-muscarinic receptor does not interact 
with Gαo. Gβ1γ2 heterotrimers but Gβ1γ5 and Gβ1γ7 did mediate binding of Gαo to this 
receptor (Hou et al., 2000).  The principal determinant of this specificity is likely the C-
terminal third of Gγ as shown by studies with chimeric Gγ subunits (Myung et al., 2006).  
However, the type of lipid modification also has an effect on receptor coupling as a 
geranylgeranyl moiety on Gγ1 or Gγ2 increased the affinity of the G protein for rhodopsin 
and the A1-adenosine receptor respectively. 
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1.3.7  Strategies used to study receptor-G protein coupling 
Receptor-G protein coupling selectivity is a fundamental step in GPCR signalling and, 
accordingly, a considerable number of studies using diverse experimental strategies have 
been directed at trying to elucidate its molecular basis.  I will summarise these strategies 
below with particular reference to those used in this study. 
The most frequently used approach is to study biochemical or physiological responses 
mediated by stimulation of a given GPCR in either native tissue or heterologous cell 
systems.  The nature of the observed responses then allows investigators to draw 
conclusions about the identity of the receptor-activated G proteins.  For example, robust 
increases in intracellular cAMP levels are most likely due to activation of Gαs subunits, 
whereas a reduction is most likely due to activation of Gαi/o subunits.  Pertussis toxin, 
which catalyses the ADP-ribosylation of a cysteine at the c-terminus of Gαi/o subunits 
preventing their functional interaction with the receptor, has also proved a useful tool.  
Responses, then, can either be divided into pertussis toxin sensitive (Gαi/o) responses or 
pertussis toxin insensitive (all other Gα family members).  However, there are several 
drawbacks to dissecting receptor-G protein coupling using these methods.  The first is that 
this method cannot distinguish between Gα subunits of the same family, for example Gαi1, 
2, 3 and Gαo1, are all sensitive to pertussis toxin, and could inhibit adenylate cyclase.  
Secondly, effector regulation is subject to various forms of feedback and cross-regulation.  
Furthermore, G protein subunits released on activation of the G protein heterotrimer may 
converge on the same effectors to have antagonistic or synergistic effects (Milligan, 1994; 
Wess, 1998). J. Robert Lane, 2007    Chapter 1  
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1.3.7.1   [
35S] GTPγS binding assays 
To avoid the problems associated with measuring downstream signalling events it is 
possible to directly measure receptor mediated G protein activation.  One method to do this 
is to measure guanine nucleotide exchange on the Gα subunit using the [
35S] GTPγS assay.  
[
35S] GTPγS is a non-hydrolysable form of GTP and therefore resistant to the GTPase 
activity of the Gα subunit.  Thus uptake of the radiolabelled GTP analogue gives a direct 
measurement of nucleotide exchange.  Guanine nucleotide exchange is a very early event 
in the signal transduction cascade, and is an attractive event to monitor because it is less 
subject to amplification or regulation by other cellular processes than more distal events 
(e.g. regulation of gene expression) that are required for reporter gene assays. Therefore, it 
provides an excellent measure of the basic pharmacological characteristics and the relative 
efficacy of a series of compounds at a GPCR that might often be compromised when 
measuring downstream effects.  However, one drawback is that the signal-to-noise ratio of 
the assay is often quite low, particularly when looking at receptors that couple to G 
proteins other than those in the Gαi/o family due to the relative expression levels of 
different G proteins within cells and the high basal GTP turnover of Gαi/o subunits.  This 
can be circumvented by using antibodies raised against individual Gα subunits in an 
immunopreciptiation step.  This effectively allows the selection of the Gα subunit of 
interest and therefore improves the signal window (Milligan, 2003). 
 
1.3.7.2  Immuno-neutralisation of G proteins 
The well established technique of immunoneutralisation of G proteins takes advantage of 
the observation that antibodies directed against the C-terminal tail of Gα subunits prevent 
functional interaction of the receptor with the G protein.  Therefore, antibodies raised J. Robert Lane, 2007    Chapter 1  
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against and specific for different Gα subunits can be used to dissect receptor/G protein 
signalling.  However, this technique is unable to distinguish between G proteins with 
identical C-terminal sequences, for example Gαi1/Gαi2 and Gαq/Gα11 (Milligan, 1994). 
 
 
1.3.7.3  Co-expression of receptors and G proteins and reconstitution 
experiments 
The transient or stable expression of both receptor and G protein into a heterologous cell 
system in which the receptor and G protein are not expressed is a commonly used approach 
to study receptor/G protein coupling efficiency (Senogles et al., 2004).  The ability of a 
given receptor to activate different G proteins can be easily assessed.  However, there are 
several caveats with this method.  Firstly, the relative expression of receptor and G protein 
must be controlled since relative levels of these two proteins can affect the efficiency and 
perhaps the specificity of interaction (Kenakin, 1997).  However, it is unlikely that all of 
the receptor-G protein interactions observed using this strategy represent physiologically 
relevant interactions.  Secondly, all mammalian cell lines will already express an array of 
G proteins, although this problem can be overcome by several means.   For example the 
receptor and G protein of interest can be expressed in a heterologous cell system without 
endogenous G protein,  exemplified by the expression of mammalian α and βγ subunits in 
insect Sf9 cell lines (Gazi et al., 2003; Grunewald et al., 1996).  The use of Sf9 cells has 
the advantage that the endogenous insect cell G proteins are expressed at a very low level 
as compared to the introduced mammalian G protein.  Another technique allowing the 
investigation of the coupling of a receptor to a particular Gαi/o subunit is the use of 
pertussis-toxin resistant mutants of these Gα subunits.  The pertussis toxin-resistant variant 
of the Gα subunit of interest can be expressed in a heterologous cell line along with the J. Robert Lane, 2007    Chapter 1  
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receptor of interest.  Subsequent treatment with pertussis toxin will render all endogenous 
Gαi/o subunits unable to functionally interact with the receptor so that the interaction 
between the receptor and pertussis toxin resistant variant Gαi/o can be studied in isolation 
(Senogles, 1994; Senogles et al., 2004; Wise et al., 1997). 
 
 
1.3.7.4  Receptor-G protein fusion proteins 
Receptor G protein fusion proteins can be expressed from chimeric cDNAs in which the 5′ 
end of G protein α-subunits are linked directly to the 3′ tail of a G protein-coupled receptor 
(Figure 1.5). Consequently, the stoichiometry of expression of the two protein partners 
should always be 1:1 irrespective of the cell system used for expression or the absolute 
levels of expression of the fusion protein.  Furthermore, the receptor and G protein will 
have the same co-localisation within the cell.  c   Estimates of ligand efficacy vary 
frequently with levels of GPCR expression and thus are also sensitive to the stoichiometry 
of expression of GPCR, G protein and effector polypeptides (Hildebrandt, 2006; Milligan, 
2002). Therefore, as long as the measure of agonist function is taken directly at a point of 
GPCR–G protein interaction, rather than at some downstream or temporally distant point, 
measurement of ligand intrinsic activity should be free from this constraint. The fusion 
protein approach, then, should ensure that measurements of agonist-binding affinity and 
EC50 for G-protein activation are directly comparable for the same receptor coupling to 
each G protein.     
 
1.3.7.5  Chimeric receptors 
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In the summary of domains important for receptor-G protein coupling, data was included 
from both mutagenesis studies and from the use of chimeric receptor and G proteins.  
However, a potential caveat of mutagenesis studies is that abolition or a change in 
receptor/G protein coupling could be due to an alteration of the overall folding of the 
receptor rather than that particular region being involved in G protein coupling(Wong, 
2003).  A perhaps more convincing strategy to identify the G protein coupling region is the 
use of chimeric receptors.  In this approach, intracellular regions are exchanged between 
GPCRs of differing G protein coupling specificities (Wess, 2002; Wong, 2003).  
Substituting these regions of the ‘donor receptor’ onto the corresponding region in another 
‘acceptor receptor’ should result in the acceptor receptor gaining the G protein coupling 
specificities of the donor receptor.  A summary of work to date using chimeric receptors, 
including the region of the receptor exchanged, is displayed in Table 1.2.  Studies using 
chimeric receptors derived from highly homologous receptors are perhaps the most 
relevant since disruption of receptor structure is likely to be minimal. 
 
As described above the high homology of G protein α subunits makes the use of chimeric 
receptors to highlight regions of G proteins important in receptor coupling particularly 
appealing.  This technique has highlighted the c-terminus of Gα subunits as an important 
region governing receptor-G protein coupling selectivity as described in section 1.3.6. 
 
 
Table 1.2: Chimeric GPCRs that showed a change in G protein-coupling specificity. 
Chimeric receptors (R1-R2) were constructed with the indicated intracellular region of 
donor receptor (R2) substituted into the corresponding region of acceptor (R1). I2 = 2
nd 
intracellular loop; I3 = 3
rd intracellular loop; I3N = N-terminal region of the 3
rd 
intracellular loop; IC3 = C-terminal region of the 3
rd intracellular loop, C = C-terminal tail.  
All of the chimeric receptors presented have acquired the G protein selectivity of R2, while J. Robert Lane, 2007    Chapter 1  
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the majority of those tested either retained the coupling to the acceptor receptor or became 
functionally promiscuous. No coupling = coupling not detectable with the assay system 
used: ND = not determined (Taken from Wong, 2003). 
Acceptor receptor (R1)  Donor receptor (R2)  Chimeric receptor R1-R2: 
G protein selectivity 






R2  R1  Other G  
proteins 
α2AR  Gαi/o  β2AR  I3 Gαs + ND  ND 
mGluR3  Gαi/o mGluR1  I2+I3+C Gαq + ND  ND 
D3 no  coupling  D2 I3  Gαi/o +  ND  ND 
D2  Gαi/o M 1 I3  Gαq + ND  ND 
D2 no  coupling  thrombin  I2  Gαq + ND  no  Gαs 
M2  Gαi/o M 3 I2  Gαq + ND  no  Gαs 
M2 G αi/o M 3 I3  Gαq + -  ND 
M3 G αq M 2 I3  Gαi/o +  -  ND 
M2 G αi/o M 3 I3N Gαq + +  ND 
A1A G αi/o A 2A  I3, I3N  Gαs + +  ND 
β2AR  Gαs  α2AR  I3N+I3C+C Gαi/o +  +  ND 
β2AR  Gαs  α1AR  I3, I3N  Gαq + +  ND 
β2AR  Gαs thrombin  I2  Gαq + +  ND 
PACAPR2  Gαs PAFR  I3  Gαq + +  ND 
VP2  Gαs VP1 I2  Gαq + +  no  Gαi/o 
VP1 G αq VP2 I3  Gαs + +  no  Gαi/o 
M1 G αq  β1AR  I3, I3N  Gαs + +  Gαi/o, 
Gαz 
M2 G αi/o, Gαz  β1AR  I3N Gαs + +  Gαq 
M1 G αq  β1AR  I2+I3N, I2+I3  Gαs + -  no  Gαi/o, 
Gαz 
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1.3.8  Molecular basis of G protein activation 
1.3.8.1  Receptor activation and GDP release 
 
Activated receptors bind to G proteins and catalyze GDP release from Gα, which is the 
rate limiting step in G protein activation.  Until GTP binds, a high affinity complex 
between the agonist-bound receptor and Gα subunit is formed.  Based on the current 
models of this interaction, the nucleotide binding pocket is 30 Ǻ away from the receptor 
(Bourne, 1997; Fotiadis et al., 2006).  The conformational change induced by the receptor 
must cause GDP release over this distance and has been investigated by analysis of the 
affect of various mutations on the basal and receptor-catalyzed nucleotide exchange rates 
of the G protein.  However, there is little direct evidence of specific receptor-mediated 
conformational changes within G proteins and the molecular mechanisms for receptor 
mediated nucleotide exchange.  The α5-helix links the C-terminus of Gα to the β6/α5 loop 
containing the guanine ring-binding TCAT motif.  Mutations in this motif greatly enhance 
GDP release (Posner et al., 1998).  Indeed, an activating mutation A
366S Gαs causes 
pseudo-hypoparathryoidism in male patients and a homologous mutation in Gαi also 
enhances GDP release (Iiri et al., 1994; Posner et al., 1998).  Alanine scanning 
mutagenesis of Gαt identified three residues on the inward face of the helix which when 
mutated substantially increased rates of basal and receptor-catalysed exchange and several 
residues on the outward face of this helix that decreased catalysed exchange (Marin et al., 
2001).  Interestingly, a flexible five glycine linker inserted between the extreme C-
terminus and the α5-helix severely reduced receptor-mediated nucleotide exchange but did 
not effect binding to the receptor.  However, G protein coupling was only minimally 
reduced when the length of this region was doubled but the rigidity of the contact between J. Robert Lane, 2007    Chapter 1  
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the C-terminus and GDP-binding pocket was maintained (Natochin et al., 2001).  A recent 
study using site-directed spin-labeling showed receptor-activation dependant alterations in 
the structure of the α5-helix at sites distant from the receptor-G protein interface (Oldham 
et al., 2006).  These conformational changes were uncoupled from receptor activation by 
the insertion of a five glycine linker suggesting, then, that the rigidity of the connection 
between the C-terminus and the GDP binding pocket is important. The introduction of an 
isoleucine-to-proline mutation at the C-terminus of the α5-helix has been shown to reduce 
the stimulatory activity of D2 dopamine receptor mimetic peptide on nucleotide exchange 
Gαi1 (Nanoff et al., 2006) indicating that perturbations in this region are transmitted to the 
GDP binding pocket. 
 
As for the α5-helix, the β6 strand may transmit receptor binding to the α4/β6 to the 
binding pocket at the β6/α5 loop.  In accordance, mutations within this region have been 
shown to reduce receptor-catalyzed activation despite normal receptor binding (Onrust et 
al., 1997).  Intramolecular contacts with the N-terminal region have also been implicated in 
nucleotide exchange.  Mutations within this region or within regions interacting with the 
N-terminal β1 and β3 strands may perturb the hydrophobic core of the α subunit, thereby 
reducing the affinity for GDP (Oldham, 2006).  Two models have been proposed for 
receptor-mediated GDP release (Figure 1.6).  The first uses the N-terminal helix of Gα as 
a lever arm to pull the Gβγ away from Gα.  This would allow GDP release as Switches I 
and II are pulled away from the nucleotide binding pocket (Iiri et al., 1998).  The second 
model proposes that the receptor uses the αN-helix to force Gβγ into Gα, allowing the N-
terminus of Gγ to engage the helical domain of Gα.  This interaction may cause the 
interdomain gap between the helical and GTPase domains of Gα to open, leading to GDP 
release (Cherfils and Chabre, 2003)   For both of these models, it is proposed that the Gβγ 
dimer acts as a guanine nucleotide exchange factor.  In support of this proposal, alanine J. Robert Lane, 2007    Chapter 1  
33 
mutations at the switch interface of Gβ have been shown to prevent receptor-catalyzed 
nucleotide exchange, and mutations within the c-terminus of Gγ have been shown to 
increase the rate of nucleotide exchange (Ford et al., 1998).  Accordingly, a study using 
bioluminescence resonance energy transfer to probe structural rearrangements in 
α2Aadrenoceptor-Gαi1β1γ2 complexes showed agonist activation of the receptor causes a 
rearrangement of the receptor-G protein complex.  It was proposed that this conformational 
rearrangement causes the Gα-Gβγ interface to open, in turn causing the opening of the 
GTPase and helical domain through the interdomain linker region,  resulting in GDP 
release (Gales et al., 2006).   Glycine to proline mutations in each of the interdomain 
linkers of Gαt enhances the basal nucleotide exchange rate of Gα, in agreement with this 
interdomain rearrangement (Majumdar et al., 2004). 
 
All of the conformational changes described above are supported by data from both 
biochemical and mutagenesis studies.  However, without the crystal structure of an 
activated receptor bound to a G protein heterotrimer, many questions remain about the 
orientation of these two proteins, the sites of interaction between them and the 
conformational changes that lead to GDP release.  It was recently demonstrated that both 
light-activated rhodopsin and a soluble mimic of the active receptor form trapped 
intermediate complexes with a GDP-released "empty pocket" state of the heterotrimer in 
the absence of GTP (or GTPγS). The results suggested that activated receptor-mediated 
changes in the receptor-interacting regions of Gα, and not the absence of bound guanine 
nucleotide, are the predominant factors which dictate Gα conformation and dynamics in 
this activated receptor-bound state of the heterotrimer (Abdulaev et al., 2006). 
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1.3.8.2  GTP binding-mediated alteration of the receptor G protein complex 
 
The concentration of GTP in the cell exceeds that of GDP by several fold, consequently the 
receptor-G protein complex is transient due to the rapid binding of GTP.  The binding of 
GTP to the Gα subunit causes a structural rearrangement of Gα(GTP), and its orientation 
with both the Gβγ dimer and the receptor.  This rearrangement allows interaction with 
downstream effectors.  Conformational rearrangements in the three switch regions between 
Gαi1 when bound to GDP or GTPγS were revealed by crystal structures of these complexes 
(Coleman et al., 1994; Lambright et al., 1994; Mixon et al., 1995).  This structural 
rearrangement was thought to eliminate the Gβγ binding surface of the α subunit therefore 
leading to subunit dissociation.    However, studies monitoring the structural 
rearrangements of the receptor and the G protein heterotrimer using fluorescence and 
bioluminescence resonance energy transfer suggest that the receptor and G protein subunits 
may remain closely associated following receptor activation (Bunemann et al., 2003; Gales 
et al., 2006). 
 
In addition to the conformational changes in the switch regions, GTP binding also causes a 
conformational change in the myristoylated N-terminus of Gα.  Site-directed fluorescence 
labelling indicates that the myristoylated N-terminus moves into an even more 
hydrophobic environment, perhaps suggesting that the conformational changes associated 
with GTP binding expose an intramolecular binding site for the N-terminus (Preininger et 
al., 2003).  The non-myristoylated N-terminus of Gα becomes disordered upon binding 
GTP. 
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1.3.8.3  G protein inactivation 
Termination of the G protein signal is achieved upon the intrinsic hydrolysis of GTP to 
GDP by the Gα subunit and re-association or rearrangement of the heterotrimer.  Again, 
structural insight into the mechanism of GTP hydrolysis was provided by crystal structures 
of the complexes Gαi1.GDP and Gαi1.AlF4
- (Coleman et al., 1994).  Aluminium fluoride is 
an activator of Gα subunits and binds along with GDP in the active site as a tetraco-
ordinate AlF4
- ion.  In the crystal structure of Gαi1.GDP.AlF4
-
, the AlF4
- ion is in a square 
planar configuration with the oxygen of the β-phosphate and a water molecule acting as 
transaxial ligands forming a tetragonal bipyramid.  It was proposed that this conformation 
represents a transition state for the hydrolysis of GTP.  The crystal structure of this 
transition state revealed several residues with important roles in the GTPase activity of 
Gαi1.  A conserved glutamine (Glu
204) polarizes and orients the nucleophilic water 
molecule.  Mutation of this glutamine to a leucine results in a GTPase-deficient Gα subunit 
that is effectively constitutively active (Landis et al., 1989). A conserved arginine (Arg
178 
in Gαi1) stabilises the transition state, by stabilising the developing negative charge on the 
leaving γ phosphate and facilitating its release.  ADP ribosylation of this arginine by 
cholera toxin abolishes the GTPase activity of Gαs and Gαt, as does the mutation of this 
residue to a cysteine, both resulting in a constitutively active Gα subunit.  Indeed, this 
mutation has been shown to cause sporadic endocrine tumours and McCune-Albright 
syndrome (Bourne, 1987; Weinstein and Shenker, 1993).  Two mutations in the nucleotide 
binding pocket, a glycine to valine substitution in the P-loop, and a glycine to alanine 
mutation (Berghuis et al., 1996; Raw et al., 1997) in switch II stabilise a Gαi1.(GDP.Pi) 
complex associated with substantial conformational change in switch II.  An additional 
lysine-to-proline mutation in Switch I accelerates a conformational change in the Switch 
regions, but decreases the rate of GTP hydrolysis (Thomas et al., 2004).  Consequently, the 
dynamics of the Switch regions may be critical for GTP hydrolysis. J. Robert Lane, 2007    Chapter 1  
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The intrinsic GTP hydrolysis activity varies among Gα family members, where Gαi/o 
family members (1.8-2.4 min
-1 at 30 ºC) and Gαs family members have a higher GTPase 
activity than members of the Gαq (0.8 min
-1 at 30 ºC ) or Gα12 (0.2 min
-1 at 30 ºC) 
families.  Differences in the helical domains, N and C-termini may provide the structural 
basis for this observation (Cabrera-Vera et al., 2003). 
 
1.3.8.4  GTPase-activating proteins 
 
It was noted that the intrinsic GTPase activity of many purified Gα subunits was much 
slower than the deactivation rates of G protein signalling in vivo.  This suggested the 
influence of GTPase accelerating proteins (or GAPs).  The first GAPs identified were the 
Gα effectors PLCβ1 and PDEγ (Gαt) (Arshavsky and Bownds, 1992; Berstein et al., 
1992).  This illustrates that effectors, following activation by Gα, can negatively regulate 
the amplitude and duration of the G protein signal.  However, in addition to effector 
mediated feedback inhibition another class of GAPs have been identified: the regulators of 
G-protein signalling (RGS).  These proteins share a common 120 amino acid RGS domain 
that forms a bundle of nine α-helices that bind to the switch regions of Gα.  The RGS 
domain enhances the GTPase activity of Gα by stabilising the transition state conformation 
and orientating the Gα backbone to stabilise the nucleophilic water molecule (Tesmer et 
al., 1997a).   
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1.3.8.5  Interaction of activated G proteins with their downstream effectors 
Once Gα.GTP has dissociated from or perhaps altered its conformational relationship with 
the Gβγ dimer, it can interact directly with effector proteins to continue the signal cascade.  
The tissue distribution, effector molecules and known disease relevance of all Gα family 
members is summarized in Table 1.1.  Each Gα family activates a distinct profile of 
effectors.  The molecular basis of this divergence has not been completely elucidated but 
co-crystallization studies of Gαs in a complex with the catalytic domains of adenylate 
cyclase identified the α2 helix and the α3-β5 loop as being particularly important 
(Ghahremani et al., 1999; Tesmer et al., 1997b).  Furthermore, within a Gα family, each 
different Gα subunit exhibits a different profile of effector activation.  For example, Gαi2 is 
required for a dopamine D2S receptor-mediated inhibition of forskolin-stimulated adenylate 
cyclase activity, whereas Gαi3 is required to inhibit PDE!-induced (Gαs coupled) 
enhancement of adenylate cyclase activity (Ghahremani et al., 1999).  Thirdly, some Gα 
subunits couple only to one effector, such as Gαt to cGMP phosphodiesterase.   
 
Initially Gβγ was thought to facilitate the completion of the G protein signal by passively 
binding to and hastening the return of the heterotrimer to the plasma membrane, thereby 
preventing noise or spontaneous Gα activation in the absence of receptor stimulation.  It is 
now known that Gβγ  interacts with and influences several effectors including PLCβ, 
several isoforms of adenylate cyclase, PI-3 kinases, Ca
2+ channels and K
+ channels 
(Oldham, 2006). 
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1.4  Receptor theory, agonist directed receptor trafficking and 
protean agonism 
Receptors bind a ligand on the extracellular side and following activation by an agonist, 
conformational changes occur that allow the intracellular region of the GPCR to bind to 
and activate the heterotrimeric G protein.  Pharmacological theory proposes that ligands 
can be characterised by the nature of their functional effects generated by their interaction 
with their target receptor. These effects are governed by two important properties: the 
affinity of the ligand for its receptor, and efficacy, the ability of the ligand once bound to 
elict a response (Kenakin, 2001).  This has led to the classification of receptor ligands as 
agonists, partial agonists, neutral antagonists or inverse agonists.  According to this 
classification, full agonists possess sufficiently high intrinsic efficacy such that they 
maximally stimulate all cellular responses linked to a given receptor.  Partial agonists 
possess lower degrees of intrinsic efficacy and therefore give sub-maximal responses.  
Initially, it was thought that an agonist ligand was the regulator to select or induce the 
active conformation of the receptor.  The current model(s) of GPCR function uses the 
concept of allosterism,which was first described for ion channels and enzymes and 
subsequently  applied to receptors. These ideas culminated in the ternary complex model 
for GPCRs, which was first published by De Lean and colleagues (De Lean et al., 1980) 
This model describes a receptor that,when activated by an agonist, moves laterally 
in the cell membrane to physically couple to a trimeric G protein. This introduced a novel 
concept in receptor models, namely that the sensitivity of the system(and potency of 
agonists) was subject to the availability of an external protein (i.e. a G protein). Supporting 
this model were data showing that physical complexes between receptors and G proteins 
couldbe isolated after addition of agonist to receptor systems (Limbird and Lefkowitz, 
1978) 
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 However, the observation that mutations in the third intracellular loop of the β2-
adrenoceptor resulted in its constitutive activation led to an appreciation that receptors can 
exist in the active state even without the effects of an agonist (Samama et al., 1993).  This 
led to the revision of the ternary complex model, which postulated that receptor activation 
required the agonist-promoted formation of an active, “ternary” complex of agonist, 
receptor and G protein.  The revised model was termed the two state model.  This includes 
the explicit isomerisation of the receptor to the active (R*) state prior to coupling to G 
proteins.  This model explains constitutive activation as a shift in the equilibrium between 
receptor molecules in the inactive state (R) and the active states (R*), resulting in a higher 
proportion of receptor molecules in the R* state.  Conversely, inverse agonists have a 
higher affinity for, and will shift the equilibrium towards, the inactive state (R).  Therefore, 
inverse agonists will reduce the basal activity of a constitutively active receptor.  Neutral 
antagonists bind with equal affinity to both R and R* and therefore have no effect on the 
basal activity of constitutively active receptors.    An extension of this two state model is 
termed the cubic ternary complex model and differs in that it allows G-proteins to bind to 
inactive receptors.  This cubic ternary
 complex model implies the existence of a receptor 
conformation
 that can couple to its G-protein partner, but is unable to evoke a response, 
allowing
 a ligand with high affinity for this receptor conformation to behave as a neutral 
antagonist or inverse agonist (Weiss et al., 1996a; Weiss et al., 1996b; Weiss et al., 1996c).   
It was assumed that the ability of the ligand to impart (or reduce) stimuli once that ligand is 
bound to the receptor is an inherent parameter that is constant for each ligand at a given 
receptor, irrespective of where that receptor is expressed.  For example, a full agonist 
would be expected to activate all of the signalling pathways linked to a receptor to the 
same degree as the endogenous ligand for that receptor.  Similarly, a ligand that 
antagonised one signalling pathway via a specific receptor should antagonise every 
pathway coupled to that receptor to the same extent.  This assumption is still widely held 
and forms the basis of drug discovery today (Urban et al., 2006a).  Most drug screening J. Robert Lane, 2007    Chapter 1  
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programmes employ an experimental model system and it is assumed that, due to intrinsic 
system-independent efficacy, that the pharmacological characteristics of a drug seen in 
these experimental conditions can be extrapolated to in vivo systems.  However, data 
demonstrating differential pharmacology of the same ligand at the same receptor through 
different signalling pathways has emerged over the last decade and are not consistent with 
this assumption (Kenakin, 2001; Perez and Karnik, 2005; Urban et al., 2006a).   I will 
summarise these considerable and diverse data below. 
 
1.4.1  Examples of functional selectivity 
The capability of certain serotonergic ligands to differentially activate signal transduction 
pathways associated with the human serotonin 5-HT2A and 5-HT2c receptors was shown.  It 
was observed that the relative efficacy of a series of ligands for each of the receptors 
differed depending upon whether PLC-mediated accumulation of IP or PLA2-mediated 
release of arachidonic acid (AA) was measured (Berg et al., 1998).  Importantly, responses 
to the reference ligand were obtained along with each test ligand for each experiment.  A 
cysteine to phenylalanine mutation in TM III of the α1b-adrenoceptor constitutively 
activates the receptor resulting in G protein coupling in the absence of agonist (Perez et al., 
1996).  However, this mutation results in the activation of the PLC pathway, and not 
phospholipase A2.  Furthermore it was shown that these two pathways are coupled to two 
different G proteins (Perez et al., 1993).  It was found that phenylethylamine ligands from 
full to partial agonists were able to recognise this selective active state.  However, a series 
of structurally-distinct imidazoline agonists, such asoxymetazoline, did not change in 
either their signalling or binding characteristics.  This same mutation has been shown to 
cause similar phenotypes in a cross-section of GPCRs that couple to different G-proteins 
for example the angiotensin receptor (Noda et al., 1996) and the bradykinin receptor (Ishii J. Robert Lane, 2007    Chapter 1  
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et al., 1997).  In fact, a large area around this residue in TM III seems responsible for 
active state isomerisation suggesting that this region is a possible switch region controlling 
key steps in the isomerisation from the inactive to active structure (Parnot et al., 2000).   
 
1.4.2  Evidence from kinetic & binding studies 
Using a series of weak to full β2-adrenergic agonists Seifert et al. (2001) examined their 
ability to both stabilise the ternary complex and activate GTPase activity.  No correlation 
was observed between the efficacy of ligands to stabilise the ternary complex and to 
activate GTPase suggesting that the receptor conformation that stabilises the ternary 
complex is different from that which can stabilise the ternary complex (Seifert et al., 
2001).  Several β2 adrenergic agonists were shown to display different order of efficacies 
in their ability to hydrolyse different purine nucleotides than was seen for their ability to 
activate adenylate cyclase in the presence of the different nucleotides (Seifert et al., 1999).  
Perhaps some of the most convincing evidence for multiple signalling states comes from 
biophysical studies using purified β2-adrenergic receptors.  The labelling of specific sites 
on the receptor with specific probes allows for the detection of changes in the bound 
fluorophore, such as fluorescence lifetime and emission. Therefore variations in receptor 
conformation can be detected (Ghanouni et al., 2001).  Similarly, rapid kinetics of 
fluorescent neurokinin A (NKA) binding in parallel with intracellular calcium and cAMP 
measurements allowed the determination of multiple activation states in the tachykinin 
NK2 receptor (Palanche et al., 2001). 
 J. Robert Lane, 2007    Chapter 1  
42 
1.4.3  Evidence from reversal of efficacy (protean agonism) 
Protean agonists were predicted to exist from theoretical arguments based upon multiple 
active conformations of GPCRs (Kenakin, 2001).  It was predicted that a protean agonist 
could act both as an agonist or an inverse agonist at the same GPCR.  The reversal from 
agonism to inverse agonism would only occur when an agonist produces an active 
conformation of lower efficacy than a totally active conformation.  It was shown that 
proxyfan, a high-affinity histamine H3-receptor ligand, acted as a protean agonist at 
recombinant H3 receptors expressed in Chinese hamster ovary cells (Gbahou et al., 2003).  
However, using neurochemical and behavioural assays in rodents and cats, proxyfan 
displayed a spectrum of activity ranging from full agonism to full inverse agonsim.  
Protean agonism, then, is a direct demonstration of the existence of alternative agonist 
active states different from the constitutively active state. 
 
1.4.4  Evidence from differential phosphorylation, desensitisation, 
internalisation and palmitoylation 
In addition to multiple signalling states, there is also evidence to suggest that there are 
multiple deactivation states.  Since different ligands can invoke different active 
conformations, it makes sense that the mechanism to deactivate these states may also be 
different from one another.  Perhaps the most compelling and pharmaceutically-relevant 
example of this is the observation that DAMGO but not morphine could induce rapid 
phosphorylation and internalisation of the µ-opioid receptor and that cAMP-dependent 
protein kinase could phosphorylate in vitro the µ-opioid receptor in the presence of 
morphine but not DAMGO (Arden et al., 1995; Chakrabarti et al., 1998).  J. Robert Lane, 2007    Chapter 1  
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To explain these observations, the concept of agonist-directed trafficking was described.   
It is clear that GPCRs, like all proteins, can adopt numerous conformations according to 
thermal energy.  What is not clear is how many of these conformations are capable of 
activating G proteins.  As described in section 1.3.2, certain regions of a GPCR’s 
intracellular surface, when available and in the correct conformation, are capable of 
activating G proteins.  With this in mind, it would suggest that the inactive form of the 
receptor prevents access of G proteins to these regions.  Therefore, any disruption to the 
GPCR tertiary structure, for example, exerted by the binding of a ligand, could make these 
regions available for G protein activation.  It follows then that a receptor can adopt more 
than one activated R* state.  According to this model, each agonist is theoretically able to 
promote its own specific active receptor state leading to a limitless number of receptor 
conformations (Kenakin, 1995).  However, a criticism of this theory is that some of these 
conformations may not be physiologically pertinent, i.e. several different conformations 
may have essentially the same physiological consequences.  Leff et al. (1997) proposed an 
alternative model where the receptor might exist in three states, an inactive (R) and two 
active conformations (R*,R**), thereby still accounting for multiple G protein coupling 
but limiting the number of receptor conformations to those that are theoretically 
physiologically active (Leff et al., 1997).  However, since even for the most well 
characterised GPCRs with rich pharmacology the number of ligands are limited, the 
difference between these two theories is debatable.  The phenomenon of multiple 
signalling states of GPCRs has been described by a number of names including agonist 
directed trafficking, functional selectivity, biased agonism, protean agonism, differential 
engagement and stimulus trafficking.   
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1.5  Dopamine receptors 
 
Dopamine is the predominant catecholamine neurotransmitter in the mammalian brain, 
where it controls a number of functions such as locomotor activity, emotion, cognition, 
food intake and endocrine regulation.  It also acts in the periphery as a modulator of 
cardiovascular function, hormone secretion, renal function and gastrointestinal motility.  
The dopaminergic signalling pathways have been the focus of a vast body of research over 
the past forty years.  This is due to its involvement in the wide ranging and important 
functions listed above and its dysregulation being linked to several pathological conditions.  
These include Parkinson’s disease, schizophrenia, Tourette’s syndrome and 
hyperprolactinema (Missale et al., 1998).  Dopamine receptor antagonists have been 
developed to block hallucinations and delusions that occur in schizophrenic patients, 
whereas dopamine receptor agonists are effective in alleviating the symptoms of 
Parkinson’s disease.  The treatment of diseases associated with dopamine imbalances is 
associated with severe side effects.  The blockade of dopamine receptors can induce 
extrapyramidal effects similar to those resulting from dopamine depletion, and high doses 




1.5.1  Classification of dopamine receptors 
 
Initial pharmacological studies identified two distinct populations of dopamine receptor, 
one positively coupled to adenyl cyclase (D1) and one which was not (D2) The cDNAs of 
five distinct dopamine receptor subtypes have been isolated and characterized and three 
novel subtypes have been characterised D3, D4 and D5.  However, all dopamine receptor J. Robert Lane, 2007    Chapter 1  
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subtypes fall into one of the two initially recognised receptor categories both in terms of 
their structure and pharmacology.  The D1 and D5 receptors share a very high homology in 
their transmembrane domains and ligand binding characteristics, and a similar homology is 
shared between D2, D3 and D4 receptors (Missale et al., 1998).  The genomic organisation 
of the dopamine receptors suggests that they derive from the divergence of two gene 
families that mainly differ in the absence or presence of introns in their coding sequences.  
D1-like receptor genes do not contain introns in their coding regions, a characteristic shared 
with many G-protein coupled receptors.  In contrast, the genes encoding the D2-like 
receptors are interrupted by introns (Jackson and Westlind-Danielsson, 1994; O'Dowd, 
1993).  Analysis of the structure of D2 like receptors revealed that the D2 receptor-coding 
region contains six introns, the D3 coding region five and the D4 receptor three (Missale et 
al., 1998).  The presence of introns within the coding region allows the generation of splice 
variants, for example, the D2 receptor has two main variants, called D2s and D2l, which are 
generated by alternative splicing of an 87bp exon between introns 4 and 5 (Gingrich and 
Caron, 1993). Splice variants of the D3 receptor encoding non-functional proteins have also 
been identified.  Analysis of the gene for human D4 receptor revealed the existence of 
polymorphic variations within the coding sequence.  A 48-bp sequence in the third 
cytoplasmic loop exists either as a direct repeat sequence, as a four fold repeat, or a seven 
fold repeat.  D4 receptors containing up to 11 repeats have been found.   The D5 receptor 
has two related pseudogenes on human chromosomes 1 and 2.  They are 98 % identical to 
each other and 95 % identical to the human D5 receptor and encode truncated, non-
functional forms of the D5 receptor. 
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1.5.2  Localisation of dopamine receptor subtypes 
 
In the brain, the D1 receptor is the most widespread dopamine receptor and is expressed at 
higher levels than any other dopamine receptor.  Its expression has been demonstrated in 
the striatum, the nucleus accumbens, the olfactory tubercle, limbic system, hypothalamus 
and thalamus (Fremeau et al., 1991; Weiner et al., 1991).  In comparison the D5 receptor is 
much less widely expressed and has been detected in the hippocampus, thalamus and 
certain areas of the forebrain (Meador-Woodruff et al., 1992).  The expression of D1 and 
D5 at both pre and post-synaptic locations has been demonstrated although the postsynaptic 
localisation is more prevalent (Levey et al., 1993).   The D2 receptor is found mainly in the 
striatum, in the olfactory tubule, and in the hypothalamus (Gurevich and Joyce, 1999; 
Jackson and Westlind-Danielsson, 1994). Co-localisation with the D1 receptor is rare.  
Compared with the D2 receptor, the D3 receptor is expressed in roughly 10-fold lower 
density.  The D3 receptor has a specific distribution within limbic areas such as the 
ventromedial shell of the nucleus accumbens, but low levels of expression have been 
observed in the hippocampus and in various cortical layers.  In the human brain it was 
demonstrated that D3 mRNA was often expressed in D2 mRNA positive neurons (Gurevich 
and Joyce, 1999; Landwehrmeyer et al., 1993).  High dopamine D4 expression has been 
demonstrated in the frontal cortex, amygdala, hippocampus, hypothalamus and 
mesencephalon.  In the periphery, it has been shown that all dopamine receptor subtypes 




 J. Robert Lane, 2007    Chapter 1  
47 
1.5.3  Functions of dopamine receptors in the brain 
 
The effects of dopamine on motor activity have been extensively investigated, and the 
activation of D1, D2 and D3 receptors has been implicated.  Activation of pre-synaptic D2 
autoreceptors decreases locomotor activity whereas post synaptic D2 receptor activation 
increases locomotor activity. Conversely, the D3 receptor seems to play a mainly inhibitory 
role in locomotor activity.  (Jackson and Westlind-Danielsson, 1994; Missale et al., 1998).  
Activation D1 receptors alone has been shown to have little effect on locomotor activity, 
but the concomitant activation of D1 and D2 receptors has been shown to be required for D2 
agonists to produce maximal locomotor stimulation.  The mesolimbocortical dopamine 
pathway is implicated in reward and reinforcement mechanisms demonstrated by the 
observation that administration of psycho-stimulants and drugs of abuse elict an increase in 
dopamine release in the mesolimbic areas.  Pharmacological studies show that both D1 and 
D2 receptors are involved in this pathway.  In the case of drug administration, it has been 
shown that both D1 and D2 receptors are involved in the reinforcing properties of different 
drugs of abuse, with D2 receptors mediating the stimulant drug reinforcement and D1 
receptors playing a permissive role.  The mesolimbic dopamine pathway also plays a role 
in learning and memory, again involving both D1 and D2 receptors (Missale et al., 1998). 
 
 
1.5.4  Dopamine and disease 
 
Parkinson’s disease is a neurodegenerative disorder with an insidious onset and a 
prolonged course over many years.  The primary cause of the symptoms of this illness is 
the death of dopamine-producing neurons of the substantia nigra and the resultant 
depletion of dopamine in the striatum (Hornykiewicz, 1998).  The therapeutic intervention J. Robert Lane, 2007    Chapter 1  
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for Parkinson’s disease is based on the assumption that activation of postsynaptically 
located dopamine receptors will provide some return of balance to the system. The 
preferred mode of treatment of the symptoms of this illness is with L-dopa, which is taken 
up by surviving dopamine neurons and converted to dopamine, which, in turn, can be 
stored and released.  Loss of dopamine leads to changes in expression levels for both D1 
and D2 receptors in the striatum and changes in dopamine-mediated activity.  However, for 
many patients significant loss of effectiveness in L-dopa treatment and inability and 
inability to reverse dementia or depression occurs after five or more years of treatment 
(Joyce, 2001).  Therefore dopamine agonists have an advantage over L-dopa treatment, 
since they will bypass the degenerating neurons and directly stimulate the intact, although 
denervated post synaptic receptors in the striatum.  Furthermore, agonists that target 
specific dopamine receptor subtypes may have more specific therapeutic effects and 
perhaps target certain clinical symptoms.  Within the basal ganglia D2 and D3 receptors and 
only extremely low levels of the D4 receptor are expressed indicating that stimulation of D2 
and D3 receptors prominently contributes to the antiparkinsonian effects of most of the 
compounds used (Gurevich and Joyce, 1999).  Indeed relief of Parkinsonian symptoms is 
most consistently observed with drugs that target with D2-like receptors (Joyce, 2001). 
 
The dopamine hypothesis of schizophrenia proposes that the symptoms result from 
disturbances in the normal dopaminergic transmission in the brain.  These abnormalities 
affect two of the main dopamine pathways in the brain – the mesolimbic pathway and the 
mesocortical pathway- producing changes in brain activity (Lieberman, 2004).  Increased 
dopaminergic transmission in the mesolimbic pathway is though to cause the positive or 
psychotic symptoms of schizophrenia, which include delusions and hallucinations.  
Reduced activity in the mesocortical pathway, which projects into the frontal cortex, 
produces hypodopaminergic activity in these regions.  This is believed to underlie the 
negative symptoms such as apathy, social withdrawal and poverty of thought.  Evidence J. Robert Lane, 2007    Chapter 1  
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for the key role of dopamine came initially from examining the effects of drugs that either 
stimulate or reduce dopaminergic activity.  Psychostimulant drugs that increase dopamine 
release, such as amphetamine, have been shown to induce psychosis in healthy individuals 
following repeated administration.   Similarly treatment with the dopamine precursor L-
dopa induces psychotic symptoms in a high proportion of patients with Parkinson’s 
disease.  Conversely, both typical and atypical antipsychotics, which are effective in 
treating psychosis show antagonistic activity at D2 receptors.  In fact there is a strong 
correlation between the clinical efficacy of typical antipsychotics and their binding affinity 
for the D2 receptor.  Furthermore, a number of studies have implicated the D3 receptor as 
being a potential target for antipsychotics (Joyce, 2001; Joyce and Millan, 2005).  All 
dopaminergic antagonists used in the treatment of schizophrenia demonstrate high affinity 
for the D3 receptor.  Interestingly, the atypical antipsychotic clozapine has 7-fold higher 
affinity for the D2 receptor as compared to the D3 receptor (Guo et al., 1998).  However, it 
has predominant actions through neurons expressing the D3 receptor.  Therefore occupancy 
of the D3 receptor by antipsychotics cannot be excluded as a target site for therapeutic 
intervention.  However, direct evidence for abnormal dopamine levels is less clear cut.   
For example, in vivo research using nuclear magnetic imaging has shown that patients with 
schizophrenia release more dopamine into synapses upon neuronal stimulation as 
compared to healthy individuals (Guillin et al., 2007).  Increased levels of both D2 and D3 
receptors have been detected in the caudate nucleus, putamen and nucleus accumbens, but 
this may be due to antipsychotic drug treatment.  In vivo imaging studies using positron 
emission tomography (PET) and single-photon emission tomography (SPECT) in patients 
with schizophrenia have also proved inconsistent.   Some studies reported increased D2 
receptor density in largely drug-naïve individuals with schizophrenia but others showed no 
differences between schizophrenia and control groups.  Although dopaminergic dysfuntion 
appears to play a key role in the pathophysiology of schizophrenia, it is increasingly J. Robert Lane, 2007    Chapter 1  
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1.5.5  Dopamine receptor structure 
 
Analysis of the primary structure of the cloned dopamine receptors revealed that they are 
indeed members of the seven transmembrane domain GPCR family (Jackson and 
Westlind-Danielsson, 1994; Missale et al., 1998).   The D2-like receptors possess moderate 
sequence homology with the D1 like receptors.  For example, the rat D1 and D2 receptors 
possess only 41% homology in transmembrane domains.  In contrast, the D3 receptor 
possesses 52 % homology with the D2 receptor, with 75% homology in the transmembrane 
domains (Gingrich and Caron, 1993; Jackson and Westlind-Danielsson, 1994; Missale et 
al., 1998).  The N-terminal region has a similar number of amino acids in all the receptor 
subtypes and carries a variable number of consensus N-glycosylation sites.  The D1 and D5 
receptors possess two such sites, one in the N-terminal and the other one in the second 
intracellular loop.  The D2 receptor has four potential glycosylation sites, the D3 has three 
and the D4 possesses only one.  The C-terminal region is about seven times longer for D1-
like receptors as compared to that of the D2-like receptors.  In both cases this region is rich 
in threonine and serine residues and contains a cysteine residue that is the site of 
palmitoylation and conserved in many GPCRs.  In the D1-like receptors this residue is 
located near the beginning of this region at end of TM VI. In the D2-like receptors the c-
terminus ends with this region.  Two cysteine residues in the 2
nd and 3
rd intracellular loops, 
which are conserved in all Class I GPCRs, have been suggested to form an intermolecular 
disulphide bridge to stabilise the receptor structure 
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D2-like receptors possess a long third intracellular loop, which is common to receptors 
interacting with the Gαi/o subfamily of G proteins to inhibit AC whereas the D1-like 
receptors are characterized by a short third loop as for many Gαs coupled receptors 
(Gingrich and Caron, 1993; Jackson and Westlind-Danielsson, 1994; Missale et al., 1998).   
The D2 receptor exists as two alternatively spliced isoforms differing in the insertion of a 
stretch of 29 amino acids in the third intracellular loop (D2s and D2l).  As described 
previously this region plays an important role in receptor/G protein coupling. 
 
Site directed mutagenesis and protein modelling have suggested that the agonist-binding 
site occurs within the hydrophobic TM domains (Kalani et al., 2004; Shi and Javitch, 
2002).  Highly conserved residues within these domains define a narrow binding pocket 
that probably corresponds to the agonist-binding site.  Important residues were predicted 
by computational modelling and confirmed by previous mutagenesis studies.  For the 
dopamine D2 receptor Asp
114 in TM III is an important residue.  The carboxyl group of the 
aspartate forms a tight salt bridge (2.6 Å) with the primary amino group of dopamine. This 
residue is conserved over all five human dopamine receptors, as well as in all human 
biogenic amine receptors. Mutation studies have implicated this residue in the direct 
binding of the dopamine to D2 (Kalani et al., 2004; Shi and Javitch, 2002). The residues 
Ser
193 and Ser
197 in TM V hydrogen-bond to the metahydroxyl and parahydroxyl groups, 
respectively, of the catechol ring of dopamine, playing an essential role in recognizing 
dopamine. These two residues are conserved over all five human dopamine receptors and 
have been shown to be involved in direct binding of ligand through mutation studies (Shi 
and Javitch, 2002). Ser
194 is also conserved over all five human dopamine receptors, and 
mutation studies indicate that it is involved in binding of the ligand.  Ser
194 might serve as 
an alternate to Ser
193 in hydrogen bonding to the metahydroxyl group of the catechol for 




118 (TM III), Phe
164 (TM IV), Phe
189, Val
190 (TM V), Trp




394 (TM VI) of the D2l receptor are thought to form a mostly hydrophobic 
pocket for dopamine (Kalani et al., 2004). It was shown that Trp
386 and Phe
390 of the 
conserved WXXFF motif in TM VI are within the 4.5-Å binding pocket, but Phe 
389 is 7.2 
Å away from dopamine.  Furthermore, it was proposed that the second extracellular loop 
has a critical role in contributing to the binding site for small molecular weight aminergic 
ligands, much in the same way as this loop dives down into the binding-site crevice and 
contacts retinal in rhodopsin (Shi and Javitch, 2004).  As for all Class I GPCRs the DRY 
motif proximal to TM III plays a crucial role in receptor activation. 
1.5.5.1  Dopamine receptor oligomerisation 
As described above the higher order organisation has been visualised by atomic force 
microscopy for mouse rhodopsin (Fotiadis et al., 2003).  A considerable amount of 
evidence points to other GPCRs existing as dimers or oligomers.  Accordingly, dopamine 
receptor oligomerisation has been demonstrated in a number of different studies, with 
examples of both homo-oligimerisation and hetero-oligomerisation.  Homo-
oligomerisation has been demonstrated for the D2 receptor, with evidence provided by 
ligand binding studies, (Vivo et al., 2006) cysteine cross-linking (Guo et al., 2005), and by 
visualisation of oligomeric complexes by Western blotting (Lee et al., 2003b).  
Furthermore, residues within TM IV were shown to be a key contact sites in this 
interaction (Guo et al., 2005; Javitch, 2004).  Furthermore, in the cysteine cross linking 
study it was shown that the susceptibility of substituted cysteine residues within TM IV to 
crosslinking was differentially altered
 by the presence of agonists and inverse agonists. The 
TM IV dimer
 interface in the inverse agonist-bound conformation was consistent
 with the 
dimer of the inactive form of rhodopsin modelled with
 constraints from atomic force 
microscopy. Crosslinking of a
 different set of cysteines in TM IV was slowed by inverse 
agonists
 and accelerated in the presence of agonists; crosslinking of
 the latter set locks the J. Robert Lane, 2007    Chapter 1  
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receptor in an active state. It was proposed that
 a conformational change at the TM IV 
dimer interface is part of
 the receptor activation mechanism (Guo et al., 2005).  Similarly 
the homo-oligomerisation of dopamine D1 receptors has been demonstrated (George et al., 
1998) as has that of the D3 receptor (Elmhurst et al., 2000).  As described above, all the 
dopamine receptor subtypes have an overlapping localisation of expression.  It is perhaps 
likely then that these highly homologous receptors will form heterodimers and accordingly  
D2/D3 dopamine receptor hetero-oligomers has been demonstrated in vitro (Scarselli et al., 
2001) as have D1/D2 dopamine receptor oligomers (Dziedzicka-Wasylewska et al., 2006).  
Dopamine receptors have also been shown to form hetero-dimers or oligomers with other 
GPCRs.  D2 receptors have been shown to form heterodimers with the CB1 cannabinoid 
receptor (Kearn et al., 2005), the A2A adenosine receptor (Canals et al., 2003) and the 
somatostatin receptor subtype SSTR5 (Rocheville et al., 2000).  Similarly, D1 has been 
shown to form heterodimers with the A1 adenosine receptor (Gines et al., 2000).  The 
functional consequences of these interactions, with particular focus on the signaling 
pathways of the D2-like receptors, will be discussed later. 
 
1.5.6  Dopamine receptor pharmacology 
As might be predicted from their sequence homology, the D1-like and D2-like dopamine 
receptors have pharmacological profiles that are distinct from each other.  However, the 
individual members within D1-like or D2-like receptor families have pharmacological 
profiles that are extremely similar (Missale et al., 1998).  The individual dopamine receptor 
subtypes, their principal signal transduction, and a list of selective antagonists and agonists 
are displayed in Table 1.3. 
The pharmacological profile of the D5 receptor is similar, yet distinct from that of the D1 
receptor.  The most consistent difference is represented by dopamine itself which has a 10 J. Robert Lane, 2007    Chapter 1  
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fold  higher affinity for the D5 receptor as compared to that of D1 (Missale et al., 1998).  
Analysis of the pharmacological profiles of the D2-like receptors shows that there are no 
compounds that discriminate between the short and the long variants of the D2 receptor, 
although a marginal difference in the affinities of sulpiride and raclopride for the two 
isoforms has been described (Malmberg et al., 1993).  The pharmacological profile of the 
D3 receptor reveals that some agonists and antagonists can distinguish it from the D2 
receptor.  Dopamine itself has a 20 times higher affinity at the D3 as compared to the D2 
receptor (Sokoloff et al., 1990).  With the use of chimeric D2/D3 receptors, this difference 
has been related to the third intracellular loop (Robinson et al., 1994).  Similarly, many 
agonists show a higher affinity for the D3 receptor as compared to the D2 receptor, 
although interestingly apomorphine does not.  The inverse agonist/antagonist spiperone 
shows a 10 fold higher affinity for the D2 receptor.  The antagonists S33084, nafadotride 
and (+)S14297 have all been shown to have selectivity at the D3 receptor (Millan et al., 
1994; Millan et al., 2000; Missale et al., 1998).  The pharmacological profile of the D4 
receptor closely resembles those of the D2 and D3 receptors, but specific differences have 
emerged.  The most important feature distinguishing the D4 from the D2 and D3 receptors is 
its high affinity for clozapine (Van Tol et al., 1991).  Conversely, the antagonist raclopride 
shows lower affinity at D4 receptor as compared to the D2 and D3. J. Robert Lane, 2007    Chapter 1  
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Table 1.3: The dopamine receptor subtypes, their principle signal transduction 
pathway, and pharmacological profiles 
The selectivity of these agonists is less than two orders of magnitude. [
3H] raclopride 
exhibits a similar high affinity for D2 and D3 receptors (low affinity for D4) but has been 
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1.5.7  Signal transduction of dopamine receptors  
1.5.7.1  Signal transduction of D1- like dopamine receptors 
 
It has been shown in a variety of cell lines that the D1 receptor robustly stimulates cAMP 
accumulation.  D5 has also been shown to be coupled to the stimulation of adenylate 
cyclase (Missale et al., 1998).  It is generally assumed that the activation of adenylate 
cyclase by D1-like receptors is mediated by the Gαs subunit of G proteins.  In the 
neostriatum, however, the brain region with the densest dopamine innervation and the 
highest expression of the D1 receptor, expression of Gαs is very low but expression of the 
highly homologous Gαolf is high (Corvol et al., 2001; Zhuang et al., 2000).  Gαolf null 
mutant mice exhibit little dopamine-stimulated adenylate cyclase and lack other functional 
and behavioural responses to D1 dopamine receptor stimulation, including cocaine of D1 
agonist-induced locomotor activation and induction of c-fos expression (Corvol et al., 
2001).   However,  there is evidence that D1 can also couple to Gαz and Gαo (Sidhu et al., 
1998).  The selective concentration of adenylate cyclase subtype V in the neostriatum 
suggested that it mediates dopamine receptor signalling, a hypothesis confirmed with the 
creation of adenylate cyclase V null mutant mice in which neostriatal D1 receptor-
stimulated cAMP accumulation is markedly diminished (Iwamoto et al., 2003).  The 
increase in intracellular cAMP mediated by the D1 receptor via Gαs/olf has been linked to 
the activation of protein kinase A (PKA) (Neve et al., 2004).   The PKA substrates that 
have been implicated in dopamine D1-like receptor mediated signalling include DARPP32 
(a bifunctional signalling protein that inhibits protein phosphatase 1 and PKA), ion 
channels (for example the inhibition of K
+ currents through several types of inwardly 
rectifying channels).  D1 like receptors modulate intracellular calcium levels by a variety of J. Robert Lane, 2007    Chapter 1  
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mechanisms; for example via the stimulation of PLC producing inositol 1,4,5 
trisphosphate, which mobilizes intracellular calcium stores (Neve et al., 2004).  
 
1.5.7.2  D2-like receptor signalling 
Dopamine D2-like receptor G protein coupling 
 
As mentioned above the D2 dopamine receptor family consists of two isoforms, the short 
form (D2s) and the long form, the D2l receptor, which are alternatively spliced transcripts of 
the same gene.  These isoforms differ only by the presence of an additional 29 amino acids 
and their expression is coincident in all tissues although the ratios differ between tissues 
(Missale et al., 1998).  Localization studies of the two isoforms demonstrated that the D2l 
receptor is strongly expressed in neurons of the striatum and nucleus accumbens, and that 
the D2S receptor is found in the cell bodies and axons of the mesencephalon and 
hypothalamus (Khan et al., 1998).  This suggests that the D2S receptor is predominantly a 
presynaptic auto receptor and that the D2l receptor is predominantly found post synaptically 
(Usiello et al., 2000).  It is therefore likely that the D2 isoforms have unique localisation 
and serve distinct functions.   
 
The G-protein coupling specificity of the D2s receptor and D2l receptor remains 
controversial.  A difference in coupling of these two receptors was initially suggested by 
pertussis toxin studies in JEG-3 cells (Montmayeur and Borrelli, 1991) and further study 
indicated that D2l interacts specifically with Gαi2 (Montmayeur et al., 1993).    A similar 
result was obtained by antisense ablation of αi2 and αo1 in GH4C1 cells stably transfected 
with one of the two receptor isoforms (Liu et al., 1994).  However, an experiment using the 
expression of PTX insensitive mutant Gαi1-3 subunits, again in GH4C1 cells, suggested that 
the D2s receptor signalled preferentially through the Cys
352Ile Gαi2 mutant whilst the D2l J. Robert Lane, 2007    Chapter 1  
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receptor signalled through the Cys
351Ile Gαi3 mutant (Senogles, 1994).  In transfected 
fibroblast cells, CCL1.3, D2l receptors were found to couple to Gαi2 and Gαi3 but not Gαo1 
or Gαi1 (O'Hara CM, 1996).  However, in transfected NS20Y neuroblastoma cells, D2l 
receptors coupled to Gαo1, but not to any other Gαi subunits (Watts et al., 1998).  Similarly, 
in AtT-20 cells, D2L coupled to Gαo1 and to Gα i3, whereas D2S coupled to both Gαo1 and 
Gαi2 (Wolfe and Morris, 1999).  In baculovirus-infected Sf9 cells co-transfected with D2S 
and either Gαi1 or Gαi2, D2S receptors were found to couple with higher efficacy to Gαi1 
than they did to Gαi2 (Grunewald et al., 1996).  Accumulating evidence from a number of 
studies now implicate Gαo1 as the subtype most robustly activated by D2l and D2S.  This is 
confirmed by a study showing D2-like receptors predominantly couple to Gαo1 in mouse 
brain (Jiang et al., 2001).  Studies using an array of agonists at both the D2l and D2S 
receptors showed that different agonists conferred differential G protein coupling.  It was 
concluded from this that the degree of selectivity of G-protein activation by the D2l 
receptor can depend of the conformation of the receptor stabilised by an agonist (Gazi et 
al., 2003).  
 
The regions flanking each extremity of the loop adjacent to transmembrane domains V and 
VI have been shown to be fundamental to the coupling of receptor with G proteins.   
However, the insert present in D2l does not affect these regions as it adds 29 amino acids at 
a position 31 residues C-terminal from transmembrane domain V.  Mutagenesis was used 
to assess the role of residues within the insert region.  Two mutants produced a modest 
change in coupling: in both cases it involved a negatively charged amino acid being 
substituted for a non-polar amino acid.  The D2l insert is predicted to have a helical 
structure, and it was postulated that these substitutions might modify this structure 
(Guiramand et al., 1995).  However, a more recent experiment substituted the insert region 
for a non-homologous region of identical length.  It was demonstrated that this epitope 
substitution generated a functional receptor with no difference in down-stream signalling J. Robert Lane, 2007    Chapter 1  
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as compared to the wild type D2l receptor (Kendall and Senogles, 2006).  Therefore this 
indicates that the alternatively spliced insert region, itself, does not appear to play a direct 
role in signal transduction.  Another study in HEK293 cells showed that two random point 
mutations of the D2S receptor changed the coupling specificity.  While the wild-type D2S 
receptor couples predominantly to Cys
352Ile Gαi2, the D2S receptor mutant Arg
233Gly 
couples preferentially to Cys
351Ile Gαi3 and the D2S receptor mutant Ala
234Tyr couples 
preferentially to Cys
351Ile Gαi1 (Senogles et al., 2004).  This underlies the importance of 
this region of the third cytoplasmic loop is crucial for determining Gαi/o protein coupling 
selectivity.   
 
The human D4 receptor is similar to D2 in that it activates multiple pertussis toxin-sensitive 
G proteins, including Gαi2, Gαi3, Gαo1 (Li-Xin Liu, 1999).  The rat D4 receptor has been 
reported to couple preferentially to Gαz and the transducin subtype Gαt2 (Yamaguchi et al., 
1997).  Although the D3 and D2 receptors show marked sequence homology and 
pharmacological similarity the D3 receptor was initially reported not to couple to G-
proteins as shown by the lack of a guanine nucleotide shift of agonist binding curves, and 
an inability to inhibit adenyl cyclase in cell lines (Sokoloff et al., 1990; Tang et al., 1994).  
However, more recently it has been shown that the D3 receptor does weakly inhibit 
adenylate cyclase in some cell lines (Chio et al., 1994; Freedman et al., 1994; Potenza et 
al., 1994), with one group showing selective inhibition of adenyl cyclase type V, but not 
types I or VI in HEK 293 cells (Robinson and Caron, 1997).  A subsequent study using 
[
35S] GTPγS binding to investigate the activation of G proteins coupled to D3 and D2 
receptors stably expressed in CHO cells found that antibodies against the c-terminus of 
Gαi/o reduced dopamine-induced G protein activation for both D3 and D2 membranes, 
whereas Gαs antibodies had no effect at either site.  In contrast, incubation with anti-
Gαq/α11 antibody did not affect dopamine-induced G protein activation at D2 receptor but 
attenuated D3-induced G protein activation.  This suggests that D3 receptors may couple to J. Robert Lane, 2007    Chapter 1  
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Gαq/α11 and would be consistent with the observation that pertussis toxin treatment, which 
inactivates only Gi/o proteins, only submaximally (80%) blocked dopamine-stimulated 
[
35S]GTPγS binding in CHO-D3 cells (Newman-Tancredi et al., 1999).  The efficient 
coupling of the dopamine D3 receptor to Gαo1 was demonstrated in SH-SY5Y cells but not 
HEK293 cells.  The abundance of this G protein subunit was demonstrated in both cell 
lines and it was postulated that the presence of adenylate subtype V was required for 
coupling of the dopamine D3 receptor to Gαo1 (Zaworski et al., 1999). 
 
Interestingly, the D3 receptor has been shown to bind agonists with a high affinity that is 
relatively insensitive to GTP (Neve et al., 2004).  The insensitivity of the D3 receptor to 
GTP could reflect GTP-resistant coupling to G proteins or a receptor structure that is 
constrained in a conformation with high affinity for agonists regardless of interactions with 
G proteins.  A study expressing the D3 receptor in E coli and, therefore, in the absence of 
endogenous G proteins with which the receptor can interact showed that agonist binding 
was minimally affected by G protein coupling, pointing to a constrained receptor structure 
(Vanhauwe et al., 2000). 
 
 
Investigations into the molecular basis of G protein coupling specificity using 
chimeric D2/D3 receptors 
 
Dopamine D2 and D3 receptors are highly homologous making them extremely suitable for 
investigations into the structural basis of G protein selectivity using chimeric receptors.  
An initial experiment showed that a chimeric dopamine receptor containing the third 
intracellular loop of the D2 receptor retained D3 like affinities for dopaminergic ligands but 
did not functionally couple to adenyl cyclase (McAllister et al., 1993).  However, a 
subsequent experiment showed that a chimeric D2 receptor containing the third J. Robert Lane, 2007    Chapter 1  
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intracellular loop of the D3 receptor exhibited lower affinity for agonists but did not 
investigate coupling specificity (Robinson and Caron, 1996).  A study using a D3 receptor 
with the third intracellular loop of the human D2 receptor showed that although the 
chimeric receptor retained D3 receptor binding, the receptor was negatively coupled to 
adenyl cyclase through a pertussis toxin sensitive pathway apparently mediated by the D2 
third intracellular loop.  This response was not seen for D3 receptors, and the inhibition 
seen with the chimera was less than that seen with the D2 receptor, implying that additional 
sequences in the D2 receptor contribute to normal G-protein coupling (Van Leeuwen et al., 
1995).  To determine which area of the D2 dopamine receptor’s third intracellular loop 
contributes to G-protein coupling, a study constructed reciprocal chimeric D2/D3 receptors 
with fusion points near the centre of the third intracellular loop.  Both of these chimeras 
were able to effectively inhibit adenyl cyclase activity to almost the same extent as that 
seen with the D2 receptor.   This implies that both the N and C-terminal portions of the D2 
receptor ICL 3 are capable of independently supporting functional Gi coupling although 
both may be required for maximal coupling.  However, in this study no inhibition of 
adenyl cyclase activity was seen in cells transfected with the D3 receptor (Lachowicz and 
Sibley, 1997).  Chimeras were constructed in which a twelve amino acid sequence located 
at the C-terminal portion of the third intracellular loop was exchanged between dopamine 
D2 and D3 receptors. Chimera constructions did not modify substantially the 
pharmacological profiles as compared to their respective wild-type receptors. However, the 
D2 receptor chimera, containing the C-terminal portion of the third intracellular loop of the 
D3 receptor, had a lower potency to inhibit cyclic AMP production. The reciprocal 
construction generated a D3 receptor that was fully coupled to this second messenger in 
Chinese hamster ovary (CHO) cells pathway, whereas the native D3 receptor was not. 
These results suggest that the sequence selected is important for specific coupling 
characteristics shown by these two dopamine receptor homologues (Filteau et al., 1999). 
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D2-like receptor downstream signalling 
 
The first signalling described pathway for the D2-like receptors was the inhibition of 
adenylate cyclase and therefore the inhibition of cAMP accumulation.  As for D1-like 
receptors, the genetic deletion of adenylate cyclase V abolishes D2 receptor mediated 
inhibition of adenylate cyclase in the mouse neostriatum.  This null mutation also 
eliminates the locomotor inhibitory effects of D2 receptor blocking anti-psychotic drugs, 
demonstrating the behavioural significance of this pathway (Lee et al., 2002).  Therefore, 
current experimental evidence favours a D2 ÆGαo1Æ adenylate cyclase V pathway.  As 
opposed to the effects of D1-like receptors, by decreasing the activity of adenylate cyclase 
and therefore the levels of intracellular cAMP, it is expected that D2 receptor stimulation 
decreases PKA activity (Neve et al., 2004).  For example, stimulation of D2-like 
autoreceptors reverses PKA-dependent phosphorylation of tyrosine hydroxylase at Ser
40, a 
phosphorylation event that activates the enzyme (Lew et al., 1999).  In addition to effects 
mediated by α subunits, many pathways modulated by D2-like receptor activation are 
mediated by βγ subunits released upon α subunit activation (Neve et al., 2004).  D2 
stimulation exerts a powerful influence over K
+ currents; indeed, D2 stimulation decreases 
cell excitability by increasing K
+ currents in most brain areas.  All of the D2-like receptors 
activate a G protein-regulated inwardly rectifying potassium channel (GIRK or Kir3), a 
channel that carries one of several potassium currents modulated by dopamine in midbrain 
dopamine neurones and neostriatal D2 receptor-expressing neurons with activation 
mediated by βγ subunits (Neve et al., 2004).  The D3 receptor was shown to be as efficient 
as D2l receptors at coupling to GIRK channels in the rat mesencephalon (Kuzhikandathil et 
al., 1998).  D2 and D4 receptors have been shown to co-precipitate with GIRK2 (Lavine et 
al., 2002).  It has been shown that dopamine release regulating D2 autoreceptors mediate 
their effect via GIRK channels rather that by inhibition of adenylate cyclase (Cass and J. Robert Lane, 2007    Chapter 1  
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Zahniser, 1991).  All D2-like receptors decrease the activity of L, N and P/Q type Ca
2+ 
channels via pertussis toxin-sensitive G proteins.  For example D2 receptors inhibit N-type 
C
2+ channels in a pathway involving βγ subunits (Hernandez-Lopez et al., 2000).  D2-
receptors have been shown to activate MAP kinases, including both isoforms of the 
extracellular signal-regulated kinase (ERK).  It has been demonstrated that the D3 mainly 
utilizes the βγ pathway associated with Gαi activation, which involves the transactivation 
of EGFR in HEK-293 cells. In contrast, the α subunit of the Gi heterotrimer plays a main 
role in D2-mediated ERK activation (Beom et al., 2004). This study indicated that 
dopaminergic neurons could regulate ERK activity more flexibly through alternative usage 
of either the D2 or D3 pathway depending on the cellular situation.  The stimulation of 
dopamine D1, D2, D5 but not D3 and D4 receptors has been shown to cause the robust 
translocation of β-arrestin to the plasma membrane (Cho et al., 2006; Kim et al., 2001).  
This suggests that desensitization of the D3 receptor is weakly associated with G protein-
coupled receptor kinase (GRK)/beta arrestin and indeed calveolin 1 directed interalisation.  
Further work from this same group showed that the D3 receptor undergoes robust protein 
kinase C (PKC)-dependent sequestration that is accompanied by receptor phosphorylation 
and the desensitisation of signaling D3.  Filamin A was shown was shown to be essential 
for both the efficient signaling and sequestration of the D3 receptor (Cho et al., 2007).  In 
another study focusing on the dopamine D3 presynaptic autoreceptor it has been suggested 
that the D3 receptor, filamin A and beta arrestin form a signaling complex that is 
destabilised by agonist- or expression based increases in GRK2/3 activity.  These findings 
suggest that the D3 receptor, filamin A and beta-arrestin from a signaling complex that is 
destabilised by agonist or expression-mediated increases in GRK2/3 activity (Kim et al., 
2005).  D2 receptors have been shown to activate a cytosolic, Gβγ stimulated form of 
phospholipase C (PLCβ1) resulting in reduced L type Ca
2+ currents (Kanterman et al., 
1991).  This pathway may contribute to D2 receptor mediated activation of both ERK and 
CREB in neostriatal neurons.  D2-like receptor activation in the neostriatum exerts variable J. Robert Lane, 2007    Chapter 1  
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effects on Na
+ channels via several intracellular signalling pathways, perhaps dependent on 
the subtype of D2-like receptor expressed by a given cell.  Heterologously expressed D2, D3 
and D4 receptors have been shown to activate the widely expressed Na
+/H
+ exchanger 
NHE1(Neve et al., 2004).  Glutaminergic neurotransmission is enhanced in D2 receptor 
null mutant mice, probably reflecting the loss of both presynaptic control of glutamate 
release and post-synaptic inhibition of glutaminergic responses by the D2 receptor (Cepeda 
et al., 2001).  One possible mechanism for this effect is that D2 stimulation results in 
changes in Na
+ and K
+ currents, resulting in cell hyperpolarisation and preventing the 
removal of the Mg




Dopamine receptor hetero-dimer/oligomerisation and consequences on cell signalling 
 
As discussed above, the D2-like dopamine receptor subtypes have been shown to form 
hetero-oligomeric complexes with other dopamine receptor subtypes and other GPCRs.  
The functional implications of these interactions will now be discussed.  For example, 
there is considerable evidence, both behavioural and functional, for interactions between 
brain dopamine and adenosine systems and between dopamine and somatostatin.  Receptor 
heterodimerisation is likely to be a molecular mechanism of these interactions (Agnati et 
al., 2003).  Interestingly the formation of a hetero-oligomeric complex between the D2 
dopamine receptor and the CB1 cannabinoid receptor results in a change in G protein 
coupling of the CB1 receptor, normally a Gαi/o coupled receptor.  In this case, D2 receptor 
activation, simultaneously with CB1 receptor stimulation, results in the receptor complex 
coupling to Gαs protein in preference to the expected Gαi/o proteins. The result of this 
interaction is an increase in the second messenger cAMP, reversing an initial synergistic 
inhibition of adenylate cyclase activity seen at sub-threshold concentrations of cannabinoid J. Robert Lane, 2007    Chapter 1  
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agonist (O'Dowd et al., 2005).  Scarselli et al. demonstrated that cells expressing D2 and D3
 
receptors exhibited 7-OH-DPAT-mediated reduction in adenylate cyclase VI activity
 far 
above that produced by wild type D2 receptors.  In cells transfected with D3 receptors 
alone, no
 detectable decrease in adenylate cyclase VI activity was observed in response
 to 
dopamine agonists. The formation
 of D2/D3 heterodimers may therefore give rise to novel 
receptors
 with unique pharmacological and physiological properties that
 are different from 
the activities produced by D2 or D3 receptors
 alone (Scarselli et al., 2001).  It is clear then 
that the formation of heterodimers/hetero-oligomers may have significant effects on the 
downstream signalling of dopamine receptors.  Consequently, dopamine receptor 
heterodimers may prove to be attractive targets for therapeutic intervention (Cepeda et al., 
1993).   
 
1.6  Project Aims 
The dopamine D2 and D3 receptors are highly homologous GPCRs, with a similar 
pharmacology and over-lapping expression.  They are also therapeutic targets for both the 
treatment of Parkinson’s disease and schizophrenia.  An understanding of their signalling 
pathways would therefore be beneficial to the treatment of these diseases.  Despite these 
similarities, the G protein coupling specificities of these two receptors seem to be markedly 
different.  The D2 receptor has been shown to couple to all members of the Gαi/o family of 
G proteins, although the order of preference remains controversial.  The promiscuity of the 
D2 receptor in coupling to all four Gαi/o subunits, plus the rich pharmacology of this 
receptor make it an ideal subject for an investigation of agonist-directed G protein 
coupling.  This then was the first aim of this study. 
 
The D3 receptor is also thought to couple to Gαi/o subunits, but with less efficiency.  
Several groups have described the selective coupling of D3 to Gαo1, with one group 
suggesting the presence of adenylate cyclase V is required for efficient coupling.   The J. Robert Lane, 2007    Chapter 1  
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second aim of this study, then, was to investigate the G protein coupling specificities of 
both the D2 and D3 receptors.  The high homology of these receptors makes them ideal for 
an investigation of receptor/G protein coupling specificity using chimeric receptors.  As 
described in this introduction, this approach has been used with these receptors 
extensively, and these studies have highlighted the third intracellular loop as being 
particularly important for the coupling of the D2 receptor to downstream effectors such as 
adenylate cyclase.  It was of interest then to investigate whether this region is important for 
the differential G protein signalling of the two receptors. 
 
In this introduction, I have described the G protein cycle, from the activation of a receptor 
by an agonist, the subsequent activation of and nucleotide exchange at its heterotrimeric G 
protein partner, the dissociation or rearrangement of the subunits with the heterotrimer and 
their coupling to their downstream effectors.  The structural changes that occur within both 
the receptor and G protein have also been described.  Functional assays which monitor 
receptor mediated G protein activation are integral to both basic research and the drug 
discovery process. Ligand-induced regulation of the binding of [
35S] GTPγS is a widely 
used technique that allows the direct measurement of receptor mediated nucleotide 
exchange at a G protein α subunit.  However, the cost and restrictions associated with the 
use of radiolabels makes this assay increasingly less attractive particularly for drug 
discovery.  The final aim of this project was to develop a viable alternative to this assay, 
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Figure 1.1: The G protein cycle 
The nature of the guanine nucleotide-bound Gα subunit controls the extent and temporal 
kinetics of G-protein signaling. Conversion of a G protein heterotrimer from the inactive, 
(GDP-bound), to active (GTP-bound) state is promoted by interaction with a guanine 
nucleotide exchange factor (GEF), the most common of which are members of the GPCR 
family. Subsequent conformational changes promote separation of the GTP- bound α-
subunit from the βγ complex, whereupon both elements of the G protein can regulate the 
activity of effector proteins that include second messenger generating enzymes and ion 
channels (see Table 1.1 for details). The intrinsic GTPase activity of the G protein α-
subunit hydrolyses the terminal phosphate of bound GTP and terminates function. This 
activity is accelerated by GTPase-activating proteins, the largest family of which are the 
regulators of G protein signaling (RGS) proteins. Reassociation of Gα-GDP with the βγ 
complex terminates effector regulation by the βγ-subunits (Table 1.1) and completes the 
cycle. Further interaction with a GEF is now required to reinitiate the cycle (Milligan and 
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Figure 1.2:  The structure of G protein-coupled receptors (GPCRs) 
A schematic diagram of a G protein-coupled receptor (GPCR) is shown (A), illustrating the 
extracellular N-terminal domain, the seven transmembrane domains (TM I-VII, red to 
blue) linked by alternating intracellular (ICL1-3) and extracellular (ECL 1-3) loops and the 
intracellular domain including helix VIII.  The ribbon model of dark (inactive) rhodopsin 
(B) (1U19) shows the orientation of TMI-VII and 11-cis-retinal (grey spheres).  Conserved 
side-chains important for G protein coupling are illustrated (magenta), including the 
E(D)RY motif adjacent to TM III (yellow) and NpxxYx5F motif on TM VII and VIII (blue 
and violet).  The extracellular (C) and intracellular (D) faces of rhodopsin are shown.  
Receptor activation results in an outward movement of TM VI (yellow arrow), which 
opens a gap in the cytoplasmic face of the receptor, exposing residues critical for G protein 
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Figure 1.3:  Classification and diversity of GPCRs 
 
Three main families (I (A), II (B) and III (C)) can be easily recognized when comparing 
their amino-acid sequences. Receptors from different families share no sequence similarity, 
suggesting a remarkable example of molecular convergence. Family I (A) contains most 
GPCRs including receptors for: small ligands, where the binding site is localized within the 
seven TMs; for peptides whose binding site includes the N-terminal, the extracellular loops 
and the superior parts of TMs; for glycoprotein hormones where the binding site is mostly 
extracellular but at least with contact with extracellular loops 1 and 3.  Family II (B) 
GPCRs have a similar morphology to family I GPCRs, but they do not share any sequence 
homology. Their ligands include high molecular weight hormones such as glucagon, 
secretin, VIP-PACAP and the Black widow spider toxin.  Family III (C) contains 
glutamate receptors (mGluRs) and the Ca
2+ sensing receptors. The ligand binding domain 
for family III GPCRs is located in the amino terminus, which is often described as being 
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Figure 1.4: Structure of the G protein heterotrimer 
 
(A) Sequence alignment of the N- and C- terminal regions of selected Gα-subunits. 
Residues that are subject to N-linked myristoylation, thio-palmitoylation or N-linked 
palmitoylation are highlighted in orange, green and yellow, respectively. In each case, M 
(black) is the protein synthesis initiator, methionine, which is eliminated during protein 
synthesis. Residues comprising the N-terminal αN helix are highlighted in red and residues 
at the extreme C-terminus of Gα are shown in blue. The αN helix is required for binding 
βγ-subunits, and particular βγ contacts are boxed in black, the extreme C-terminus plays a 
key role in specific receptor recognition. In the secondary structure diagram below the 
aligned sequences, βγ and receptor interaction sites are highlighted in red and blue, 
respectively. Only selected domains of Gα are shown, and for simplicity the domains 
between αA and the α2 helix have been omitted as indicated by the dotted line (Milligan 
and Kostenis, 2006).  (B) The Ribbon model of Gαi(GDP)β1γ1 heterotrimer (1GOT), where 
α is blue, β is green and γ is gold. The three Switch regions in Gα are highlighted in 
yellow. GDP (red) is buried between the GTPase and helical domains of Gα. (C) The 
subunits have been rotated to show the intersubunit interface, which is primarily composed 
of the αN-helix (truncated in this view) and Switch II on Gα and blades 1–3 on Gα. (D) 
When the GDP-bound (1TAG), GTPγS-bound (1TND) and heterotrimeric (1GOT) 
structures of Gα are aligned, significant conformational differences are found in the three 
Switch regions (compare gray and colored backbone). The crystal structures indicate that, 
upon GTP binding (green backbone), the three Switch regions collapse toward the c-
phosphate of GTP. The Gα(GDP) conformation is likely a short-lived transition state in 
vivo due to the large hydrophobic surface presented by this conformation of the Switch 
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Figure 1.5: GPCR-G protein fusion proteins 
Physical linkage of the N-terminal of a G-protein α-subunit to the C-terminal tail of a 
GPCR from which the stop codon has been removed allows expression of a single 
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Figure 1.6: Proposed mechanisms of GDP release 
 
Two models have been proposed in which the activated receptor may use Gβγ to catalyze 
GDP release. In the lever-arm hypothesis (A), the receptor uses the αN-helix as a lever to 
pull Gβγ away from Gα (1), thereby prying Switch II away from the nucleotide-binding 
pocket (2) and causing GDP release (3). The alternative gear-shift model (B) requires that 
the receptor push Gβγ closer to Gα (1). This allows the N-terminus of Gγ to engage the 
helical domain (2), thus forcing the binding pocket open due to the reorientation of the two 
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2  Materials and Methods 
 
2.1  Materials 
2.1.1  General Reagents, enzymes and kits 
 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
Rainbow Markers 
 
BDH, Lutterworth, Leicestershire, UK 
22mm coverslips, microscope slides, sodium di-hydrogen orthophosphate, potassium 
hydroxide, potassium chloride, methanol, isopropanol 
 
Duchefa. Haarlem, The Netherlands 
Yeast extract, tryptone, agar 
 
Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK 
Glycine, HEPES, sucrose, SDS, potassium di-hydrogen orthophosphate, calcium chloride, 
manganese chloride 
 
Invitrogen BV, Gronigen, The Netherlands 
NuPage Novex pre-cast 8-12 % Bis-tris gels, MOPS running buffer 
 
Konica Europe, Hohenbrunn, Germany 
X-ray film 




Pierce, Perbio Science UK Ltd, Tattenhall, Cheshire, UK 
Supersignal West Pico chemiluminescent substrate 
 
Promega UK Ltd., Southampton, UK 
All restriction endonucleases, T4 DNA ligase, Pfu polymerase, Wizard Plus SV minipreps 
 
Qiagen, Crawley, West Sussex, UK 
QiaQuik PCR purification kit, QiaQuik gel extraction kit, Qiafilter maxiprep kit. 
 
Roche Diagnostics Ltd., Lewes, East Sussex, UK 
Complete EDTA free protease inhibitor tablets, 1Kb DNA ladder, Shrimp Alkaline 
Phosphatase 
 
Sigma-Aldrich Company Ltd., Poole Dorset, UK 
Magnesium chloride, sodium chloride, sodium hydroxide, sodium acetate, DTT, di-sodium 
orthophosphate, tris base, EDTA, bromophenol blue, Hoescht stain, rubidium chloride, 
Triton X-100, DMSO glycerol, tween 20, ethylene glycerol, formaldehyde, ampicillin, 
kanamycin, sodium azide, pertussis toxin 
 
Semat International, Hatfield, UK 
GF/C glass filters 
 
Thermoelctron, Ulm, Germany 
Oligonucleotides 
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2.1.2  Pharmacological compounds 
 
Sigma, Poole, Dorset, UK 
(+)-butaclamol, dopamine, (-)-quinpirole, m-tyramine, p-tyramine, S-(-)-3-(3-
hydroxyphenyl)-N-propylpiperidine (S-(-)-PPP), R-(+)-3-PPP, R-(-)-10,11-dihydroxy-N-n-
propylnorapomorphine (NPA), R(+)-7-Hydroxy-DPAT hydrobromide (7-OH-DPAT)  
 
Tocris, Bristol, UK 
Spiperone Hydrochloride  
 
2.1.3  Radiochemicals 
 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
[
3H]Spiperone (65-140 Ci/mmol)  
 
PerkinElmer Life and Analytical Sciences, Boston, MA   
[
35S]GTPγS
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2.1.4  Tissue Culture  
American Tissue Culture Collection, Rockville, USA 
HEK293T cells 
 
Costar, Cambridge, M.A., USA 
5 mL, 10 mL, and 25 mL pipettes, 75 cm
   and 125 cm




Invitrogen BV / Gibco, Groningen, The Netherlands 
Lipofectamine transfection reagent, Optimem-1, L-glutamine (200 mM), Flp-In T-Rex-293 
cell line, Zeocin, Blasticidin, dialysed Fetal Bovine Serum, Penicillin-Streptomycin, 
DMEM (+L-glutamine, - pyruvate)  
 
Qiagen, Crawley, West Sussex, UK 
Effectene transfection reagent 
 
Roche Diagnostics Ltd., Lewes, East Sussex, UK 
Hygromycin B 
 
Sigma-Aldrich CompanyLtd., Poole, Dorset, UK 
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2.1.5  Antisera 
 
Cambridge Research Biochemicals (CRB) Ltd., Billingham, Cleveland, UK 
Antisera were raised against peptides based on the C-terminal 10 amino acids of Gαi1/2, 
Gαq ,Gαs and were characterised in house. 
 
Applied Biosystems, Foster City, USA 
FMAT Blue® GAM (Goat anti-Mouse IgG) Conjugate, FMAT Blue® GAM (Goat anti-
Rabbit IgG) Conjugate 
 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
Sheep anti-mouse IgG-HRP conjugate, donkey anti-rabbit IgG-HRP conjugate 
 
Molecular Probes, Eugene, Oregon, USA 
Anti-mouse Alexa ® 594 IgG conjugate, antimouse Alexa  ® 594 igG conjugate 
 
 
2.2  Buffers and Reagents 
 
2.2.1  Buffers and Reagents for molecular biology 
 
LB medium (Luria-Bertani Medium) 
Bacto-tyrptone 10 g 
Bacto-yeast extract 5 g 
NaCl 10 g J. Robert Lane, 2007    Chapter 2  
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Dissolved in 950 ml of distilled H2O, pH adjusted to 7.0 with 5 M NaOH.  Volume 
adjested to 1 L with distilled H2O and sterilized by autoclaving for 20 mins at 15 lbs/sq.in. 
 
 
LB media (Luria-Betrani Medium) containing agar (LBA) 
Was made as above except for the addition of 15 g/L of bacto-agar prior to autoclaving. 
 
Ethidium Bromide (10 mg/ml) 
1 g of ethidium bromide was added to 100 ml of H20 and left stirring for several hours.  
Container was wrapped in magnesium foil and stored at room temperature. 
 
Tris acetate (TAE) (50 x) 
242 g Tris base, 57.1 ml glacial acetic acid, 100 ml 0.5 M EDTA (pH8.0). This was made 
up to a final volume of one litre with distilled H20. 10 ml of this stock was diluted in 490 
ml of H20 as required to make 1x buffer. 
 
Solution 1 for preparation of competent Bacteria 
1 M Potassium acetate, 1 M RbCl2, 1 M CaCl2, 1 M MnCl2, 80 % (w/v) glycerol 
Final volume is made up with de-ionised water and pH adjusted to 5.8 with 100 mM 
Acetic acid.  The solution is filter sterilised by passage through a 0.22 micron filter and 
stored at 4 ºC.    
 
Solution 2 for preparation of competent bacteria 
100 mM MOPS pH 6.5, 1 M CaCl2, 1 M RbCl2, 80% (w/v) glycerol 
Final volume is made up with de-ionised water and pH adjusted to 6.5 with 100 mM 
concentrated HCl.  The solution is filter sterilised by passage through a 0.22 micron filter 
and stored at 4 ºC.    J. Robert Lane, 2007    Chapter 2  
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Gel loading buffer 
0.25 % bromophenol blue, 40 % sucrose (w/v) dissolved in distilled H2O 
 
2.2.2  Buffers and Reagents for biochemical assays 
 
Tris-EDTA buffer (TE) 
10 mM Tris Base, 0.1 mM EDTA dissolved in distilled H2O, pH 7.4 
 
Tris-EDTA-Magnesium chloride buffer (TEM) 
50 mM Tris base, 1 mM EDTA, 12.5 mM MgCl2 dissolved in distilled H2O, pH7.4 
 
Phosphate Buffered Saline (PBS)  
140 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4, pH 7.4 
 
STE buffer 
10mM Tris-HCl, 150 mM NaCl, 1mM EDTA, pH 8.0 
 
GTPγS filtration / SPA assay buffer 
20 mM HEPES, 100 mM NaCl, 6 mM MgCl2, 40µM ascorbic acid pH 7.4 
 
GTPγS immunoprecipitation Assay buffer (10 x) 
200 mM Hepes, 30 mM MgCl2, 1 M NaCl, 2 mM Ascorbic acid pH 7.4 
 
GTPγS immunoprecipitation assay – solubisation buffer 
100 mM Tris, 200 mM NaCl, 1 mM EDTA, 1.25 % NP40, pH7.4 J. Robert Lane, 2007    Chapter 2  
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GTPγS immunoprecipitation Assay- bead suspension buffer 
BSA (2 %), 0.1 % NaN3 in distilled H2O 
 
 
Laemmli Buffer (2x) 
0.4 M DTT, 0.17 M SDS, 50 mM Tris, 5 M urea, 0.01 % (w/v) bromophenol blue 
 
2.3  Molecular Biology 
2.3.1  LB plates 
LBA was made as detailed above. After autoclaving, medium was allowed to cool to 50ºC 
before addition of a thermolabile antibiotic to the following final concentrations; ampicillin 
(100 µg/ml), kanamycin (50 µg/ml).  Plates (10 cm Petri dishes) could then be poured 
directly from the flask, using about 25 ml of liquid per dish.  Any air bubbles were 
removed by flaming the surface of the medium with a Bunsen burner before the agar has 
hardened.  Once hardened, plates were inverted and stored at 4 ºC   
 
2.3.2  Preparation of competent bacteria 
E coli strain XL1 Blue was used for all transformation procedures.  A sample of XL1 Blue 
was taken via stabbing with a sterile pipette tip.  This was streaked out onto a minimal agar 
plate and incubated at 37 ºC overnight.  A single colony was selected and used to inoculate 
a 5 ml LB culture, which was grown for 16 hours at 37ºC in a rotary shaker.  Next day this 
culture was used to inoculate 100 ml of L-Broth and grown until the optical density at 550 
nM is 0.48 - approximately 90 minutes of incubation.  After chilling on ice for 5 min the 
cells were spun at 1811 x g for 10 minutes at 4ºC in 50 ml sterile falcon tube.  Each pellet J. Robert Lane, 2007    Chapter 2  
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was re-suspended in 20 ml of solution 1 by gentle pipetting, then chilled on ice for 5 
minutes and spun as before.  Each pellet was then resuspended in 2 ml of buffer 2 by 
gentle pipetting and chilled on ice for a further 15 minutes.  Cells were then aliquoted in 
220 µl volumes and stored at -80 ºC until required.  
2.3.3  Transformation of competent cell with plasmid DNA 
220 µl aliquots of competent XL1 Blue were taken from -80 ºC storage and thawed on ice. 
Using a sterile pipette tip 50-100 ng of plasmid DNA in a volume of 2 µl was added to a 
sterile 15 ml falcon tube containing 50 µl of competent bacteria.  Tubes were left on ice for 
30 minutes.  The tubes were then transferred to a water bath, which had been preheated to 
42 ºC and heat shocked for 60 seconds.  Tubes were immediately transferred to ice and 
allowed to chill for 5 minutes before 450 µl of LB was added to each tube. Cultures were 
incubated for 60 minutes at 37 ºC in a rotary shaker.  200 µl of each culture was spread on 
a LB Agar plate with appropriate antibiotic.  Plates were inverted and left to incubate at 37 
ºC for 16 hours.  Transformed colonies were selected and cultured overnight at 37 °C in 5 
ml LB containing appropriate antibiotic. 
 
2.3.4  Preparation of plasmid DNA 
2.3.4.1  Miniprep 
Plasmid cDNA was prepared using the Promega WizardTM Plus SV miniprep purification 
system.  A 5 ml culture of transformed cells was grown overnight at 37 °C as described 
above.  1.5 ml of the culture was spun at 15,600 x g and the pellet resusupended in 250 µl 
of resuspension buffer (50 mM Tris-HCL pH 7.5, 10mM EDTA, 100 µg/ml RNase) 
followed by lysis with 250 µl of lysis solution (0.2 M NaOH, 1% SDS).  The resulting 
lysate was neutralised with 205 µl of neutralisation solution (4.09 M guanidine J. Robert Lane, 2007    Chapter 2  
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hydrochloride, 0.76 M potassium acetate, 2.12 M glacial acetic acid, pH 4.2) to precipitate 
any unwanted chromosomal DNA.  This was removed by centrifugation (15,600 x g for 10 
minutes) and the resulting supernatant was transferred to a DNA purification column wash 
solution (60 mM potassium acetate, 10mM Tris-HCl pH 7.5, 60 % ethanol).  Finally, the 
cDNA was eluted from the column with 50µl of sterile water. 
2.3.4.2  Maxiprep 
To achieve a larger scale of purified DNA the Qiagen Plasmid Maxi system was used. This 
was performed according to the manufacturer's instruction; refer to Qiagen purification 
handbook (Qiagen, 1999).  Briefly, a single colony was picked from a plate of transformed 
bacteria and used to inoculate a starter culture of 5 ml LB containing appropriate selective 
antibiotic.  This was incubated for 8-9 hours in a rotary shaker at 37 ºC.  The entire starter 
culture was used to inoculate a 200 ml LB culture in a conical flask containing appropriate 
antibiotics.  This was grown at 37 ºC for 12-16 hours with vigorous shaking.  Bacterial 
cells were harvested by centrifugation at 3468 x g using a Beckman JA-14 rotor for 15 
minutes at 4 ºC.  The bacterial pellet was resuspended in 10 ml of chilled buffer P1 (50 
mM Tris-HCl pH 8.0, 10 mM EDTA, 100 µg/ml RNAse A) and lysed with 10 ml of 
chilled buffer P2 (200mM NaOH, 1 % SDS).  The lysate was neutralised with 10 ml of 
cooled buffer P3 (3.0 M potassium acetate pH 5.5).  The sample was then spun at 3220 x g 
for 30 minutes at 4ºC.  During this spin the Qiagen-tip 500 column was equilibrated with 
10 ml of buffer QBT (750mM NaCl, 50 mM MOPS pH 7.0, 15% isopropanol).  The 
supernatant was poured into the column, the column washed with 60 ml of buffer QC (1.0 
NaCl, 50 mM MOPS pH 7.0, 15% isopropanol) and the DNA eluted from the column with 
15 ml of buffer QF (1.25 M NaCl, 50 mM Tris-HCl pH 8.5, 15 % isopropanol).  The DNA 
was precipitated by adding 10.5 ml of isopropanol and the mixture spun at 27216 x g for 
30 min at 4ºC.  The resulting pellet was washed with 5 ml of 70% ethanol and then allowed 
to air dry.  Finally the DNA was re-dissolved in 05.-1.0 ml of sterile water. J. Robert Lane, 2007    Chapter 2  
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2.3.5  Quantification of DNA 
This was determined by spectrophotomeric measurement of the amount of ultraviolet 
radiation absorbed by DNA bases.  In routine DNA measurements the stock DNA was 
diluted by a factor of 100 in sterile distilled H2O.  The absorbance unit being equal to 50 
ug/ml of double stranded DNA (Maniatis et al., 1982).  The sample concentration could 
then be determined using the following formula. 
 
Sample concentration = OD260 x dilution factor (100) x 50ug/ml 
 
The purity of the sample was then determined by measuring the absorbance at 280nm, the 
ratio 
OD260/OD280 provided an estimate of purity with a value of 1.8 representing a pure 
preparation.  Typically, DNA samples gave a ration in the range 1.6-2.0.  This was 
adequate for all the procedures for which their use was required. 
 
2.3.6  Digestion of DNA with restriction endonucleases 
For all restriction endonucleases used, one unit of restriction endonuclease activity was 
capable of completely digesting 1ug of DNA in 60 minutes at the appropriate temperature.  
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Plasmid DNA  1 µg (1ul of 1ug/µl) 
Restriction enzyme  1 µl of each 
10X buffer (determined by restriction enzymes used)  2 µl 
Sterile distilled dH20 x  µl 
Final Volume  20 µl 
 
The reaction was then incubated at 37 ºC in a water bath for 3-24 hours.   All enzymes 
required an incubation temperature of 37 ºC unless otherwise stated by the manufacturer. 
 
2.3.7  Elecrophoresis of agarose gels 
Digested DNA fragments were separated and analysed using agarose gel eletrophoresis.  A 
1% agarose gel was prepared using 1 x TAE buffer and 0.6 µg/ml ethidium into a 
horizontal gel tank (Life technologies, Gibco, Horizon 58 model).  After the gel has set 
completely, enough 1 x TAE buffer was then added to cover the gel to a depth of 5 mm.  
DNA samples were mixed with a one sixth volume of gel loading buffer and loaded into 
the slots of the submerged gel.  A voltage of 100 mA was applied across the gel.  DNA 
bands stained with ethidium bromide could then be viewed by ultraviolet light, and 
photographed using an UV transilluminator.  
 
2.3.8  Purification of DNA from agarose gels 
DNA bands of interest were located using an UV transilluminator and were excised from 
the agarose gel with a sterile disposable scalpel blade.  Excised gel fragments were 
transferred to a sterile Eppendorf tube.  Recovery and purification of the fragments was 
achieved by using the QIAquick gel extraction kit.  Excised DNA fragments were 
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loaded onto a QIAquick purification column, washed with an ethanol based wash solution 
(PE) and finally the DNA eluted from the column with sterile water. 
 
2.3.9  Dephosphorylation of Vector DNA 
Once plasmid DNA had been digested by restriction endonucleases it was then 
dephosphorylated to prevent re-ligation of vector DNA during the ligation reaction.  This 
was performed using Shimp Alkaline Phosphatase (SAP) (Roche), following the 
manufacturers protocol. A typical reaction is outlined below 
To inactivate restriction endonucleases the sample was heated at 65 º C for 15 min.  The 
following reaction mix was then set up:  
 
Digested vector DNA   20 µl 
Phosphatase buffer 10X  5 µl 
SAP 6  µl 
Sterile dH20 19  µl  
Final Volume  50 µl 
 
This mix was incubated at 37 ºC for 1 hour.  Heating the sample at 65 ºC for 15 min then 
inactivated the enzyme. 
 
2.3.10  Ligation of DNA fragments 
Once plasmid DNA and PCR fragments had been digested and purified via the methods 
described above, the amount of DNA present in the samples was determined by ethidium 
bromide fluorescent quantification.  Ligation of digested PCR fragments to the digested 
vector DNA was achieved using a T4 DNA ligase kit (Promega).  For ligations with sticky 




Vector DNA  x µl 
Insert DNA  x µl 
T4 DNA Ligase  1 µl 
10 x ligase buffer  1 µl 
Sterile dH20  x µl 
Final Volume  10 µl 
 
Approximately 200 ng of vector DNA was used per reaction. A vector to insert ratio of 1:3 
was typically used, and multiple insert fragments could be used in a given ligation reaction.  
The reaction was left for 3 hours at room temperature or overnight at 4 ºC and then 3 µl 
transformed into competent bacteria.  
 
 
2.3.11  Polymerase Chain Reaction 
PCR reactions were established in a volume of 50 µl containing 10ng of template DNA, 
0.2 mM dNTPs (dATP, dCTP, dGTP, dTTP) 25 pmol of sense and anti-sense 
oligonucleotide primers, 1 x Pfu polymerase buffer and 1 unit of Pfu polymerase enzyme.  
Reactions were carried out on an Eppendorf gradient Thermocycler.  PCR cycles used 
were: 
 
Denaturation Annealing    Extension  Cycles 
95 ºC , 1 min  50-60 ºC, 1 min  72 ºC , 2 min  30 
95 ºC , 1 min  50-60 ºC, 1 min  72 ºC, 10 min  1 
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2.3.12  PCR for Mutagenesis (introduction of mutations using 
QuikChange site directed mutagenesis kit) 
Point mutations were introduced using QuikChange kit (Stratagen) according to the 
manufacturer's instructions 
 
2.3.12.1  Design of Primers 
Primers had a length of between 25 to 45 bases, a melting temperature Tm greater than or 
equal to 78ºC and a minimum GC content of 40%.   
2.3.12.2  PCR 
The following reaction mixes were made: 
 
DNA template  1 µl  2.5 µl  5 µl  7.5 µl 
  (20 ng)  (50 ng)  (100 ng)  (150 ng) 
Forward primer (125 ng/ µl)  1 µl  1 µl  1 µl  1 µl 
Reverse primer (125 ng/ µl)  1 µl  1 µl  1 µl  1 µl 
Pfu DNA polymerase  1 µl  1 µl  1 µl  1 µl 
Pfu buffer (10x)  5 µl  5 µl  5 µl  5 µl 
dNTPs  1 µl  1 µl  1 µl  1 µl 
Dimethylsulphoxide (DMSO)  1 µl  1 µl  1 µl  1 µl 
Deionised H2O  39 µl  37.5 µl  35 µl  32.5 µl 
Total Volume  50 µl  50 µl  50 µl  50 µl 
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Primers were heated to 95 ºC for 2 minutes using a heating block before addition to 
reaction to reduce secondary structure.  The reactions were carried out in a thermoycler 
with the following steps: 
 
Rapid thermal ramp to 95 ºC  
Hold at 95 ºC for 3 minutes 
 
These conditions were used for 1 cycle 
 
Hold at 95 ºC for 30 seconds 
Cool to 55 ºC  
Hold at 55 ºC for 1 minute  
Rapid thermal ramp to 68 ºC  
Hold at 68 ºC for 24 minutes 
 
These conditions were used for 18 cycles 
 
Following this 1 µl of the restriction endonuclease Dpn I was added to each reaction and 
the tube incubated at 37 ºC for 3 hours.  This step was carried out to digest the methylated 
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2.4  Generation of Dopamine receptor constructs 
2.4.1  Dopamine Receptor subcloning into pcDNA3 
2.4.1.1  D2 Dopamine receptor subcloning into pcDNA3  
cDNA of the long isoform of the human D2 dopamine receptor (D2l) was obtained from A. 
Wise (GSK, Harlow, UK) in the vector pDEST12.2.  D2l cDNA was amplified by PCR 
using the following primers:  
 
sense;     5’ AAA AGA ATC CGC CAC CAT GGA TCC ACT GAA TCT GTC C 3’  
antisense;   5’ AAA ACT CGA GTC AGC AGT GGA GGA TCT TCA GGA AGG 3’   
 
Underlined bases indicate the restriction sites EcoRI (sense) and XhoI (antisense).  The 
resulting PCR fragment was digested with EcoRI and XhoI and inserted into pcDNA3. 
 
2.4.1.2  D3 and chimeric D3/2 Dopamine receptor subcloning into pcDNA3 
cDNA of the human D3 dopamine receptor and the chimeric D3/2 dopamine receptor was 
obtained from A. Wise (GSK, Harlow, UK) in the vectors pRC and pcDNA3.1 
respectively.  The two cDNAs were amplified by PCR using the following primers: 
 
Sense;    5’CCC AAG CTT ATG GCA TCT CTG AGT CAG CTG 3’ 
Antisense;   5’ AAA AAA AAC CAT GGA AGA CAG GAT CTT GAG GAA GGC 3’ 
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Underlined bases indicate the restriction sites HindIII (sense) and Xho I (antisense).  The 
resulting PCR fragment was digested with HindIII and Xho I and inserted into pcDNA3. 
 
2.4.2  Construction of the Myc-Dopamine Receptor: G-protein α 
subunit fusion proteins 
Pertussis toxin-resistant a2A-adrenoceptor–G-protein fusion proteins had been prepared as 
described previously (Wise and Milligan, 1997).  Briefly, Cys
351 of rat Gα i1, i2, i3, o1 was 
mutated to isoleucine by site-directed mutagenesis and then used to create the α2A-
adrenoceptor–Gα fusion proteins using the porcine a2A-adrenoceptor in pcDNA3 as 
described by Wise and Milligan.  These constructs were cloned into pcDNA3 using a 
created 5’ Kpn I site and 3’ EcoR1 site with a Nco I site in between receptor and G-protein 
a subunit cDNAs.   
 
2.4.2.1  Nco I site removal from D2l by mutagenesis 
To create D2l:G protein α subunit proteins, the first step was to remove the Nco I site from 
within the D2l cDNA by site directed mutagenesis using a QuikChange Mutagenesis kit 
(Stratagene,
 La Jolla, CA) and the following primers:  
 
Sense;    5'-CC GAC CCG TCC CAT CAT GGT CTC CAC AG -3';  
Antisense; 
 5'-CT GTG GAG ACC ATG ATG GGA CGG GTC GG -3'.
  
 
Bold letters indicate altered bases. The PCR product was then
 digested with Dpn I and 
transformed into bacteria.   
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2.4.2.2  Nco I site removal from Gαo1 and Gαi1 by mutagenesis 
In a similar manner Nco I sites were removed from both the Gαi1 and Gαo1 cDNAs in the 
respective a2A-adrenoceptor–Gα fusion protein cDNAs using the following primers:  
 
Gαi1: 
Sense;    5'-TT GCC ATC ATT AGA GCG ATG GGG AGA TTG AAA ATC G -3';  
antisense;   5'-C GAT TTT CAA TCT CCC CAT CGC TCT AAT GAT GGC AA -3',  
 
Gαo1:  
Sense;    5'-CC ATT GTG CGG GCG ATG GAT ACT CTG GG -3';  
Antisense;   5'-CC CAG AGT ATC CAT CGC CCG CAC AAT GG -3'.   
 
2.4.2.3  Myc-D2l (Nco I -) 
Primers encoding the Myc epitope sequence were used to generate N-terminally tagged 
Myc-D2l and remove the stop codon:  
 
Sense;  5'- AGA ACG GGG TAC CTT ATG GAA CAA CAA AAA CTT ATT TCT 
GAA GAA GAT CTG GAT CCA CTG AAT CTG TCC TGG TAT GAT G -3'  
Antisense;   5'-AA AAA AAA CCAT GGA GTG GAG GAT CTT CAG GAAGGC -3'.   
 
Underlined bases indicate introduced restriction sites (sense: Kpn I, antisense; Nco I), bases 
in bold indicate introduced N-terminal Myc tag.  The PCR fragment was digested using 
Kpn I and Nco I. 
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2.4.2.4  Myc –D3 / D3/2  
Primers encoding the Myc epitope sequence were used to generate N-terminally tagged 
Myc-D3 and Myc-D3/2 and remove the stop codon: 
 
Sense;   5’-AAA AAA AG GTA CCA TGG AAC AAA AAC TTA TTT CTG 
AAG AAG ATC TGG CAT CTC TGA GTC AGC TGA GTA GC-3’ 
 
Antisense;   5’ –AAA AAA AAC CAT GGA AGA CAG GAT CTT GAG GAA GGC – 
3’ 
 
Underlined bases indicate introduced restriction sites (sense: Kpn I, antisense; Nco I), bases 
in bold indicate introduced N-terminal Myc tag.  The PCR fragment was digested using 
Kpn I and Nco I. 
 
2.4.2.5  Construction of D2l:G protein fusion proteins 
 
The α2A-adrenoceptor–Gα fusion proteins (Nco I-) were excised from pcDNA3 using Kpn I 
and EcoR1, digested with Nco I, and the Gα subunit cDNA purified.  The Gαi subunit 
cDNAs were then cloned into pcDNA3 with the Myc-D2l Nco I (-) PCR fragment to create 
the four D2l Dopamine Receptor:G-protein α subunit fusion proteins. 
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2.4.2.6  Construction of D3:G protein fusion proteins and D3/2 subunit cDNA 
fusion proteins 
 
As for D2l, Gαi subunit cDNAs were purified and cloned into pcDNA3 with the Myc-D3 or 
Myc-D3/2 PCR fragment to create four D3 receptor: G protein α subunit fusion proteins and 
four chimeric D3/2 recptor: G protein α subunit fusion proteins. 
 
 
2.4.3  Construction of Myc-D2l-YFP fusion protein 
2.4.3.1  Myc-D2l 
Primers encoding the Myc epitope sequence were used to generate N-terminally tagged 
Myc-D2l and remove the stop codon: 
 
Sense 5’-ACA GAC CCA AGC TTA TGG AAC AAA AAC TTA TTT CTG AAG 
AAG ATC TGG ATC CAC TGA ATC TGT CCT GG-3’ 
 
Antisense 5' 5' CGG GGT ACC GCA GTG GAG GAT CTT CAG GAA 3' 
 
Underlined bases indicate introduced restriction sites (sense: Hind III, antisense; Kpn I), 
bases in bold indicate introduced N-terminal Myc tag.  The PCR fragment was digested 
using Hind III and KpnI.   
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2.4.3.2  eYFP 
eYFP cDNA was obtained from Clontech (USA).  Primers were used to amplify eYFP 
cDNA with the desired 5' and 3' restriction sites 
 
Sense: 5' CGG GGT ACC ATG GTG AGC AAG GGC GAG GAG 3'   
Antisense: 5' TTT TCC TTT TGC GGC CGC TTA CTC GAT GTT GTG GCG GAT 3'  
 
Underlines bases indicate introduced restriction sites (sense; Kpn I ; antisense Not I).  The 
PCR fragment was digested using Kpn I and Not I. 
 
2.4.3.3  Generation of D2l:eYFP fusion 
pcDNA3 was digested using the restriction endonucleases Hind III and Not I and the Myc-
D2l and eYFP PCR fragments ligated into the sites. 
 
2.5  G protein α subunit constructs 
 
2.5.1  Generation of G protein mutants 
2.5.1.1  Gαi1 L
204Q mutation 
Human Gαi1 Q
204L CDNA in the plasmid pcDNA3.1 was obtained from UMR cDNA 
Resource Center, (University of Missouri-Rolla,Rolla, USA).  To change L
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wild type human Gαi1 cDNA a QuikChange Mutagenesis kit was used as described above 
using the following primers. 
Sense:    5’-TTT GAT GTG GGA GGT CAG AGA TCT GAG CGG AAG-3’ 
Antisense:   5’-CTT CCG CTC AGA TCT CTG ACC TCC CAC ATC AAA-3’ 
Bases in bold indicate changed bases. 
 




203A and give a constitutively inactive human Gαi1 mutant cDNA a 
QuickChange Mutagenesis kit was used as described above using the following primers 
and the wild type human Gαi1 in pcDNA3.1 as a template: 
 
Sense; 5’ CAT TTT AAA ATG TTT GAT GTG GGA GCT CAG AGA TCT CGG 3’ 
Antisense; 5’ CCG AGA TCT CTG AGC TCC CAC ATC AAA CAT TTT AAA ATG 
Bases in bold indicate changed bases. 
 
2.5.1.3  Construction of G-protein alpha subunit / Fc fragment fusions 
Constitutively active and inactive mutant Gαi1 cDNA was cloned into the vector αFcMCS 
to give a G protein α subunit: Fc fragment fusion protein cDNA. Gαi1 mutant cDNA was 
amplified using the following primers, removing a stop codon and inserting the relevant 5' 
and 3' restriction sites: 
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Sense:    5’ AAAA AAG CTT ATG GCC TGC ACG CTG AGC 
Antisense:   3’ AAG GAA AAA AGC GGC CGC AAA GAG ACC ACA ATC TTT 
TAG ATT 
 
Underlined bases indicate restriction sites (sense, Hind III; antisense: Not I) 
PCR fragments were digested with Hind III and Not I and cloned into αFcMCS which had 
been digested with the above restriction endonucleases.  
 
2.6  Expression of Gαi family G-proteins in E Coli 
cDNAs for all of four rat Gαi family members (Gαi1, 2 ,3 , o1) were previously subcloned into 
the prokaryotic expression vector pT7.7 and then transformed into the E coli strain BL21 
DE3. (work performed in house by A. Wise)  This is a strain of bacteria suitable for the 
expression of genes in the vector pT7.7.   Glycerols of these transformed bacteria were 
stored at -80 ºC until required.    A scrape of the required glycerol was taken using a sterile 
pipette tip and cultured to a 5 ml scale for 16 hours at 37 ºC in LB containing 100 µg/ml 
ampicillin.  2.5 ml of each of these 5 ml cultures were transformed into 2 x 100ml LB 
containing 100 µg/ml ampicillin and grown at 37 ºC until an absorbance of 0.4 at 550 nm 
has been reached.  One of the two cultures was then induced with 1mM IPTG and both 
cultures incubated at 30 ºC for a further 4 hours.  Cells were then harvested by 
centrifugation at 4000 rpm for 30 minutes at 3220 x g, supernatant discarded and pellets 
frozen at -80 ºC.  Cell pellets were thawed and resuspended in 20 ml STE buffer.  Cells 
were lysed with two passes through a French press set at 950 PSI.  Cell lysates were 
cleared by centrifugation at 10000 x g for fifteen minutes and the supernatant removed and 
kept on ice.  Protein concentration was determined using a BCA assay and lysates stored in 
1 ml aliquots at –80 ºC. 
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2.7  Cell culture 
 
2.7.1  Routine cell culture 
 
For cell growth sterile pipettes and flasks were used for all manipulation, and all tissue 
culture work was carried out in a sterile flow cabinet.  To initiate growth of a specific cell 
line, cells were brought up from liquid nitrogen storage and the aliquot was thawed rapidly 
at 37 ºC.   To remove DMSO the entire aliquot (1 mL) was then added to a sterile 15 ml 
falcon tube, 10 ml of appropriate growth media (prewarmed to 37 ºC ) added and tube spun 
at 180 x g for 5 minutes.  Supernatant was removed and cells resuspended in 10 ml of 
appropriate media and transferred to a 75 cm
2 flask. 
 
2.7.2  Cell subculture 
 
Typically cells were grown to approximately 80-100% confluency before being 
subcultured into new flasks using the following procedure.  Media was removed, 2 ml of 
trypsin solution added and flask incubated at 37 ºC for 3 minutes.  Cells were detached by 
administering a sharp slap to the side of the flask.  8 ml of appropriate media containing 
serum was added to halt the enzymatic action of trypsin.  Cells were then spun at 180 x g at 
room temperature to pellet cells.  The supernatant was discarded and cells resuspended in 5 
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2.7.3  Coating of coverslips and 24 well plates with poly-D-lysine 
 
Coverslips were prepared by washing in 70 % ethanol, then washing several times with 
dH20 and then autoclaving in a sealed container.  Coverslips were placed into the wells of a 
six well dish using sterile forceps, working in a flow cabinet.  2 ml poly-D-lysine (1 mg/ml 
in sterile dH20) was added to each well, removed, and the procedure repeated.  The coated 
plates were allowed to dry for 30 minutes in flow cabinet and then sealed and stored at 4 
ºC until required. 
 
2.7.4  Transient transfection using lipofectamine  
 
Transfections using lipofectamine were performed as per the manufacturer’s instructions.  
Briefly, cells were grown to approximately 60-80 % confluency before transfection.  4-10 
µg of DNA at a concentration of 0.1µg/µl in sterile water was used for each 10 cm dish. 
The amount of DNA and lipofectamine used was dependent on the number of 10 cm dishes 
being transfected.  Lipofectamine was diluted with optimem in a 1:30 ratio.  DNA was also 
diluted with optimem to the same given volume.  A typical transfection mix for one 10 cm 
dish is detailed below: 
    Tube  1   Tube  2 
DNA     40-80  µl 
Optimem-1    520-560  µl 580  µl 
LipofectamineTM   -   20  µl 
 
The DNA-optimem and Lipofectamine-Optimem mixtures were combined and left to 
complex at room temperature for 30 minutes.  Cells to be transfected had growth media 
removed and to ensure no traces of serum remained; 6 ml optimem was added to the dish.  J. Robert Lane, 2007    Chapter 2  
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This was left for 20 minutes at 37 ºC and then removed.  The Optimem / Lipofectamine / 
DNA mix was then diluted to an appropriate volume (6 ml total volume per 10 cm dish) 
and then added to the monolayer of cells.  This was returned to the incubator for 4 hours, 
before the transfection reagents were removed and replaced with an appropriate volume of 
growth media.  Cells were then allowed a further 48 hours of growth before harvesting for 
assays. 
 
2.7.5  Transfections using Effectene® for immunocytochemistry 
experiments 
 
Effectene ® (Qiagen,) was used according to the manufacturer’s instructions.  When 
confluent, HEK293T cells were split in a 1:40 ratio and 2 ml was transferred into each well 
of 6 well plates containing coverslips. cDNA was diluted to 0.1 µg/µl.  For each 6 well 
plate the following mix was used:  
 
0.5 µg (5 µl) of Gα cDNA + 0.3 µg (3 µl) D2l YFP cDNA  =  0.80µg (8 µl) total 
 
The final DNA mix was diluted with buffer EC to a total volume of 100 µl * no. of 6 well 
plate wells.  Enhancer ( 8 µl enhancer per 1 µg of total DNA for each transfection) was 
added.  This was incubated at room temperature for 2-4 min.  10 µl Effectene reagent was 
added to the DNA-enhancer mixtures and mixed by pipetting up and down 5 times.  
Samples were incubated at room temperature for 5-10 min to allow transfection complex 
formation.   Fresh growth medium (1.6 ml) was added to each well.   Growth medium (600 
µl x no. of wells) was added to the tube containing the transfection complexes.  This was 
mixed by pipetting up and down twice, and then immediately added to the cell monolayers.  
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2.7.6  Generation and maintenance of Flp-In T-REx cell lines 
inducibly expressing pertussis toxin insensitive G protein α subunits. 
 
Prior to transfection cells were maintained in Dulbecco’s modified Eagle’s medium 
without sodium pyruvate, 4500 mg/liter glucose, and L-glutamine supplemented with 10% 
(v/v) fetal calf serum, 1% antibiotic mixture, 15 µg/ml blasticidin and Zeocin (100 µg/ml 
final) at 37 °C in a humidified atmosphere of air/CO2 (19:1).  One day prior to transfection 
media was removed and replace with media without zeocin or blasticidin (basal media).  
To
 generate Flp-In T-REx HEK293 cells able to inducibly express
 the G protein α subunit 
of interest, the cells were transfected with a
 mixture containing the pOG44 and desired G –
protein α subunit cDNA in the pcDNA5/FRT/TO
 vector in a ratio of 9:1 to give a total of 5 
µg DNA per 10 cm dish.  Transfections were performed using lipofectamine as described 
above and basal media was used to stop the transfection.  24 hours after transfection cells 
were split in a ratio of 1:20.  48 hours after transfection the medium was changed to 
medium supplemented with 15 µg/ml blasticidin and 100 µg/ml hygromycin (selective 
medium) to initiate selection of stably transfected cells.  Selective media was replaced 
every 4 days until foci could be identified.  The entire polyclonal population was then 
pooled and screened for tetracycline regulated gene expression.  Cells were plated in 
selective medium and expression of gene of interest induced by adding 1 µg/ml 
tetracycline.  Expression of relevant G protein was tested using Western Blotting. 
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2.7.7  Generation and maintenance double cell lines stably 
expressing Dopamine receptor and expressing pertussis toxin insensitive 
G protein α subunits from the inducible Flp-In locus 
 
To constitutively stably co-express the D2L receptor in Flp-In T-REx HEK293 cells able to 
inducibly express
 the G protein α subunit of interest, the appropriate cells were
 further 
transfected with the receptor cDNA in pcDNA3
 using lipofectamine
TM
 as described above, 
and resistant cells were selected in the
 presence of 1 mg/ml G418. Resistant clones were 
picked, cultured, and screened for
 receptor expression using [
3H] Spiperone saturation 
binding and G-protein expression using Western blotting. 
 
2.7.8  Induction of inducible gene of interest in Flp-In T-REx cells 
Cells were grown in serum free media for 24 hours prior to induction.   Typically 
expression of gene of interest was induced with 1 µg /µl tetracycline 48 hours prior to cell 
harvest.  
 
2.7.9  Pertussis Toxin Treatment 
The ADP-ribosylation of a C-terminal cysteine for all Gαi subunits is catalysed by 
Pertussis toxin (from Bordella Pertussis), preventing functional interaction between 
receptor and G protein and thus blocking receptor activation of the G protein.  Cells were 
treated with 25 ng/ml pertussis toxin in appropriate growth media and incubated at 37 ºC 
16 hours prior to cell harvesting.  
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2.7.10  Cell harvesting 
Cells were washed 3 times with ice cold PBS, before resuspension in ice cold PBS and 
centrifugation at 450 x g.  Supernatant was discarded and the resultant cell pellet was 
frozen at - 80ºC until required. 
 
2.7.11  Preparation of cell membranes 
 
Cells were harvested as above, frozen at −80°C for at least 1 hour and resuspended in 15 
ml of TE buffer (10mM Tris, 0.1mM EDTA, pH7.4). Cell suspensions were then 
homogenised using an Ultra Turrax for 3 x 20 s. The homogenate was centrifuged at 
1700×g for 10 min and the supernatant was collected and centrifuged at 48 000×g for 45 
min at 4°C. The resulting pellet was resuspended in TE buffer and stored at −80°C in 
aliquots of 1ml. The protein concentration was determined by BCA protein quantification 
assay as described below. 
 
2.8  Protein Biochemistry 
 
2.8.1  BCA protein quantification assay 
 
To determine the protein concentration in cell lysates bicinchonic acid (BCA) and copper 
sulphate solutions were used.  Proteins reduce Cu(II) ions to Cu(I) in a concentration 
dependent manner.  BCA is a highly specific chromogenic reagent for Cu(I) forming a 
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proportional to the protein concentration.  The protein concentration was determined using 
known concentrations of BSA solutions as standard (0.2-2 mg/ml) 
 
 One part reagent B was added to 49 parts reagent A.  200 µl of this solution was added to 
10 µl of each protein sample/standard in a 96 well plate.  The absorbance was read after 
incubation at 37 ºC for 30 min. 
 
2.8.2  Preparation of samples for SDS gel electrophoresis 
 
Cell membranes were prepared as above, diluted to a 1 mg/ml protein concentration in TE 
buffer and then mixed 1:1 with Laemmli buffer and heated for 5 minutes at 85 ºC before 
loading onto SDS-PAGE gels. 
 
2.8.3   SDS polyacrylamide gel electrophoresis (SDS PAGE) 
Samples were prepared as above and resolved on NuPAGE ® Novex precast bis-tris gels 
(invitrogen).  The NuPage ® system is based upon a bis-tris HCl buffered (pH 6.4) 
polyacrylamide gel, containing a separating gel that operates at pH 7.0.  Gels with a 
polyacrylamide concentration of 4-12% achieved the best separation of the proteins of 
interest and were used exclusively.  To run the gels NuPage ® MOPS SDS running buffer 
was used.  The gels were run at 200 V in the Xcell Sureblock
TM mini-cell  
 
2.8.4  Western blotting 
Following SDS-PAGE the proteins were electrophorectically transferred onto a 
nitrocellulose membrane at 30 V for 90 minutes in transfer buffer (0.2 M glycine, 25mM 
Tris, 20% (v/v) methanol) using the Xcell II
TM blot module (Invitrogen).  The membranes J. Robert Lane, 2007    Chapter 2  
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were blocked with 5% (w/v) fat free milk in PBS/ 0.2% (v/v) Tween 20 for 2 hours at 
room temperature or 16 hours at 4 ºC.  The membranes were then incubated with the 
appropriate primary antibody in 5% (w/v) fat free milk PBS / 0.2% (v/v) Tween 20 
overnight at 4 º C or 2 hours at room temperature.  After removing the primary antibody 
and washing the membrane 4 times for 5 minutes each with PBS/ PBS / 0.2% (v/v) Tween 
20, the blots were treated with the appropriate HRP-conjugated secondary antibody in 
blocking buffer for 1 hour at room temperature.  After repeating the washing step, the 
reactive proteins were visualised by enhanced chemiluminescence and exposure onto 
photosensitive film.  For western blot analysis the following antibody dilutions were used 
unless specified otherwise: 
 
Primary Antibodies; 
Antigen Raised Against  Antibody  Dilution 
C-terminal 10 amino acids of Gαi1,2   SG3 1:2500 
 1319  G  1:2500 
C –terminal 10 amino acids of Gαi3  I3D 1:2500 
C –terminal 10 amino acids of Gαo1 OC2  1:5000 
C-terminal 10 amino acids of Gαq  CQ5 1:5000 




HRP conjugated donkey α mouse  1:10,000 
HRP conjugated donkey α mouse  1:10,000 
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2.9  Pharmacological Assays 
2.9.1  Radioligand binding  
2.9.1.1  Saturation binding assays using [
3H]-spiperone 
Cell membranes (10 µg protein) were incubated in triplicate with [
3H]-spiperone (0.001–2 
nM) in a total volume of 1 ml buffer (20 mM HEPES, 6 mM MgCl2, 1 mM EDTA, 1 mM 
EGTA, pH 7.4). Non-specific binding was determined by the inclusion of 10 µM (+)-
butaclamol. The reaction was initiated by the addition of membranes and the tubes were 
incubated at 25 °C for 3 hours. The reaction was terminated by rapid filtration using a 
Brandel cell harvester with three 5 ml washes of ice-cold PBS (140 mM NaCl, 10 mM 
KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4). The filters were soaked in 3 ml scintillation fluid 
and radioactivity present was determined by liquid scintillation spectrometry. 
2.9.1.2  Agonist competition versus [
3H]-spiperone binding 
Cell membranes (10 µg protein) were incubated with 0.05 nM [
3H]-spiperone and various 
concentrations of dopamine, in triplicate, in a final volume of 1 ml buffer (20 mM HEPES, 
6 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 40µM ascorbic acid, pH 7.4). Non-specific 
binding was determined by the inclusion of 10 µM (+)-butaclamol. The reactions were 
initiated, incubated and terminated as described above. The effect of guanine nucleotides 
on dopamine binding was assessed by the addition of 100 mM NaCl and 100 µM GTP to 
the buffer. 
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2.9.2  [
35S] GTPγS binding assays 
2.9.2.1  [
35S] GTPγS binding assay with termination by filtration 
Cell membranes (10 µg) were incubated in 900 µl buffer (20 mM HEPES, 100 mM NaCl, 
6 mM MgCl2, 40µM ascorbic acid pH 7.4) containing 10 µM GDP and various 
concentrations of agonist. All experiments were performed in triplicate. The reaction was 
initiated by the addition of cell membranes and incubated at 30 °C for 30 min. A 100 µl 
volume of [
35S]-GTPγS (0.1 nM final concentration) was then added and the incubation 
continued for a further 30 min. The reaction was terminated by rapid filtration with a 
Brandel cell harvester and three 4 ml washes with ice-cold PBS. Radioactivity was 
determined as described for saturation analysis.  For antagonist dose-response assays an 
‘EC50’ concentration of dopamine was added along with various concentrations of 
antagonist. 
2.9.2.2  [
35S] GTPγS binding assay with immunoprecipitation step 
[
35S]GTPγS-binding experiments were initiated by the addition of cell membranes 
containing 10 fMol of the various fusion constructs to an assay buffer (20 mM Hepes 
(pH 7.4), 3 mM MgCl2, 100 nM NaCl, 10 µM GDP, 0.2 mM ascorbic acid, 50 nCi of 
[
35S]GTPγS) in the presence or absence of dopamine. Non-specific binding was 
determined in the same conditions but with the addition of 100 µM GTPγS. Reactions were 
incubated for 30 min at 30 °C and were terminated by the addition of 0.5 ml of ice-cold 
buffer, containing 20 mM Hepes (pH 7.4), 3 mM MgCl2 and 100 mM NaCl. The samples 
were centrifuged at 16000 g for 15 min at 4 °C, and the resulting pellets were resuspended 
in solubilisation buffer (100 mM Tris, 200 mM NaCl, 1 mM EDTA, 1.25% Nonidet P-40) 
plus 0.2% SDS. Samples were precleared with Pansorbin, followed by J. Robert Lane, 2007    Chapter 2  
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immunoprecipitation with relevant antiserum. Finally, the immunocomplexes were washed 
twice with solubilisation buffer, and bound [




35S] GTPγS binding assay – scintillation proximity assay 
[
35S]GTPγS binding assays were performed at room temperature in 384-well format.  
 
Membranes (10 µg/point) were diluted to 0.4 mg/ml in assay buffer
 (20 mM HEPES, 
100 mM NaCl, 10 mM MgCl2, pH 7.4) supplemented with
 saponin (10 mg/l) and 
preincubated with 10 µM GDP and wheat germ agglutinin SPA beads (Amersham
 
Biosciences) (0.5 mg) and incubated at room temperature for 45 min with agitation. 
Various concentrations
 of D2 dopamine receptor agonists were added, followed by
 
[
35S]GTPγS (1170 Ci/mmol; Amersham Biosciences) at 0.3 nM (total
 volume of 46 µl), 
and binding was allowed to proceed at room
 temperature for four hours.  Bound 
[
35S]GTPγS was determined by scintillation counting on a ViewLux ultraHTS Microplate 
Imager (PerkinElmer). 
 
2.9.3  Data analysis 
Data were analysed using the computer program GraphPad Prism (GraphPad Software). 
[
3H]Spiperone saturation binding curves were fitted best by a one binding site model from 
which the Bmax (receptor expression level) and Kd (dissociation constant for [
3H]spiperone) 
were derived. Data from competition experiments were fitted to two binding site and one 
binding site models, and the best fit was determined using an F-test.  Concentration–
response curves for agonist and inverse agonist effects on [
35S]GTPγS binding were 
analysed by non-linear least squares regression analysis using a sigmoidal concentration / J. Robert Lane, 2007    Chapter 2  
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response relationship with a Hill coefficient of 1 and EC50 and Emax (maximum effect) 
values were derived from this analysis. 
 
2.10    Antibody Generation and Characterisation Protocols 
2.10.1  Immunisation, hybridoma generation, tissue culture and 
antibody purification 
Plasmid immunisation, rapid immunisation using recombinant Gαi1, hybridoma generation 
and maintenance and antibody purification was all performed by I. Kinghorn (Antibody 
Technology Group, BioPharm and Protein Technology, Bioreagents & assay development, 
GlaxoSmithKline, Stevenage, UK) 
 
2.10.1.1  Immunisation  
A myristoylated preparation of recombinant rat Gαi1-subunit (25 µg) was purchased from 
calbiochem (Merck KGaA, Darmstadt, Germany) this was incubated at RT ºC  with 100 
µM GTPγS in a buffer containing 100 mM NaCl, 20 mM HEPES, 3 mM MgCl2, 1 mM 
EDTA, 200 nM GDP, pH 8.0 for 30 minutes (Performed by B. Powney, Screening  & 
Compound Profiling, GSK, UK) .  Repetitive Immunisation at Multiple Sites (RIMMS) 
immunisations were carried out using a procedure simplified from (Bynum et al., 1999). 
Over a period of 11 days, 10µg protein (rGi1 + 10µM GTPγS) emulsified in Complete 
Freunds adjuvant and RIBI adjuvants (Sigma) were injected at 6 subcutaneous sites 
proximal to draining lymph nodes in 2 anaesthetised female SJL mice (Harlan, UK). After 
6 and 11 days, mice were immunised with 5 µg protein in RIBI adjuvant at 4 sites. Three 
days after the final boosts, a cell suspension harvested from popliteal, superficial inguinal, 
axillary and barachial lymph nodes was prepared.  In a similar manner plasmid J. Robert Lane, 2007    Chapter 2  
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immunisations were performed with gold particles coated with cDNA of Glu
204Leu Gαi1, 
cloned into the vector αFcMCS using a gene gun.  As described in section 2.5.1.3, the stop 
codon of the Glu
204Leu Gαi1 gene was removed and therefore upon cloning into the 
multiple cloning site of αFcMCS, the cDNA of a Glu
204Leu Gαi1 human Fc fragment 
fusion protein was generated.    
2.10.1.2  Cell Fusion 
Lymph node cells were centrifuged with myeloma cells (P3X63/Ag8.653, Kearney) and 
fused using PEG1500 (Roche). The cell pellet following the fusion procedure was 
resuspended in JRH610 containing 10% hybridoma cloning factor (Sigma), 10% FCS 
(Hyclone), pen/strep, 1 x HAT (InVitrogen) and 1.35% methycellulose (Sigma 4000cps). 
The fusion suspension was distributed between 5 Nunc omnitrays 4 Genetix Petriwell 
plates for selection and cloning in a single step. After 10-11 days culture, colonies were 
imaged and picked using an automated robotic colony picker (Genetix ClonepixFL, ). 
Individual monoclonal hybridoma colonies (1632) were deposited into Greiner 96 well 
plates containing 200 µl/well of the above medium without methylcellulose and 1 x HT in 
place of HAT. 
 
2.10.2  ELISA assay 
0.05 M carbonate-bicarbonate pH 9.6 buffer was made by adding 1 x carbonate-
bicarbonate buffer capsule (Sigma) to 100ml of dH2O.  An antigen solution of the 
appropriate concentration was made using this buffer.  200 µl of this solution was added to 
each well of a 96 well microtitre plate, and the plate incubated for 16 hours at 4 ºC.  The 
antigen solution was then removed and the plate washed three times in PBS / 0.1% (v/v) 
Tween 20.  To minimise non-specific binding a blocking step was included where 200 µl 
PBS / 5% BSA was added to each well and incubated at room temperature for 1 hour, after J. Robert Lane, 2007    Chapter 2  
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which washing was repeated as above.  Primary antibodies were diluted in PBS / 0.1% 
(v/v) Tween 20 in a ratio of 1:3 sequentially to give a range of concentrations.  200 µl of 
the diluted antibody was added to each well, and plates incubated at 4 ºC overnight.  The 
negative control in all cases was a species matched, non specific immunoglobulin diluted 
in PBS / 0.1% (v/v) tween 20.  Plates were then washed as above and the appropriate HRP 
conjugated secondary antibody added at a dilution of 1:1000 in PBS / 0.2 % Tween 20 and 
plates incubated for 1 hour at room temperature and then washed as above.  100 µl of 
SureBlue
TM TMB HRP substrate per well (KPL, Gaithersburg, USA) was then added.  
Reaction was stopped by addition of 100 µl of 1N HCl, and plates read at a wavelength of 
450 nm 
 
2.10.3  FMAT assay for screening of hybridoma clones  
2.10.3.1  Cell culture and transfection 
HEK293T cells were grown to 80-90% confluency in 225 cm
3 tissue culture flasks in 
DMEM +10% dialysed FCS (25 ml tissue culture media / flask).  Transfections were 
performed using an in-house transfection reagent ‘Gemini (GSC103 DOPE)’ (GSK, 
Stevenage, UK).  For each flask the following transfection mixtures were set up: 
85 µg DNA     +   12.25 ml Optimem 
250 µl Gemini   +   12.25 ml Optimem 
These two mixtures were combined and allowed to complex for 30 minutes at room 
temperature.  The entire complex was then added to the flask of cells and mixed with the 
25 mL of tissue culture media.  Transfected cells were left at 37 ºC in a humidified 
atmosphere of air / CO2 (19:1) for 48 hours prior to cell harvest.  Cells were then washed J. Robert Lane, 2007    Chapter 2  
117 
once with 50 mL PBS / flask, and then harvested in 10 mL PBS-dissociation buffer / flask.  
Cells were pelleted by centrifugation at 450 x g.  Supernatant was discarded and the 
resultant cell pellet was either resuspended in PBS / 1% BSA / 0.1% NaN3 for immediate 
use in an FMAT assay, or resuspended in 10% DMSO / FBS and stored at -80 ºC in 1 mL 
aliquots until required. 
2.10.3.2  Thawing of frozen cell aliquots 
Frozen cell aliquots were thawed rapidly in a 37 ºC water bath and washed once with PBS 
(4 ºC) as described in section 2.10.2.2. The supernatant was discarded and the pellet was 
resuspended in PBS / 1% BSA / 0.1% NaN3. 
2.10.4  General FMAT assay protocol 
Prior to use in the FMAT assay, the number of viable cells present in the PBS /1% BSA / 
0.1% NaN3 cell suspension was determined by counting using a Vi-Cell XR  
Cell Viability Analyzer (Beckman Coulter Inc., Fullerton, CA,USA).  Typically the 
number of viable cells / ml was in the region of 1 x 10
7.  Cells were resuspended to 1 x 10
5 
viable cells per ml.  For the wild type Gαi1 transfected HEK293 cell preparations 
nucleotide (GTPγS or GDPβS) was added to a final assay concentration of 100 µM.  The 
secondary antibodies, either donkey anti-rabbit FMAT blue ® or donkey anti-mouse 
FMAT blue ® (Applied Biosystems, Foster City, CA, U.S.A.), were added to a final 
dilution of 1:2000.  50 µl of this solution was added per well of a 384 well FMAT ® plate 
to give 5,000 cells per well.  This well contained 1 µl of the appropriate primary antibody.  
The antibody dilutions used typically are displayed below. 
 
Rabbit α-Gαi1/2 polyclonal antisera (1319 glycine, in house) - 1:500 in PBS J. Robert Lane, 2007    Chapter 2  
118 
 Mouse  α-FLAG monoclonal antisera (GSK, Stevenage, UK) – 1:500 in PBS 
 
Plates were covered with aluminium foil, and left for at least 2 hours at room temperature.  
Bound fluorescence was detected using a FMAT 8200 high throughput screening system   
(Applied biosystems) and analysed using FMAT™ software. 
 
 
2.10.4.1  FMAT assay protocol specific for primary hybridoma screen 
 
FMAT assay protocol was performed as described in 2.10.4.  Hybridoma clone tissue 
culture supernatant (5 µl) and HEK293 cell / FMAT donkey anti-mouse FMAT blue ® / 
PBS / 1% BSA / 0.1 % NaN3 suspension were added to 384 well FMAT ® plates. All 
manipulations were carried out using an automated liquid handling robot based on a 
Beckman BiomekFx.  Plates were read following at least 2 hours incubation at room 
temperature. 
Bound fluorescence was detected using a FMAT 8200 high throughput screening system 
(Applied Biosystems, Foster City, CA, U.S.A.) taking advantage of the Zymark Twister
® 
robotic plate handler and four input stacks. The FMAT software allows robotic plate 
handling to remove and load plates to and from the scanner.   
 
2.10.5  Hybridoma expansion and immunoglobulin purification 
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Hybridomas from wells of interest were expanded into 24 well plates (Greiner, 
Stonehouse, Gloustershire, UK), cryopreserved and subcloned in semisolid medium to 
ensure stability. To generate purified mAbs, hybridomas were expanded further into 2 x 
T225 cm
2 flasks in the above medium without HCF and HT and cells pelleted, resuspended 
in medium without serum and cultured until cell viability dropped to ca. 10%. 
Immunoglobulins were purified from the conditioned medium using immobilised Protein 
A (Prosep-A) and the Perbio buffer system according to manufacturers instructions. 
Purified mAbs were dialysed against and stored in PBS (Sigma). Isotypes were determined 
using a typing stick kit from Amersham Biosciences (All mAbs were IgG1 kappa). 
 
2.10.6  Epitope Mapping of Antibodies using PepSet
TM from 
Mimotopes 
2.10.6.1  Re-dissolving peptides in PepSet
TM 
A PepSetTM peptide Library of 86 16mer peptides corresponding to the entire sequence of 
Gαi1 and overlapping by four amino acids was obtained from Mimotopes.  Before use in an 
epitope mapping assay the supplied peptides must be dissolved and aliqouted into smaller 
volumes.  The following procedure is based on a standard procedure outlined by the 
manufacturer.   Peptides were reconstituted with 200 µl of 80% dimethyl sulfoxide 
(DMSO) / 20% degassed dH2O and tubes repeatedly inverted for 5 minutes.  Tubes were 
then inspected to make sure peptide had totally dissolved.  It was necessary to sonicate the 
entire pepset for 5 minutes in a sonication bath to completely dissolve all the peptides.  
20ul of each peptide solution was then aliquoted into one well of a 96 well polypropylene 
deep well plate.  Deep well plates were sealed and stored at -20 º C until use. J. Robert Lane, 2007    Chapter 2  
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2.10.6.2  Epitope Mapping Assay 
 
Prior to use the peptide solutions created as above were diluted to a working strength of 
1:1000 in a PBS / 0.1 % Tween 20 / 0.1% (w/v) NaN3 solution.  These solutions can be 
stored for one day at 4 ºC or -20 ºC for longer storage.   Non-specific adsorption was 
blocked by adding 200 µl of blocking buffer( PBS, 5% fat free milk powder, 0.1% tween 
20)  to each well streptavidin coated 96 well plate (mimotopes) and incubation for 1 hour 
at room temperature.  Plates were washed 4 times with PBS / 0.1% tween 20 and 
remaining buffer removed by vigorously slapping the plates well side down onto a 
benchtop covered with absorbent paper towels.  100 µl of diluted peptide solution was 
transferred into the corresponding well positions of the streptavidin coated plate.  The 
plates were then placed on a shaker table and the reaction allowed to proceed for 1 hour at 
room temperature.  After incubation the solution was flicked out and the washing 
procedure repeated as described above.  Relevant antibodies were diluted 1:1000 in PBS/ 
0.1% tween 20 / 0.1 % NaN3.  100 µl of this diluted serum was added to each of the wells 
of the plates containing captured peptides.  Plates were placed on a shaker table and 
incubated with agitation for 16 hours at 4 º C.  The washing step was repeated as above.  
Bound antibody was detected using a suitable either anti-rabbit or anti-mouse HRP labelled 
secondary antibody at a final dilution of 1:2000 in  PBS / 5% fat free milk powder / 0.1% 
tween 20.  100 µl of the dilute conjugate was dispensed into each well and incubated at 
room temperature for 1 hour.   The washing step was repeated as above and finally the 
plates were washed twice with PBS.  Presence of peroxidase was measured by adding 100 
µl SureBlue
TM TMB HRP substrate per well (KPL, Gaithersburg, USA).  Reaction was 
stopped by addition of 100ul of 1N HCl, and plates read at a wavelength of 450nm 
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2.10.7  Immunocytochemistry 
2.10.7.1  Hoescht nuclear staining 
Cells were cultured and transfected as described in section 2.7.5.  Cells were washed 1 x 
with room temperature PBS, and then incubated with hoescht stain (1:1000 dilution in 
PBS) for 15 minutes at 37 º C in the incubator. 
2.10.7.2  Immunocytochemistry 
Cells were washed 2 x with room temperature PBS (leaving PBS on for 5 mins each time). 
Fixation of cells was performed by incubation for 10 mins with 10% Formaldehyde in PBS 
solution at room temperature for exactly 10 minutes.  Cells were then washed three times 
with ice cold PBS (leaving PBS on for 5 mins each time).  Blocking and cell 
permeabilisation was achieved in one step with a10 minute incubation in PBS + 3% marvel 
milk + 0.15% triton X100.  Primary antibodies were diluted 1:1000 in PBS / 3% marvel 
milk / 0.15% triton X100.  500ul of this solution was spotted onto nescofilm and coverslips 
were placed cell side down onto this spot and incubated for 1 hour at room temperature.  
Coverslips were then returned to 6 well plates cell side up and washed 3 x with ice cold 
PBS as before.  Secondary antibody was diluted as follows in PBS + 3% marvel milk + 
0.15% triton X100:  
 
α-mouse Alexa 594 – 1:400  
α-rabbit Alexa 594 – 1:600 
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This was spotted onto nescofilm and coverslips applied as above and incubation was for 1 
hour at room temperature   Cells were washed as above and then mounted onto slides using 
Immuno-Mount solution and stored at 4°C until use. 
 
2.10.7.3  Modified Immuncytochemical method:  Aluminium Fluoride Stimulated 
Whole Cell Assay  
All AlF4
- protocols were performed in 6 well plates. Cells were washed using GTPγS 
buffer (50 mM Tris, 5 mM MgCl2, 100 mM NaCl, 0.2 mM EGTA, pH 7.4), followed by 
incubation at room temperature for 1 hour with AlF4
- solution (50 mM Tris, 5 mM MgCl2, 
100 mM NaCl, 0.2 mM EGTA, 10mM NaF, 0.03 mM AlCl3, 3% fat Marvel milk (w/v), 
0.2% Saponin (v/v)).  Cover-slips were subsequently washed with PBS and fixed using 4% 
Formaldehyde in PBS. Cover-slips were washed three times with 4
oC PBS.  Cells were 
incubated with the relevant secondary antiserum for one hour at room temperature (PBS, 
3% marvel milk (w/v), 0.2% saponin (v /v)). Finally, cells were washed with ice cold PBS 
and mounted using Immu-Mount for microscopy. 
 
2.10.7.4  NPA stimulated GTPγS Whole Cell Assay 
All agonist stimulated assays were performed in 6 well plates.  Cells were washed using 
GTPγS buffer (50 mM Tris, 5 mM MgCl2, 100 mM NaCl, 0.2 mM EGTA).  Cells were 
then incubated in GTPγS buffer + 0.2 % (v/v) Saponin / 3% (v/v) Marvel Milk / with 10 
µM GTPγS or 100 µM GDPβS and with or without 1 µM NPA, with an appropriate 
concentration of primary antibody, for 1 hour at room temperature.  Cover-slips were then 
washed with PBS and fixed using fixed using 4% Formaldehyde in PBS.  The experiment 
was completed as for section 1.10.7.4. J. Robert Lane, 2007    Chapter 2  
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2.10.8  Epifluoresence Microscopy 
Formaldehyde fixed cells, expressing the Dopamine D2l fusion protein and appropriate G 
protein α subunit were imaged in 2D using an inverted Nikon TE2000-E microscope 
(Nikon Instruments, Melville, NY) equipped with a x 60, (NA=1.4), oil immersion Plan 
Fluor Apochromat lens, a z-axis linear encoder and a cooled digital Cool Snap-HQ CCD 
camera (RoperScientific/Photometrics, Tucson, AZ). Epifluorescence excitation light was 
generated by an ultra high point intensity 75 W xenon arc Optosource lamp (Cairn 
Research, Faversham, Kent, UK) coupled to a computer controlled Optoscan 
monochromator (Cairn Research, Faversham, Kent, UK). Monochromator was set to 500/5 
nm and 575/12nm for the sequential excitation of eYFP and Alexa Fluor 594 respectively. 
excitation light was transmitted through the objective lens using the following single pass 
dichroics; Q515LP for eYFP and Q595LP for Alexa Fluor 594 and emitters; HQ535/30 nm 
for eYFP  and HQ645/75 nm for Alexa Fluor 594. Using these filter sets, the fluorophores 
were easily separated with no bleed through. Images were collected using a Cool Snap-HQ 
digital camera operated in 12-bit mode. Computer control of all electronic hardware and 
camera acquisition was achieved using Metamorph software (version 6.3.7; Molecular 
Devices Corp.,Downing, PA).  For one experiment exposure and intensity was set using 
the positive control condition and this used for all other conditions. 
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3  Protean agonism at the dopamine D2 receptor 
3.1  Introduction 
 
There is a wealth of experimental evidence that some GPCRs can couple to multiple G 
protein α subunits (Wess, 1998).  Similarly, a large number of GPCRs are able to generate 
multiple intracellular signals, and for those with a rich pharmacology of synthetic small 
molecule ligands it has often been possible to observe differential pharmacology for 
particular end points (Perez and Karnik, 2005; Urban et al., 2006a)  This has resulted in an 
appreciation, that instead of a receptor having a single active state, different ligands may 
stabilise different conformational states that differ from the constitutively active state (see 
Fig 3.1A + B) (Kenakin, 2003).   With the expansion of the simple ‘active or inactive’ two 
state model, the proposed extended ternary complex (ETC) model which takes into account 
constitutive activity of receptors, the potential for an essentially infinite number of receptor 
states could be predicted (Fig 3.1C).  In this model the multiplier γ confers a different 
affinity of the receptor for G proteins when the receptor is ligand bound.  Therefore, every 
value of γ defines a new ligand-bound receptor state.  Accordingly, differences in agonist 
pharmacology to regulate signals via different G proteins is frequently described as 
‘agonist-directed trafficking’ (Kenakin, 1995; Urban et al., 2006a).  The majority of these 
observations have focused on measuring the varying efficacy of ligands to regulate the 
production of two separate second messengers rather than directly measuring differential 
activation of two individual G proteins.    It should be noted that in addition, although 
GPCRs are defined by their capacity to activate hetero-trimeric G proteins, a number of 
ligand-induced signals appear not to require G protein interactions.  In the case of the β2 
adrenoceptor for example, such separation of signal transduction has resulted in the 
identification of ligands that can be defined as inverse agonists for their effects on adenyl J. Robert Lane, 2007    Chapter 3 
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cyclase activity but as agonists for their capacity to stimulate phosphorylation of the 
ERK1/2 MAP kinases (Azzi et al., 2001; Galandrin and Bouvier, 2006).  Ligands that 
display either positive or negative efficacy when assessed in different assays or in different 
experimental conditions are named protean ligands (Kenakin, 2001).  In agreement with 
the idea of agonist directed trafficking, namely that different ligands stabilise different 
receptor conformations, it follows that for two distinct signalling pathways a ligand could 
be an agonist for one but an inverse agonist/ antagonist for another.  Observation of this 
provides compelling evidence for multiple ligand stabilised receptor conformations. 
 
The dopamine D2l receptor is one of the most well studied and characterised GPCRs.  As 
with a series of GPCRs that interact with members of the pertussis toxin sensitive G 
proteins, this receptor is able to promiscuously modulate signals via each of Gαi1, Gαi2, 
Gαi3, and Gαo1 (Gazi et al., 2003).  However, ligand pharmacology can be greatly 
influenced by the ratio of GPCR to G protein expression (Milligan, 2000) and this can be 
difficult to define in cells, particularly in comparisons between different G proteins.  One 
method to overcome this is to employ GPCR-G protein fusions that ensure a fixed 1:1 
stoichiometry of GPCR and G protein (Milligan et al., 2004).  Another consideration is that 
pertussis toxin sensitive G proteins, in particular Gαi2 and Gαi3, are expressed by all 
mammalian cells.  It is therefore essential to develop some method by which the coupling 
of one particular Gαi subunit to the receptor of interest can be monitored.  A strategy used 
previously is to employ variants of each of Gαi1, Gαi2, Gαi3, and Gαo1 which have been 
rendered insensitive to the ADP-ribosyltransferase activity of pertussis toxin by mutation 
of the cysteine which is the site of modification to an isoleucine.  In addition to the fusion 
proteins another strategy is to use cell lines stably expressing the D2l receptor in which 
varying amounts of each CysÆIle variant G protein α subunit can be expressed in an 
entirely tetracycline-dependent manner.  Flp-In™ T-REx host cell lines (Invitrogen) have a 
single Flp recombinase target (FRT) site located at a transcriptionally active genomic locus J. Robert Lane, 2007    Chapter 3 
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that allows you to generate isogenic inducible expression cell lines using targeted 
integration.  Using these two strategies, in which the relative levels of receptor and G 
protein expression can be controlled, I will demonstrate that S-(-)-3-(3-hydroxyphenyl)-N-
propylpiperidine (S-(-)-3-PPP) is a protean ligand at the D2l receptor, being an agonist for 
activation of Gαo1 but an antagonist/inverse agonist at Gαi1, Gαi2, Gαi3.  This observation 
provides evidence for the concept that the dopamine D2l receptor can exist in multiple 
conformational states and indicates that it is possible to selectively direct the nature of D2l 
receptor signalling by the use of synthetic ligands.  
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3.2  Results 
 
3.2.1  Generation and characterisation of dopamine D2l receptor: 
CysÆIle G protein alpha subunit fusion proteins   
 
The promiscuous coupling of the dopamine D2l receptor to all four pertussis toxin sensitive 
mutants (Gαi1, Gαi2, Gαi3, and Gαo1) has been previously established.  Gαi2 and Gαi3 are 
expressed endogenously by all cells, so to investigate any variations in the ability of 
ligands at the D2l receptor to activate the different G protein α subunits it was necessary to 
use a model system in which the specific interactions of the receptor with each individual 
G protein α subunit could be investigated.  Pertussis toxin mediated ADP-ribosylation 
occurs at a cysteine residue at the fourth position from the C-terminus (Figure 3.2A) on 
members of the Gαi family.  This abrogates functional contact between receptor and Gαi, 
thus maintaining the G protein in its inactive formation.  Consequently the interaction 
between receptor and endogenous Gαi can be abolished.  To allow study of a specific Gαi 
subunit introduced into a cell, mutants of Gαi with the C-terminal cysteine residue mutated 
to an isoleucine can be used.  This mutation makes the G protein resistant to pertussis toxin 
catalysed ADP-riboyslation.  Consequently, cells can be transfected with the pertussis 
toxin insensitive mutant Gαi subunit of interest and then treated with pertussis toxin to 
ADP-ribosylate endogenous Gαi subunits and ensure functional coupling only occurs 
between the introduced pertussis toxin insensitive mutant and the receptor of interest 
(Figure 3.2B).   Another consideration when investigating the coupling of a receptor to 
different G-proteins is to control the relative expression levels of both receptor and G-
protein.  One solution to this is to use receptor-G-protein fusion proteins in which the Cys 
to Ile, pertussis toxin insensitive mutants of Gαi1, Gαi2, Gαi3 and Gαo1, were linked in 
frame with the C-terminal tail of the human D2l  (Figure 3.3).  This ensured that the J. Robert Lane, 2007    Chapter 3 
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stoichiometry of receptor to G protein would be identical for each G protein studied and 
that the relative cellular distribution and orientation of receptor and G protein would be 
uniform.   
 
3.2.1.1  Characterisation of dopamine D2l receptor-CysÆIle variant G protein α 
subunit fusion proteins 
Each fusion protein was expressed transiently in HEK293T cells, and 16 hours prior to cell 
harvest, these cells were treated with pertussis toxin (25 ng/ml,).  Following cell harvest 
membrane preparations were made.  Saturation binding assays employing [
3H] spiperone 
showed that each fusion protein was expressed to similar levels of around 1.5 pMol.mg
-1 of 
membrane protein and bound this ligand with a similar high affinity (Table 3.1).  It should 
be noted that the levels of receptor expression sufficiently high that it is likely that 
depletion of [
3H] spiperone will have occurred.  Calculations suggest that after binding to 
the receptor the concentration of free ligand will have effectively decreased to 85% of the 
total added.  This can result in the estimation of the KD (the affinity) being too high.  
However, experimentally ligand depletion of 10% is generally ignored, consequently the 
effect of ligand depletion in the above experiments will not have a dramatic effect on the 
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Table 3.1: [
3H] spiperone binds with similar and high affinity to various D2l receptor-
G protein fusions 
 
Experiments were performed in triplicate to n = 3 
 
3.2.1.2  Increasing amounts of D2l-Cys
351Ile Gαo1 lead to a proportional increase 
in [
35S] GTPγS binding 
 
HEK293T cells were transfected with cDNA encoding the D2l-Cys
351Ile Gαo1 fusion 
protein, membrane preparations made and receptor binding site density estimated using 
[
3H] spiperone (Table 3.1). Various amounts of membranes (and therefore varying 
amounts of receptor) were incubated with 10 µM GDP and with or without the presence of 
10µM dopamine using a [
35S] GTPγS assay with an immunoprecipitation step.  Antiserum 
raised against the C-terminal tail of Gαo1 was used for the immunoprecipitation step.  For 
D2l-Cys
351Ile Gαo1 an increase in receptor added to the reaction from 1 to 25 fMol lead to a 
proportional increase in both basal and dopamine-stimulated [
35S] GTPγS binding (Figure 
3.3B).  Basal levels of [
35S] GTPγS binding could reflect constitutive activity of the 
dopamine receptor-Gαo1 fusion, or perhaps the basal [
35S] GTPγS loading of increasing 
amounts of Gα subunit added to the reaction. 
Receptor: G Protein fusion Kd, nM (± S.E.M.)  Bmax fMol.mg-1 (± S.E.M.) 
D2lGαi1  0.049 (0.003) 1500  (49) 
D2lGαi2  0.051 (0.003) 1415  (24) 
D2lGαi3  0.057 (0.002) 1976  (14) 




3.2.2  The ligands p-tyramine and S-(-)-3-PPP only stimulate [
35S] 
GTPγS binding at the D2l-Cys
351Ile Gαo1 fusion protein 
 
To test the ability of a selection of ligands to act at the D2l receptor and stimulate each of 
the four Gαi subunits [
35S] GTPγS binding was used.  Dopamine stimulated [
35S] GTPγS 
binding at all four G protein α subunits (Figure 3.4) with a significantly higher potency at 
D2l-Cys
351Ile Gαo1 (Table 3.2). [
35S]GTPγS binding was also stimulated for all fusion 
proteins by N-propylapomorphine (NPA), quinpirole, m-tyramine and R (+) 3-(3-
hydroxyphenyl)-N-propylpiperidine (R-(+)-3-PPP), although, when compared to 
dopamine, only NPA was a full agonist at each construct.   Again, with the exception of 
NPA and 7-OH DPAT, potency of the ligands was greatest for D2l-Cys
351Ile Gαo1.  For the 
partial agonists m-tyramine and R (+) 3-(3-hydroxyphenyl)-N-propylpiperidine (R-(+)-3-
PPP), a significantly higher efficacy in relation to a maximal dopamine stimulation for the 
D2l-Cys
351Ile Gαo1 construct was observed.  However, the ligands p-tyramine and S (-) 3-
(3-hydroxyphenyl)-N-propypiperidine (S-(-)-3-PPP) displayed agonism only at the D2l-
Cys
351Ile Gαo1 fusion protein.  Whilst p-tyramine displayed greater agonist efficacy than S-
(-)-3-PPP at the D2l-Cys
351Ile Gαo1 fusion subsequent studies employed S-(-)-3-PPP since 
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Table 3.2: The potency and efficacy of ligands at D2l receptor-G protein fusions 
 
 Experiments were performed in triplicate to n = 3. 
na = no significant dose dependent response observed 
‘% DA’ refers to Emax value of [
35S] binding as compared to maximal dopamine 
stimulation.  The values of potency or efficacy for each ligand at the four different D2l-
fusion proteins were compared using one way ANOVA with a Tukey’s post test using 
GraphPad Prism version 4. A significant difference was observed in pEC50 between D3/2 
receptor fusion proteins for dopamine; D2Gαo1 > D2Gαi1 > D2Gαi2 = D3/2Gαi3 (P<0.01) 
 
 

































50 (2)  4.92 (0.32)  40 (13)  4.97 
(0.30) 














61 (2)  4.67 (0.30)  33 (2)  4.59 
(0.23) 











99 (1)  4.72 (0.76)  59 (27)  5.62 
(0.42) 





143 (6)  7.64 (0.23)  96 (18)  7.48 
(0.31) 







34 (1) na    7.83 
(0.30) 
21 (2)  7.99 
(0.21) 
51 
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3.2.3  S-(-)-3-PPP only shows a high affinity binding site in 
competition with [
3H] spiperone at D2l-Cys
351Ile Gαo1 fusion protein 
 
To further characterise this apparent example of ligand directed trafficking, where S-(-)-3-
PPP favours coupling only to Gαo1, it was important to investigate the relative affinity of 
S-(-)-3-PPP for each of the four fusion proteins (Figure 3.5), using competition binding 
versus [
3H] spiperone.  The ability of dopamine to compete with [
3H] spiperone to bind to 
the various D2l-G-protein fusions was best fit by a two-site model in which between 30 and 
50 % of the sites displayed higher affinity (pKh = 7.1-7.7) and the remainder lower affinity 
(pKl = 5.6-5.8) for dopamine.  The presence of 100 µM GTP in such assays resulted in this 
competition becoming monophasic (pKiGTP = 5.5-5.9) in each case.   For pKh, pKl and 
pKiGTP binding sites there was no significant difference in affinity between the four fusion 
constructs (Table 3.3).  In contrast, the ability of S-(-)-3-PPP to compete with [
3H] 
spiperone was monophasic in the absence of GTP and essentially unaffected by the 
presence of GTP (pK = 6.2-6.5) for the D2l-Gαi1, D2l-Gαi2, D2l-Gαi3 CysÆIle variant fusion 
proteins (Figure 3.5).  However, a bi-phasic competition curve was observed for S-(-)-3-
PPP binding at the D2l-Cys
351Ile Gαo1 fusion protein (pKh = 8.4, pKl = 6.2). This was 
converted to a monophasic curve (pK = 6.3) in the presence of GTP (Table 3.3).  These 
results are in agreement with observations from [
35S]GTPγS binding studies showing that  
S-(-)-3-PPP is a partial agonist at D2l-Gαo1. At D2l-Gαi1, D2l-Gαi2, D2l-Gαi3 fusion proteins 
S-(-)-3-PPP still has a similar affinity for the receptor but does not show the high affinity 
state indicative of agonist action though these G protein alpha subunits.  This suggests that 
at D2l-Gαi1, D2l-Gαi2, and D2l-Gαi3 S-(-)-3-PPP is an antagonist or inverse agonist. 
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Table 3.3: The binding characteristics of dopamine and S-(-)-3-PPP with D2l receptor-
G protein fusions  
 
Experiments were performed in triplicate to n = 3. 
One way ANOVA with Tukey’s post-hoc test was performed using GraphPad Prism 
version 4.  No significant differences in values of pKh, pKl or pKiGTP were observed for 
dopamine.  For S-(-)-3-PPP no significant differences in values of pKl or pKiGTP at each of 
the four fusion proteins were observed.  However a high affinity binding site (pKh) for S-(-
)-3PPP was observed only at the D2l-Cys
351Ile Gαo1 fusion protein. 
 
 
3.2.4  S-(-)-3-PPP acts as an antagonist or inverse agonist at D2l-
CysÆIle Gαi1, Gαi2, Gαi3, but as a partial agonist at D2l-Cys
351Ile Gαo1. 
 
To further explore a possible ‘protean’ characteristic of S-(-)-3-PPP at the D2l receptor I 
compared effects at D2l-Cys
351Ile Gαo1 and D2l-Cys




D2l-Gαi1 D 2l-Gαi2 D 2l-Gαi3 D 2l-Gαo1 














5.75 (0.08)  6.27 
(0.06) 
5.63 (0.17)  6.47 
(0.11) 
5.58 (0.12)  6.26 
(0.07) 
5.82 (0.18)  6.24 
(0.07) 
%Rh  44 (7)    55 (4)    36 (4)    29 (4)  29 (2) 
pKiGTP 
(±SEM) 
5.53 (0.01)  6.23 
(0.02) 
5.81 (0.01)  6.52 
(0.11) 
5.50 (0.11)  6.27 
(0.11) 
5.86 (0.07)  6.3 
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S-(-)-3-PPP inhibited the capacity of an EC50 concentration of dopamine to stimulate 
binding of [
35S] GTPγS to both fusion constructs with pIC50 = 4.68 ± 0.07 (D2l-Cys
351Ile 
Gαi2) and 5.09 ± 0.12 (D2l-Cys
351Ile Gαo1) (Figure 3.6A).  However, the maximal effect of 
S-(-)-3-PPP at D2l-Cys
351Ile Gαo1 in this assay confirmed its partial agonist action at Gαo1, 
because it failed to reduce binding of [
35S]GTPγS to the level observed in the absence of 
dopamine. By contrast, at D2l-Cys
352Ile Gαi2 S-(-)-3-PPP completely blocked dopamine 
stimulation and, indeed, acted as an efficacious inverse agonist (Figure 3.6B).  Spiperone 
is frequently described as an inverse agonist at the dopamine receptor and unsurprisingly 
acted as an effective inverse agonist at D2l-Cys
351I Gαi2.  Furthermore, spiperone fully 
reversed the effect of dopamine at D2l-Cys
351Ile Gαo1 (Figure 3.6A).  Similar studies also 
demonstrated that both spiperone and S-(-)-3-PPP also acted as antagonists/inverse 
agonists at both D2l-Cys
351Ile Gαi1 and D2l-Cys
351Ile Gαi3 (Figures 3.6C, 3.6D). 
 
 
3.2.5  Generation and characterisation of stable cell lines expressing 
Gαi1, Gαi2, Gαi3, and Gαo1 in an inducible manner 
As described above the fusion proteins are extremely useful tools to study receptor G-
protein interactions since they define the receptor to G protein ratio as 1:1 for each G-
protein.  However, they are an inherently artificial system, and it was therefore important 
to investigate if S-(-)-3-PPP would behave as a protean agonist at the D2l receptor when 
coupling to different Gαi subunits in a system expressing separated receptor and G protein.  
To achieve this, a series of HEK293 cell lines were generated based on the Flp-In T-REx 
system (Figure 3.7).  This system allows the expression of a gene of interest from a single, 
defined chromosomal locus by addition of tetracycline.  The Flp-In T-REx host cell line 
containing a single Flp recombinase target ‘FRT’ homologous recombination site and 
stably expressing the Tet Repressor gene, was co-transfected with the cDNAs of  Pertussis J. Robert Lane, 2007    Chapter 3 
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toxin resistant Cys to Ile mutants of Gαi1, Gαi2, Gαi3, Gαo1 in the vector pcDNA5/FRT/TO 
along with the Flp recombinase cDNA contained within the vector pOG44.  This 
recombinase catalyses a homologous recombination event between the FRT site in the host 
genome and that of the pcDNA5/FRT/TO vector.  Cells which have the CysÆIle variant 
Gαi/o cDNA of interest stably integrated into the FRT site were selected by antibiotic 
selection using hygromycin.  Since all clones should, theoretically, be equivalent, clones 
were pooled and the polyclonal mix tested for ability to inducibly express the CysÆIle 
Gαi/o subunit of interest.  Western blotting using antisera raised against the C-terminal tail 
of each Gα subunit showed inducible expression of Gαi1, Gαi2, Gαi3, Gαo1 only upon 
treatment with 1 µg/ml of tetracycline 24 hours prior to cell harvest (Figure 3.8). 
 
3.2.5.1  Generation and characterisation of cell lines stably and constitutively 
expressing dopamine D2l receptor and expressing Gαi1, Gαi2, Gαi3, or Gαo1 
CysÆIle mutants from the inducible Flp-In locus 
Using these cell lines, further cell lines were generated that stably and constitutively 
express dopamine D2l receptor, with the inducible expression of Gαi1, Gαi2, Gαi3 , or Gαo1 
CysÆIle mutants as described in the section 2.7.7.  Consequently by treatment with 
pertussis toxin to cause ADP-ribosylation of endogenously expressed forms of ‘Gαi’ I 
anticipated this would produce a system in which D2l mediated stimulation of [
35S] GTPγS 
binding must reflect only activation of a single, defined G protein.  Flp-In T-REx cells 
which inducibly express the Gαi1, i2, i3, or o1 Cys Æ Ile pertussis toxin insensitive mutants 
were transfected with dopamine D2l receptor cDNA and stable cell lines generated.  Clones 
generated were screened for receptor expression by radioligand binding using a single near 
saturating concentration of [
3H] spiperone.  Non-specific binding was estimated using 10 
µM (+)-butaclamol (Figure 3.9).   Clones showing significant expression of receptor were 
frozen down in liquid nitrogen until required for further characterisation.   One clone for J. Robert Lane, 2007    Chapter 3 
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each of the four different Gαi stable cell lines was selected as follows: D2l + Gαi1; clone 5, 
D2l + Gαi2; clone 15, D2l + Gαi3; clone 3, D2l + Gαo1; clone 4, and further characterised.    
Initial studies confirmed expression of the G protein of interest in all cases in a 
‘tetracycline-on’ fashion.  At a 24 hours time point, maximal expression of each G protein 
was achieved by treatment with between 0.5 -1.0 µg.ml
-1 tetracycline (Figure 3.10).  
Levels of the D2l receptor constitutively expressed by each of the cell lines was not 
affected by tetracycline induced turn on of the G-proteins (Table 3.4).   
 
Table 3.4: Expression levels of the D2l receptor are unaffected by expression of 
various G proteins 
 
Experiments were performed in triplicate to n = 3. 
An unpaired Student’s t-test (p>0.05) was performed using GraphPad Prism version 4.  No 
significant differences in Bmax values were observed in receptor expression with and 





-1 Tet.  -  + 
  [
3H] Spiperone Binding 
Cell Line  Bmax, fMol.mg
-1  
(± S.E.M.) 
Kd, nM      
(± S.E.M.) 
Bmax, fMol.mg
-1   
(± S.E.M.) 
Kd, nM      
(± S.E.M.) 
D2 + Gαi1  988 (108)  0.02 (0.01)  1156 (261)  0.03 (0.01) 
D2 + Gαi2  1448 (191)  0.02 (0.01)  1861 (225)  0.04 (0.01) 
D2 + Gαi3  538 (52)  0.03 (0.01)  510 (120)  0.02 (0.02) 
D2 + Gαo1  3790 (396)  0.06 (0.02)  3864 (249)  0.07 (0.02) J. Robert Lane, 2007    Chapter 3 
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3.2.6  S-(-)-3-PPP stimulates the binding of [
35S] GTPγS upon 
induction of Cys
351Ile Gαo1 expression but not Cys
352Ile Gαi2 expression 
 
As could be expected, there was no capacity of dopamine to stimulate binding of [
35S] 
GTPγS in membranes of pertussis toxin treated cells, where expression of CysJIle G 
protein α subunit was not induced by tetracycline treatment (Figures 3.11A, 3.12A).  In 
equivalent membranes of cells where expression of Cys
352Ile Gαi2 was induced by 
tetracycline, dopamine produced a robust stimulation of [
35S] GTPγS binding.  This 
stimulation of [
35S] GTPγS binding by dopamine was both substantial and concentration-
dependent.  The potency of dopamine (pEC50 = 6.05 ± 0.11) was significantly higher than 
that seen at the D2l-Cys
352Ile Gαi2 fusion protein (pEC50 = 5.25 ± 0.16, un-paired Student’s 
t-test, P<0.05) (Table 3.2, Figure 3.4).  However, in the same membranes S-(-)-3-PPP was 
unable to enhance [
35S] GTPγS binding at all (Figure 3.11B).  In membranes expressing 
the D2l receptor and induced to express Cys
351Ile Gαo1 dopamine also stimulated [
35S] 
GTPγS binding in a concentration-dependent manner.  Again the potency of dopamine was 
significantly higher (pEC50 = 7.56 ± 0.17) than recorded for the D2l-Cys
352Ile Gαi2 fusion 
protein (pEC50 = 6.15 ± 0.15, un-paired Student’s t-test, P<0.01) ( (Table 3.2, Figure 3.4).    
S-(-)-3-PPP also stimulated the binding of [
35S] GTPγS in a concentration-dependent 
manner and behaved as a partial agonist (Figure 3.12B).  The Emax relative to maximal 
dopamine stimulation was 20%, similar to the value recorded in receptor-G protein fusion 
experiments (Table 3.2, Figure 3.4).  The potency of S-(-)-PPP (pEC50 = 6.65 ± 0.10) was 
significantly higher than seen at the D2l-Cys
351Ile Gαo1 fusion protein (pEC50 = 6.25 ± 0.09, 
un-paired Student’s t-test, P<0.05) (Table 3.2, Figure 3.4).   
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3.2.7   S-(-)-3-PPP shows a high affinity binding site in competition 
with [
3H] spiperone binding but only in the presence of  Cys
351Ile Gαo1 
expression and not Cys
352Ile Gαi2 expression 
 
In cells expressing the D2l receptor and without induction of Cys
352Ile Gαi2 expression the 
competition of dopamine with [
3H] spiperone gave a monophasic curve of low affinity (pKl 
~5.4) that was unaffected by addition of 100 µM GTP (pKiGTP ~5) (Figure 3.13A, Table 
3.5).  However, with tetracycline induction of Cys
352Ile Gαi2 expression the competition of 
dopamine with [
3H] spiperone produced a biphasic curve, with the appearance of a high 
affinity site (pKh ~7.6) which was eliminated by the presence of GTP.  In contrast, both 
with and without tetracycline induction of Cys
352Ile Gαi2 expression the capacity of S-(-)-
3-PPP to compete with [
3H] spiperone was both monophasic and unaffected by the 
presence of GTP (pK ~ 5.8) (Figure 3.13B, Table 3.5).  In equivalent membranes of 
pertussis toxin treated cells expressing D2l and allowing the inducible expression of Gαo1, 
dopamine versus [
3H] spiperone competition binding identified both high (pKh ~ 7.3, 
Table 3.5) and low (pKl ~ 4.6) affinity sites only following induction of Gαo1 Cys
351Ile 
expression (Figure 3.14A).  In the presence of GTP the high affinity site was lost.  In 
contrast to membranes expressing D2l and Cys
352Ile Gαi2, for membranes expressing D2l 
and induced to express Cys
351Ile Gαo1,  S-(-)-3-PPP identified both high (pKh ~8.3) and low 
affinity (pKl ~ 6.4) states (Figure 3.14B).  Again the high affinity site was lost in the 
presence of GTP.  In view of the higher potency of dopamine at the D2l receptor when 
expressed in membranes of the relevant Flp-In T-REx cell line with either Cys
352Ile Gαi2 or 
Gαo1 Cys
351Ile expression induced compared to that seen for the D2l-Cys
352Ile Gαi2 or D2l-
Gαo1 Cys
351Ile fusion proteins, it is interesting to note that the affinities for dopamine are 
not generally significantly different at these two systems, and where significant difference J. Robert Lane, 2007    Chapter 3 
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exists, the affinity is higher at the D2l-fusion protein (Tables 3.3 + 3.5, un-paired Student’s 
t-test, P<0.05). 
 
Table 3.5: The binding characteristics of dopamine and S-(-)-3-PPP at the D2l 
receptor with and without the induction of Cys
352Ile Gαi2 or Cys
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Experiments were performed in triplicate to n = 3 
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3.2.8   S-(-)-3-PPP acts as a partial agonist at the D2l receptor upon 
induction of expression of Cys
351Ile Gαo1 but as an antagonist upon 
induction of Cys
352Ile Gαi2 expression 
 
The action of S-(-)-3-PPP and spiperone in cells expressing the D2l receptor and expressing 
Cys
352Ile Gαi2 or Cys
351Ile Gαo1 upon treatment with tetracycline was explored.  
Stimulation of [
35S] GTPγS binding by an EC50 concentration of dopamine was completely 
reversed by both spiperone and S-(-)-3-PPP in membranes where expression of Cys
352Ile 
Gαi2 had been induced (Figure 3.15A).  However, in membranes where Cys
351Ile Gαo1 
expression was induced, although spiperone again completely reversed dopamine 
stimulation of [
35S] GTPγS binding, S-(-)-3-PPP produced only partial inhibition, 
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Figure 3.1: The multiple signalling states of GPCRs 
A+B)  Two views of GPCRs 
A) The receptor has recognition capability for ligands but once ligand is bound the receptor 
becomes a uniform activation unit (single active state) that goes on to mediate the same 
GPCR activities in the cell for each of the four ligands indicated in the diagram by the 
arrows. 
B) The receptor has bipolar recognition capability in that the binding of different ligands 
can lead to different receptor conformations leading to a texture with respect to the 
recognition properties of the receptor for cellular machinery.  This signalling capability is 
more versatile and complex. For example, in this diagram, four different ligands binding to 
the receptor will each affect the ability of the receptor to couple to any of three different G-
proteins (marked G1, G2, and G3).    
C)  Extended Ternary Complex model showing a pleiotropic receptor interacting 
with two G-proteins; G1 and G2. 
In this model both unliganded forms of the receptor; active state (Ra)and inactive state (Ri) 
are shown.  A represents the Ligand, G is the G protein, Ka is the affinity of the ligand for 
the inactive receptor state, αKa is the affinity of the ligand for the active receptor state, Kg 
is the affinity of the activated receptor for the G protein when the ligand is not bound, γKg 
is the affinity of the receptor for the G protein when ligand is bound and L is the allosteric 
constant for the receptor defined as [Ra]/[Ri].  Such a system will be controlled by the 
relative concentrations of the two G-protein types, the ability of the agonist to induce the 
receptor coupling to each G-protein (γ1 and γ2), the capability of the agonist to induce the 
receptor active state (α) and the natural constitutive activity of the receptor (L).  
Consequently, differences in γ can lead to different agonist selective receptor states.  Both 








































A) Receptor as an on-off switch  B) Receptor as bipolar recognition unit 
C) Extended Ternary Complex model for interaction of one receptor with two G-
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Figure 3.2: The use of pertussis toxin insensitive variants of Gi family G-proteins to 
study specific interactions between a receptor and a Gi G-protein of interest. 
A) Pertussis toxin  (PTX) catalyses the transfer of an ADP-ribose group from NAD
+ to 
specific amino acid residues on Gi family G protein α subunits.  This occurs at a conserved 
cysteine residue four amino acids from the C-terminus and leads to receptor-G protein 
uncoupling.  Mutation of this cysteine residue to isoleucine renders the G protein 
insensitive to pertussis toxin catalysed modification. 
B) PTX-insensitive CysÆIle mutants of the Gαi family can be introduced into cells along 
with the receptor of interest (in this case dopamine D2l).  The interaction between the 
receptor and the CysÆIle Gαi can be studied in isolation following exposure of cells to 
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Figure 3.3: Generation and characterisation of dopamine D2l receptor-CysÆIle 
variant G protein α subunit fusion proteins   
A) A series of fusion proteins were generated by linking Cys-Ile mutant, pertussis toxin-
insensitive variants of Gαi1, Gαi2, Gαi3 and Gαo1 in frame with the C-terminal tail of the 
human D2L receptor. 
B) D2l-Cys
351Ile-Gαo1 was expressed transiently in HEK293 cells. Following pertussis 
toxin treatment (25ng/ml, 24 h) cells were harvested, membranes generated and fusion 
protein expression estimated using [
3H] spiperone saturation binding (Table 3) [
35S]GTPγS 
binding studies were performed in the absence and presence of 100µM dopamine and with 
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Figure 3.4: Characterisation of the actions of various D2 agonists at D2l receptor-G 
protein fusion proteins 
Each of the dopamine D2l receptor-CysÆIle variant Gα fusion proteins; (A) D2l-Gαi1 , (B) 
D2l-Gαi2, (C) D2l-Gαi3, (D) D2l-Gαo1 was expressed transiently in HEK293 cells. 
Following pertussis toxin treatment (25ng/ml, 24 h) cells were harvested, membranes 
generated and [
35S]GTPγS binding studies performed in the absence and presence of 
varying concentrations of a variety of ligands (dopamine ( ♦), m-tyramine (■ ), p-tyramine 
( ), R-(+)-3-PPP (S ), S-(-)-3PPP ( U), quinpirole  ( V), NPA ( ●), 7 –OH DPAT())  
reported to have affinity and efficacy at dopamine D2 receptors. Data are representative 
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Figure 3.5:  In ligand binding studies S-(-)-3PPP displays both low and high affinity 
states only at the D2l-Gαo1 fusion protein 
Membranes of pertussis toxin-treated HEK293 cells expressing (A) D2l-Gαi1 , (B) D2l-
Gαi2, (C) D2l-Gαi3, (D) D2l-Gαo1 were used in competition binding studies employing 0.1 
nM [
3H] spiperone and varying concentrations of either (i) dopamine or (ii) S-(-)-3PPP.  
The assays were performed in the absence (green squares) or presence (red triangles) of 
100 µM GTP.  In the absence of GTP, both high and low affinity states for dopamine were 
observed for each fusion protein whereas this was only true for S-(-)-3PPP at the D2l-Gαo1 
fusion protein. The presence of GTP converted each competition curve to a single 
monophasic state displaying low affinity for either dopamine or S-(-)-3PPP.  Data are 
representative and full details are provided in Table 3.3.  The curves are the best fit curves 
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Figure 3.6:  S-(-)-3PPP is an agonist at D2l-Gαo1 but an antagonist/inverse agonist for 
the other D2l-G protein fusion proteins 
A, B. Membranes from pertussis toxin-treated HEK293 cells expressing either D2l-Gαo1 
(red triangles) or D2l-Gαi2 (green squares) were used in [
35S]GTPγS binding studies. 
Dopamine at an EC50 concentration for each fusion (0.3µM D2l-Gαo1, 3µM D2l-Gαi2) along 
with varying concentrations of either S-(-)-3PPP (A) or spiperone (B) were employed. On 
the y-axis 100 is the stimulation produced by dopamine in the absence of a second ligand 
and 0 the basal activity in the absence of ligands. 
C, D. Equivalent experiments to those of A and B were performed with membranes 
expressing D2l-Gαi1 (open red triangles) or D2l-Gαi3 (open red squares). C. Studies with 
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Figure 3.7:  The Flp-In
TM  T-REx
TM HEK293 system can be used to express a gene of 
interest by induction of expression upon treatment of the cells with tetracycline 
Schematic cartoon showing the cloning of a gene of interest (GOI) into a Flp-In
TM  T-
REx
TM HEK293 host cell line (Invitrogen), to generate a stable cell line where the GOI is 
expressed from a single location in the host genome upon induction of expression with 
tetracycline treatment of cells (diagram based on information from Invitrogen Flp-In. T-
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Figure 3.8:  Characterisation of Flp-In T-REx cells harbouring pertussis toxin-
insensitive mutant G proteins at the Flp-In locus 




351Ile Gαi3 or Cys
351Ile Gαo1 cloned into the Flp-In locus.  These cells were treated 
with tetracycline (1.0 µg/ml for 24 h prior to cell harvest). Cell membranes were then 
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Figure 3.9:  Characterisation of Flp-In T-REx cells constitutively expressing the D2l 
receptor and harbouring pertussis toxin-insensitive mutant G proteins at the 
inducible Flp-In locus 




351Ile Gαi3 or Cys
351Ile Gαo1 cloned into the Flp-In locus. These cells were further 
transfected to constitutively and stably express the D2l receptor.  A single, near saturating 
concentration of 1 nM [
3H] spiperone was used to assess the relative constitutive 
expression levels of D2l receptor of various clones generated  from D2l receptor cDNA 
transfection, with non-specific binding estimated using 10 µM (+)-butaclamol.  Only 
clones showing significant expression of D2l receptor were retained and further 























Figure 3.10:  Characterisation of Flp-In T-REx cells harbouring pertussis toxin-
insensitive mutant G proteins at the Flp-In locus and constitutively and stably 
expressing the D2l receptor 




351Ile Gαi3 or Cys
351Ile Gαo1 cloned into the Flp-In locus. These cells were further 
transfected to constitutively and stably express the D2l receptor (see Table 3.3 for details). 
These cells were treated with concentrations of tetracycline (Tet) between 0 and 1.0 µg/ml 
for 24 h. Cell membranes were then prepared, resolved by SDS-PAGE and immunoblotted 
to detect Gαi1, Gαi2, Gαi3 or Gαo1 (A). Densitometric scans were used to quantitate relative 
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Figure 3.11:  D2l receptor stimulates [
35S] GTPγS binding to Cys
352Ile Gαi2 in 
membranes of pertussis toxin-treated Flp-In T-REx cells only when G protein 
expression is induced 
 
Flp-In T-REx HEK293 cells stably expressing the D2l receptor and harbouring Cys
352Ile 
Gαi2 at the Flp-In locus were treated with or without 1 µg/ml tetracycline for 24 h. Both 
sets of cells were also treated with pertussis toxin. Membranes from these cells were (A), 
used to measure basal [
35S]GTPγS binding and the effect of 10 µM dopamine on this, (B) 
to measure the ability of varying concentrations of dopamine (pEC50 = 6.05±0.11) ( green 
squares) or S-(-)-3-PPP (red circles) to modulate [
35S]GTPγS binding following induction 
of Cys
352Ile Gαi2. An unpaired Student’s t-test was performed using GraphPad Prism 
version 4.  A highly significant difference between basal and dopamine stimulated [
35S] 
GTPγS binding was observed upon induction of Cys
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Figure 3.12:  D2l receptor stimulates [
35S] GTPγS binding to Cys
351Ile Gαo1 in 
membranes of pertussis toxin-treated Flp-In T-REx cells only when G protein 
expression is induced 
Flp-In T-REx HEK293 cells stably expressing the D2l receptor and harbouring Cys
351Ile 
Gαo1 at the Flp-In locus were treated with or without 1 µg/ml tetracycline for 24 h. Both 
sets of cells were also treated with pertussis toxin (25ng/ml, 16 hours prior to cell harvest). 
Membranes from these cells were (A), used to measure basal [
35S]GTPγS binding and the 
effect of 10 µM dopamine on this, (B) to measure the ability of varying concentration of 
dopamine (pEC50 = 7.56 ± 0.17) (green squares) or S-(-)-3PPP (pEC50 = 6.65 ± 0.10) (red 
circles) to modulate [
35S]GTPγS binding following induction of Cys
351Ile Gαo1. A very 
significant difference between basal and dopamine stimulated [
35S] GTPγS binding was 
observed upon induction of Cys
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Figure 3.13:  A high affinity binding site for dopamine but not for S-(-)-3PPP appears 
with induced expression of Cys
352Ile Gαi2 
Flp-In T-REx HEK293 cells stably expressing the D2l receptor and harbouring Cys
352Ile 
Gαi2 at the Flp-In locus were treated with ( filled symbols) or without (open symbols) 
tetracycline  and pertussis toxin as in Figure 3.10.  Membranes from these cells were 
employed in competition binding assays using 0.1 nM [
3H]spiperone and varying 
concentrations of either dopamine (A) or S-(-)-3PPP (B) in the absence (red squares) or 
presence ( green circles) of 100µM GTP. Data are representative and full details are 
provided in Table 3.5.  The curves are the best fit curves to one, or two site models 
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Figure 3.14:  A high affinity binding site for both dopamine and for S-(-)-3PPP 
appears with induced expression of Cys
352Ile Gαo1 
Flp-In T-REx HEK293 cells stably expressing the D2l receptor and harbouring Cys
352Ile 
Gαo1 at the Flp-In locus were treated with ( filled symbols) or without (open symbols) 
tetracycline  and pertussis toxin as in Figure 3.11.  Membranes from these cells were 
employed in competition binding assays using 0.1 nM [
3H]spiperone and varying 
concentrations on either dopamine (A) or S-(-)-3PPP (B) in the absence (red squares) or 
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Figure 3.14 
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Figure 3.15:  S-(-)-3PPP is an antagonist of D2l-mediated activation of Cys
351Ile Gαi2 
but a partial agonist for Cys
351Ile Gαo1 
Flp-In T-REx HEK293 cells stably expressing the D2l receptor and harbouring Cys
352Ile 
Gαi2 (A) or Cys
352Ile Gαo1 (B) at the Flp-In locus were treated with  tetracycline and 
pertussis toxin as in Figures 3.10, 3.11. Dopamine at an EC50 concentration for each cell 
line (0.1µM D2l + Cys
352Ile Gαo1, 1µM D2l + Cys
352Ile Gαi2) was used to stimulate 
[
35S]GTPγS binding and the effects of varying concentrations of spiperone (green circles) 
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3.3  Discussion 
 
There is now a large body of evidence for the existence of multiple receptor states.  The 
labelling of specific sites on the purified β2 adrenoceptor with fluorescent probes has 
allowed the detection of changes in the bound flourophore, and thereby elucidated 
variations in receptor conformations, and suggested that agonist binding and activation 
occur through a series of discrete conformational intermediates (Ghanouni et al., 2001; 
Swaminath et al., 2004).  These discrete receptor conformations stabilised by different 
ligands can result in the ability of different ligands to control pairs of signal transduction 
pathways that are modulated by that GPCR (Perez and Karnik, 2005).  An increasing body 
of data emerging over the past decade support this conclusion as certain ligands were 
shown to have quite diverse functional consequences at the same receptor (Clarke and 
Bond, 1998; Ghanouni et al., 2001; Gonzalez-Maeso et al., 2003; Kenakin, 1995).  Such 
observations are important since they provide suggestions of mechanisms that may explain 
the differential functional properties of individual agonists that are selective for a single 
receptor, and furthermore give insights into the flexibility of GPCR structure.   
 
There is a huge amount of evidence to suggest that many GPCRs can couple to multiple G 
protein α subunits, from within the same sub family or even from distinct subfamilies 
(Wess, 1998).  It could be predicted that different agonist-stabilised receptor conformations 
could differentially couple to a population of G proteins.   A number of studies have 
identified differences in the potency or efficacy of agonist ligands to interact with more 
than one G protein.  Of particular relevance to this study is work done with the D2l 
receptor, which was co-expressed with four different G-proteins in Sf9 cells using a 
baculovirus expression system.  Functional interaction was demonstrated between the 
receptor and the four Gi G-proteins.  Furthermore, it was demonstrated that different J. Robert Lane, 2007    Chapter 3 
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agonists differentially activate the four G-proteins (Gazi et al., 2003).  Members of the Gαi 
subfamily are widely expressed, and are similar in sequence and therefore structure.  It is 
hardly surprising then, that GPCRs can interact with and activate more than one member of 
this family if they are co-expressed.  Consequently, efforts to study receptor-G-protein 
selectivity are hampered by the expression of a number of these G-proteins in all 
mammalian cells and tissues.  As demonstrated by Gazi et al. (2003), one way to overcome 
this is to use insect cell systems (Clawges et al., 1997; Cordeaux et al., 2001; Gazi et al., 
2003), where levels of expression, or the sequence conservation, of such G proteins is low.  
Consequently, mammalian G proteins can be introduced into such cells, along with the 
GPCR of interest and activation is then largely restricted to the exogenous G protein.  
However, to allow the use of mammalian cell lines an alternative has been to use pertussis 
toxin-resistant variants of these G-proteins (Ghahremani et al., 1999; Senogles et al., 2004; 
Wise et al., 1997) in which the Cys residue that is the target for pertussis toxin-mediated 
ADP ribosylation is altered to another amino acid and which retain the ability to interact 
with GPCRs.  These mutants can be expressed in mammalian cells which are subsequently 
treated with pertussis toxin.  The endogenously expressed forms of Gαi become ADP-
ribosylated and therefore are not able to functionally interact with the receptor.  Previous 
detailed studies on Gαi1 replaced Cys with every other natural amino acid and assessed the 
impact on GPCR-mediated activation (Bahia et al., 1998) and similar studies were 
subsequently performed with Gαi3 (Dupuis et al., 1999).  
 
Both pertussis toxin-resistant mutants and insect cell lines are extremely useful to 
investigate an interaction between a receptor and specific G protein α subunit in isolation.  
However, relative expression levels of receptor and G protein must be controlled.  It is well 
established that alterations in GPCR to G protein ratio can alter ligand function and 
receptor pharmacology (Milligan, 2000).  Consequently to study differential agonist 
actions at different G proteins or, indeed, any aspect of receptor-G-protein selectivity it is J. Robert Lane, 2007    Chapter 3 
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essential that this ratio is carefully controlled.  This can, however, be a challenge.  For 
example, in previous studies examining interactions between D2l and different G protein α 
subunits in insect Sf9 cells, receptor to G protein ratios ranging from 1:3 to 1:14 were 
reported for the different G proteins (Gazi et al., 2003). 
 
In my work two methods have been used to meet this challenge.  Firstly, the use of 
receptor-G-protein fusion proteins, so stoichiometry of receptor to G protein must be 1:1 
(Milligan et al., 2004).  Although an artificial system, GPCR-G protein fusions can greatly 
improve signal to background in [
35S] GTPγS binding studies (Milligan et al., 2004).  The 
second strategy used was the inducible expression of individual G proteins from a single, 
defined site of chromosomal integration in Flp-In T-REx HEK 293 cells (Canals et al., 
2006; Milasta et al., 2006).  Although the Flp-In T-REx HEK 293 cells cannot ensure 
exactly the same expression level for each G protein, each G protein is produced from the 
same chromosomal site and this overcomes potential differences in the effectiveness of 
expression level that might arise from expression from different sites of integration.  In 
combination with both of the above strategies, pertussis toxin insensitive mutants were 
used.  A standard Cys to Ile alteration was selected as Ile and other branched chain, 
hydrophobic amino acids preserved the efficacy of GPCR-G protein interactions (Bahia et 
al., 1998; Moon et al., 2001a; Moon et al., 2001b).  This not only ensures for the receptor-
G protein fusions and the inducible cell lines that receptor pharmacology for coupling to 
individual Gαi subunits can be investigated in isolation, but in the case of the Flp-In cell 
lines that G-protein expression can be induced into an essentially ‘null’ background.   In 
summary then, two different techniques to investigate D2l receptor G-protein coupling 
were developed, receptor-G-protein fusions in which the ratio of receptor to G protein is 
rigidly controlled and Flp-In T-REx stable cell lines in which receptor-G protein 
interactions could be investigated between the two proteins expressed as separate entities. 
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As could be expected, the majority of dopamine D2 agonists stimulated [
35S] GTPγS 
binding to all of the four receptor-G protein fusion proteins.  This agrees with previous 
work suggesting that the D2l receptor will promiscuously couple to all Gαi subfamily 
members (Gazi et al., 2003; Robinson and Caron, 1997; Senogles et al., 2004; Watts et al., 
1998).  However, in agreement with Gazi et al. (2003) there was a significant variation in 
potency and efficacy in coupling to each G protein.  For example, dopamine showed a 
significantly higher potency at D2l-Cys
351Ile Gαo1 in comparison with the other Gi subunits.  
This is in agreement with a general consensus that Gαo1 is the Gαo/i subunit that is most 
robustly activated by D2l  (Neve et al., 2004) and furthermore the G protein subtype that is 
predominantly coupled to D2-like receptors in mouse brain (Jiang et al., 2001).  It could 
also be extrapolated then, that dopamine stabilises a structure which favours coupling to 
Gαo1.  Similarly, for all partial agonists tested, potency and efficacy was significantly 
higher at D2l-Cys
351Ile Gαo1.  However, the full agonist NPA showed no significant 
different in efficacy in relation to maximal dopamine stimulation or potency at any of the 
Gαi/o subunits.  This suggests that NPA stabilises a conformation of the receptor which 
does not discriminate between the four Gαi/o proteins.  This, in comparison to the 
differential action of dopamine, for example, at the four different G proteins can be 
considered an example of agonist directed G protein coupling. In general, the potency of 
the ligands used was higher for activation of Gαo1 than for Gαi2. There were not 
statistically valid differences between the values obtained for Gαi1, Gαi2 and Gαi3 for 
enough compounds to allow us to convincingly state rank-order potency differences (that 
might reflect selective stabilization of distinct states of the receptor) for interactions with 
Gαi1 versus Gαi2 for example. This may reflect that the amino acid sequence identities for 
Gαi1, Gαi2 and Gαi3 are all between 86% and 94%, whereas for each of these against Gαo, 
sequence identity lies between 70-73%.  It might, therefore, be postulated that greater 
variation in ligand conformational states could be observed for interactions with Gαo 




Most obvious, however, was the failure of p-tyramine and S-(-)-3-PPP to stimulate [
35S] 
GTPγS binding to Cys
351Ile Gαi1, Cys
352Ile Gαi2 and Cys
351IleGαi3 despite their action as 
partial agonists at Cys
351Ile Gαo1.   Subsequent studies were performed with S-(-)-3-PPP 
because the potency of p-tyramine was sufficiently low to limit its usefulness for detailed 
studies.  S-(-)-3-PPP was able to fully inhibit dopamine stimulated [




351Ile Gαi3, and, indeed, acted as an efficacious 
inverse agonist.  However, consistent with its action as a partial agonist, even at maximally 
effective concentrations it was unable to fully block dopamine stimulated binding of [
35S] 
GTPγS at Cys
351Ile Gαo1, and the maximal level of inhibition was consistent with the direct 
measures of its partial activity.  Consistent with these observations using fusion proteins, 
when receptor and CysÆIle Gα mutants were expressed as separate entities in the Flp-In 
T-REx stable cell lines, S-(-)-3-PPP was unable to stimulate [
35S] GTPγS binding at 
Cys
352Ile Gαi2, but produced robust concentration-dependent [
35S] GTPγS binding above 
basal levels at Cys
351Ile Gαo1.  As could be expected, S-(-)-3-PPP caused complete 
inhibition of dopamine stimulated [
35S] GTPγS binding when the expression of Cys
352Ile 
Gαi2 was induced, but only partial inhibition when Cys
351Ile Gαo1 was induced, consistent 
with its action as a partial agonist for this pathway.  It is interesting to note the higher 
potency observed at the D2l receptor upon induction of expression of Gαi2 or Gαo1 in 
comparison to the equivalent D2l-receptor fusion proteins.  However, the affinity of 
dopamine or S-(-)-3PPP for the D2l receptor in these two different models is similar.  Since 
the ratio of receptor to G protein must be 1:1 in the fusion proteins, this indicates that in 
the Flp-In T-REx D2l receptor plus either Gαi2 or Gαo1 cell lines there could be a receptor 
reserve accounting for this increase in potency.   
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This apparent protean effect was corroborated by competition binding studies, comparing 
the binding profiles of both dopamine and S-(-)-3-PPP.  Dopamine showed both high and 
low affinity states for all four G protein environments, consistent with its action as an 
agonist.  In the presence of GTP the high affinity site was lost, consistent with the 
dissociation of the receptor from the GTP bound α subunit.  Conversely, S-(-)-3-PPP only 
showed a high affinity site in the presence of Cys
351Ile Gαo1 but not at any of the other the 
CysÆIle Gαi mutants.  This was true for both the receptor-CysÆIle G protein α subunit 
mutant fusion proteins and for the cell lines where either expression Cys
352Ile Gαi2 or 
Cys
351Ile Gαo1 could be induced by tetracycline treatment.  The Flp-In T-REx cell lines in 
particular showed clearly how the G protein environment has a significant effect on S-(-)-
3-PPP pharmacology.  For both dopamine and S-(-)-3-PPP, without the induction of G 
protein, where the receptor is in essentially a Gαi/o ‘null’ environment, competition binding 
was best fit by a monophasic, low affinity curve.  However, with the induced expression of 
either Cys
352Ile Gαi2 or Cys
351Ile Gαo1 dopamine gained a GTP-sensitive high affinity 




It is interesting to note that in the case of the dopamine receptor-CysÆIle G protein α 
subunit mutant fusion proteins, as demonstrated by the action of spiperone, a higher 
constitutive activity is observed at the Cys
351Ile Gαi2 fusion protein as compared to that 
observed when the D2l receptor is coupled to Cys
352Ile Gαo1.  It would appear then that the  
S-(-)-3PPP is an inverse agonist at Gαi2 when there is high constitutive activity, but an 
agonist at Gαo1 where the observed constitutive activity negligible.  This is consistent with 
the desription of a protean agonist as described by Kenakin (Kenakin, 2001).  However, for 
the work using the FlpIn TREx stable cell lines where the receptor and G protein are 
expressed as separate polypeptides no such difference in constitutive activity is observed, 
and the action of S-(-)-3PPP could better be described by the term functional selectivity.  J. Robert Lane, 2007    Chapter 3 
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This term desribes the observation that many ligands can differentially activate signaling 
pathways mediated via a single G protein-coupled receptor in a manner that challenges the 
traditional definition of intrinsic efficacy.  In this case then S-(-)-3PPP stabilises a 
conformation of the D2L receptor that selectively couples to Gαo1. 
 
In conclusion then, data from both the binding and the [
35S]GTPγS studies indicated that 
the D2l generated a high affinity state for S-(-)-3-PPP and allowed G protein activation by 
this ligand only in the presence of Gαo1. This protean agonism or functional selectivity is a 
clear demonstration that different agonists at the D2l receptor can stabilise different 
receptor conformations. Moreover, this may have implications for the physiological action 
of S-(-)-3-PPP.  S-(-)-3-PPP has been described, using both biochemical and behavioural 
experiments, as an agonist at dopamine autoreceptors, but an antagonist at post-synaptic 
dopamine receptors (Arnt et al., 1983; Hjorth et al., 1983).  Interestingly, the localisation of 
Gαi/o proteins has been shown to be different at post and pre-synaptic densities.  In post 
synaptic densities Gαi2 and Gαi3 were shown to be more prevalent, whereas at pre-synaptic 
densities Gαo1 was shown to be more prevalent (Aoki et al., 1992).  It could be extrapolated 
then, that the differential antagonistic and agonistic effects of S-(-)-3-PPP at postsynaptic 
dopamine receptors and pre-synaptic dopamine receptors respectively, could lie at the 
different G protein environments of these two receptor populations as demonstrated by the 
results in this chapter.   
 
In two studies with S-(-)-3-PPP, patients with schizophrenia showed improvements in both 
positive and negative symptoms, but a limited duration of effectiveness (Lahti et al., 1998).  
It has been postulated that this is due to the action of S-(-)-3-PPP as a D2-like dopamine 
receptor partial agonist and that this would have a ‘dopamine system stabilisation effect’ 
ie. normalisation of both dopamine hypo- and hyperactivity in the pathologically affected 
dopaminergic tracts observed in schizophrenic patients (Lieberman, 2004).  Similarly, the J. Robert Lane, 2007    Chapter 3 
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atypical antipsychotic aripiprazole (Abilify) which now has FDA approval for the 
treatment of schizophrenia, has also been characterised as a partial agonist at D2 receptors 
and again to have a dopamine stabilisation effect (Burris et al., 2002; Cosi et al., 2006).  
However, the intrinsic activity and potency of aripiprazole at the D2 receptor is both cell 
line and assay dependent.   For example, aripiprazole has been shown to be a partial 
agonist for inhibition of cAMP accumulation in a CHO cell line but an antagonist for [
35S] 
GTPγS binding (Shapiro et al., 2003).  Most significant, however, is the observation that, 
like S-(-)-3-PPP, the drug is reported to antagonise post-synaptic D2 receptors but partially 
activate presynaptic autoreceptors (Kikuchi et al., 1995).  In agreement with these findings, 
a recent paper demonstrated the differential signalling of aripiprazole for several D2l 
mediated pathways (Urban et al., 2006b).  These observations are consistent with 
aripiprazole, like S-(-)-3-PPP, having differential pharmacology at different signalling 
pathways, and it would be interesting to ascertain if aripiprazole has similar protean 
characteristics in terms of G protein coupling. 
         
‘Protean’ effects of ligands have been demonstrated both in vitro at the β1 and β2 
adrenergic receptors (Galandrin and Bouvier, 2006) and for functional in vivo end points at 
the histamine H3 receptor (Gbahou et al., 2003).  As suggested above, this concept may 
have relevance to the reported differences in clinical effects of ligands that appear to target 
the same receptor.  The utility of fusion constructs for evaluating receptor signalling 
mechanisms for systems that are otherwise designed to be catalytic with a spare receptor 
reserve, for example, has been highlighted (Colquhoun, 1998; Hildebrandt, 2006). The 
invariant ratio of receptor to G protein α subunit overcomes differences in expression that 
can complicate comparisions among different receptors and G proteins. This is an 
attractive quality when investigating phenomena such agonist directed trafficking and 
protean ligands.  This is highlighted by recent work using the thromboxane A2 receptor 
(TPα) fused to either Gα12 or Gα13 (Zhang et al., 2006).  This study indicated that the J. Robert Lane, 2007    Chapter 3 
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purported antagonist pinane thromboxane A2 stimulated no response at the TPα- Gα12 
fusion protein but was an agonist at the TPα- Gα13 fusion protein.  Although not suggested 
by the authors, these results indicate that pinane thromboxane A2 could well be a ‘protean’ 
agonist. 
 
 J. Robert Lane, 2007    Chapter 4 
180 
4  An investigation of the G protein-coupling specificity 
of D2 and D3 dopamine receptors 
4.1  Introduction 
 
The G protein coupling selectivity of dopamine D2 receptors has been well studied, and it 
is now generally accepted that D2 receptors couple efficiently and promiscuously to all 
four Gαi/o subtypes, although the relative order of preference remains controversial (Gazi et 
al., 2003; Jiang et al., 2001; Senogles et al., 2004; Watts et al., 1998).  There has been a 
large amount of research directed at the elucidation of the signalling pathways of the D2 
dopamine receptor due to identification of this receptor as a therapeutic target for 
schizophrenia (Seeman, 2006).   Similarly, there has been considerable interest in the D3 
receptor as a target for antipsychotic drugs (Joyce, 2001; Joyce and Millan, 2005; Sokoloff 
et al., 2006). Human dopamine D2 and D3 receptors have an overall amino acid similarity 
of 52% which increases to 78% if only transmembrane regions are considered (Sokoloff et 
al., 1990).  Consequently D2 and D3 receptors exhibit a similar pharmacological profile 
(Ahlgren-Beckendorf and Levant, 2004). However, signal transduction by the D3 receptor 
is less clearly understood than that of the D2 receptor.  Studies to elucidate cellular 
responses to D3 receptor activation are hampered by the similar pharmacological profiles 
of D2 and D3, the co-expression of these receptors in brain tissue and the lack of 
definitively selective pharmacological tools.  It follows then, that the majority of data has 
been obtained by expression of the receptors in heterologous systems.  This has lead to a 
number of different and conflicting results.  Initial reports indicated that the D3 receptor 
expressed in a variety of cell systems did not exhibit a decrease in affinity for agonists in 
the presence of guanyl nucleotides as would be expected for a G protein coupled receptor 
(Freedman et al., 1994; Sokoloff et al., 1990; Tang et al., 1994).  Consistent with this J. Robert Lane, 2007    Chapter 4 
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observation, several studies reported that the D3 receptor did not modulate adenylate 
cyclase activity (Sokoloff et al., 1990; Tang et al., 1994) 
 
However, subsequent studies using heterologous expression systems showed some 
pertussis toxin-sensitive inhibition of adenylate cyclase (Cox et al., 1995; Griffon et al., 
1997; Hall and Strange, 1999).  Of particular note, in HEK293 cells or COS-7 cells, 
stimulation of D3 receptors attenuated forskolin-stimulated adenylate cyclase activity, but 
only when cells were co-transfected with the adenylate cyclase V isozyme (Robinson and 
Caron, 1997). In agreement with this dopaminergic agonists dose-dependently stimulated 
[
35S] GTPγS binding in Sf-9 insect cells (Alberts et al., 2000), Chinese hamster ovary 
(CHO) cells (Jurgen et al., 2000; Malmberg et al., 1998; Newman-Tancredi et al., 1999; 
Vanhauwe et al., 1999) and SH-SY5Y human neuroblastoma cells (Zaworski et al., 1999) 
in which the D3 receptor was expressed.  Furthermore, this effect was abolished by 
pertussis toxin, suggesting coupling to Gαi/o proteins.  This first objective of this project, 
therefore, was to elucidate the intrinsic coupling specificities of both D2l and D3 dopamine 
receptors in parallel.  As for the characterisation of agonist directed coupling at the D2l 
receptor (chapter 3), the need to devise a model system in which the interaction between a 
specific receptor and G protein could be studied in isolation was crucial.  To this end, 
pertussis-toxin resistant variants of Gαi/o G proteins were again employed.  Similarly, it is 
also important to control the relative expression levels of both receptor and G protein.  
Again, both receptor-G protein fusion proteins and Flp-In T-REx cell lines in which the 
receptor was constitutively expressed and the G protein was expressed from the inducible 
Flp-In locus were utilised.   In this chapter the use of these strategies confirmed the 
promiscuous coupling of the D2l receptor to Gαi1, Gαi2, Gαi3, and Gαo1.  Furthermore, the 
efficient and specific coupling of D3 to Gαo1 but not Gαi1, Gαi2 and Gαi3 was 
demonstrated. 
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The second aim of this project was to investigate the molecular basis of the differential G 
protein-coupling specificities of the dopamine D2l and D3 receptors.  An accepted and 
widely-used approach that has led to a wealth of information about the molecular basis of 
receptor-G protein-coupling selectivity is to analyze hybrid receptors constructed between 
functionally distinct members of a GPCR subfamily (Wess, 1998).   Perhaps due to the 
high homology of the  D2 and D3 receptors, a number of investigations into coupling of D3 
receptors have been performed using D2/D3 receptor chimera constructions (McAllister et 
al., 1993; Robinson and Caron, 1996; Robinson et al., 1994; Van Leeuwen et al., 1995). 
These studies indicated that the third intracellular loop of D2 and D3 receptors is important 
for the coupling to AC. However, in D3/D2 receptor chimeras that fully coupled to 
inhibition of cAMP production, agonist binding to these chimeras was still resistant to the 
effect of GTP or its analogues (Van Leeuwen et al., 1995). A subsequent study identified 
more specific components of the third intracellular loop of the human dopamine D2 
receptor involved in the coupling of these receptors with adenylate cyclase (Filteau et al., 
1999).  This study used reciprocal chimera constructions between hD2 and hD3 dopamine 
receptors with the exchange of a divergent twelve amino acid section in the c-terminus of 
the third intracellular loop of each receptor.   The chimeric D3 receptor with a twelve 
amino acid section of D2 (termed D3/2, Figure 4.1) gained coupling to adenylate cyclase.   
In this chapter, the same chimera has been used.  As for the native D2l and D3 dopamine 
receptors, the G protein coupling specificity of this chimeric D3/2 receptor was 
characterised, showing coupling to Gαi1, Gαi2, Gαi3 and Gαo1.  Therefore, the exchange of a 
twelve amino acid section of the third intracellular loop of D3 with that of the D2 receptor 
confers promiscuous D2-like coupling selectivity to the D3 receptor. 
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4.2  Results 
4.2.1  The use of a chimeric D3/2 receptor to investigate regions of D2l 
and D3 important for G protein coupling selectivity  
To investigate regions within the D2l and D3 receptors which are important in directing 
potential differences in G protein selectivity, an accepted approach is the use of chimeric 
receptors in which one region of a donor receptor is replaced with the equivalent region of 
the acceptor receptor.  In this case the chimera used was a D3 receptor with a twelve amino 
acid section of the C-terminus of the third intracellular loop (IC loop 3) replaced with the 
equivalent region of D2 (Figure 4.1).  The twelve amino acids are of entirely different 
sequence but are flanked by homologous regions to their C-terminal side close to 
transmembrane domain VI (TM VI) and N-terminal side.  As in chapter 3, this study used 
heterologous expression in HEK293T cells as the model system.  However, there is 
significant endogenous G protein α subunit expression in HEK293T cells, so it was 
necessary to use systems which ensured the interaction between a receptor and one G 
protein subtype could be investigated in isolation.  D2-like (i.e. both D2 and D3) dopamine 
receptors have shown their down stream signalling to be pertussis toxin-sensitive and, 
therefore, that they couple to the Gi subclass of G proteins.    Consequently, to allow the 
investigation of coupling between a specific receptor and G protein, cells can be 
transfected with cDNA of both the dopamine receptor and a pertussis toxin insensitive 
mutant Gαi/o subunit of interest, and then treated with pertussis toxin 16 hours prior to cell 
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4.2.2  Investigation of D2-like dopamine receptor coupling using 
transient co-transfection of receptor and pertussis toxin insensitive Gαi/o 
subunits 
 
4.2.2.1  Determination of dopamine receptor levels in HEK293T cells transiently 
co-transfected with either D2l, D3 or D3/2 cDNA and Cys




HEK293T cells were co-transfected with a dopamine receptor (D2l, D3 or D3/2) and either 
Cys
352Ile Gαi2 or Cys
351Ile Gαo1 and treated with or without pertussis toxin (25ng/ml) 16 
hours prior to cell harvest.  To allow a determination of the number of functionally 
competent (properly folded) receptors, the high affinity, radiolabeled dopaminergic 
antagonist, [
3H] spiperone, was used.   For saturation binding experiments, co-transfected 
HEK293T membranes (10 µg) were incubated with a range of [
3H] spiperone 
concentrations (0.001–2 nM).  Non-specific binding was determined by the inclusion of 10 
µM  (+)-butaclamol.  Incubations were carried out for 3 hours at 25 º C to achieve 
equilibrium-binding conditions, and bound radioactivity separated from free by filtration 
through GF/C filters.  Ligand affinities were calculated using Prism (Graphpad). 
 
In D2l co-transfections, a single high affinity site for [
3H] spiperone was observed with Kd 
of approximately 0.04 nM (Table 4.1).  Receptor density as indicated by the Bmax value 
was approximately 3-4 pmol/mg membrane protein in all transfections. In both cases there 
was no significant difference in Kd or Bmax between the same transfection with or without 
pertussis toxin treatment.  However, although no difference in Kd was observed, a J. Robert Lane, 2007    Chapter 4 
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significantly higher receptor density was observed for Gαo1 co-transfections as compared 
to Gαi2 transfections.    
 
By contrast, [
3H] spiperone showed a lower affinity for dopamine D3 receptor co-
transfections with a Kd of 0.1-0.15 nM, with receptor density similar to levels seen for D2l 
co-transfections.    For the chimeric D3/2 receptor co-transfections, affinity for [
3H] 
spiperone was similar to that observed for the D3 receptor with a Kd of 0.1nM for all co-
transfections.  Bmax values indicating receptor density were around four-fold lower than for 
both D2l and D3 at 0.5-1 pmol/mg (Table 4.1).  Results indicate that the chimeric D3/2 
receptor retains a ‘D3-like’ affinity for [
3H] spiperone, suggesting a functionally competent 
chimeric receptor.  As for D2l co-transfections, a significantly higher value of Bmax was 
observed in the Gαo1 co-transfections as compared to the equivalent Gαi2 co-transfections 
for both D3 and D3/2.  Again no significant difference in Kd or Bmax was observed for the 
same transfection with or without pertussis toxin treatment.  It is perhaps noteworthy, 
however, that in the case of the D3 receptor only, a significant difference in Kd between 
Gαi2 and Gαo1 for [
3H] spiperone was observed dependent on whether Gαi2 or Gαo1 
 was co-expressed. 
 
 
4.2.2.2  Estimation of Gα subunit expression levels in HEK293T cells transiently 
co-transfected with either D2l, D3 or D3/2 cDNA and Cys




G protein expression was measured for both Cys
352Ile Gαi2 and Cys
351Ile Gαo1 co-
transfections by western blotting using antisera raised against the C-terminal decapeptide 
of the respective G protein α subunits.  HEK293T cell membranes transfected with J. Robert Lane, 2007    Chapter 4 
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equivalent amounts of pcDNA3 vector were included as a control.  SDS-PAGE was 
performed using 10 µg of membrane protein loaded per lane onto a 4-12% bis-tris gel, and 
transferred to nitrocellulose.  Western blots (Figure 4.2) show that both Gαi2 and Gαo1 
were significantly over-expressed in all co-transfections with respect to the mock-
transfected cells.  There was significant variation in the levels of G protein α subunit 
detected between co-transfections, but no significant difference observed between the same 
co-transfections with or without pertussis toxin treatment. 
 
Table 4.1: [
3H] spiperone binds with similar affinity to D3 and the chimeric D3/2 
receptor when co-expressed with either Cys
352Ile Gαi2 or Cys
351Ile Gαo1 
Co-Transfection  








352Ile Gαi2  -  0.04 (0.01)  3409 (150) 
D2l Cys
352Ile Gαi2  +  0.03 (0.01)  3036 (96) 
D2l Cys
351Ile Gαo1  -  0.06 (0.01)  4488 (160) 
** 
D2l Cys
351Ile Gαo1  +  0.04 (0.01)  4815 (169) 
*** 
D3 Cys
352Ile Gαi2  -  0.10 (0.01)  1857 (169) 
D3 Cys
352Ile Gαi2  +  0.09 (0.01)  2429 (70) 
D3 Cys
351Ile Gαo1  -  0.12 (0.01)  3079 (86) 
** 
D3 Cys





352Ile Gαi2  -  0.08 (0.01)  583 (21) 
D3/2 Cys
352Ile Gαi2  +  0.14 (0.03)  509 (34) 
D3/2 Cys
351Ile Gαo1  -  0.11 (0.02)  1117 (39) 
*** 
D3/2 Cys
351Ile Gαo1  +  0.08 (0.01)  1255 (30) 
*** 
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Experiments were performed in triplicate to n = 3 
Differences in Kd and Bmax were analysed using an unpaired Student’s t-test (p<0.05).  No 
significant differences in Kd or Bmax were seen for the same transfection with or without 
pertussis toxin treatment.  Bmax and Kd values were compared between Gαi2 and Gαo1 
 co-transfections with the same receptor and pertussis toxin treatment condition. 
Significant differences seen between Gαi2 and Gαo1 co-transfections are annotated below 




4.2.2.3  Optimisation of [GDP] required in [
35S]GTPγS assays using membranes 
expressing D3 dopamine receptors 
 
In order to study the functional coupling between receptor and G protein α subunits a [
35S] 
GTPγS binding assay was established incorporating an immunoprecipitation step using 
antisera raised against the C-terminal tail of Gαi2 or Gαo1 as described in section 2.9.2.2.  
However, before embarking on detailed experiments it was important to optimise 
conditions for the assay with respect to the concentration of GDP used in the assay.  Using 
membranes from D3 + Cys
351Ile Gαo1 co-transfections, reactions were set up with 10 fMol 
of receptor per reaction, various concentrations of GDP and with or without the addition of 
10µM dopamine.  In such experiments the largest signal window (Figure 4.3) (i.e. the 
stimulation of [
35S] GTPγS binding above basal levels) was observed at 10 µM GDP. 
Consequently, GDP was used at a concentration of 10 µM for all subsequent [
35S] GTPγS 
assay experiments. 
P< 0.05 N = 3
P value Definition Summary
< 0.001 extremely significant ***
0.001 to 0.01 very significant **
0.01 to 0.05 significant *
> 0.05 not significantJ. Robert Lane, 2007    Chapter 4 
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4.2.2.4  Dopamine D2l and the chimeric D3/2 receptors couple efficiently to both 
Cys
352Ile Gαi2 and Cys
351Ile Gαo1 whilst the D3 receptor only couples through 
Cys
351Ile Gαo1.  
  
As described previously, HEK293T cells were co-transfected with a dopamine receptor 
and either Cys
352Ile Gαi2 or Cys
351Ile Gαo1 cDNA, membranes made and functional 
coupling between receptor and G protein assayed using [
35S]GTPγS binding.  For Gαi2 co-
transfections a [
35S] GTPγS assay was performed with an immunoprecipitation step using 
in-house antiserum raised against the C-terminal tail of Gαi1/2.  Correspondingly, 
experiments using membranes from Cys
351Ile Gαo1 transfected cells were performed with 
an immunoprecipitation step using an in-house antiserum raised against the C-terminal tail 
of Gαo1.  In all cases membranes containing equal amounts of receptor (10 fMol) were 
incubated with 10µM GDP with or without the presence of the endogenous dopamine 
receptor agonist dopamine.  For Cys
351Ile Gαo1 co-transfections significant agonist-driven 
stimulation of [
35S] GTPγS binding above basal levels was observed for D2l, D3 and 
chimeric D3/2 co-transfections, indicating that all three receptors can couple efficiently to 
Gαo1 (Figure 4.4B).  However, for Cys
352Ile Gαi2 co-transfections, significant dopamine-
stimulated [
35S] GTPγS binding was seen for D2l and D3/2 but not for D3 co-transfections 
(Figure 4.4A).  This suggests that, under the conditions employed, D2l coupled efficiently 
to both Gαi2 and Gαo1 whereas D3 only couples to Gαo1.  The chimeric D3/2 receptor 
couples to both Gαi2 and Gαo1 indicating that it has acquired ‘D2-like’ G protein coupling 
promiscuity.  However, it was also apparent that despite the same amount of receptor being 
added to each experiment there was significant differences between basal [
35S] GTPγS 
loading between different receptors for the Gαo1 and in a far more pronounced manner for 
the Gαi2 co-transfections.  For example, for membranes where D2l was co-transfected with 
Cys
352Ile Gαi2 the basal level of [
35S] GTPγS binding was around 200 dpm, increasing to J. Robert Lane, 2007    Chapter 4 
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500 dpm (Figure 4.4A).  By contrast, the basal level of [
35S] GTPγS binding for the D3/2 
receptor was some 4000 dpm, increasing to 8000 dpm upon stimulation with dopamine.  
The amount of receptor added was the same in each case.   This might be explained in two 
ways, firstly that the chimeric D3/2 receptor is highly constitutively active and couples more 
efficiently to Gαo1 than D2l.  However, a perhaps more likely explanation may reflect that 
the D3/2 chimera was expressed at a four-fold (Table 4.1) lower level as compared to D2l 
whereas the G protein expression was equivalent or higher (Figure 4.2).  Consequently, 
although the amount of receptor added in each condition was the same, the amount of G 
protein would be much higher per reaction for the D3/2 chimera..   It is important, therefore, 
to control relative levels of both G protein and receptor expression, in order to generate 
useful comparisons of the G protein-coupling selectivity of different receptors. 
 
4.2.3  Generation of dopamine receptor-pertussis toxin-insensitive 
CysÆIle variant G protein alpha subunit fusions 
 
In order to control relative levels of G protein and receptor expression, dopamine receptor: 
G protein fusion proteins were generated. Constraining receptor and G protein within a 
single fusion protein defines the stoichiometry of expression of the two entities as 1:1 and 
ensures their co-localisation following expression.  As described previously in section 
3.2.1, four dopamine D2l receptor-CysÆIle pertussis toxin-insensitive G α subunit fusion 
proteins were constructed.  Using the same methodology, eight further dopamine receptor- 
Cys Æ Ile G α subunit fusion proteins were generated (Figure 4.5), fusing each of the two 
remaining dopamine receptors (D3, D3/2) to each of the four Cys Æ Ile pertussis toxin 
insensitive variants  of the Gi family G protein α subunits (Gαi1, Gαi2, Gαi3, Gαo1).  After 
transfection and prior to cell harvest, HEK293T cells were treated with pertussis toxin to 
allow the interaction between the receptor and G protein within the fusion protein to be 
studied in isolation. J. Robert Lane, 2007    Chapter 4 
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4.2.3.1  Determination of the levels of dopamine receptor-G protein fusion 
protein expression using [
3H] spiperone saturation binding 
 
HEK293T cells were transiently transfected with each of the receptor-Cys Æ Ile G α 
subunit fusion protein cDNAs, treated as above with pertussis toxin, cells harvested and 
membranes made.  As for the transient co-transfection studies, receptor binding site density 
was assessed using [
3H] spiperone saturation binding.    Membranes (10 µg) were 
incubated with a range of [
3H] spiperone concentrations (0.001–2 nM).  Non-specific 
binding was determined by the inclusion of 10 µM (+)-butaclamol.   
  
As for D2l receptor plus G protein co-transfections, [
3H] spiperone displayed a high affinity 
for the D2l: G protein fusion proteins with a Kd  in the region of 0.04 nM.  There was no 
significant difference in Kd between all four D2l fusion proteins.  Receptor binding site 
density as indicated by Bmax values was approximately1.5 pmol/mg membrane protein for 
all D2l fusion proteins (Table 3.1).  The D3 receptor fusion proteins showed a lower 
affinity for [
3H] spiperone with a Kd of 0.12 nM (Table 4.2).  Receptor binding site density 
was between 0.5 and 2 pmol/mg for each of the D3 receptor fusion proteins, with the 
observed Bmax significantly higher at the D3-Gαo1 fusion protein as compared to the other 
D3 fusion proteins.  The D3/2 receptor fusion proteins showed a ‘D3-like’ affinity for [
3H] 
spiperone with Kd of some 0.12 nM.  Bmax values of receptor density were between 0.5 and 
1 pmol/ mg membrane protein.  Significantly higher values of Bmax were observed at the 
D3/2-Gαi1 and D3/2-Gαo1 fusion proteins as compared to the other D3/2 receptor fusion 
proteins. 
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Table 4.2:[
3H] spiperone binds with similar and high affinity to various D3 or D3/2 
receptor-G protein fusions 
 
Experiments were performed in triplicate to n = 3 
*** - Differences in Kd and Bmax for D3 or D3/2 receptor fusion proteins were analysed using 
a one way ANOVA with Tukey’s post-hoc test using GraphPad Prism version 4.   No 
significant difference in Kd was observed for both D3 and D3/2 receptor fusion proteins.  
However, a significant difference in Bmax was observed between D3 receptor fusion 
proteins with D3Gαo1 > D3Gαi3 = D3Gαi2 = D3Gαi1 (P<0.001), and between D3/2 receptor 
fusion proteins with D3/2Gαo1 = D3/2Gαi3 > D3/2Gαi2 = D3/2Gαi1 (P<0.001). 
 
Receptor: G Protein fusion Kd, nM (± S.E.M.) 
 
Bmax fMol.mg-1 (± S.E.M.) 
D3Gαi1  0.08  (0.01)  641   (49) 
D3Gαi2  0.15  (0.02)  527   (21) 
D3Gαi3  0.12  (0.02)  563   (14) 
D3Gαo1  0.12  (0.01)  1985 (68) 
*** 
D3/2Gαi1  0.11  (0.01)  1328 (22) 
*** 
D3/2Gαi2  0.07  (0.01)  652   (17) 
D3/2Gαi3  0.11  (0.01)  446   (11) 
D3/2Gαo1  0.11  (0.01)  1472 (34) 
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4.2.3.2  Increasing amounts of dopamine receptor-Cys Æ Ile G protein α subunit 
fusion protein leads to a proportional increase in [
35S] GTPγS binding 
 
HEK293T cells were transiently transfected with dopamine receptor-Cys
351Ile Gαo1 fusion 
proteins, cells treated with pertussis toxin and harvested.  Cell membrane preparations 
were made and receptor binding site density estimated using [
3H] spiperone binding as 
described earlier.  Varing amounts of membrane (and therefore varying amounts of 
receptor) were incubated with 10 µM GDP and with or without 10 µM dopamine using the 
[
35S] GTPγS assay with an immunoprecipitation step.  An antiserum raised against the C-
terminal tail of Gαo1 was used for the immunoprecipitation step.  For D2l-Cys
351Ile Gαo1 
(Figure 3.3C), D3-Cys
351Ile Gαo1 (Figure 4.6A) and D3/2-Cys
351Ile Gαo1 (Figure 4.6B)  an 
increase in receptor per reaction lead to a linear increase in both basal and agonist 
stimulated [
35S] GTPγS binding.  Basal levels of [
35S] GTPγS binding could reflect 
constitutive activity of the dopamine receptor-Cys
351Ile Gαo1 fusions, or perhaps the basal 
[
35S] GTPγS loading (i.e. intrinsic guanine nucleotide exchange) of increasing amounts of 
G α subunit added to the reaction. 
  
 
4.2.3.3  D3 receptor couples only to Cys
351Ile Gαo1 whereas the chimeric D3/2 
receptor couples through all four G protein α subunits  
 
To investigate the coupling selectivity of the D2l, D3 or the chimeric D3/2 receptor for each 
of the four CysÆIle Gαi/o subunits, HEK293T cells were transfected with dopamine 
receptor-CysÆIle G protein α subunit fusion protein cDNA.  Cells were pertussis toxin 
treated (25 ng/ml for 16 hours), harvested and cell membrane preparations made.  Cell J. Robert Lane, 2007    Chapter 4 
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membranes (15 fMol of receptor/ reaction) were incubated with 10 µM GDP, and with or 
without 10 µM dopamine.  A [
35S] GTPγS assay was performed with an 
immunoprecipitation step.  For Cys
351Ile Gαi1 fusion protein membranes, and Cys
352Ile 
Gαi2 fusion protein membranes, an antiserum raised against the C-terminal tail of Gαt was 
used.  For Cys
351Ile Gαi3 an antiserum raised against the C-terminal tail of Gαi3 was 
employed.  Similarly, an antiserum raised against the C-terminal tail of Gαo1 was used for 
membranes expressing the Cys
351Ile Gαo1 fusion protein.  For Gαi1 fusion transfections, 
significant stimulation above basal was seen for D2l-Cys
351Ile Gαi1 and the D3/2-Cys
351Ile 
Gαi1, but not for D3-Cys
351Ile Gαi1 (Figure 4.7A).  Similarly, for D2l-Cys
352Ile Gαi2 
significant stimulation above basal was observed in the presence of 10 µM dopamine but 
not for D3-Cys
352Ile Gαi2.  Once again, significant coupling to Gαi2 was regained for the 
D3/2 chimera-Cys
352Ile Gαi2 fusion protein (Figure 4.7B).  A similar pattern was seen with 
the dopamine receptor-Cys
351Ile Gαi3 fusion proteins, with both D2l and D3/2 fusion proteins 
showing significant agonist dependent stimulation.  However, no stimulation above basal 
was seen with the D3-Cys
351Ile Gαi3 fusion membrane preparations (Figure 4.7C).  By 
contrast, for each of the D2l, D3 and D3/2: Gαo1 fusion protein preparations significant 
stimulation above basal levels of [
35S] GTPγS binding was observed in the presence of 10 
µM dopamine (Figure 4.7D).  In summary then, it would seem that D2l coupled 
promiscuously to all four Gi subfamily members with dopamine-stimulated [
35S] GTPγS 
binding seen for Gαi1, Gαi2, Gαi3, Gαo1 fusion proteins. The D3 receptor coupled selectively 
and exclusively to Gαo1 whilst the chimeric receptor showed ‘D2-like’ G protein coupling 
behaviour, and coupled to all four Gαi subunits.   This pattern is in agreement with results 
from the receptor plus G protein co-transfection experiments (section 4.2.5). 
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4.2.4   The action of various dopamine D2l-like agonists at dopamine 
receptor: CysÆIle G protein alpha subunit variant fusion proteins 
 
To further characterise the dopamine receptor-G protein fusion proteins, the action of 
various, previously characterised dopamine D2 receptor agonists was tested in membranes 
of HEK293T cells transfected with dopamine receptor-Cys Æ Ile Gα subunit fusion 
protein cDNA, treated with pertussis toxin as above and harvested. As a general pattern, 
dopamine and NPA were able to stimulate [
35S] GTPγS binding for all D2l- CysÆIle Gαi/o 
fusion proteins (Figure 3.4D, Table 3.2).  However, for all of the agonists examined, 
stimulation of [
35S] GTPγS binding through the D3 receptor was only seen for the D3-
Cys
351Ile Gαo1 fusion protein and not for the other three D3-Gαi/o CysÆIle fusion proteins 
(Figure 4.8 A-E, Table 4.3).  This supports the previous data indicating that D2l is 
promiscuous and couples to all four Gαi/o subunits, whereas D3 selectively and exclusively 
couples to Gαo1.  Dopamine, NPA and quinpirole caused stimulation of [
35S] GTPγS 
binding in all four of the D3/2-Cys ÆIle Gαi/o fusion proteins in a concentration- dependent 
manner (Figure 4.9A-D, Table 4.4). This is in agreement with previous results showing 
that the chimeric receptor has a D2-like ability to couple promiscuously to all four Gαi/o 
subunits.     
 
As a general pattern, agonists showed increased potency at D3-Cys
351Ile Gαo1 fusion 
proteins as compared to D2l-Cys
351Ile Gαo1 fusion proteins, with dopamine, m-tyramine, p-
tyramine, R-(+)-3PPP, S-(-)-3PPP, 7-OH DPAT, and quinpirole all showing significant 
increases in potency (Figure 4.10 A, Table 3.2, Table 4.3) (P<0.05, unpaired, two-tailed 
Students t-test).  Similarly, in terms of efficacy, when compared to the maximal 
stimulation produced by the endogenous agonist dopamine at the given dopamine receptor-
Gαi/o fusion protein, the values of Emax for the  agonists p-tyramine, S-(-)-3PPP, R-(+)-
3PPP, 7-OH DPAT and quinpirole were significantly higher at D3- Cys
351Ile Gαo1 than D2l-J. Robert Lane, 2007    Chapter 4 
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Cys
351Ile Gαo1 (Figure 4.10 B, Table 3.2, Table 4.3) (P<0.05, un-paired, two-tailed 
Students t-test).  However, NPA showed no significant difference in potency or Emax 
between D2l-Cys
351Ile Gαo1 and D3-Cys
351Ile Gαo1 fusion proteins. 
 
The chimeric D3/2-Cys
351Ile Gαo1 fusion protein showed pharmacology similar to the 
dopamine D3- Cys
351Ile Gαo1 fusion protein for all agonists examined.  Indeed, there was 
no significant difference between potency (pEC50) (Figure 4.11 A) or efficacy (Emax 
relative to maximal dopamine stimulation) (Figure 4.11 A, Table 4.3, Table 4.4) (P<0.05, 
unpaired, two-tailed Students t-test).  All agonists produced a robust and concentration-
dependent stimulation of [
35S] GTPγS binding at both D3/2-Cys
351Ile Gαo1 and D3/2-
Cys
351Ile Gαi3.  Furthermore, there were no significant differences between the efficacy or 
potency of all agonists at these two dopamine D3/2 receptor-fusion proteins (Figure 4.12 A-
B, Table 4.4) (P<0.05, unpaired, two-tailed Students t-test).  For both the D3/2-Cys
351Ile 
Gαi1 and the D3/2- Cys
352Ile Gαi2 fusion proteins the agonists dopamine, NPA and 
quinpirole stimulated the binding of [
35S] GTPγS in a robust and concentration-dependent 
manner.  Furthermore, there were no significant differences between the potency or 
efficacy of dopamine and quinpirole at these two receptor-G protein fusion proteins 
(Figure 4.12 C-D, Table 4.4) (P<0.05, unpaired, two-tailed Students t-test).   It should be 
noted that the potency of both quinpirole and dopamine was significantly lower at D3/2-
Cys
351Ile Gαi1 and D3/2-Cys
352Ile Gαi2 fusion proteins (pEC50 ~ 5.5) when compared to the 
D3/2-Cys
351Ile Gαi3 or D3/2-Cys
351Ile Gαo1 fusion proteins (pEC50 ~ 7.3) indicating, perhaps, 
a lower efficiency of coupling to these α subunits (Table 4.4).   
 
The agonists m-tyramine and R-(+)-3PPP produced a concentration-dependent stimulation 
of [
35S] GTPγS binding at D3/2-Cys
352Ile Gαi2 but not D3/2-Cys
351Ile Gαi1.  Conversely 7-
OH DPAT stimulated [
35S] GTPγS binding at D3/2-Cys
351Ile Gαi1 but not D3/2-Cys
352Ile 
Gαi2.  However, the partial agonists S-(-)-3PPP and p-tyramine failed to stimulate [
35S] J. Robert Lane, 2007    Chapter 4 
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GTPγS binding at either D3/2-Cys
351Ile Gαi1 or D3/2-Cys
352Ile Gαi2 (Figure 4.9, Table 4.4).  
This is, perhaps, another example of agonist directed trafficking as described for the D2l 
receptor in chapter 3.   
 
There were differences, however, between the pattern of agonist action as described for D2l 
and that seen at the chimeric dopamine receptor.  For the D2l receptor the ligands S-(-)-
3PPP and p-tyramine failed to stimulate activation of Gαi1, Gαi2, Gαi3 (Table 3.2, Figure 
3.2), whereas at the chimeric D3/2 receptor these ligands produced a robust response at Gαi3 
and Gαo1 (Table 4.4, Figure 4.9 A-D).  Similarly the ligands m-tyramine and R-(+)-3PPP 
stimulated [
35S] GTPγS binding to all four Gαi/o subunits with D2l receptor fusions but only 
to Gαi2, i3 and o1 with chimeric D3/2 receptor fusions.  Furthermore the rank order of 
potency of dopamine for the four different Gαi/o subunits differed between D2l and D3/2.  
For the D2l receptor the order of potency for dopamine was; D2l-Cys
351Ile Gαi1 = D2l-
Cys
352Ile Gαi2 = D2l-Cys
351Ile Gαi3 < D2l-Cys
351Ile Gαo1, whereas for D3/2 it was; D3/2- 
Cys
351Ile Gαi1 = D3/2-Cys
352Ile Gαi2 < D3/2-Cys
351Ile Gαi3 = D3/2- Cys
351Ile Gαo1.   
  
In summary, from experiments using dopamine receptor-Cys Æ Ile Gα subunit fusion 
proteins, the chimeric D3/2 dopamine receptor retains some ‘D3-like’ pharmacology in 
terms of affinity for [
3H] spiperone, the efficacy of agonists at Gαo1 and the potency of 
agonists at Gαo1.  However, with the exchange of a twelve amino acid section of the 3
rd 
intracellular loop of the D3 receptor of the equivalent region of the D2 receptor, the 
chimeric D3/2 dopamine receptor has gained D2l-like promiscuous coupling to the Gαi sub-
family G proteins.   Moreover, the pattern of agonist action in terms of rank-order of 
potencies or potential agonist directed trafficking differs between the D3/2 and D2l 
receptors. 
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Experiments were performed in triplicate to n = 3.  
‘% DA’ refers to Emax value of [
35S] binding as compared to maximal dopamine 
stimulation.  The term ‘na’ refers to conditions in which no concentration-dependent 
stimulation of [



























Dopamine  na   na  na    7.60 
(0.09)  100 
m-
tyramine 






na   na  na    5.26 
(0.09) 
84 
 (6)  
R-(+)-3-
PPP 




















na   na  na    10.0 
(0.08) 
68 
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Table 4.4: The potency and efficacy of ligands at D3/2 receptor-G protein fusions 
 
Experiments were performed in triplicate to n = 3.  
‘% DA’ refers to Emax value of [
35S] binding as compared to maximal dopamine 
stimulation.  The term ‘na’ refers to conditions in which no concentration-dependent 
stimulation of [
35S] GTPγS binding was observed.  The potency of dopamine and 
quinpirole at the four different D3/2 receptor-Gα subunit fusion-proteins were compared 
using a one-way ANOVA with Tukey’s post-hoc test using GraphPad Prism version 4.  
However, a significant difference was observed in pEC50 between D3/2 receptor fusion 
proteins for dopamine; D3/2Gαo1 = D3/2Gαi3 > D3/2Gαi2 = D3/2Gαi1 (P<0.001) and quinpirole; 
D3/2Gαo1 = D3/2Gαi3 > D3/2Gαi2 = D3/2Gαi1 (P<0.01). 
 






















(0.06)  100 
5.55  
(0.18)  100 
7.24 
(0.32)  100 
7.26 
(0.12)  100 
m-tyramine 
na    
4.07  
(0.16)  53 (9) 
6.22 
(0.17)  81(9) 
6.37 
(0.09)  79 (3) 
p-tyramine 
na     na    
5.53 
(0.14) 45  (5) 
5.22 
(0.16) 80 (1)  
R-(+)-3-
PPP  na    
4.09  
(0.24) 68  (11) 
6.08 
(0.08) 68  (7) 
5.98 
(0.14) 92 (4) 
S-(-)-3-PPP 
na     na    
6.68 
(0.36)  40 (3) 
6.88 
(0.10)  50 (4) 
Quinpirole 5.60 
(0.09)  121 (13) 
5.34  
(0.69)  119 (3) 
7.42 
(0.21)  103 (4) 
7.61 
(0.08)  102 (3) 
NPA 9.38 
(0.08) 121 (12) 
8.55  
(0.06) 118  (1) 
9.28 
(0.03) 91 (3) 
9.14 




(0.19) 76 (8)  na    
10.73 
(0.88) 34  (5) 
10.19 
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4.2.5   Generation and characterisation of cell lines stably and 
constitutively expressing D3 or chimeric D3/2 receptor and expressing Gαi1, 
Gαi2, Gαi3, or Gαo1 CysÆIle mutants from the inducible Flp-In locus 
  
As for the Flp-In T-REx cell lines expressing pertussis toxin-insensitive CysÆIle variants 
of Gαi1, 2, 3 or o1 at the inducible Flp-In locus and constitutively and stably expressing 
dopamine D2l receptor (section 3.2.7), equivalent stable cell lines were generated 
constitutively  expressing the dopamine D3 receptor or D3/2 chimeric receptor.  Briefly Flp-
In T-REx cells which inducibly express the Gαi1, i2, i3, or o1 CysÆIle pertussis-toxin 
insensitive mutants were transfected with dopamine D3 or D3/2 receptor cDNA and stable 
cell lines generated as described (section 2.7.7).  Clones generated were screened for 
receptor expression by radioligand binding using a near saturating concentration of [
3H] 
spiperone.  Non-specific binding was estimated using 10 µM (+)-butaclamol.   Clones 
showing significant expression of D3 dopamine receptor (Figure 4.13 A-D) or chimeric 
D3/2 dopamine receptor (Figure 4.14 A-D) were frozen down in liquid nitrogen until 
required for further characterisation.  From experiments using both co-expression of 
receptor and pertussis toxin-insensitive G protein α subunits, or receptor-G protein fusion 
proteins it was clear that D2l could couple promiscuously to all four Gα i/o subunits whereas 
D3 coupled selectively to Gαo1.  Consequently, for subsequent experiments characterising 
Flp-In T-REx cells expressing pertussis toxin-insensitive Gα subunits upon induction with 
tetracycline and constitutively expressing a dopamine receptor, it was decided to focus 
Cys
351Ile Gαo1 cell lines and one other from Cys
351Ile Gαi1, Cys
352Ile i2, Cys
351Ile i3.  
Cys
352Ile Gαi2 cell lines were chosen to be consistent with the co-transfection work. 
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4.2.6   Characterisation of Flp-In T-REx cells expressing Cys
352Ile 
Gαi2 or Cys
351Ile Gαo1 from the inducible Flp-In locus and constitutively 
expressing the D3 dopamine receptor. 
 
D3 dopamine receptor expression levels both with and without the induction of G protein 
expression, were monitored using [
3H] spiperone binding, with non-specific binding 
determined using 10µM (+)-butaclamol. The D3 receptor + Cys
352Ile Gαi2 cell line selected 
(D3 Cys
352Ile Gαi2 clone 7) had a receptor expression level of approximately 0.2 pmol/mg 
membrane protein with no significant difference between expression with and without the 
induction of Gαi2.  The D3 + Cys
351Ile Gαo1 (D3 Cys
351Ile Gαo1 clone 8) cell line had an 
expression level of around 1 pmol/mg without induction of Cys
351Ile Gαo1 and 1.5 
pmol/mg upon induction of Cys
351Ile Gαo1.  For both the D3 + Cys
352Ile Gαi2 and D3 + 
Cys
351Ile Gαo1 cell lines, the affinity for [
3H] spiperone was 0.1nM (Table 4.5).  As for 
both co-transfections and fusion proteins, a markedly lower affinity for [
3H] spiperone was 
seen in D3 receptor Flp-In cell lines than for the equivalent D2l  receptor Flp-In cell lines.  
Induction of G protein expression was monitored by western blotting using antisera raised 
against the C-terminal of the appropriate G protein (Figure 4.15A).  For the D3 receptor + 
Cys
352Ile Gαi2 cell line, significant levels of Gαi1/2 were seen without induction of 
expression by tetracycline treatment.  As in the case of the D2l + Cys
352Ile Gαi2 double 
stable cell line this reflects high levels of endogenous Gαi2 expression by HEK293 cells.  A 
significant increase in Gαi2 expression was, however, seen following treatment of the cells 
with 1µg/ml tetracycline. This is consistent with the induced expression of the Cys
351Ile 
Gαi2 pertussis toxin-sensitive mutant.   Without induction of G protein expression in the D3 
+ Cys
351Ile Gαo1 cell line, no expression of Cys
351Ile Gαo1 (Figure 4.15B) was observed by 
western blotting, underlining the low expression of this G protein α subunit in HEK293 
cells.  Following treatment with tetracycline significant expression of Cys
351Ile Gαo1 was 
induced. J. Robert Lane, 2007    Chapter 4 
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Table 4.5:Expression levels of the D3 receptor are unaffected by tetracycline-induced 
expression of Cys
352Ile Gαi2 or Cys
351Ile Gαo1 expression 
  
Experiments were performed in triplicate to n = 3. 
An unpaired Student’s t-test was performed using GraphPad Prism version 4 (P<0.05).  No 
significant difference in Bmax values were observed in receptor expression with and without 
induction of G protein expression. 
 
4.2.7   Agonist-dependent [
35S] GTPγS binding is observed in 
membranes of the D3 + Cys
351Ile Gαo1 cell line only upon induction of 
expression of Cys
351Ile Gαo1.  No stimulation of [
35S] GTPγS binding 
above basal is observed in membranes of the D3 + Cys
352Ile Gαi2 cell line 
with or without the induced expression of Cys
352Ile Gαi2  
 
To further characterise the D3 + Cys
352Ile Gαi2 and D3 + Cys
351Ile Gαo1 cell lines  the 
ability of a single concentration of dopamine to induce [
35S] GTPγS binding for both, 
membranes (10 fMol of receptor) was investigated.  A [
35S] GTPγS binding assay was 
performed with or without 10 µM dopamine, and terminated by fast flow filtration onto 
GF/C filter paper.  For the D3 receptor plus Cys
352Ile Gαi2 cell line no stimulation of [
35S] 
GTPγS binding was observed above basal with the addition of 10 µM dopamine, with or 
1µg/ml Tet.  -  + 
  [
3H] Spiperone Binding 
Cell Line  Bmax, fMol.mg
-1  
(± s.e.m.) 




 (± s.e.m.) 
Kd, nM      
(± s.e.m.) 
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without induction of Cys
352Ile Gαi2 expression (Figure 4.16A).  This underlines the 
inability of the D3 receptor to couple to Gαi2 and is consistent with results using both 
transient co-transfection of receptor and G protein and receptor-G α subunit fusion 
proteins.  There is however an increase in basal [
35S] GTPγS levels upon induction of 
Cys
352Ile Gαi2, which may reflect the intrinsic ability of G protein α subunits to load [
35S] 
GTPγS.  For the D3 receptor plus Cys
351Ile Gαo1 cell line, agonist-dependent [
35S] GTPγS 
binding above basal was seen only when Cys
351Ile Gαo1 expression was induced by 
tetracycline treatment.  This underlines effective coupling of D3 to Cys
351Ile Gαo1 as seen 
previously in experiments using both receptor and G protein co-transfections and receptor-
G α subunits fusions.  Again upon induction of Cys
351Ile Gαo1 expression, basal levels of 
[
35S] GTPγS binding were observed to increase significantly (Figure 4.16B). 
 
 
4.2.8   Characterisation of Flp-In T-REx cells expressing Cys
352Ile 
Gαi2 or Cys
351Ile Gαo1 from the inducible Flp-In locus and constitutively 
expressing the chimeric D3/2 dopamine receptor 
 
Expression levels of the chimeric D3/2 dopamine receptor were monitored by [
3H] 
spiperone binding, with non-specific binding determined with the addition of 10 µM (+)-
butaclamol.  For the selected cell line constitutively expressing D3/2 plus Cys
351Ile Gαi2 the 
receptor was around 0.5 pMol/mg membrane protein (Table 4.6).  For the selected cell line 
expressing D3/2 plus Cys
351Ile Gαo1 receptor density was approximately 0.3 pMol/mg.  In 
both cases the D3/2 receptor showed D3-like affinity for [
3H] spiperone with a Kd of ~ 0.1 
nM.  For both cell lines no significant difference was seen for either receptor expression 
levels or affinity for [
3H] spiperone with or without the induction of G protein α subunit 
expression. 
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Table 4.6: Expression levels of the D3/2 receptor are unaffected by tetracycline 




Experiments were performed in triplicate to n = 3. 
An unpaired student’s t-test was performed using GraphPad Prism version 4 (P<0.05).  No 
significant differences in Bmax values were observed in receptor expression with and 
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(± s.e.m.) 
Bmax, fMol.mg
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4.2.9   Agonist-dependent [
35S] GTPγS binding is observed in 
membranes of the expressing D3/2 upon induction of expression of 
Cys
351Ile Gαo1or Cys
352Ile Gαi2  
 
For the cell line expressing the  D3/2 chimera and inducibly expressing Cys
352Ile Gαi2, 
without the induction of Cys
352Ile Gαi2 expression, the addition of 10 µM dopamine was 
unable to stimulate [
35S] GTPγS binding above basal levels (Figure 4.17A).  However, 
upon induction of Gαi2 expression a small but significant increase in basal levels of [
35S] 
GTPγS binding was seen, reflecting an increase in G protein levels within the cell.  Upon 
addition of 10 µM dopamine a significant stimulation of [
35S] GTPγS binding was seen 
above basal levels.  This reflects the ability of the chimeric D3/2 receptor to couple to 
Cys
352Ile Gαi2, and indicates that the chimeric receptor has a promiscuous, D2-like, G 
protein coupling as apposed to the selective coupling to Gαo1 seen for D3.   This is in 
agreement with both the experiments using both the co-expression of receptor and G 
protein α subunit or receptor-G protein fusion proteins. 
 
For the cell line expressing the D3/2 chimera and inducibly expressing Cys
351Ile Gαo1, [
35S] 
GTPγS binding was not stimulated above basal levels with the addition of 10 µM 
dopamine (Figure 4.17B).  With induction of Cys
351Ile Gαo1 expression an increase in 
basal [
35S] GTPγS binding was again seen, and upon addition of 10 µM dopamine there 
was a significant stimulation of [
35S] GTPγS binding above basal, underlining the efficient 
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Figure 4.1:  Schematic representation of the chimeric dopamine receptor (D3/2) 
consisting of a dopamine D3 receptor with twelve amino acids in the c-terminus of 
intracellular loop 3 exchanged by the equivalent region in the D2 receptor 
Human dopamine D2 and D3 receptors are shown, highlighting the 3
rd intracellular loop 
and transmembrane domain VI (TM VI).  A chimera was made where the highlighted 
sequence of the D3 receptor was replaced by the equivalent region of the D2 receptor 
(residues coloured red). The exchanged twelve amino acids are flanked by homologous 
regions to the c-and n-terminal sides.  This chimera was generated by sequential site-
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Figure 4.1 
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Figure 4.2:  Characterisation of HEK293T transiently co-transfected with pertussis 
toxin-insensitive Cys
352Ile Gαi2 or Cys
351Ile Gαo1 cDNA and dopamine receptor (D2l, 
D3 or D3/2) cDNA. 
HEK293T cells were transiently co-transfected with pertussis toxin-insensitive Cys
352Ile 
Gαi2 or Cys
351Ile Gαo1 cDNA and dopamine receptor (D2l, D3 or D3/2) cDNA. These cells 
were treated with or without pertussis toxin (25ng/ml) 16 hours prior to cell harvest. Cell 
membranes were then prepared, resolved by SDS-PAGE and immunoblotted to detect 
either Gαi2 or Gαo1.  Receptor expression levels were estimated using [
3H] spiperone 
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Figure 4.3:10 µM GDP was the optimal concentration for [
35S] GTPγS assays using 
membranes from HEK293T cells co-transfected with dopamine D3 receptor and 
Cys
351Ile Gαo1 cDNA 
HEK293T cells were transiently co-transfected with pertussis toxin-insensitive Cys
351Ile 
Gαo1 cDNA and D3 dopamine receptor cDNA. These cells were treated with pertussis toxin 
(25ng/ml) 16 hours prior to cell harvest. Cell membranes were then prepared, resolved by 
SDS-PAGE and immunoblotted to detect either or Gαi2 or Gαo1.  Receptor expression 
levels were measured in [
3H] spiperone saturation binding studies.  A [
35S] GTPγS assay 
was set up with 10 fMol of receptor, various concentrations of GDP and with or without 
the addition of 10µM dopamine.  An immunoprecipitation step was included in the assay, 
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Figure 4.3 








   
HEK293T were transiently co-transfected with a dopamine receptor (D2l, D3 or D3/2) 
cDNA and either Cys
352Ile Gαi2  (A) or Cys
351Ile Gαo1 (B).  Cells were treated with or 
without pertussis toxin (25ng/ml) 16 hours prior to cell harvest. Membranes from these 
cells were used to measure basal [
35S]GTPγS binding and the effect of 100 µM dopamine 
on this.  A [
35S] GTPγS protocol was used that included an immunoprecipitation step using 
in-house antisera raised against the C-terminal tail of Gαi2 (A) or Gαo1 (B).   The 
significance of differences between basal and dopamine stimulated [
35S] GTPγS binding 
was determined using an unpaired Students t-test (P<0.05), significant differences are 
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Figure 4.4 
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Figure 4.5:  Generation of dopamine D3 receptor or chimeric D3/2 receptor-CysÆIle 
variant G protein α subunit fusion proteins   
A series of fusion proteins were generated by linking Cys-Ile mutant, pertussis toxin-
insensitive variants of Gαi1, Gαi2, Gαi3 and Gαo1 in frame with the C-terminal tail of the 
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Figure 4.6: Characterisation of dopamine D3 receptor and chimeric D3/2 receptor-
CysÆIle variant G protein α subunit fusion proteins: addition of increasing amounts 
of fusion protein into [
35S] GTPγS reactions results in a proportional increase in [
35S] 




351Ile-Gαo1 was expressed transiently in HEK293T cells. 
Following pertussis toxin treatment (25 ng/ml, 24 h) cells were harvested, membranes 
generated and fusion protein expression estimated using [
3H] spiperone saturation binding 
(Table 4.2). [
35S]GTPγS binding studies were performed in the absence and presence of 
100 µM dopamine and with varying amounts of receptor-G protein fusion protein (D3-
Cys
351Ile-Gαo1:1-50 fMol per reaction, D3/2-Cys
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Figure 4.7: Dopamine stimulated [
35S] GTPγS binding above basal levels was 
observed only when the dopamine D3 receptor was fused to Gαo1. 
HEK293T were transiently transfected with dopamine (D2l, D3 or D3/2 ) receptor-CysÆIle 
G α subunit fusion protein cDNAs; (A) dopamine receptor-Cys
351Ile Gαi1, (B) dopamine 
receptor-Cys
352Ile Gαi2 (C) dopamine receptor-Cys
351Ile Gαi3 (D) dopamine receptor-
Cys
351Ile Gαo1. Cells were treated with or without pertussis toxin 16 hours prior to cell 
harvest. Membranes from these cells were used to measure basal [
35S]GTPγS binding and 
the effect of 100 µM dopamine on this.  A [
35S] GTPγS protocol was used that included an 
immunoprecipitation step using antisera raised against the C-terminal tail of Gαi1/2 (A + B), 
Gαi3 (C) or Gαo1 (D).   The significance of differences between basal and dopamine 
stimulated [
35S] GTPγS binding was determined using an unpaired Students t-test 
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Figure 4.7 




Figure 4.8:  G protein fusion proteins identify agonists at the D3 receptor but only 
when coupled to Gαo1 
  
Each of the dopamine D3 receptor-CysÆIle variant Gα fusion proteins; (A) D3-Gαi1 , (B) 
D3-Gαi2, (C) D3-Gαi3, (D + E) D3-Gαo1 was expressed transiently in HEK293 cells. (A-D) 
show data in terms of [
35S] GTPγS bound as measured by fluorescence emitted following 
excitation of scintillant beads, arbitrary units (a.u.). (E) Shows data in terms of [
35S] 
GTPγS bound as a % of maximal dopamine signal for D3-Gαo1 as agonists failed to 
generate a response for the other D3-Gαi/o fusion proteins.  Following pertussis toxin 
treatment (25ng/ml, 16 h) cells were harvested, membranes generated and [
35S]GTPγS 
binding studies performed in the absence and presence of varying concentrations of a 
variety of ligands (dopamine ( ♦), m-tyramine (■ ), p-tyramine ( ), R-(+)-3-PPP (S ), S-
(-)-3PPP ( U), quinpirole  ( V), NPA ( ●), 7 –OH DPAT())  reported to have affinity 
and efficacy at dopamine D2-like receptors. Data are representative and full details are 
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Figure 4.9:  G protein fusion proteins identify agonists at the D3/2 receptor when 
coupled to all four pertussis-toxin resistant Gαi/o subunits 
  
Each of the dopamine D3/2 receptor-CysÆIle variant Gα fusion proteins; (A) D3/2-Gαi1 , 
(B) D3/2-Gαi2, (C) D3/2-Gαi3, (D + E) D3/2-Gαo1 was expressed transiently in HEK293 
cells.  Following pertussis toxin treatment (25ng/ml, 16 h) cells were harvested, 
membranes generated and [
35S]GTPγS binding studies performed in the absence and 
presence of varying concentrations of a variety of ligands (dopamine ( ♦), m-tyramine (■ ), 
p-tyramine ( ), R-(+)-3-PPP (S ), S-(-)-3PPP ( U), quinpirole  ( V), NPA ( ●), 7 –OH 
DPAT())  reported to have affinity and efficacy at dopamine D2 like receptors. Data are 
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Figure 4.9 
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Figure 4.10:  Comparison of the potency and efficacy at the D2l-Gαo1 fusion protein 
and D3-Gαo1 fusion protein receptor of various agonists reveals a trend towards both 
higher potency and efficacy at the D3 receptor. 
The potencies (A) and efficacies (B) of various ligands at either the D2l-Gαo1 fusion protein 
(Figure 3.4D, Table 3.2) or the D3-Gαo1 fusion protein (Figure 4.8 E, Table 4.3) were 
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Figure 4.10 
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Figure 4.11:  Comparison of the potency and efficacy at the D3-Gαo1 fusion protein 
and D3/2-Gαo1 fusion protein of various agonists shows no significant differences in 
efficacy. 
The potencies (A) and efficacies (B) of various ligands at either the D3-Gαo1 fusion protein 
(Figure 4.8 E, Table 4.3) or the D3/2-Gαo1 fusion protein (Figure 4.9 D, Table 4.4) were 
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Figure 4.11 
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Figure 4.12:  Comparison of the potency and efficacy of various agonists at the D3/2-
Gαi3 and D3/2-Gαo1 fusion proteins. 
The potencies (A) and efficacies (B) of various ligands at either the D3-Gαi3 fusion protein 
(Figure 4.8 C, Table 4.4) or the D3/2-Gαo1 fusion protein (Figure 4.8 D, Table 4.4) were 
compared using an unpaired Student’s t-test (P<0.05).  Similarly the potencies (C) and 
efficacies (D) of quinpirole, dopamine and NPA at either D3/2-Gαi1 or D3/2-Gαi2 were 
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Figure 4.12 
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Figure 4.13:  Characterisation of Flp-In T-REx cells harbouring pertussis toxin-
insensitive mutant G proteins at the Flp-In locus 
Flp-In T-REx cell lines were established with either (A) Cys
351Ile Gαi1, (B) Cys
352Ile Gαi2, 
(C) Cys
351Ile Gαi3 or (D) Cys
351Ile Gαo1 cloned into the Flp-In locus. These cells were 
further transfected to constitutively and stably express the D3 receptor.  Saturation [
3H] 
spiperone binding was employed to assess the constitutive expression levels of D3 receptor 
of various clones. A single, near-saturating concentration of 1 nM [
3H] spiperone was used, 
with non-specific binding estimated using 10 µM (+)-butaclamol.  Only clones showing 
significant expression of D3 receptor were retained and further characterised (Table 4.3). 
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Figure 4.14:  Characterisation of Flp-In T-REx cells harbouring pertussis toxin-
insensitive mutant G proteins at the Flp-In locus 
Flp-In T-REx cell lines were established with one of (A) Cys
351Ile Gαi1, (B) Cys
351Ile 
Gαi2, (C) Cys
351Ile Gαi3 or (D) Cys
351Ile Gαo1 cloned into the Flp-In locus. These cells 
were further transfected to constitutively and stably express the D3/2 receptor.  Saturation 
[
3H] spiperone binding was employed to assess the constitutive expression levels of the 
D3/2 chimera of various clones. A single near saturating concentration of 1 nM [
3H] 
spiperone was used, with non-specific binding estimated using 10 µM (+)-butaclamol.  
Only clones showing significant expression of D3/2 receptor were retained and further 
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Figure 4.15:  Characterisation of Flp-In T-REx cells harbouring pertussis toxin-
insensitive mutant G proteins at the Flp-In locus and constitutively expressing either 
the D3 or D3/2 receptor 
Flp-In T-REx cell lines were established with either Cys
351Ile Gαi2 or Cys
351Ile Gαo1 
cloned into the Flp-In locus. These cells were further transfected to constitutively and 
stably express the D3 receptor or chimeric D3/2 receptor (see Table 4.5 for details). These 
cells were treated with or without tetracycline (Tet.) (1.0 µg/ml for 24 h). Cell membranes 
were then prepared, resolved by SDS-PAGE and immunoblotted to detect either Gαi2 (A) 
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Figure 4.16:  Significant agonist-stimulated binding of [
35S] GTPγS is observed in 
Flp-In T-REx HEK293 cells constitutively expressing the dopamine D3 receptor, only 
upon expression of Cys
351Ile Gαo1 
 
Flp-In T-REx HEK293 cells stably expressing the D3 receptor and harbouring either 
Cys
352Ile Gαi2 (A) or  Cys
351Ile Gαo1 (B) at the Flp-In locus were treated with or without 1 
µg/ml tetracycline for 24 h. Both sets of cells were also treated with pertussis toxin. 
Membranes from these cells were used to measure basal [
35S] GTPγS binding and the 
effect of 10 µM dopamine on this. A highly significant difference between basal and 
dopamine-stimulated [
35S] GTPγS binding was observed upon induction of Cys
351Ile Gαo1 
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Figure 4.17:  Significant agonist-stimulated binding of [
35S] GTPγS is observed in 
Flp-In T-REx HEK293 cells constitutively expressing the chimeric dopamine D3/2 
receptor, upon expression of Cys
352Ile Gαi2 and Cys
351Ile Gαo1. 
Flp-In T-REx HEK293 cells stably expressing the chimeric D3/2 receptor and harbouring 
either Cys
352Ile Gαi2 (A) or  Cys
351Ile Gαo1 (B) at the Flp-In locus were treated with or 
without 1 µg/ml tetracycline for 24 h. Both sets of cells were also treated with pertussis 
toxin. Membranes from these cells were used to measure basal [
35S] GTPγS binding and 
the effect of 10 µM dopamine on this. A very significant difference between basal and 
dopamine stimulated [
35S] GTPγS binding was observed upon induction of Cys
352Ile Gαi2 
or Cys






 J. Robert Lane, 2007    Chapter 4 
238 
Figure 4.17 
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4.3  Discussion 
 
Structurally, the D2 and D3 receptors exhibit 52% overall amino acid homology with the 
transmembrane domains exhibit 75% homology (Sokoloff et al., 1990).  Since the 
transmembrane regions of the catecholamine receptors are believe to constitute the ligand 
binding sites the high homology of these domains explains the lack of compounds with 
high selectivity between D2 and D3 receptors.  The G protein coupling of D2 has been well 
characterised with a general consensus for promiscuous coupling to Gαi1, Gαi2, Gαi3, Gαo1 
(Gazi et al., 2003; Ghahremani et al., 1999; Jiang et al., 2001; Senogles, 1994; Watts et al., 
1998).  However, despite the high homology and similar pharmacology of D2 and D3 
receptors, the coupling of D3 has remained poorly characterised (Ahlgren-Beckendorf and 
Levant, 2004).  The present study was based on the expression of D2 and D3 receptors and 
pertussis toxin resistant CysÆIle Gαi/o subunits in the heterologous expression models 
based on HEK293 cells.  This was combined with the use of receptor-G protein fusion 
proteins or Flp-In T-REx cell lines constitutively expressing dopamine receptor and 
expressing pertussis toxin resistant variant G α subunits from the inducible Flp-In locus to 
control relative expression levels of receptor and G protein α subunit.  [
35S] GTPγS binding 
was employed to directly monitor receptor-G protein coupling.  These techniques allowed 
the characterisation, and direct comparison of the G protein coupling specificities of 
dopamine D2 and D3 receptors.   
 
This study confirmed the promiscuous coupling D2 to Gαi1, Gαi2, Gαi3 and Gαo1 already 
described by other studies (Gazi et al., 2003).  Contrastingly, D3 was shown to couple 
efficiently and selectively only to Gαo1.  This is consistent with several studies which 
demonstrated the inhibition of adenylate cyclase by agonist stimulation of D3 through a 
pertussis toxin sensitive, and therefore Gαi/o pathway (Robinson and Caron, 1997; Van J. Robert Lane, 2007    Chapter 4 
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Leeuwen et al., 1995; Vanhauwe et al., 1999).  Furthermore, studies using [
35S] GTPγS 
binding have implicated coupling to pertussis toxin sensitive Gαi/o subunits, with two 
studies in particular showing efficient selective coupling to Gαo1(Beom et al., 2004; 
Zaworski et al., 1999) although Zaworski et al. postulated that efficient coupling to Gαo1 
required the expression of adenyl cyclase subtype V.  However, the study described in this 
chapter is the first to assess coupling to each of the four Gαi/o subunits directly.  
Furthermore, constraining receptor to G protein expression stoichiometry in a 1:1 ratio 
with the use of receptor-G protein fusion proteins allowed a direct comparison between the 
coupling of D3 to each Gαi/o subunit.  In the previous chapter it was postulated that a 
greater variation in ligand conformational states exerted on the D2l could be observed for 
interactions with Gαo1 rather than between Gαi1, Gαi2 and Gαi3.  This may reflect the high 
amino acid homology between Gαi1, 2 and 3 (85-90%) whereas for each of these against 
Gαo1, sequence identity is lower and lies between 70-73%.  Similarly, the coupling of D3 
to Gαo1 and not to other members of the Gαi subfamily may be a result of this relative 
dissimilarity between Gαo1 and the other Gαi subunits.  It could be said then that Gαo1 is 
more promiscuous in its coupling to receptors than other Gαi/o subunits.   
 
A comparison of the potencies and relative efficacies of various agonists at D2l and D3 
revealed a trend towards higher potency and efficacy at the D3 receptor.   This could be 
explained by the observation of several groups that agonists such as dopamine quinpirole 
and 7 OH DPAT bind the D3 receptor with a much higher affinity (by a factor of 20, 100 
and 10 respectively) (Missale et al., 1998; Sokoloff et al., 1990).  NPA however, showed 
no difference in potency at D2 or D3.  Again binding data for the highly related molecule 
apomorphine showed no difference in affinity for D2 and D3 (Sokoloff et al., 1990).  The 
higher affinity for dopamine of D3 relative to D2, and as shown in this study the higher 
potency of dopamine at the D3 receptor, is consistent with its action as a presysnaptic 
autoreceptor.  The D3 dopamine receptor, in addition to serving in a
 classical postsynaptic J. Robert Lane, 2007    Chapter 4 
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sensory role, is also a presynaptic autoreceptor
 that is predominantly expressed in parts of 
the brain controlling
 behaviour, including that involved with emotion and movement 
(Joseph et al., 2002).  Indeed, studies on the distribution of D3 receptor in the brain
 show 
that it is expressed on virtually all dopaminergic neurons, strongly supporting the idea of 
the D3 as an autoreceptor (Diaz et al., 2000; Gurevich and Joyce, 1999).   Since the D3 
receptor has a higher affinity for dopamine than D2 receptor the D3 receptor may regulate 
dopamine release at lower dopamine concentrations
 than D2.   Experiments
 with D3 knock-
out mice have shown this to be the case and that D3 acts in the striatum/nucleus
 acumbens 
by modulating dopamine secretion rates rather than dopamine synthesis
 or dopamine 
transporter activity (Joseph et al., 2002).  This presynaptic role is perhaps also consistent 
with the selective coupling of D3 to Gαo1.   Localisation of Gαi/o proteins has been shown to 
be different at post and pre-synaptic densities, with Gαo1 shown to be more prevalent at 
pre-synaptic densities (Aoki et al., 1992). In agreement with this autoreceptor hypothesis, 
only a negligible
 fraction of plasma membrane D3 receptors internalise as a result of
 
persistent dopamine stimulation, even with increased GRK activity,
 so that the plasma 
membrane population of D3 receptors remains relatively
 constant in order to provide 
continuous monitoring
 of ligand concentrations (Kim et al., 2005).  As discussed in the 
previous chapter, S-(-)-3PPP has been shown to be an agonist at presynaptic dopamine 
receptors (Arnt et al., 1983; Hjorth et al., 1983), but an antagonist at post synaptic 
dopamine receptors.  It is likely then that S-(-)-3PPP acts both through presynaptic 
dopamine D2 and D3 receptors coupled to Gαo1.  Furthermore, S-(-)-3PPP has significantly 
higher potency and efficacy at the dopamine D3 receptor as compared to that at the 
dopamine D2 receptor, so perhaps S-(-)-3PPP is able to act through presysnaptic D3 
receptors at a lower concentration.  It would be interesting to assess the relative importance 
of the action of S-(-)-3PPP at dopamine D2 versus D3 presysnaptic receptors.   
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There is considerable evidence that dopamine D2 and D3 receptors are co-localised within 
specific populations of cerebral neurons, both post-synaptically to dopaminergic 
projections and pre-synaptically on dopaminerigic neurons themselves (Diaz et al., 2000; 
Gurevich and Joyce, 1999; Joseph et al., 2002; Joyce, 2001).  This introduces the 
possibility that dopamine D2 and D3 receptors may form hetero-oligomeric complexes.  In 
two separate studies it was demonstrated that several agonists exhibit a higher potency for 
inhibition of forskolin induced cAMP in membranes of cells where D2l and D3 had been 
co-transfected as compared to D2l transfected alone (Maggio et al., 2003; Scarselli et al., 
2001).  Both of these studies were carried out in a system where D3 was unable to couple 
to and inhibit a chimeric adenylate cyclase consisting of elements of ACV and ACVI.  The 
authors argue that the agonists have a higher potency at D2l/D3 receptor heterodimers as 
compared to D2l receptors.  Immunoprecipitation studies provided further evidence of a 
D3/D2 hetero-oligomer (Scarselli et al., 2001).  My results show that agonists have a higher 
potency at D3 receptors.  The results of Maggio et al. (2003) could be explained by the 
agonist binding preferentially to the D3 receptor in a D2/D3 receptor heterodimer due to a 
demonstrated higher affinity.   Furthermore, negative co-operativity in ligand binding 
across a D2l dimer has been demonstrated (Vivo et al., 2006), and due to the relative 
homology between D2 and D3 it is perhaps likely that this would also occur for a D2/D3 
heterodimer.  Cross-talk within a dimer, where one receptor can activate another receptor’s 
G protein partner has been demonstrated using functional complementation of two non-
functional opioid receptor-G protein fusions (Pascal and Milligan, 2005).  It is possible 
then that D3, although unable to couple to adenylate cyclase, binds the agonist, and that 
this, by a crosstalk mechanism within the D2/D3 dimer results in the activation of the G 
protein partner of D2l resulting in the inhibition of the chimeric adenylate cyclase V/VI.  
My results suggest that this partner could be any one of Gαi1, Gαi2 or Gαi3 since D3 can 
couple to Gαo1.  It would be interesting to investigate this hypothesis using the functional 
complementation method used by Pascal and Milligan (2005).  An alternative hypothesis is J. Robert Lane, 2007    Chapter 4 
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that the D3/D2 heterodimer recruits G proteins more efficiently, or couples to an alternative 
G protein as demonstrated for the dopamine D2 receptor / cannabinoid CB1 receptor 
heterodimer (Kearn et al., 2005).  It is possible that in cells where both dopamine D2 and 
D3 receptors are co-expressed and co-localised that three populations of receptors could 
exist; D2l homodimers, D3 homodimers and D3/D2 heterodimers.  Furthermore, these 
different populations will have different pharmacologies and perhaps have different 
downstream signalling pathways.  Consequently the action of dopamine or a dopaminergic 
ligand on a particular neuron may depend on the relative levels of each of the three 
different populations. Perhaps relevant to this idea, is the fact that both schizophrenia and 
cocaine abuse are associated with a marked elevation of mesolimbic D3 receptors (Joyce, 
2001; Segal et al., 1997; Staley and Mash, 1996).  Taking into account the protean 
characteristic of S-(-)-3PPP at the D2l receptor, as described in chapter 3,  it would be 
interesting to look at the action of this ligand at a D3/D2l heterodimer.   
  
To understand the physiological actions of a G protein coupled receptor it is important to 
identify the specific G proteins with which this receptor can interact.   A significant 
number of GPCRs have been shown to couple to multiple G protein subtypes.    The 
molecular basis of this selectivity has been the focus of a great many studies (Wess, 1998; 
Wong, 2003).   However, despite the wealth of information regarding the coupling 
specificities of a multitude of G protein coupled receptors, surprisingly little is known 
about how they exert this selectivity at a molecular level.  No obvious sequence homology 
was observed even for GPCRs that couple to the same G protein subtype, and no consensus 
motif predictive of G protein coupling has been identified (Moller et al., 2001).   A vast 
number of studies with many different GPCRs have shown that the selectivity of G protein 
recognition is determined by multiple intracellular receptor regions. The most critical 
regions are the second intracellular loop and the N and C terminal regions of the third 
intracellular loop (Wess, 1997).   J. Robert Lane, 2007    Chapter 4 
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In this chapter, the exchange of a twelve amino acid section of the D3 receptor with the 
equivalent region of the D2 receptor was seen to confer ‘D2-like’ promiscuous G protein 
coupling to the D3 receptor.  Indeed, with the exchange of this intracellular region, the D3/2 
chimera stimulated [
35S] GTPγS binding to Gαi1, Gαi2, Gαi3 and Gαo1, as opposed to the 
specific and selective coupling to Gαo1 of D3.  This is in agreement with a previous study 
using receptors transiently expressed in CHO cells.  This showed that in that system the D3 
receptor was unable to inhibit adenylate cyclase whereas agonist stimulation of the D2 
receptor inhibited forskolin induced cAMP accumulation.  An identical D3/2 chimera to the 
one used in my study gained the ability to inhibit adenylate cyclase.   In the reciprocal 
chimera, the potency of coupling with adenylate cyclase activity was reduced.  It would 
seem then that this observed gain in the ability to couple to adenylate cyclase, with the 
exchange of a twelve amino acids in the C-terminal of intracellular loop of D2 into D3, lies 
at the level of a gained ability to couple to one or a combination of Gαi1, Gαi2, and Gαi3.  A 
characteristic of this twelve amino acid sequence is that nine amino acid residues carrying 
charged or polar groups in the D2 sequence are replaced at equivalent positions by aliphatic 
or hydrophobic groups in the D3 receptor.  Furthermore the flanking sequences to this 
region (EKKATQ, close to TMVI, and the N-terminal TSL) are conserved in both 
receptors, so exchange of this region is unlikely to disrupt receptor structure.  A vast body 
of evidence has shown that the C-terminal portion of the third intracellular loop of G 
protein coupled receptors is important for their coupling to G proteins (Wess, 1998). 
Furthermore, it has been suggested that the C-terminal portion of the third intracellular 
loop of G protein coupled receptors form a short α-helix that is extremely important for the 
interaction with heterotrimeric G proteins (Burstein et al., 1995; Wade et al., 1996).  It is 
possible that proline residues present in this portion of the third intracellular loop of the D3 
receptor disrupt this α helical structure. 
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The affinity for the inverse agonist [
3H] spiperone at the chimeric D3/2 receptor is not 
significantly different from that of the wild-type D3 receptor.  This perhaps indicates that 
the exchange of the twelve amino acid section of D3 with that of D2 has not disrupted the 
binding domain of this ligand.  Furthermore the potency of ligands when the chimera is 
coupled to Gαo1 is not significantly different to that of D3 coupled to Gαo1, again indicating 
that the binding affinity of these ligands is also not affected, in agreement with previous 
work (Filteau et al., 1999; McAllister et al., 1993).  However, there is a marked decrease in 
potency of the full agonists dopamine and quinpirole when the chimera is coupled to Gαi1 
or Gαi2 as compared to Gαi3 or Gαo1, in effect the rank order of potency for dopamine 
could be described as: Gαi3 = Gαo1 >> Gαi1 or Gαi2.  This order of preference can, as for 
that of D2 and D3, be related to the relative structural similarities of the Gαi/o subunits.  
Gαi3 has a greater sequence similarity to Gαo1 as compared to that of Gαi1 or Gαi2, in the 
extreme c-terminus (Figure 5.1), a region shown to be important in receptor-G protein 
coupling (Slessareva et al., 2003; Wess, 1998).   
 
The different rank order of dopamine potency observed at the D2 receptor (Gαi1 = Gαi2 = 
Gαi3 < Gαo1) as compared to that of the chimeric D3/2 receptor, could point towards a 
difference in coupling specificity.  This perhaps indicates that additional sites within the D2 
receptor confer G protein coupling specificity particularly in relation to coupling to Gαi1 
and Gαi2.  In agreement with this, a previous study demonstrated that both N and C-
terminal portions of the third intracellular loop were capable of supporting functional 
coupling of D2 to adenylate cyclase, but that both were required for maximal Gαi coupling 
(Lachowicz and Sibley, 1997).  Indeed, the fact that the reciprocal chimera to the one used 
in this study showed only a reduction in the potency of coupling to adenylate cyclase as 
compared to D2 rather than a complete abolition of coupling, indicates the presence of 
additional G protein coupling domains within the D2 receptor (Filteau et al., 1999). 
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It is interesting to note that a significantly higher receptor binding site density was 
identified in dopamine receptor plus Gαo1 co-transfections as compared to Gαi2 co-
transfections.  A similar pattern is could be seen in the D3 fusion proteins with a higher 
value of Bmax for receptor-Gαo1 fusions as compared to the others, but not for the D2 fusion 
proteins or the chimeric D3/2 fusions.  Recent biophysical studies on recombinantly 
expressed receptors reconstituted with purified G proteins have supported the idea of the 
basic unit of signal transduction of the BLT1 leukotriene B4 receptor as a pentamer 
containing two receptors and the three subunits of a G protein hetero-trimer (Baneres and 
Parello, 2003; Milligan, 2007).  One explanation for the higher receptor density observed 
with Gαo1 could be that D2, D3 and D3/2 may couple more efficiently to Gαo1. This 
interaction, then, may stabilise the dimer more effectively than the other G protein α 
subunits.  However, in contrast, the levels of receptor was unaffected by the induction of 
Gα subunit expression in all Flp-In T-Rex stable cell lines, so the above pattern seen with 
the co-transfection of receptor and G protein may well be due to inconsistencies with 
transient transfection such as the relative qualities of DNA. 
  
In summary then, the coupling specificities of dopamine receptors D2l and D3 have been 
characterised with D2l shown to couple to Gαi1, Gαi2, Gαi3 and Gαo1.  D3 was shown to 
selectively couple to Gαo1.  The use of a chimeric receptor has identified a twelve amino 
acid section in the C-terminus of the third intracellular loop of D2 to be important in 
directing coupling to Gαi1, Gαi2, and Gαi3.  It would seem that Gαo1 is more promiscuous in 
its coupling to receptors than other Gαi subunits, and perhaps has fewer requirements in 
receptor structure to become activated.  It would be interesting to employ a system taking 
advantage of the differential signalling specifities of D2 and D3, and use chimeric Gαi1 / 
Gαo1 subunits to determine the molecular basis of the relative promiscuousity of Gαo1.   
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5  The generation and characterisation of antibodies 
that identify only the active conformation of Gi-family 
G protein α subunits  
5.1  Introduction 
 
Eighteen different G protein α subunit subtypes have been identified.  As discussed in both 
chapter 4 and chapter 5, the ability of a single GPCR to interact with various and different 
G protein α subunits has been the subject of a large body of work and is now widely 
accepted (Wess, 1998; Wong, 2003).   The dissection of the specificity of interactions 
between receptors, G proteins and effectors, requires tools to allow the selective 
identification of G proteins involved in a particular pathway.  Early attempts to define the 
specificity of interactions between receptors and G proteins made considerable use of 
exotoxins produced by the bacteria Vibrio cholerae and Bordetella pertussis.  As discussed 
in the previous chapters, pertussis toxin catalysed ADP ribosylation of the Gαi/o family of 
G protein α subunits prevents functional coupling between receptors and these G proteins.  
Similarly, cholera toxin catalysed ADP-ribosylation of Gs converts the G protein to an 
essentially irreversibly activated form which no longer required agonist occupation of a 
receptor to produce regulation of adenyl cyclase.  However, with the realisation that there 
could be multiple G-protein gene products which acted as substrates for these toxins 
expressed in a single cell or tissue, it became clear that more selective tools would be 
required to discriminate between receptor functions transmitted to effectors by the 
individual G proteins. 
  
The isolation of cDNA sequences corresponding to G-protein α subunits allowed the 
generation of antisera against short peptides which represent sections of the primary amino J. Robert Lane, 2007    Chapter 5 
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acid sequence unique to specific G proteins.  Antisera which are likely to be useful in the 
analysis of receptor-G protein interactions must be highly selective for individual G-
protein α subunits.  Taking into account the high sequence homology of G protein α 
subunits (Figure 5.1, Table 5.1) this restricts the choice of peptides to regions of relative 
dissimilarity.  However, as demonstrated by my results in chapters 3 and 4, receptors can 
distinguish between G protein α subunits from different sub-families and even between G 
protein α subunits within the same sub-family, for example the selective coupling of D3 to 
Gαo1 and not the other members of the Gαi/o sub-family.  It is clear then that sections of G-
protein subunits which can be deduced to play key roles in interactions with receptors and 
effectors are likely to be most appropriate for the development of antisera (Milligan, 1994; 
Mullaney and Milligan, 2004).  Considerable evidence has identified the extreme C-
terminal region of G-protein α subunits as a key site for functional interactions between 
receptors and G proteins (Slessareva et al., 2003; Wess, 1998).  On this basis antibodies 
generated against peptides corresponding to the last ten amino acids of individual G-
protein α subunits have been the most widely used to study functional interactions between 
receptors and G proteins (Milligan, 1994; Mullaney and Milligan, 2004).  The relative 
dissimilarity of this region between various G protein α subunits is illustrated in Table 5.2   
The specificity of antisera generated in this manner towards different G protein α subunits 
has been demonstrated, and anti-Gαi1/2, Gαi3, Gαo1, Gαs and Gαq/11 antisera have 
previously been generated and characterised (Milligan, 1993; Milligan, 1994; Mullaney 
and Milligan, 2004; Mullaney et al., 1995).  The first aim of the work described in this 
chapter was the generation of antisera specific to Gαi1/2, Gαs and Gαq/11.  As for previous 
studies antisera were raised against decapeptides corresponding to the C-terminal ten 
amino acids of these G protein α subunits   It was essential to characterise the selectivity of 
these antisera towards the G protein α subunits against which they were raised.  This was 
achieved by the expression of the various G protein α subunits in systems which 
essentially offer a null background for the specific G α subunit of interest.  This aspect of J. Robert Lane, 2007    Chapter 5 
249 
antibody characterisation was achieved by Western blotting.  Another application of 
antisera raised against the C-terminal tail of G α subunits, and specific to individual G 
protein α subunit subtypes has been their use in a modified form of a [
35S] GTPγS assay 
(Milligan, 2003).  This modified form of the [
35S] GTPγS assay, like more conventional 
assays, allows the measurement of receptor mediated G protein activation by measuring 
the uptake of the non-hydrolysable [
35S] GTPγS.  However, by the inclusion of an 
immunoprecipitation step using antisera selective to the particular G protein of interest, 
this allows the enrichment of a particular [
35S] GTPγS bound G protein α subunit.  This 
enrichment gives a reduced background of bound [
35S] GTPγS, providing an enhanced 
signal window.  This technique is particularly useful when investigating the coupling of 
receptors to G protein α subunits other than those from the Gαi/o family.  To further 
characterise the antisera generated in this project, their utility in a [
35S] GTPγS assay with 
pulldown step was also assessed.  The antisera generated would not only be useful reagents 
for use in this project, but if the immunisation program was successful, would be useful 
reagents for use in the industrial environment. Using these antisera for the modified [
35S] 
GTPγS assay described above, in combination a technique such as the scintillation 
proximity assay (SPA), would allow the development of a high throughput [
35S] GTPγS 
screening assay that could be used not only for Gαi but also Gαq and Gαs coupled receptors 
(Ferrer et al., 2003). In this chapter antisera raised against the C-terminal tail of Gαi1/2, Gαq 
and Gαs were shown to be selective towards the relevant G protein.  Furthermore, the 
effective use of each antisera for the immunoprecipitation of the G protein against which 
they were raised was also demonstrated as part of a modified [
35S] GTPγS assay. 
  
GPCRs represent one of the largest gene families in the human genome (Milligan, 2003; 
Windh et al., 2002). They are the most tractable and effective set of targets for therapeutic 
drug design. Thus, screens for ligands that interact with GPCRs are integral to both basic 
research and the drug discovery process.  Although recent studies have indicated that J. Robert Lane, 2007    Chapter 5 
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GPCRs can provide information to cells that does not require activation of heterotrimeric 
G proteins (Seta et al., 2002), by definition all GPCRs must function, at least partially, via 
interaction and activation of G proteins. It is well established that the key step in this 
process is induced guanine nucleotide exchange on the G-protein α-subunit. As 
demonstrated in chapters 4 and 5 the nucleotide exchange process can be monitored by 
measuring the binding of [
35S] GTPγS.  This technique has been successfully used in high 
throughput drug screening programs (Wise et al., 2003).  However, from the perspective of 
the pharmaceutical industry the [
35S] GTPγS assay has two drawbacks, both relating to use 
of radioactive isotopes.  Firstly, the expense associated with the use and disposal of 
radioactive material make the [
35S] GTPγS assay a less attractive technique for use in 
industry.  However, a perhaps more limiting issue is that pharmaceutical companies have a 
defined quota for the disposal of radioactive material.  This then limits the number of 
screening programs that can be performed using a [
35S] GTPγS binding assay.  There is 
therefore, an opportunity to develop an alternative, non-radioactive assay equivalent to the 
[
35S] GTPγS assay.  The aim of the final section of this study was to develop monoclonal 
antibodies that are selective against the active GTP-bound conformation of a G protein α 
subunit.  These monoclonal antibodies could then be used to develop a high throughput 
screening assay equivalent to the [
35S] GTPγS assay.  To allow integration of this study 
with the work on dopamine D2-like receptors described in chapters 3 and 4, it was decided 
to try to generate antibodies that recognise the GTP-bound form of Gαi1. 
 
Upon activation by extracellular signals, the receptors catalyze the exchange of bound 
GDP for GTP at the G protein α subunit. The GTP-bound form of the heterotrimer is 
unstable and heterolytically dissociates or undergoes a conformational rearrangement to 
form active GTP-α and βγ complexes. The structures of both the inactive (GDP bound) 
and active (GTP bound) conformations of Gαi1 have been elucidated and this has provided 
information concerning the conformational changes occurring upon nucleotide exchange J. Robert Lane, 2007    Chapter 5 
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and indeed the mechanism of GTP hydrolysis (Coleman and Sprang, 1998; Kleuss et al., 
1994; Mixon et al., 1995; Wall et al., 1998).  This work has also demonstrated specific 
roles in transition state stabilisation of two highly conserved residues. Glutamine
204 
stabilises and orients the hydrolytic water in the trigonal-bipyrimidal transition state 
(Figure 5.38)  Arginine
178 stabilises the negative charge at the equatorial oxygen atoms of 
the pentacoordinate γ phosphate intermediate (Coleman et al., 1994).  Mutations of both of 
these residues, namely Arg
178Cys and Glu
204Leu, produce variants of Gαi1 which are 
effectively consititutively active.  The interaction between the amide nitrogen of residue 
Gly
203 in the alpha 2 helix of Gαi1 and the gamma phosphate of GTP stabilises the active 
(GTP) bound conformation (Mixon et al., 1995).  Mutation of glycine
203 to alanine 
prevents effective nucleotide exchange, and this variant is effectively constitutively 
inactive.  Furthermore the complex Gly
203Ala Gαi1.GDP was shown to have an equivalent 
structure to wild type Gαi1.GDP (Mixon et al., 1995). 
 
This understanding of the different structural conformations of the inactive GDP bound 
and active GTP bound Gαi1 allowed the design of a strategy for the generation of 
antibodies selective towards the active conformation.  Two immunisation strategies were 
used: The first was immunisation with recombinant human Gαi1 which had been pre-
incubated with GTPγS to lock the protein into the active conformation.  The second 
strategy was plasmid immunisation using cDNA of the constitutively active variant Gαi1 
Glu
204Leu.  The technique of hybridoma production, combined with high throughput 
screening facilities available at GlaxoSmithKline (Stevenage, UK), allows the production 
and screening of many different monoclonal antibodies raised against an antigen (Harlow, 
1988).  Using the immunisation strategies described above it was most likely that the 
majority of antibodies would be selective towards Gαi1 but not show selectivity towards 
the inactive or active conformations.  Therefore, design of an effective high throughput 
screen to recognise antibodies with the desired characteristics was crucial to this project.   J. Robert Lane, 2007    Chapter 5 
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To achieve this I made use of the non-hydrolysable nucleotide GTPγS, or the metabolically 
stable nucleotide GDPβS to force Gαi1 into active or inactive conformations.   The 
constitutively active (Gln
204Leu Gαi1) or inactive mutants (Gly
203Ala Gαi1), described 
above, also proved effective tools for use in this screening process.  This chapter describes 
the successful generation and characterisation of three separate monoclonal antibodies 
which are selective against the active (GTP bound) conformation of Gαi1.  Further 
characterisation of these antibodies could result in the development of a non-radioactive 
assay equivalent to the [
35S] GTPγS assay. 
 
5.2  Results 
5.2.1  Antisera raised against C-terminal decapeptide of G protein 
α  subunits 
To date, the most successful approach to generate selective probes for G protein α subunits 
has been the generation of anti-peptide G protein α subunit antisera.  The sequence 
homology of G protein α subunits is relatively high (Table 5.1).    Previous studies have 
identified peptides generated corresponding to the C-terminal ten amino acids of G protein 
α subunits to be effective in the generation of antisera selective to individual G protein α 
subunit subtypes.  The relative dissimilarity of this region among the selected G-protein 
subtypes is illustrated in Table 5.2.  In order to generate useful probes selective for 
different G protein subtypes, antisera were generated against the decapeptides 
corresponding to the C-terminal ten amino acids of Gαt, Gαq and Gαs (Table 5.3).  
Antibodies were generated by CRL Cambridge Ltd (Cambridge, UK).  Two animals were 
immunised for each decapeptide.  The antiserum was been purified by affinity 
chromatography and therefore consists of antibodies specific to the antigen. The antibodies J. Robert Lane, 2007    Chapter 5 
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were purified by eluting in a low pH buffer (glycine eluate pH 2.5) and then a high pH 
buffer (triethylammonium chloride (TEA) pH 11.5). The eluates were neutralised 
immediately and dialysed against phosphate buffered saline pH 7.4; therefore all the 
antibodies were supplied in PBS (with 0.01% sodium azide and 1% trehalose). The two 
different eluates supplied contain antibodies that have been eluted at high or low pH 









41 41 100 Gαs-S
50 51 45 45 Gαo2
51 51 46 46 94 Gαo1
50 54 44 44 71 72 Gαi3
51 51 44 43 70 70 86 Gαi2 
52 55 44 44 73 73 94 88 Gαi1 
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Table 5.2: The C-terminal ten amino acids of various G protein α subunits.  
Residues coloured red and highlighted yellow indicate identical residues.  Dark blue letters 
on a light blue background indicate conservative residues.  Black letters on a green 
background indicate a block of similar residues.  Green letters indicate weakly similar 




















G α subunit  C-terminal 10 amino acids 
Gαt  KENLKDCGLF 
Gαi1  KNNLKDCGLF 
Gαi2  KNNLKDCGLF 
Gαi3  KNNLKECGLY 
Gαo1  ANNLRGCGLY 
Gαs  RMHLRQYELL 




Table 5.3: Antisera against Gαs Gαq/11  and Gαi1/2  were generated by CRL 
Laboratories Ltd. (Cambridge, UK) using the peptides below.  
The sequences of peptides shown correspond to the C-terminal ten amino acids of the 
listed G protein α subunit.  The N-terminal cysteine allows the coupling of the peptide to a 





















Animal #  Peptide sequence  G-protein α subunit 
1314  [C]RMHLRQYELL  Gαs 
1315  [C]RMHLRQYELL  Gαs 
1316  [C]QLNLKEYNLV  Gαq/11 
1317  [C]QLNLKEYNLV  Gαq/11 
1318  [C]KENLKDCGLF  Gαt,i1,i2 
1319  [C]KENLKDCGLF  Gαt,i1,i2 J. Robert Lane, 2007    Chapter 5 
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5.2.2  Characterisation of antisera raised against the C-terminal ten 
amino acids of Gαt 
 
Antisera were successfully generated against a decapeptide corresponding to the C-
terminal ten amino acids of Gαt.  The specificity towards the decapeptide was confirmed 
by CRL laboratories by ELISA.  However, the selectivity of the antisera towards Gαi1/2 had 
to be determined.  Mammalian cell lines express an array of Gα subunits, with Gαi2 and 
Gαi3 appearing to be expressed in all cell types.  To investigate the selectivity of these 
antisera for individual members of the Gαi subfamily a system was needed in which the 
individual G protein α subunits could be expressed in isolation.  The successful expression 
of various G protein α subunits in E coli has been described previously (Wise and 
Milligan, 1995).  Briefly cDNA of Gαi1, Gαi2, Gαi3, and Gαo1 was cloned into the 
expression vector pT7.7 and this subsequently transformed into the BL21 strain of E coli.  
Expression of the relevant Gαi/o subunits was induced with the addition of IPTG.  Protein 
was then separated by SDS PAGE and Western blotting performed using the various 
antisera generated in this project and compared with in-house antisera already 
characterised and known to be selective against various Gα subunit subtypes.  An in-house 
antiserum (SG3) raised against the C-terminal ten amino acids of Gαt, gave a single band 
between 35 and 50 kDa only for samples where the expression of Gαi1or Gαi2 has been 
induced (Figure 5.1A).  A faint band was seen where Gαi3 is induced indicating some 
cross reactivity with this subtype.  The in-house antiserum I3B (raised against a 
decapeptide corresponding to the C-terminal tail of Gαi3) only gave a single band when the 
expression of Gαi3 was induced.  The in-house antiserum, OC2, was raised against the C-
terminal ten amino acids of Gαo1.  Using this antibody, a single band between 35 and 50 
kDa was seen when the expression of Gαo1 was induced (Figure 5.1A).  Furthermore, a J. Robert Lane, 2007    Chapter 5 
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band was also seen for the sample where expression of Gαi3 was induced, highlighting the 
cross reactivity of this antibody with both Gαo1 and Gαi3.  This cross reactivity is perhaps 
not surprising given the high sequence similarity of the C-terminal ten amino acids of these 
two Gα subunits (Table 5.2).  The glycine eluate of the antiserum raised against a 
decapeptide corresponding to the last ten amino acids of Gαt , derived from animal 1318, 
gave a band between 35 and 50 kDa for samples in which expression of Gαi1, Gαi2, Gαi3 
and Gαo1 was induced (Figure 5.1B).  This indicates that this antiserum is not able to 
discriminate between all Gα subtypes within the Gαi family.  In contrast, the TEA eluate 
from animal 1318 and the glycine and TEA eluate from animal 1319 all showed selectivity 
for Gαi1 and Gαi2 only giving a single band between 35 and 50 kDa when the expression of 
these two subtypes were induced. 
 
As part of an effort to further characterise these antisera, their ability to immunoprecipitate 
the [
35S]GTPγS bound forms of the relevant Gα subunits was assessed.  To this end, a [
35S] 
GTPγS assay with an immunocapture step was performed using membranes from cells co-
expressing the D2l receptor and Gαi1 and with or without the addition of 100 µM dopamine.  
At the immunocapture step equivalent reactions were set up for both dopamine stimulated 
and unstimulated conditions using either the in-house Gαi1/2 selective antisera (SG3), or the 
glycine eluate of the antiserum from animal 1319 raised against the C-terminal decapeptide 
of Gαt.  The pulldown using the glycine eluate 1319 gave higher counts for both basal and 
dopamine-stimulated conditions as compared to the in-house antiserum (Figure 5.2).   
 
Since the glycine eluate of the antiserum from animal 1318 had been shown to recognise 
Gαi1, Gαi2, Gαi3 and Gαo1 in Western blots, it was of interest to establish whether this 
antiserum could efficiently immunocapture a [
35S] GTPγS labelled subunit other than those 
of Gαi1/2.  A [
35S] GTPγS assay with an immunocapture step was performed using 
membranes from cells expressing the corticotrophin releasing factor (CRF) receptor fused J. Robert Lane, 2007    Chapter 5 
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to Gαi3 (supplied by L. Jenkins, University of Glasgow) and with or without the addition of 
1µM sauvagine as agonist.  The glycine eluate of antiserum from animal 1318 showed 
comparable counts to those seen when using the in-house antiserum (I3B) for both basal 
and agonist stimulated conditions (Figure 5.3).  This shows then, that the glycine eluate 
from animal 1318 is capable of the immunoprecipitation of [




5.2.3  Characterisation of antisera generated against a decapeptide 
corresponding to the C-terminal decapeptide of Gαq 
Antisera were generated against a decapeptide corresponding to the C-terminal ten amino 
acids of Gαq and affinity towards the decapeptide was confirmed in an ELISA (CRL 
laboratories).  As for the antisera generated against Gαt the selectivity of this interaction 
had to be confirmed.  Again, a system where Gαq could be expressed in a Gαq-null 
background had to be used.  In this case Gαq/Gα11 null EF88 cells could be used (Stevens 
et al., 2001).  EF88 cells were or were not transiently transfected with Gαq (performed by 
Laura Ormiston, Molecular Pharmacology, University of Glasgow), membranes 
preparations made and proteins separated by SDS PAGE.  Western blots were performed 
using the antisera raised against the C-terminal decapeptide of Gαq and compared with an 
equivalent and previously characterised in-house antiserum (CQ5).  The in-house 
antiserum CQ5 gave a single band between 35 and 50 kDa only in EF88 cell membranes 
where Gαq had been transiently expressed (Figure 5.4A).  Similarly, both the glycine and 
TEA eluates of antiserum from animals 1316 and 1317 (Figures 5.4B-E), gave a single 
band between 35 and 50 kDa, again only in EF88 cell membranes where Gαq had been 
transiently expressed.  This demonstrates the selectivity of these antisera towards Gαq. 
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As for antisera raised against Gαt it was of interest to establish whether this antiserum 
could efficiently immunocapture [
35S] GTPγS bound Gαq/11.  A [
35S] GTPγS assay with an 
immunocapture step was performed using membranes from EF88 cells co-expressing the 
α1b-adrenoceptor and Gα11 (supplied by L. Jenkins, University of Glasgow) and with or 
without the addition of 1µM phenylephrine.   The glycine eluate of 1317 showed 
comparable counts to those seen when using the in-house antiserum (CQ5),  for both basal 
and agonist-stimulated conditions (Figure 5.5).  This shows then, that the glycine eluate of 
1317 not only shows affinity for Gαq on a western blot, but is capable of 
immunoprecipitation of [
35S] GTPγS bound Gαq.  Furthermore, it showed a comparable 
efficiency of pulldown to an in-house antiserum raised against the C-terminal ten amino 
acids of Gαq. 
 
 
5.2.4  Characterisation of antisera generated against a decapeptide 
corresponding to the C-terminal decapeptide of Gαs 
 
Following the generation of antisera against the C-terminal tail of Gαs their selectivity was 
confirmed both by Western blotting and immunoprecipitation.  Gαs is expressed in a wide 
range of mammalian cells and a Gαs null cell line was not available.  However, prolonged 
treatment with cholera toxin leads a decrease of Gαs levels.  Conversely, expression levels 
of Gαs within a cell can be increased by transiently transfecting cells with Gαs cDNA.  
Accordingly, to characterise the above antisera, HEK293T cells were transfected with 
cDNA corresponding to the long isoform of Gαs or a mock transfection was performed 
using an equivalent amount of the empty vector pcDNA3.  Of the cells which were mock 
transfected, one sample was subjected to a prolonged treatment with cholera toxin.  Cells 
were harvested and membrane preparations made.  Membrane protein was separated by J. Robert Lane, 2007    Chapter 5 
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SDS PAGE and western blots performed using antisera generated against the C-terminal 
decapeptide of Gαs.  The in-house antiserum CS2 showed two bands between 35 and 50 
kDa corresponding to the long and short isoforms of Gαs for all membrane preparations.  
However, the intensity of these bands varied between the three preparations.  As compared 
to the mock, un-treated HEK293T cells, the bands were more intense for the sample where 
Gαs had been transiently transfected, and less intense where the cells had been treated with 
cholera toxin (Figure 5.6A).  Similarly, the antisera generated in this project, namely the 
glycine and TEA eluates from animal 1314, showed a similar pattern.  Indeed, as compared 
to the in-house antiserum the bands were of a higher intensity and with no non-specific 
bands (Figure 5.6B-C). The antisera generated in this project against the C-terminal tail 
ten amino acids of Gαs showed selectivity towards Gαs and are equivalent, if not better, 
than an in-house antibody previously generated against the same decapeptide. 
 
The ability of this antiserum to efficiently immunocapture [
35S] GTPγS Gαs was tested.  A 
[
35S] GTPγS assay with an immunocapture step was performed using membranes from 
cells co-expressing the corticotrophin releasing factor (CRF) receptor and Gαs and with or 
without the addition of 1µM sauvagine.  The glycine eluate of 1314 showed comparable 
counts to those seen when using the in-house antiserum CS2 for both basal and agonist-
stimulated conditions (Figure 5.7).  This shows then, that the glycine eluate of 1314 not 
only shows affinity for Gαs on a western blot, but is capable of immunoprecipitating [
35S] 
GTPγS bound Gαs.  In conclusion then, antisera were raised against decapeptides of 
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5.2.5  Generation of antibodies selective to the active conformation 
of Gαi1:  
 
The second aim of this chapter was the generation of antibodies that selectively recognise 
the active (GTP bound) conformation of the Gαi1 subunit.  To achieve this goal two 
immunisation strategies were used; plasmid immunisation, or repetitive immunisation at 
multiple sites (RIMMS) using recombinant human Gαi1 which had been ‘preloaded’ with 
the non-hydrolysable GTP analogue GTPγS to force the Gα subunit into the active, GTP 
bound, conformation.  For the plasmid immunisation strategy, cDNA of a constitutively 
active mutant of Gαi1, Glu
204Leu Gαi1, was cloned into the vector αFcMCS.  The stop 
codon of the Glu
204Leu Gαi1 gene was removed and therefore upon cloning into the 
multiple cloning site of αFcMCS, a Glu
204Leu Gαi1 human Fc fragment fusion protein was 
generated.   Gold particles were coated with this cDNA and plasmid immunisation 
performed using a gene gun.  For the RIMMS procedure, recombinant human Gαi1 was 
incubated with 100 µM GTPγS, to ‘load’ the Gαi1 protein with GTPγS and to force the 
protein into its active conformation and animals immunised using a procedure modified 
from (Bynum et al., 1999).   Both of these immunisation procedures were preformed by I. 
Kinghorn (Antibody Generation, Biological Reagents and Assay Development (BRAD), 
GSK). 
 
5.2.6  Outline of hybridoma generation 
 
The generation of monoclonal antibodies using the production of hybridomas is a well 
used and characterised procedure.  In this project, as for the immunisation procedures all 
hybridoma generation and culture, as well as antibody purification was performed by I. J. Robert Lane, 2007    Chapter 5 
262 
Kinghorn (Ab generation BRAD, GSK).  I will, therefore, only include a brief and general 
outline of the steps involved in hybridoma production to put the subsequent screening and 
characterisation of antibodies into context.  For a more detailed summary of the 
immunisation procedures and hybridoma generation procedures refer to section 2.10 
The antibody generation strategy is described by Figure 5.8.   Periodic test bleeds 
collected from immunised animals can be checked for the desired antibodies.  The test 
bleed will yield small samples of polyclonal sera.  These sera should be tested in assays 
that will detect the presence of antibodies specific for the antigen.  It is not worthwhile to 
fuse antibody secreting cells from animals that do not have a useable titre of antibodies in 
their serum.  Antibody producing cells can be removed from the animal and fused with 
myeloma cells by centrifugation.  Hybridoma clones are generated using selective medium 
preventing the growth of myeloma cells. Hybridoma cells secrete antibodies into the tissue 
culture medium in which they are grown.  Consequently, samples of this tissue culture 
medium for all selected clones can be screened for antibodies with the desired 
characteristics.  Cells from positive clones are then grown and single cells cloned.  These 
single cell clones are then screened again and the final hybridoma can be expanded and 
frozen down.  
 
 
5.2.7  The FMAT assay system 
 
The success of hybridoma production depends on the production of useful antibodies with 
the desired characteristics and is dependent on the strength of the immune response and the 
development of a robust screening method.  Consequently, prior to the immunisation of 
animals it was necessary to have a robust screening method in place.  The assay format J. Robert Lane, 2007    Chapter 5 
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decided upon was a whole cell FMAT assay.  The FMAT or ‘Fluorometric Microvolume 
Assay Technology’ is a system developed by Applied Biosystems (Foster city, CA, USA) 
The FMAT 8200 high throughput screening system provides a platform that is perfectly 
suited for hybridoma screening. The FMAT system is a macroconfocal scanner that 
visualizes and quantities both cell-and bead-bound fluorescence.  Consequently then, cells 
which express the antigen of interest can be incubated with hybridoma supernatant plus the 
relevant secondary antibody conjugated with the FMAT blue ® dye (Figure 5.9).  The 
FMAT Blue® dye is a far-red emitting dye in the 650 nm range light generated from a 633 
nm helium/neon laser scans an area of 1 mm
2
2 with a depth of focus of ~100 am from the 
bottom of each well.  Because the depth of focus is relatively small with respect to the 
remaining volume of the well, the majority of the unbound flourophore remains undetected 
and need not be washed away.  The FMAT™ software is then able to subtract the 
remaining background fluorescence from the fluorescence immobilized on the cells or 
beads. As a result, all assays performed with the FMAT system are ‘mix-and-read’ and do 
not require wash steps. The integrated plate handler allows for walk-away screening for up 
to sixty 96- or 384-well plates. 
 
5.2.7.1  Development and characterization of a whole cell FMAT assay to allow 
screening of hybridomas producing antibodies that are selective against the 
active conformation (GTP bound) conformation of Gαi1 
The FMAT assay technology using whole cells expressing the desired antigen has been 
used successfully in previous antibody generation programmes to screen for hybridomas 
secreting antibodies with the desired selectivity.  For these programmes the antigen was 
generally expressed on the extracellular surface in contrast to the desired antigen in this 
screen, a Gα subunit which has an intracellular localisation.  It was necessary then, to J. Robert Lane, 2007    Chapter 5 
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develop a method of permeabilising the cell to allow access of the antibody to this antigen.  
HEK293T cells were transiently transfected with cDNA of either Gαi1 (wild type), 
Gly
203Ala Gαi1 (inactive mutant), Glu
204Leu Gαi1 (active mutant) or GPR55 (FLAG N-
terminus) as a negative control.  Transfected cells were permeabilised by four different 
techniques, the relevant FMAT blue ® secondary antibody could be added to a dilution of 
1:2000, and then added to each well of a 96 well FMAT
™ plate into the bottom of which a 
sample of the desired primary antibody was aliquot.  This general protocol is described by 
the diagram in Figure 5.9.  Following each permeabilisation step cells were washed and 
assayed in PBS + 1% BSA + 0.1% NaN3 + Triton X 100.  Cell viability following each of 
the permeabilisation methods was measured prior to assay reading.  For these experiments 
the polyclonal antiserum: glycine 1319 characterized in section 5.2.2 was used.  This 
antiserum recognizes the C-terminal ten amino acids of Gαi1/2 but would not be anticipated 
to discriminate between the inactive or active variants of Gαi1, or indeed the GTP or GDP 
bound conformations of the wild type.  Conversely, as a proof of concept, the FMAT assay 
was performed using an anti-FLAG antibody, and would only be anticipated to give a high 
signal for cells transfected with FLAG-GPR55   
 
Following cell permeabilisation using the sodium azide method, in which cells were 
washed, resuspended and assayed in PBS +1% BSA + 0.1% NaN3., the proportion of 
viable cells was 80 %.  Using the polyclonal anti-Gαi1/2 antiserum, a high signal was seen 
for all conditions with cells transfected with Gαi1 cDNA compared to the negative control 
of cells transfected with FLAG-GPR55.  The FMAT assay performed with a final 
polyclonal anti-Gαi1/2 antiserum dilution of 1:500 gave an approximately 40 fold higher 
signal (200,000 counts) for positive conditions where Gαi1 was expressed as compared to 
the negative, GPR55 transfection condition (Figure 5.10A).  In the Cytofix / Cytoperm 
method, cells were incubated with Cytofix/Cytoperm for 10 minutes at 4 ºC.  Cells then 
were washed twice with CytoPerm before the assay step.  In the hERG fixation method J. Robert Lane, 2007    Chapter 5 
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cells were resuspended in 4 % (w/v) neutral buffer formalin for 10 min at 4 ºC prior to the 
assay step.  In both cases (Figure 5.10B + C), a similar high signal was seen for Gαi1 
transfected cells in the experiments using the anti-Gαi1/2 antiserum as compared to the 
FLAG-GPR55 transfected negative control but cell viability was reduced to <10%.  In a 
Modified Kruzik’s method (Krutzik et.al 2005), cells were permeabilised in 4% (w/v) 
neutral buffer formalin for 15 min at room temperature. Methanol was added directly to 
fixative to a final concentration of 80 % and cells incubated for a further 5-10 minutes at 
room temperature.  This protocol resulted in an even lower cell viability (<1%) (Figure 
5.10D), and although higher counts were observed for Gαi1 transfection conditions 
compared to the FLAG-GPR55 transfection condition when the anti-Gαi1/2 antisera was 
used, the signal window was much reduced as compared to that seen for the equivalent 
experiment using the sodium azide permeabilisation method. 
 
High cell viability is important since the FMAT
TM software contains an algorithm to select 
for fluorescence bound only to viable cells.  Consequently, a permeabilisation procedure 
that maintains high cell viability is advantageous.  In addition, the relative simplicity of the 
sodium azide method compared to the other permeabilisation methods made it the most 
attractive for subsequent optimisation and eventual use in the antibody screening assay.  
This work was performed by Dion Daniels (BRAD, GSK, UK) and Ben Powney 
(Screening & Compound Profiling, GSK, UK). 
 
5.2.7.2  A whole cell FMAT assay for screening of hybridomas was stable for 23 
hours 
To allow for efficient screening of a large number of hybridoma supernatants it was 
necessary for the assay to be carried out in 384 well plates.  Furthermore, to allow the 
hybridoma screen to be performed overnight without supervision, the assay must be stable J. Robert Lane, 2007    Chapter 5 
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for a 24 hour period.  HEK293T cells were transiently transfected with cDNA of either 
wild type Gαi1 or the constitutively active variant Gln
204Leu Gαi1 and as a negative control 
cells were transfected with cDNA of FLAG-GPR55.  Cells were resuspended in 
permeabilisation buffer (PBS + 1% BSA + 0.1% NaN3) with or without the addition of 10 
µM GTPγS and with the addition of FMAT blue ® anti-rabbit secondary antibody.  This 
cell suspension was added to a well of a 384 well plate already containing 1 µl of anti-
Gαi1/2 antiserum (glycine 1319).  This plate was left at room temperature for 2 hours or 23 
hours prior to reading.  For the 2 hour read, a high signal (~600,000 counts) was observed 
for conditions in which Gαi1 had been transfected into cells as compared to the negative 
control, FLAG-GPR55 transfected cells (~ 20000 counts) (Figure 5.11A),.  For the 23 
hour read, a high signal was observed for the Gαi1 transfected cells (~2,000,000 counts) 
and a negligible signal seen for the FLAG-GPR55 control transfection (100,000 counts) 
(Figure 5.11B).  As expected using the anti-Gαi1/2 antiserum raised against the C-terminal 
ten amino acids of Gαt, there was no difference between the signal observed for wild type 
Gαi1 transfections and transfections of the constitutively active variant Gln
204Leu Gαi1 or 
with the addition of 10 µM GTPγS.  As described by Table 5.4 Z’ is a simple statistical 
parameter for use in evaluation and validation of high throughput screening.  By 
calculation of the Z’ number for each positive Gαi1 transfection condition in comparison to 
the negative GPR55 transfection condition a measurement of the robustness of the assay 
was gained.  For all conditions in both the 2 hour and 23 hour read the Z’ value was greater 
than 0.6 (Figure 5.12A + B).  Therefore, the assay was robust in a 384 well format, and 
that the large signal window of the assay was stable for at least 23 hours following cell 
addition.  These characteristics made it suitable for hybridoma screening.  This work was 
performed by Dion Daniels (BRAD, GSK, UK) and Ben Powney (S & CP, GSK, UK). 
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Table 5.4:  A simple characterisation of a high throughput screening assay by 
calculation of Z’. 
 
 
SD = standard deviation.  In the case of the FMAT assay control refers to the negative 
control conditions (Zhang et al., 1999). 
 
 
5.2.7.3  Frozen cells could be used in a whole cell FMAT assay for screening of 
hybridomas producing antibodies that are selective against the active 
conformation (GTP bound) conformation of Gαi1:  
To allow the preparation of all reagents needed for the screen prior to hybridoma screening 
it would be advantageous if stocks of appropriately transfected cells could be frozen down 
in advance and then brought up and defrosted when required.  Cells were transfected with 
cDNA of either wild type Gαi1, the constitutively active variant Gln
204Leu Gαi1or a mock 
transfection was performed using an equivalent amount of the empty vector pcDNA3.  
control   of mean    -   sample   of mean 
control   of   3SD     sample   of   SD 3
1 '
+
− = Z  
Z-factor value  Structure of assay  Related to screening 
1  SD = 0 (no variation)  An idea assay 
1 > Z ≥ 0.5  Separation band is large  An excellent assay 
0.5 > Z > 0  Separation band is small  A double assay 
0  No separation band, the sample signal 
variation and control signal variation 
bands touch 
A “yes/no” type assay 
<0  No separation band, the sample signal 
variation and control signal variation 
bands overlap 
Screening essentially 
impossible J. Robert Lane, 2007    Chapter 5 
268 
Cells were counted and aliquots from each condition were either left on ice or re-
suspended in foetal calf serum and frozen at -80 ºC for 2 hours.  Frozen cells were then 
thawed rapidly in a 37 ºC bath, washed twice in PBS (4 ºC) and an FMAT assay performed 
as in section 5.2.8.2 using both frozen and fresh cells.  Again, within the same treatment 
condition, there was little difference between signals observed for wild type and active 
variant Gαi1 transfections (Figure 5.13).  Furthermore, there was no difference observed 
between counts for the fresh and frozen cells for each transfected cell condition.  The 
robust signal window observed is highlighted by a Z’ value of >0.6 observed for each 
positive condition in comparison to the negative mock transfection condition (Figure 
5.12).  This experiment demonstrates that a robust assay for screening hybridomas 





5.2.8    Test bleed ELISAs against recombinant Gαi1 
 
Following the successful demonstration of a viable FMAT assay to screen hybridoma 
clones the immunisation programme was started.  Two mice were immunised for each 
immunisation strategy, either plasmid immunisation or the protein RIMMS protocol 
described above.  To check the strength of the immune response, and indeed the success of 
the immunisation, test bleeds were taken from each animal.  A set of serial dilutions was 
made of each test bleed and as a positive control the polyclonal anti-Gαi1 antiserum 
(Glycine 1319).  These were dispensed onto 96 well plates coated with rGαi1 (0.1 µg / 
well).  The secondary antibody used was either a HRP conjugated anti-mouse or anti-rabbit 
antibody as appropriate.  For the rGαi1 RIMMS for both animal 120 and 121 a small but J. Robert Lane, 2007    Chapter 5 
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significant signal was observed (Figure 5.13A), although this signal was three times 
smaller than the maximum signal observed for the anti-Gαi1 antiserum (Figure 5.13C).  
This is perhaps not surprising since the concentration of antibody in the test bleed is likely 
to be many times lower than that seen for the purified anti-Gαi1/2 antiserum It is notable, 
however, that for the plasmid immunisations, no signal was observed (Figure 5.13B).  
This indicates that this immunisation strategy was unsuccessful. 
 
 
5.2.9    Test bleed ELISAs against human IgG 
To confirm that the plasmid immunisation did not stimulate an immune response, ELISAs 
were performed using the test bleeds from the plasmid immunised animals.  A Gln
204Leu 
Gαi1-human Fc fragment fusion protein was generated.  Consequently, an immune 
response should be generated not only against Gln
204Leu Gαi1 but also against the Fc 
fragment.  Again serial dilutions of the test bleeds from the plasmid immunised animals 
were made and these dispensed into 96 well plates pre-coated with human IgG.  As a 
positive control a bleed from a plasmid immunised animal from another immunisation 
program again using a human Fc fragment fusion protein which had shown a strong 
immune response was used (supplied by I. Kinghorn, GSK).  As a negative control, a test 
bleed from an unrelated program using a RIMMS protocol, which should therefore show 
no affinity for human IgG was used (supplied by I. Kinghorn).  The positive control gave 
strong signal, and as expected the negative control gave no specific signal (Figure 5.14).  
In comparison to the positive control no signal was observed for the test bleeds from the 
Gαi1-Fc plasmid immunisation.  This suggests that the plasmid immunisation program was 
unsuccessful and failed to generate an immune response. 
 




5.2.10  Hybridoma Screen 
5.2.10.1  Conditions for hybridoma screen 
Following the positive response seen for the test bleed ELISAs from the rGαi1 
immunisation protocol, it was decided to continue with the hybridoma generation program 
as described above, both with animals from the protein immunisation and the plasmid 
immunisation.  Hybridoma clones were picked and grown up in 96 well plates.  Screening 
was to be performed in 384 well plates.  To allow complete automation of the screening 
process, including the dispensing of hybridoma supernatant from 96 well to 384 well plates 
the screen had to be set up to allow one supernatant to be screened in four wells of a 384 
well plate.  This meant that four conditions would have to be chosen to identify 
hybridomas producing antibody that was selective against the active (GTP bound) 
conformation of Gαi1.  To achieve this the following conditions were set up: 1) HEK293T 
cells transfected with wild type Gαi1 cDNA, and incubated with 100 µM GTPγS to force 
the majority of expressed Gαi1 into the active GTP bound conformation. 2) HEK293T cells 
transfected with constitutively active Gln
204Leu Gαi1 3) HEK293T cells transfected with 
wild type Gαi1 cDNA, and incubated with 100 µM GDPβS to force the majority of 
expressed Gαi1 into the inactive GDP bound conformation.  4) HEK293T cells mock 
transfected with pcDNA3 (Figure 5.15).  As in preliminary assays cells were 
permeabilised by incubation in PBS + 1% BSA + 1% NaN3.  FMAT blue ® anti-mouse 
secondary was used at a final dilution of 1:2000.  A hybridoma producing antibody that is 
selective against Gαi1 in the active GTP bound conformation should show a high signal 
against both the GTPγS loaded Gαi1 wild type condition and also the Gln
204Leu Gαi1 
condition, but not against the GDPβS loaded or mock transfection conditions.  J. Robert Lane, 2007    Chapter 5 
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Furthermore, the inclusion of a wild type Gαi1 loaded with GTPγS condition should 
prevent the identification of false positive clones which simply pick up the mutation of 
Gln
204Leu rather than the associated conformational change.  It could be expected that the 
majority of hybridomas will produce antibody which is selective against Gαi1 but does not 
distinguish between the active and inactive conformations.   
 
5.2.10.2  Primary hybridoma screen: identification of 3 hybridoma showing 
selectivity towards the active (GTP bound) conformation of Gαi1   
A total of 1632 hybridoma clones were screened originating both from the rGαi1 rapid 
immunisation and the plasmid immunisation strategies.   Positive clones were identified 
using the FMAT™ software. This gave a visual representation of fluorescent signal/cell 
number, and allows easy identification of positive clones.  To confirm this identification, 
an Excel spreadsheet (Microsoft) was designed to identify both clones which recognise 
Gαi1, but do not show any selectivity between the inactive and active state and those which 
are conformation selective.  In both cases a ratio of signal of the positive versus the 
negative conditions that was greater than or equal to 2 was highlighted as a positive result.     
For clones showing non-conformational selectivity a higher signal was observed for the 
three conditions in which HEK293T cells had been transfected with either Gαi1 wild type 
or Gln
204Leu Gαi1 compared to that seen for the mock-transfected HEK293T cells. As 
could be expected, the majority of positive clones simply displayed selectivity towards the 
Gαi1 transfected conditions as compared to the mock-transfection (see Table 5.5).  The 
large number of clones displaying this profile is perhaps again indicative that expression 
levels of both the wild type and constitutively active forms of Gαi1 were equivalent.   
However, three hybridoma clones (8D11, 6F12, 8A6) showed a profile indicative of 
selectivity towards the active or GTP bound conformation of Gαi1 (Figure 5.16).  In all J. Robert Lane, 2007    Chapter 5 
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cases the signal observed for either HEK293T cells expressing wild type Gαi1 preloaded 
with GTPγS or cells expressing the constitutively active mutant Gln
204Leu Gαi1 was 
considerably higher than that observed for cells expressing wild type Gαi1 preloaded with 
GDPβS or the mock-transfected cells.  It should be noted that for all three of the above 
hybridoma clones the observed signal for cells expressing wild type Gαi1 loaded with 
GDPβS was higher than that observed for mock transfected cells.  This increased level of 
signal must be due to the increased level of Gαi1 expressed within the cell.  This could be 
explained by two scenarios; firstly that the antibody has an affinity for the GDP bound 
(inactive) state of the receptor, albeit lower than that observed for the GTP bound (active) 
state, or secondly that the concentration of GDPβS used was not sufficient to force the 
entire population of Gαi1 into the inactive conformation.  However, the ‘signal window’ 
observed between the GTPγS loaded condition and the GDPβS loaded condition was large 
enough to warrant further characterisation of these three hybridoma clones. 
 
 
Table 5.5: Summary of results from initial hybridoma screen 
Clones showing selectivity towards Gαi1 had higher counts for conditions in which Gαi1 
was expressed as compared to the mock transfection condition.  Clones showing selectivity 
towards the active conformation of Gαi1 had higher counts for the Gαi1 + 100µM GTPγS or 
the Gln





Number of clones showing 
selectivity to Gαi1 
Number of clones showing 
selectivity towards active 
conformation of Gαi1 
 
1632 34  3 
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5.2.10.3  Secondary hybridoma screen: Confirmation that three hybridomas show 
selectivity towards the active (GTP bound) conformation of Gαi1   
Clones, which showed selectivity towards Gαi1 transfected conditions, were subsequently 
sub-cultured.  This included the three clones with putative selectivity towards the active 
conformation of Gαi1.  All other hybridoma clones were discarded.  To confirm the results 
of the primary screen, a secondary screen was again set up using the same conditions as for 
the primary screen.  However, for the secondary screen the experiment was performed in 
triplicate to N = 3.  Again, the majority of clones showed no selectivity towards the active 
or inactive conformation of Gαi1, but simply showed high counts in conditions where Gαi1 
was expressed and negligible counts for the mock transfection condition (Figure 5.17 A-
D).  The three clones which were identified as being selective towards the active 
conformation of Gαi1 again showed higher counts in conditions where Gαi1 was in an active 
conformation as opposed to those seen for the condition in which Gαi1 was in the inactive 
(GDPβS loaded) conformation (clones 8A5, (Figure 5.17D), 8D11 (Figure 5.17D), 6F12 
(Figure 5.17C)) .  However, in comparison to the primary screen the difference between 
observed signal for active and inactive Gαi1 conditions was not as great.  Indeed, in the 
primary screen the observed fold difference between the conditions in which Gαi1 would 
be in the active conformation as compared to the inactive conformation was around 10 fold 
as compared to a < 2 fold difference in the secondary screen.  However, the signal 
observed for the mock transfection remained extremely low (Figure 5.17 A-D).  The 
higher counts observed in the condition where expressed Gαi1 was preloaded with GDPβS 
indicated that these antibodies may still have significant affinity for the inactive 
conformation of Gαi1.  However, this pattern could also be seen if the concentration of 
GDPβS used was insufficient to ensure all expressed Gαi1 was forced into an inactive GTP 
bound state. 
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5.2.10.4  FMAT screen of sub-cloned hybridoma 
In the initial generation and culture of individual hybridoma clones, a Clonepix robot was 
used to ‘pick’ individual clones from a polyclonal mix grown on a semisolid medium see 
section 2.10).  Whilst this method saved a considerable amount of time, and consequently, 
allowed the generation and screening of many more hybridoma clones, it is not 100 % 
accurate and if colonies were growing close to each other might result in a clone actually 
being a mixed polyclonal population.  If hybridoma producing non-conformation selective 
antibodies become a more prevalent members of this polyclonal population then the signal 
window observed between conditions in which Gαi1 was in an active state compared to the 
inactive state would decrease. 
 
Hybridoma which had been shown to produce antibodies selective to the active 
conformation of Gαi1 (8A5, 8D11, 6F12), were re-cloned, individual colonies picked and 
cultured.  Hybridoma tissue culture supernatant was again screened using the FMAT assay 
as in section 5.2.11.  A mix of clones was again seen with some showing higher counts for 
conditions in which Gαi1 was in the active conformation.  However, non-conformation 
selective clones were also observed (Table 5.6).  It was disappointing to note then, that 
despite the re-cloning of these hybridoma and the removal of clones which produced non-
conformation selective antibody the signal window was not significantly improved (Figure 
5.18A-C).  The clones which showed the largest signal window between Gαi1 in the active 
conformation and those in the inactive conformation were retained, subcultured and 
aliquots frozen down.  All other clones were discarded.  Retained clones were cultured on 
a large scale and antibody purified from the resulting supernatant.  Two non-conformation 
selective antibody producing hybridoma clones (6B4 and 8F5), were also retained and 
cultured to a large scale and antibody purified from the resulting supernatant (Figure 5.17 




Table 5.6: Summary of results from screen of sub-cloned hybridoma 
 
Clones showing selectivity towards Gαi1 had higher counts for conditions in which Gαi1 
was expressed as compared to the mock transfection condition (Figure 5.16).  Clones 
showing selectivity towards the active conformation of Gαi1 had higher counts for the Gαi1 
+ 100µM GTPγS or the Gln





Number. of clones 
screened 
Number of clones 
showing selectivity 
to Gαi1 
Number of clones 
showing selectivity 
towards active 
conformation of Gαi1 
8A5 24  23  9 
8D11 48  48  36 
6F12 48  48  38 
 
 
5.2.10.5  Titration experiment using purified antibody from each conformation 
selective hybridoma 
Using each purified antibody described in the previous section an ELISA-like experiment 
was set up.  A sequential 1 in 3 set of twelve dilutions were made of each antibody.  These 
were added into the wells of FMAT 384 well plates.  Similar to the FMAT screens used 
previously the five following conditions were set up:  HEK293T cells transiently 
expressing wild type Gαi1 were permeabilised in FMAT buffer and preloaded with either J. Robert Lane, 2007    Chapter 5 
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10µM GTPγS (1) or 10µM GDPβS (2).  HEK293T cells transiently expressing either the 
constitutively active variant Gln
204Leu Gαi1 (3) or the constitutively inactive variant 
Gly
203Ala Gαi1 (4) were permeabilised in FMAT buffer but not pre-incubated with guanine 
nucleotide.  Finally, cells were mock-transfected with the empty vector pcDNA3 and 
permeabilised as above (5).  An FMAT assay was performed with each of these cell 
suspensions was added to the dilution sets of the five antibodies.  The non-conformation 
selective antibodies 8A5 and 6B4 (Figure 5.19 A-B) showed little difference in counts 
between wild type Gαi1 loaded with GTPγS or GDPβS at all dilutions.  In both cases, 
counts for the Gln
204Leu Gαi1 constitutively active variant were marginally lower than the 
counts observed for the wild type Gαi1 conditions.  Similarly, the counts observed for the 
Gly
203Ala Gαi1 inactive variant were markedly lower than those observed for the wild type 
Gαi1 conditions.  In both cases, this is most likely due to lower relative amounts of Gαi1 
variant expressed as compared to the wild type Gαi1 transfected cells.  The putative 
conformation-selective antibodies (8A6/1H1, 8D11/1C1, 6F12/1E5, Figure 5.20 A-C) all 
showed higher counts for wild type Gαi1 loaded with GTPγS as compared to GDPβS.  
However, this was titre dependent with the largest ‘signal window’ observed at 
approximately 0.1 µg/ml initial antibody protein concentration for all antibodies.  Counts 
observed for the Gln
204Leu Gαi1 constitutively active mutant expressing cells were high 
and similar to those observed for the condition in which wild type Gαi1 was preloaded with 
GTPγS.  However, for the cells expressing the inactive variant Gly
203Ala Gαi1 the observed 
counts were extremely low.  Indeed for the antibodies 8A6/1H1 (Figure 5.20 A) and 
8D11/ 1C1 (Figure 5.20 B) the observed counts were 10 fold lower than those observed 
for the constitutively active variant Gln
204Leu Gαi1 or indeed wild type Gαi1 loaded with 
GTPγS.  For the antibody 6F12/1E5 (Figure 5.20 C), a three fold difference was observed.  
In all cases this difference was large enough that it could not simply be explained by the 
lower relative expression of Gαi1 (Figure 5.19A-B).  For all antibodies the observed counts 
for the mock-transfection were markedly lower (Figures 5.19, 5.20).  The best signal J. Robert Lane, 2007    Chapter 5 
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window observed between wild-type Gαi1 loaded with GTPγS and GDPβS was a modest 
two fold.  This is strikingly smaller than the ten fold difference observed between the 
active and inactive variants of Gαi1.  This suggests that either the concentration of GDPβS 
used was not sufficient to force the entire population of Gαi1 into an inactive conformation, 
or that the conformation of Gαi1 bound to GDPβS is different to that of the constitutively 
inactive variant Gly
203Ala Gαi1.  Since the cells are in a non-stimulated state, it would be 
expected that the majority of expressed Gαi1 would be in the GDP bound conformation. 
 
5.2.11  Non-conformation selective antibodies show selectivity to Gαi1.  
Conformation selective antibodies do not pick up Gαi1, Gαi2, 
Gαi3 or Gαo1 when denatured on a SDS-PAGE gel  
From the FMAT hybridoma screen and subsequent FMAT assays hybridoma clones were 
identified producing either antibodies selective towards the active GTP bound 
conformation of Gαi1 or antibodies simply selective towards Gαi1 but having equal affinity 
for both the GDP and GTP bound forms of Gαi1.  To further characterise these antibodies 
their specificity towards the other members of the Gαi/o family was tested.  To achieve this 
each of Gαi1, Gαi2, Gαi3 and Gαo1 were expressed in the BL21 strain of E coli which had 
been transformed with the vector pT7.7 into which the cDNA of each Gαi/o subunit had 
been cloned.  Expression of each Gαi/o subunit was induced with the addition of IPTG and 
protein was separated by SDS PAGE.  Western blotting was performed using the 
antibodies from each of the selected hybridoma clones.  The polyclonal anti-Gαi1/2 
antiserum raised against the last ten amino acids of Gt (1319 Glycine) was used as a 
positive control.  The conformation selective antibodies failed to pick up Gαi1, Gαi2, Gαi3 
and Gαo1 when denatured on a SDS PAGE gel (Figure 5.22A-C).  This is not surprising, 
since if they are conformation selective it is most likely than they recognise a three 
dimensional epitope which would be lost if the protein was denatured.  Interestingly, the J. Robert Lane, 2007    Chapter 5 
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non-conformation selective antibodies (6B4 and 8A5) recognised only Gαi1 and no other 
members of the Gαi/o subfamily when denatured on a western blot (Figure 5.21 A-B).  
This was surprising given the high sequence homology of Gαi/o subfamily members (Table 
5.1) particularly between Gαi1 and Gαi3.  It follows then, that the epitope(s) recognised by 
these antibodies is likely to lie within regions of divergent amino acid sequence between 
Gαi1 and the other Gαi/o subunits.  Given the design of the assay and what is known about 
expression of members of the Gαi/o subfamily it is perhaps not surprising that antibodies 
with these characteristics were generated.  Gαi2 and Gαi3 are widely expressed in the 
majority of cell types including HEK293 cells.  Since antibodies were selected which gave 
a low signal in the mock transfected HEK293 condition, it is likely that antibodies which 
showed an affinity for Gαi2 or Gαi3 and therefore relatively high counts for the mock-
transfection condition were discarded.  The anti-Gαi1/2 polyclonal antisera recognised Gαi1, 
Gαi2 and to a lesser extent Gαi3, demonstrating the expression of these Gαi/o subunits 
(Figure 5.21 C).  Coomassie stained blots demonstrate the equal amounts of protein 
loaded for each condition (Figures 5.21 and 5.22). 
 
5.2.12  Immunocytochemistry using antibodies selective against the 
active conformation of Gαi1 
 
The FMAT screen identified three hybridoma clones producing antibodies which were 
selective towards the active, GTP bound, form of Gαi1.   As part of an effort to characterise 
these antibodies further it was important to demonstrate this selectivity in another 
experimental format.  The use of these antibodies for immunocytochemistry was an 
obvious approach to use. Firstly because, as for the FMAT assay, Gαi1 could be expressed 
and remain in a native form retaining the putative three dimensional epitope recognised by 
these antibodies.  Secondly, immunocytochemistry is a widely used and useful technique, J. Robert Lane, 2007    Chapter 5 
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and therefore an appropriate choice to demonstrate the potential utility of these antibodies.  
HEK293T cells were grown on poly-D-lysine coated coverslips and transiently transfected 
with cDNA of the D2l-YFP fusion protein plus one of either wild type Gαi1, the 
constitutively active variant Gln
204Leu Gαi1, or the constitutively inactive variant Gly
203Ala 
Gαi1.   Immunocytochemistry was performed as in section 2.10.5.2.  The co-transfection of 
D2l-YFP with the relevant variant of Gαi1 allowed the identification of successfully 
transfected cells.  For the antibody 8A6/1H1 successfully transfected cells, as indicated by 
the localisation of D2l-YFP at the cell membrane, were observed for all transfections 
(Figure 5.23 A-C i).  However, a signal from the antibody was only observed for the 
active variant Gln
204Leu Gαi1 co-transfection.  As might be expected, the distribution of 
Gln
204Leu Gαi1 was at or in close proximity to the cell membrane (Figure 5.23B).  For 
both the inactive variant Gly
203Ala Gαi1 and indeed the wild type Gαi1 co-transfections no 
signal was observed (Figure 5.23A, C).  This pattern was observed for both the remaining 
conformation selective antibodies 6F12/1E5 and 8D11/1C1 (Figures 5.24 and 5.25).  It is 
of note that the wild type Gαi1 gave no signal for any of the three conformation selective 
antibodies.  It is likely that Gαi1 in a non-stimulated cell would be in the GDP bound 
conformation, and therefore would have no affinity for the conformation selective 
antibodies.  It follows then that when used for immunocytochemistry, all of the putative 
conformation selective antibodies show little affinity for the GDP bound inactive form of 
Gαi1 and high affinity for the active form.  In the FMAT assay, the signal observed for the 
GDPβS loaded wild type Gαi1 condition was lower than that observed for the GTPγS 
loaded Gαi1 condition (Figure 5.20).   However, in contrast with the results from the 
experiments using immunocytochemistry, the signal was clearly higher than that observed 
for cells expressing the inactive variant Gly
203Ala Gαi1 or indeed the mock-transfected 
cells.  This discrepancy must lie within physical differences in the two methodologies. The 
FMAT assay is a ‘mix and read’ assay whereas the immunocytochemical protocol included 
wash steps between both primary and secondary antibody application.  These wash steps J. Robert Lane, 2007    Chapter 5 
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may remove antibody bound with lower affinity to the GDP bound form as compared to 
the GTP bound form, thus improving the signal window.  It would seem then that, for the 
conformation selective antibodies, the relative signal observed for the GTP bound and 
GDP bound forms of Gαi1 and therefore the signal window is assay dependent.  This has 
obvious implications for the choice of assay format to allow the design of a robust high 
throughput assay that is equivalent to the [
35S] GTPγS assay, the ultimate aim of this study. 
 
5.2.13  Immunocytochemistry using antibodies not selective for the 
active conformation of Gαi1 
In parallel with the immunocytochemistry using antibodies selective against the active 
GTP bound form of Gαi1, equivalent experiments were performed using the antibodies 
generated by the hybridoma screen that do not distinguish between GTP and GDP forms of 
Gαi1 (6B4 and 8F5, Figures 5.26 and 5.27) and the polyclonal antiserum raised against the 
C-terminal ten amino acids of Gαi1 (1319 Glycine, Figure 5.28).  These experiments had 
two purposes; firstly to demonstrate the effective use of these antibodies in this 
methodology, and secondly to provide a control indicating the relative expression levels of 
the three variants of Gαi1 used in this experiment.  The anti-Gαi1/2 polyclonal antiserum 
gave a signal of equivalent intensity for all Gαi1 co-transfections, indicating that each of 
wild type Gαi1, Gly
203Ala Gαi1 and Gln
204Leu Gαi1 were expressed to equivalent levels 
(Figure 5.28).  This underlined that, when immunocytochemistry was performed using the 
conformation selective antibodies, the specific signal observed for the Gln
204Leu Gαi1 co-
transfected cells only, was indeed due to the selectivity of these antibodies towards the 
active form of Gαi1 rather than a difference in expression levels.   The signal observed in 
the mock-transfected cells was of a much lower intensity.  Both of the non-conformation 
selective antibodies originating from the hybridoma screen also showed a signal of equal 
intensity for all Gαi1 variant co-transfections.  This again underlined the equal expression J. Robert Lane, 2007    Chapter 5 
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levels of Gαi1 variants between all co-transfections.  In agreement with the results of 
FMAT assay, these antibodies did not distinguish between the active and inactive forms of 
Gαi1.  It is interesting to note that there was no observed signal in the pcDNA3 condition, 
in contrast to the polyclonal antisera which showed a small signal for this condition 
(Figures 5.26D, 5.27.D, 5.28D).  Although, due to differences in concentration of 
antisera/antibody used may make comparison difficult, this low signal may reflect the 
specificity of both 6B4 and 8A5 antibody towards Gαi1 over the other members of the Gαi/o 
subfamily (Figure 5.21). 
 
5.2.14   Epitope mapping of anti-Gαi1 antibodies 
Using both FMAT and immunocytochemical methods I have identified and characterised 
antibodies which are selective against the active (GTP bound) form of Gαi1.  It would be of 
interest to identify the epitope that these antibodies recognise.  This could provide 
information on the conformational changes undergone by Gαi1 upon activation and 
nucleotide exchange.  The strategy used to identify potential epitopes was epitope mapping 
using a library of 86 16mer peptides overlapping by 4 amino acids and corresponding to 
the full amino acid sequence of human Gαi1 (the peptides and residues of Gαi1 that they 
correspond to are listed in Appendix 1).  This ‘Pepset™’ library was supplied by 
Mimotopes Ltd, Australia.  The epitope mapping experiments were performed as described 
in section 2.10.4.  The polyclonal anti-Gαi1/2 antiserum raised against the C-terminal ten 
amino acids of Gαi1, as could be expected, gave a strong signal at peptide 86 (residues 339-
354) (Figure 5.29 A).  This peptide was the only peptide to contain the C-terminal ten 
amino acids of Gαi1 against which this antiserum was raised.  The antiserum also gave a 
strong signal at peptide 20.  However, this strong signal was seen for all antibodies tested 
(Figures 5.29 and 5.30), and so is almost certainly an artefact, perhaps indicating that this 
peptide has a property which makes it an attractive binding partner for all J. Robert Lane, 2007    Chapter 5 
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antibodies/antisera.  For the conformation selective antibodies 6F12/1E5 and 8D11/1C1 
and the non-conformation selective antibody 6B4 (Figures 5.30 A-B, 5.29 B), no signal 
was observed for any peptide other than peptide 20.  In the case of the conformation 
selective antibodies this is perhaps not surprising since the epitope may be a three 
dimensional one with contact points on amino acids that are in close proximity in the 
activated form of Gαi1 but not necessarily in close proximity in the linear amino acid 
sequence.  The fact that these antibodies did not pick up denatured Gαi1 protein on a 
Western blot is in agreement with this hypothesis.  It is interesting that the non-
conformation-selective antibody, 6B4, did not show any affinity for the 16mer peptides 
(Figure 5.29 B).  This indicates that either this antibody recognises an epitope that was 
missed due to the peptide set overlapping by 4 amino acids rather than 1 amino acid or 
that, as for the conformation selective antibodies, it recognises a three dimensional epitope.  
If this antibody does recognise a three dimensional epitope it is interesting that a specific 
interaction was observed with Gαi1 which had been denatured by SDS PAGE.  A small 
proportion of the protein on a SDS PAGE gel will retain some three dimensional structure, 
which may be recognised by the antibody.  The conformation selective antibody 8A6/1H1 
gave a signal higher than background for peptides 33, 64, 65. (Figure 5.30 C)  However, 
the signals observed at these peptides were lower when compared to the non-specific 
signal observed for peptide 20.  This is perhaps indicative that these signals are non-
specific interactions.  These peptides were mapped to the structure of both the inactive 
(GDP bound) structure and the active (GTP bound) structure of Gαi1 (work performed by 
T. Houslay, BRC, University of Glasgow, data not shown).  All peptides contained amino 
acids both on the surface of Gαi1 and within the molecule.  Comparison of both the inactive 
and active structures revealed no obvious regions corresponding to peptides 33 (residues 
129-144), 64 (residues253-268) and 65 (residues 257-272) which become closer in 
proximity or revealed upon activation.  The non-conformation selective antibody 8A5 gave 
small signals at peptides 47 (residues 185-200) and 56 (residues 221-236) (Figure 5.29C).  J. Robert Lane, 2007    Chapter 5 
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Again these were considerably smaller in magnitude than the signal observed for the non-
specific interaction with peptide 20.  Again these peptides were mapped to the structure of 
GTP and GDP bound Gαi1 and both peptides contained amino acids present at surface of 
the protein and concealed within the interior of the protein (data not shown).  For both 
antibody 8A5 and 8A6/1H1 then, peptides were identified using epitope mapping using the 
Pepset™ library that perhaps correspond to the epitope of these antibodies.  However, it is 
difficult to distinguish those peptides that correspond to the real epitope and those which 
are simply non-specific interactions.  Furthermore, the identification of amino acids within 
these peptides which comprise the actual epitopes cannot be identified using this method.  
As a general conclusion epitope mapping using a set over overlapping peptides 
corresponding to the amino acid sequence of Gαi1 successfully identified the linear epitope 
against which a polyclonal antiserum was raised.  However, the negative or inconclusive 
results obtained for all antibodies originating from the hybridoma screen, indicate that this 
method may not be appropriate for the identification of the epitopes recognised by 
conformation selective antibodies.  
  
5.2.15  Further characterisation of conformation selective antibodies 
The above work describes the full extent of the characterisation of three antibodies 
selective towards the active (GTP bound) state of Gαi1 that I performed during the course 
of my studies.  However, a number of obvious questions regarding these antibodies 
remained unanswered.  To this end, whilst writing up this work, I was fortunate to 
supervise a Master’s student (David Henderson, Biotechnology Msc., University of 
Glasgow).  David performed a number of key experiments which gave a clearer picture of 
the characteristics of these antibodies and also highlight their potential utility in the 
development of a label-free, non-radioactive assay for G protein activation by agonist J. Robert Lane, 2007    Chapter 5 
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ligands.  For this reason, inclusion of this work is beneficial to the reader, and a summary 




5.2.15.1  The three conformation-selective antibodies show affinity for the 
constitutively active mutants of Gαi2 and Gαo1 but not Gαq or Gαs 
 
Gαi1 is highly related in sequence, and therefore presumably in structure, to each of Gαi2, 
Gαi3 and Gαo1 but substantial less to Gαs and Gαq/11.  We therefore next assessed the 
capacity of the conformation-selective antibodies to identify wild type and constitutively 
active mutants of Gαi2 and Gαo1.  These antibodies did not recognise wild type Gαi2 or 
Gαo1 but did identify both Gln
205Leu Gαi2 and Gln
204Leu Gαo1 (Figures 5.31 A-D, 5.32 A-
D).  As controls we confirmed expression of both wild type Gαi2 and Gαo1 in parallel 
immunocytochemistry experiments using rabbit polyclonal anti-peptide antisera against the 
corresponding C-terminal decapeptide sequences (Figures 5.31 A-D, 5.31 A-D).  
Conversely, none of the conformational-selective antibodies were able to identify either 
constitutively active (Gln
227Leu Gαs, Gln
209Leu Gαq) or constitutively inactive (Gly
226Ala 
Gαs, Gly
208Ala Gαq) forms of Gαs and Gαq although in all cases staining with rabbit 
polyclonal anti-peptide antisera against the corresponding C-terminal decapeptide 
sequences was able to confirm expression of the relevant polypeptide (Figures 5.33 A-D, 
5.35 A-D). 
 
 J. Robert Lane, 2007    Chapter 5 
285 
5.2.15.2  The conformation-selective antibody 6F12 1E5 shows no affinity for the 
constitutively active mutant Arg
178Cys Gαi2 
Immunocytochemistry experiments were performed using HEK293T cells transiently 
expressing the constitutively active mutants Arg
178Cys Gαi2 (Figure 5.35A) and Gln
204Leu 
Gαi2 (Figure 5.35B).  As controls, parallel experiments were performed on HEK293T cells 
expressing wild type Gαi2 (Figure 5.35C) or mock transfected cells (Figure 5.37D).  
Although as seen in previous experiments the antibodies showed affinity for the active 
mutant Gln
204Leu Gαi2 (Figure 5.35B), they did not recognise the active mutant Arg
178Cys 
Gαi2.  Comparable expression of all Gαi2 variants was confirmed using the anti-Gαi1 
/2 polyclonal antiserum 1319 Glycine. 
 
5.2.15.3   
5.2.15.4  The three conformation-selective antibodies show affinity for the active 
complex wild type Gαi2.GDP.AlF4
- , where AlF4





- is a substitute for and mimic of the γ phosphate of GTP (Figure 5.36A and B).  As 
such addition of AlF4
- (10 µM AlCl3 + 10 mM NaF) to HEK293T cells transiently 
expressing wild type Gαi2 resulted in recognition of Gαi2 by each of the three 
conformation-selective antibodies. (Figure 5.37)   
 
 J. Robert Lane, 2007    Chapter 5 
286 
5.2.15.5  The three conformation-selective antibodies show affinity for agonist 
activated G protein subunits in a whole cell GTPγS experiment  
 
Finally we wished to assess if the conformation-selective antibodies would recognise 
agonist-activated G protein α subunits.  HEK293T cells transiently transfected to co-
express dopamine D2l-eYFP and wild type Gαi2 were exposed to the dopaminergic agonist 
nor-apomorphine (1 µM) in the presence of 10 µM GTPγS, saponin (0.2% w/v) and an 
assay buffer (50 mM Tris, 5 mM MgCl2, 100 mM NaCl, 0.2 mM EGTA) previously used 
by others to develop an in cell [
35S] GTPγS assay (Rios et al., 2006).  In these conditions 
the conformation-selective antibodies identified Gαi2 only in samples stimulated by agonist 
(Figure 5.38A-D).  These data indicate that the conformation selective antibodies 
described herein may be used to develop label-free, non radioactive assays for G protein 

















Figure 5.1: Characterisation of antisera raised against the C-terminal decapeptide of 
Gαt.   
 
A)  The glycine eluate of the antiserum from animal 1318 recognises Gαi1, Gαi2, 
Gαi3, and Gαo1. 
 
Chemically competent BL21 E coli cells were transformed with the vector pT7.7 
containing the cDNA of the relevant G α subunit.  Expression of G α subunit was induced 
with the addition of 1µg / ml IPTG.  Cells were lysed using a French press and protein 
concentration estimated using a BCA assay.  Lysate proteins (0.5 µg / well) were separated 
by SDS PAGE and Western blots performed using the glycine 1318 antiserum raised 
against the C-terminal of Gαt.   In-house antisera raised against the C-terminal decapetide 
of Gαi1/2, Gαi3 or Gαo1 were used as controls, to demonstrate the expression of the relevant 
Gαi subunit in each sample. 
 
B)       The TEA eluate of the antiserum from animal 1318 and the Glycine eluate 
from animal 1319 recognise Gαi1 and Gαi2 but not Gαi3 or Gαo1. 
 
As above Gαi1, Gαi2, Gαi3, and Gαo1 expression in BL21 E coli was or was not induced 
with the addition of 1 µg/ml IPTG.  Cell lysates made and protein (0.5 µg / well) separated 
by SDS PAGE.  Westerns were performed using antisera raised against the C-terminal 
decapeptide of Gαt. The in-house antiserum SG3 raised against the C-terminal tail of Gαt 
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Figure 5.2:  The glycine eluate of antiserum from animal 1319 was used successfully 
to immunoprecipitate Gαi2 as part of a [
35S] GTPγS binding assay with 
immunoprecipitation step 
 
HEK293T cells were transiently co-transfected with cDNA of the dopamine D2l receptor 
and the pertussis toxin-insensitive variant Cys
352Ile Gαi2.  Cells were treated with pertussis 
toxin (25 ng/ml) 16 hours prior to cell harvest.  Membrane preparations were made and 
membrane protein concentration estimated.  Receptor binding site density was estimated 
using [
3H] spiperone saturation binding (Table 4.1).  [
35S] GTPγS binding reactions were 
set up as described in 2.9.2.2, following the protocol for the [
35S] GTPγS binding assay 
with immunoprecipitation step.  [
35S] GTPγS binding was stimulated with the addition of 
100 µM dopamine.  To assess the ability of the Glycine eluate of the antiserum 1319 to 
immunopreceipitate Gαi2 this antiserum was used for the immunoprecepitation step.  As a 
comparison, an equivalent reaction was set up using the in-house antiserum (SG3) raised 
against the C-terminal tail of Gαt. Experiment was performed in triplicate.  
























































Figure 5.3:  The glycine eluate of antiserum from animal 1318 was used to 
immunoprecipitate Gαi3 as part of a [
35S] GTPγS binding assay with 
immunoprecipitation step 
 
HEK293T cells were transiently co-transfected with cDNAs of a CRF receptor-Gαi3 fusion 
protein.  [
35S] GTPγS binding reactions were set up as described in 2.9.2.2, following the 
protocol for the [
35S] GTPγS binding assay with immunoprecipitation step.  [
35S] GTPγS 
binding was stimulated with the addition of 1 µM sauvagine.  To assess the ability of the 
glycine eluate of the antiserum 1319 to immunoprecipitate Gαi3 this antibody was used in 
the immunoprecepitation step.  As a comparison, an equivalent reaction was set up using 
in-house antisera (I3C) raised against the C-terminal tail of Gαi3.  Experiments were 
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Figure 5.4:  Antisera from animals 1316 and 1317 raised against the C-terminal 
decapeptide of Gαq selectively recognise Gαq when this Gα subunit is transiently 
expressed in Gαq/11 null EF88 cells. 
 
EF88 Gαq/11 (-/-) cells were or were not transiently transfected with Gαq cDNA.  Cells 
were harvested and membrane preparations were made.  Membrane protein (0.5 µg/well) 
were separated using SDS PAGE and Western blots performed using both TEA and 
glycine eluates of purified antisera from animal 1316 (B-C) and 1317 (D-E) raised against 
the C-terminal decapeptide of Gαq.  In-house antisera (CQ5) raised against the C-terminal 
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Figure 5.5:  The glycine eluate of antiserum from animal 1317 was used to 
immunoprecipitate Gα11 as part of a [
35S] GTPγS binding assay with 
immunoprecipitation step. 
 
EF88 cells were transiently co-transfected with cDNA of the α1b adrenoceptor and Gα11.  
[
35S] GTPγS binding reactions were set up as described in 2.9.2.2, following the protocol 
for the [
35S] GTPγS binding assay with immunoprecipitation step.  [
35S] GTPγS binding 
was stimulated with the addition of 1 µM phenyephrine.  To assess the ability of the 
Glycine eluate of the antisera 1317 to immunoprecipitate Gαq this antibody was used in the 
immunoprecepitation step.  As a comparison, an equivalent reaction was set up using in-
house antisera (CQ5) raised against the C-terminal tail of Gαq/11.  Experiments were 
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Figure 5.6:  Antiserum from animal 1314, raised against the C-terminal decapeptide 
of Gαs shows a cholera toxin-induced down-regulation of Gαs in HEK293T cells 
 
HEK293T cells were either treated with cholera toxin (0.1µg / ml, 24 hrs prior to cell 
harvest) or not and membrane preparations made. HEK293T cells were also transiently 
transfected with cDNA of the long isoform of Gαs, cells harvested and membrane 
preparations made.  Membrane protein (0.5 µg / well) was separated by SDS PAGE and 
Western blots performed using both Glycine (B) and TEA (C) eluates of antiserum raised 
against the C-terminal decapeptide of Gαs from animal 1314.  An in-house antiserum 
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Figure 5.7:   The glycine eluate antiserum from animal 1314 was used to 
immunoprecipitate Gαs as part of a [
35S] GTPγS binding assay with 
immunoprecipitation step 
 
HEK293T cells were transiently co-transfected with cDNA of the CRF-Gαs fusion protein.  
[
35S] GTPγS binding reactions were set up as described in 2.2.9.2, following the protocol 
for the [
35S] GTPγS binding assay with immunoprecipitation step.  [
35S] GTPγS binding 
was stimulated with the addition of 10 µM sauvagine.  To assess the ability of the Glycine 
eluate of the antiserum 1314 to immunoprecipitate Gαs this antibody was used in the 
immunoprecipitation step.  As a comparison, an equivalent reaction was set up using in-
house antisera (CS2) raised against the C-terminal tail of Gαs.  Experiments were 
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Figure 5.8:  Outline of the various stages of hybridoma generation.  Adapted from 
‘Antibodies: A Laboratory Manual’  (Harlow, 1988) 





















































































































































































































































































































































































































































































































































































































































































dJ. Robert Lane, 2007    Chapter 5 
303 
Figure 5.9:  Schematic diagram of FMAT assay for the screening of hybridoma raised 
against Gαi1 
 
HEK293T cells were transfected with cDNA of human Gαi1.  These cells were then 
permeabilised (section 5.2.11).  The relevant FMAT blue ® secondary antibody was added 
to this cell suspension to a final dilution of 1:2000.    The cell suspension was then added 
to each well of an FMAT plate containing the antibody/hybridoma clone tissue culture 
supernatant of interest.  Following an incubation time of 2 hours the plate was read on an 
8200 Cellular Detection System.  The FMAT Blue® dye is a far-red emitting dye in the 
650 nm range. 
 
The 8200 Cellular Detection System scans the bottom of microtiter plates at a depth of 
focus of 100 µm. The use of a red 633 nM HeNe laser greatly diminishes the 
autofluorescence from test materials and cells, resulting in low background noise.  Any 
fluorescence that is not bound to a cell or bead that has settled to the bottom of the assay 
plate will be undetected, eliminating the need for wash steps. Reagents are added 
simultaneously which diminishes incubation and reagent addition steps and increases 
productivity.  Consequently, antibodies that are selective against Gαi1 will give a high 
fluorescent signal for cells that express Gαi1. 
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Figure 5.10:  Permeabilisation of cells using a PBS / 1% BSA / 0.1% sodium azide 
buffer proved the most effective method for use in an FMAT assay to screen for 
hybridoma producing antibodies selective against the active conformation of Gαi1. 
 
HEK293T cells were transfected with either cDNA of wild-type Gαi1, the inactive variant 
Gly
203Ala (Gαi1 G
203A), or the active variant Gln
204Leu (Gαi1 Q
204L).  As a control cells 
were transfected with the cDNA of FLAG-GPR55.  Cells were permeabilised using: A) 
PBS / 1% BSA / 0.1% NaN3 buffer, B) a Cytofix / Cytoperm method, C) a hERG fixation 
method, D) a modified Kruzik’s method (see section 5.1.11 for details).  Using these 
permeabilised cell suspensions an FMAT assay was performed as in section 2.10.3.  
Briefly a donkey anti-rabbit FMAT blue ® secondary antibody or a donkey anti-mouse 
FMAT blue ® secondary antibody was added to each cell suspension to a final dilution of 
1:2000.  These cell suspensions were than added to wells of a 96 well FMAT ® plate 
containing 1 µl of either an anti-Gαi1/2 polyclonal antisera (1319G) (i) or an anti-FLAG 
monoclonal antibody (ii).  Plates were incubated in the dark for 2 hours at room 
temperature and then fluorescence detected using an 8200 Cellular Detection System 
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Figure 5.11:  An FMAT assay using a polyclonal antiserum raised against the C-
terminal tail of Gαi1/2 remains robust after a 23 hour incubation   
 
 
HEK293T cells were transiently transfected with cDNA of either wild type Gαi1 (WT) or 
the constitutively active variant Gln
204Leu Gαi1 (204L).   As a control cells were 
transfected with cDNA of FLAG-GPR55 construct.  Cells were resuspended in 
permeabilisation buffer (PBS + 1% BSA + 0.1% NaN3) with or without the addition of 10 
µM GTPγS and with the addition of FMAT blue ® anti-rabbit secondary antibody.  This 
cell suspension was added to a well of a 384 well plate already containing 1 µl of anti-
Gαi1/2 antisera (glycine eluate of 1319).  This plate was left in the dark at room temperature 
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Figure 5.12:  The storage of aliquots of pre-transfected HEK293T cells at -80 ºC prior 
to use in FMAT assay has no effect on fluorescent signal or robustness of assay 
 
Cells were transfected with cDNA of either wild type Gαi1 or the constitutively active 
variant Gln
204Leu Gαi1.  A mock transfection was performed using an equivalent amount of 
the empty vector pcDNA3.  48 hours following transfection, cells were harvested and 
washed twice with PBS (room temperature)  Cells were counted and aliquots from each 
condition were either left on ice or resuspended in foetal calf serum and frozen at -80 ºC 
for 2 hours.  Frozen cells were then thawed rapidly in a 37 ºC bath, washed twice in PBS (4 
ºC) and both frozen and fresh cells resuspended in PBS + 1% BSA + 1% NaN3 plus FMAT 
blue ® anti-rabbit secondary.  This cell suspension was added to wells of a 384 well 
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Figure 5.13:  ELISA using test bleeds from both rGαi1 rapid immunisation and 
plasmid immunisation strategies against rGαi1.  All animals immunised with rGαi1 
showed an affinity for rGαi1.  No signal above background was observed for test 
bleeds from plasmid immunised animals. 
 
Two mice were immunised for each immunisation strategy, either plasmid immunisation 
using cDNA of the active variant Gln
204Leu Gαi1 (B) or the rapid immunisation protocol 
(A) as discussed in section 5.2.5.  Test bleeds were taken from each animal (protein 
RIMMS: animals 120 and 121, plasmid immunisations, animals 122 1 and 122 2) and sets 
of serial dilutions were made of each test bleed and, as a positive control, a polyclonal anti-
Gαi1 antiserum (Glycine 1319) (C).  These were dispensed onto 96 well plates coated with 
rGαi1 (0.1 µg / well).  The secondary antibody used was either a HRP conjugated anti-
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Figure 5.14:  ELISA using test bleeds from plasmid immunisation strategies against 
human IgG.  No signal above background was observed for test bleeds from plasmid 
immunised animals. 
 
Serial dilutions of the test bleeds from the plasmid immunised animals (animals 122 1 and 
122 2) were made and these dispensed onto 96 well plates pre-coated with human IgG.  As 
a positive control, a bleed from a plasmid immunised animal from another immunisation 
program again using a human Fc fragment fusion protein which had shown a strong 
immune response was used  (animal 116 1) (supplied by I. Kinghorn, GSK).  As a negative 
control a test bleed from an unrelated program using a protein RIMMS protocol, which 
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Figure 5.15:  Diagram illustrating the four conditions used in the whole cell FMAT 
assay to screen each hybridoma clone tissue culture supernatant. 
 
The conditions are as follows:   
 
1) HEK293T cells transfected with wild type Gαi1 cDNA, permeabilised in PBS + 1% 
BSA + 0.1% NaN3  (FMAT Buffer), and incubated with 100 µM GTPγS to force majority 
of expressed Gαi1 into active GTP bound conformation.  
 
2) HEK293T cells transfected with constitutively active Gαi1 Q
204L cDNA, permeabilised 
in PBS + 1% BSA + 0.1% NaN3 (FMAT Buffer).  
 
3) HEK293T cells transfected with wild type Gαi1 cDNA, permeabilised in PBS + 1% 
BSA + 0.1% NaN3  (FMAT Buffer), and incubated with 100 µM GDPβS to force majority 
of expressed Gαi1 into inactive GDP bound conformation.   
 
4) HEK293T cells  mock transfected with pcDNA3, permeabilised in PBS + 1% BSA + 
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Figure 5.16:  Initial hybridoma screen identifies three hybridoma clones producing 
antibody which showed selectivity towards the active conformation of Gαi1 
1824 hybridoma clones were screened using the FMAT assay described in Figure 5.9.  
The conditions used were as described in Figure 5.15:  Briefly HEK293T cells were 
transfected with wild type Gαi1 cDNA, and incubated with 100 µM GTPγS (GTP) or 100 
µM GDPβS (GDP), transfected with the active mutant Gln
204Leu Gαi1 cDNA (Q204L) or 
mock transfected with pcDNA3 (MOCK).  Three hybridoma clones were identified as 
having selectivity towards the active (GTP bound) conformation of Gαi1: 8A5 (A), 8D11 
(B) and 6F12 (C) 
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Figure 5.17:  Secondary FMAT screen of hybridoma clones:  The three clones 
identified as showing selectivity towards the active (GTP bound) conformation of Gαi1 
showed a similar selectivity upon repetition of the screen 
 
Hybridoma clones that, in the primary FMAT screen, showed high counts for the 
conditions in which Gαi1 was expressed as compared to the mock transfected cells were 
retained and sub-cultured.  To confirm the results obtained in the primary screen, tissue 
culture supernatant from these clones was again screened using the FMAT whole cell 
assay.  The conditions used were as described in Figure 5.15:  Briefly HEK293T cells 
were transfected with wild type Gαi1 cDNA, and incubated with 100 µM GTPγS (GTP) or 
100 µM GDPβS (GDP), transfected with the active mutant Gln
204Leu Gαi1 cDNA 
(Q204L) or mock transfected with pcDNA3 (MOCK). The experiment was performed in 
triplicate to N = 3.  Each separate figure (A-D) refers to one FMAT plate, the three 
conformation selective clones identified in the primary screen were 6F12 (C) and 8A5, 
8D11 (D) 
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Figure 5.18:  FMAT screen of hybridoma clones following re-cloning of the three 
clones identified as showing selectivity towards the active (GTP bound) conformation 
of Gαi1:  Displayed are daughter clones that showed the best profile, selected from 
each of the three parental hybridoma cell lines. 
 
Each of the hybridoma cell lines that produced an antibody selective for the active GTP 
bound conformation of Gαi1 (8A5, 6F12, 8D11) were re-cloned.  Using hybridoma clone 
tissue culture supernatant from all of the clones created by this re-cloning process, an 
FMAT screen was performed using the same conditions as for the primary FMAT 
hybridoma screen.   A summary of data from all clones screened is displayed in Table 5.6 .  
The data for the clone showing the best profile for each parental cell line is displayed as 
follows: A) 8A5 1C1 B) 6F12 1E5 C) 8D11 1H1. 
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Figure 5.19:  Titration experiment using purified non-conformation selective 
antibodies produced by hybridoma clones 8F5 and 6B4 
 
Similar to the FMAT screens used previously the five following conditions were set up:  
HEK293T cells transiently expressing wild type Gαi1 preloaded with either 10 µM GTPγS 
or 10 µM GDPβS, HEK293T cells expressing either the constitutively active variant 
Gln
204Leu Gαi1 or the constitutively inactive variant Gla
203Ala Gαi1 or cells mock-
transfected with the empty vector pcDNA3.  FMAT blue anti-mouse ® antibody was 
added to the cell suspensions to a final dilution of 1 in 2000.  Each of these cell 
suspensions was added to serial 1 in 3 dilution sets of either 6B4 (A) or 8F5 (B).  Plates 
were incubated in the dark for 2 hours at room temperature and then fluorescence detected 
using an 8200 Cellular Detection System (Applied Biosystems). J. Robert Lane, 2007    Chapter 5 
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Figure 5.20:  Titration experiment using purified conformation selective antibodies 
produced by hybridoma clones 8A5/1C1, 6F12/1E5 and 8D11/1H1 
 
As for figure 5.20 the five following conditions were set up:  HEK293T cells transiently 
expressing wild type Gαi1 preloaded with either 10 µM GTPγS or 10 µM GDPβS, 
HEK293T cells expressing either the constitutively active variant Gln
204Leu Gαi1 or the 
constitutively inactive variant Gla
203Ala Gαi1 or cells mock-transfected with the empty 
vector pcDNA3.    FMAT blue anti-mouse ® antibody was added to the cell suspensions to 
a final dilution of 1 in 2000.  Each of these cell suspensions was added to serial 1 in 3 
dilution sets of either 8A5/1C1 (A), 6F12/1E5 (B) or 8D11/1H1 (C).  Plates were 
incubated in the dark for 2 hours at room temperature and then fluorescence detected using 
an 8200 Cellular Detection System (Applied Biosystems). 
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Figure 5.21:Non-conformation selective antibodies 6B4 and 8F5 selectively recognise 
Gαi1 over other members of the Gαi/o family on a Western blot. 
 
Chemically competent BL21 E coli cells were transformed with the vector pT7.7 
containing the cDNA of the relevant Gα subunit.  Expression of G α subunit was induced 
with the addition of 1µg / ml IPTG.  Cell lysate proteins (0.5 µg / well) were separated by 
SDS PAGE and Western blots performed using the non-conformation selective antibodies 
6B4 (A-i) and 8F5 (B-i).   An in-house antiserum raised against the C-terminal decapeptide 
of Gαi1/2 (C-i), was used as a control.  To assess the relative amount of protein loaded for 
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Figure 5.21 




Figure 5.22:  Conformation selective antibodies 8A5/1C1, 6F12/1E5 and 8D11/1H1 do 
not recognise members of the Gαi/o family denatured by SDS PAGE. 
 
In parallel with experiments described in Figure 5.22, chemically competent BL21 E coli 
cells were transformed with the vector pT7.7 containing the cDNA of the relevant G α 
subunit.  Expression of G α subunit was induced with the addition of 1µg / ml IPTG.  Cell 
lysate proteins (0.5 µg / well) were separated by SDS PAGE and Western blots performed 
using the conformation selective antibodies 8A5/1C1 (A-i), 6F12/1E5 (B-i) and 8D11/1H1 
(C-i).   To assess the relative amount of protein loaded for each sample the nitrocellulose 
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Figure 5.23:  Immunocytochemistry using the conformation selective antibody 
8A6/1H1 
 
HEK293T cells were grown on poly-D-lysine coated coverslips.  These cells were co-
transfected with cDNA of the D2l-YFP fusion protein and either wild type Gαi1 (A), 
Gln
204Leu Gαi1 active variant (B), or the inactive variant Gly
203Ala Gαi1 (C).  
Immunocytochemistry was performed as in section 2.10.7.  Nuclear staining was 
performed using Hoescht stain.  The conformation selective antibody 8A6/1H1 was used at 
a final dilution of 1:100.  The fluorescently labelled secondary antibody anti-mouse Alexa 
Fluor 594 was used at a final concentration of 1:400.  Fluorescence detected from i) D2l-
eYFP, ii) Alexa Fluor 594, iii) Hoescht stain are shown.  Scale marker represents 10 µM. J. Robert Lane, 2007    Chapter 5 
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Figure 5.24:  Immunocytochemistry using the conformation selective antibody 
6F12/1E5 
 
In parallel with the experiment described by Figure 5.23, HEK293T cells were grown on 
poly-D-lysine coated coverslips.  These cells were co-transfected with cDNA of the D2l-
YFP fusion protein and either wild type Gαi1 (A), Gln
204Leu Gαi1 (B) active variant or the 
inactive variant Gly
203Ala Gαi1 (C).  Immunocytochemistry was performed as in section 
2.10.7.  Nuclear staining was performed using Hoescht stain.  The conformation selective 
antibody 8A6/1H1 was used at a final dilution of 1:100.  The fluorescently labelled 
secondary antibody anti-mouse Alexa Fluor 594 was used at a final concentration of 1:400.  
Fluorescence detected from i) D2l-eYFP, ii) Alexa Fluor 594, iii) Hoescht stain are shown.  
Scale marker represents 10 µM. 
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Figure 5.25:  Immunocytochemistry using the conformation selective antibody 
8D11/1C1 
 
In parallel with the experiment described by Figure 5.23, HEK293T cells were grown on 
poly-D-lysine coated coverslips.  These cells were co-transfected with cDNA of the D2l-
YFP fusion protein and either wild type Gαi1 (A), Gln
204Leu Gαi1 (B) active variant or the 
inactive variant Gly
203Ala Gαi1 (C).  Immunocytochemistry was performed as in section 
2.10.7.  Nuclear staining was performed using Hoescht stain.  The conformation selective 
antibody 8D11/1C1 was used at a final dilution of 1:100.  The fluorescently labelled 
secondary antibody anti-mouse Alexa Fluor 594 was used at a final concentration of 1:400.  
Fluorescence detected from i) D2l-YFP, ii) Alexa Fluor 594, iii) Hoescht stain are shown.  




















































Figure 5.26:  Immunocytochemistry using the non-conformation-selective antibody 
6B4 
 
In parallel with the experiment described by Figure 5.23, HEK293T cells were grown on 
poly-D-lysine coated coverslips.  These cells were co-transfected with cDNA of the D2l-
eYFP fusion protein and either wild type Gαi1 (A), Gln
204Leu Gαi1 (B) active variant or the 
inactive variant Gly
203Ala Gαi1 (C).  As a control HEK293T cells were co-transfected with 
the vector pcDNA3 (D). Immunocytochemistry was performed as in section 2.10.7.  
Nuclear staining was performed using Hoescht stain.  The non-conformation selective 
antibody 6B4 was used at a final dilution of 1:100.  The fluorescently labelled secondary 
antibody anti-mouse Alexa Fluor 594 was used at a final concentration of 1:400.  
Fluorescence detected from i) D2l-YFP, ii) Alexa Fluor 594, iii) Hoescht stain are shown.  






























Figure 5.27:  Immunocytochemistry using the non-conformation selective antibody 
8F5 
 
In parallel with the experiments described by Figure 5.23, HEK293T cells were grown on 
poly-D-lysine coated coverslips.  These cells were co-transfected with cDNA of the D2l-
YFP fusion protein and either wild type Gαi1 (A), Gln
204Leu Gαi1 active variant (B), or the 
inactive variant Gly
203Ala Gαi1 (C).  As a control HEK293T cells were co-transfected with 
the vector pcDNA3 (D). Immunocytochemistry was performed as in section 2.10.7.  
Nuclear staining was performed using Hoescht stain.  The non-conformation selective 
antibody 8F5 was used at a final dilution of 1:100.  The fluorescently labelled secondary 
antibody anti-mouse Alexa Fluor 594 was used at a final concentration of 1:400.  
Fluorescence detected from i) D2l-YFP, ii) Alexa Fluor 594, iii) Hoescht stain are shown.  
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Figure 5.28:  Immunocytochemistry using an anti-Gαi1/2 polyclonal antiserum raised 
against a decapeptide corresponding to the C-terminal ten amino acids of Gαt (1319 
Glycine) 
  
In parallel with the experiments described by Figure 5.23, HEK293T cells were grown on 
poly-D-lysine coated coverslips.  These cells were co-transfected with cDNA of the D2l-
YFP fusion protein and either wild type Gαi1 (A), Gln
204Leu Gαi1 active variant (B) or the 
inactive variant Gly
203Ala Gαi1 (C).  As a control HEK293T cells were co-transfected with 
cDNA of the D2l-YFP fusion protein and pcDNA3 (D). Immunocytochemistry was 
performed as in section 2.10.7.  Nuclear staining was performed using Hoescht stain.  The 
polyclonal antiserum 1319 glycine was used at a final dilution of 1:500.  The fluorescently 
labelled secondary antibody anti-rabbit Alexa Fluor 594 was used at a final concentration 
of 1:600.  Fluorescence detected from i) D2l-YFP, ii) Alexa Fluor 594, iii) Hoescht stain 
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Figure 5.29:  Epitope mapping of non-conformation selective antibodies using a set of 
overlapping 16mer peptides corresponding to the amino acid sequence of human Gαi1 
 
A set of 16mer peptides overlapping by 4 amino acids and corresponding to the entire 
amino acid sequence of Gαi1 were generated by Mimotopes Ltd.  The epitope mapping 
experiments were performed as described in section 2.10.6. 100 µl of peptide solution 
added to wells of a streptavidin coated 96 well plate.  Following a1 hour incubation, the 
biotinylated peptides were bound to the streptavidin coated plate.  The peptide solution was 
removed and replaced with a 1:1000 dilution of antibody in PBS/ 0.1% Tween 20/ 0.1% 
NaN3.  Antibodies used were as follows: 6B4 (B) and 8F5 (C).  The polyclonal antiserum 
1319 Glycine raised against the C-terminal ten amino acids of Gαi1/2 was used as a positive 
control (A).  HRP conjugated secondary antibody was used at a dilution of 1:2000 in PBS/ 
0.1% Tween 20/ 0.1% NaN3.  The presence of peroxidase, indicating a specific interaction 
between a given peptide and the primary antibody, was detected using the substrate 
Sureblue™ TMB.   
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Figure 5.30:  Epitope mapping of conformation selective antibodies using a set of 
overlapping 16mer peptides corresponding to the amino acid sequence of human Gαi1 
 
The epitope mapping experiments were performed as described in Figure 5.29.  
Antibodies used were as follows: 8A5/1H1 (A), 8D11/1C1 (B) and 6F12/1E5 (C) at a 
1:1000 dilution HRP conjugated secondary antibody was used at a dilution of 1:2000 in 
PBS/ 0.1% Tween 20 / 0.1% NaN3.  The presence of peroxidase, indicating a specific 
interaction between a given peptide and the primary antibody, was detected using the 
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Figure 5.31:  The conformation-selective antibody 6F12/1E5 shows selectivity for the 
constitutively active mutant Gln
205Leu Gαi2  
 
HEK293T cells were grown on poly-D-lysine coated coverslips.  These cells were co-
transfected with cDNA of the D2l-YFP fusion protein and either wild type Gαi2 (A), Gαi2 
Gln
205Leu active variant (B) or the active variant Gln
204Leu Gαi1 (C).  As a control 
HEK293T cells were co-transfected with cDNA of the D2l-YFP fusion protein and 
pcDNA3 (D). Immunocytochemistry was performed as in section 2.10.7.  Nuclear staining 
was performed using Hoescht stain.  The conformation selective antibody 6F12/1E5 was 
used at a final dilution of 1:200.  The fluorescently labelled secondary antibody anti-mouse 
Alexa Fluor 594 was used at a final concentration of 1:400.  Fluorescence detected from (i) 
D2l-YFP, (ii) Alexa Fluor 594 bound to 6F12/1E5, (iii) Hoescht stain are shown.  To 
demonstrate expression of transfected Gα protein a parallel immunocytochemistry 
experiment was performed using the rabbit polyclonal anti-peptide antiserum raised against 
the corresponding C-terminal decapeptide sequences of Gαi1/2 (iv).  Scale marker 
represents 10 µM. 
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Figure 5.32:  The conformation-selective antibody 6F12/1E5 shows selectivity for the 
constitutively active mutant Gln
204Leu Gαo1 
 
HEK293T cells were grown on poly-D-lysine coated coverslips.  These cells were co-
transfected with cDNA of the D2l-YFP fusion protein and either wild type Gαo1 (A), 
Gln
204Leu Gαo1 active variant (B) or the active variant Gln
204Leu Gαi1 (C).  As a control 
HEK293T cells were co-transfected with cDNA of the D2l-YFP fusion protein and 
pcDNA3 (D). Immunocytochemistry was performed as in section 2.10.5.  Nuclear staining 
was performed using Hoescht stain.  The conformation selective antibody 6F12/1E5 was 
used at a final dilution of 1:200.  The fluorescently labelled secondary antibody anti-mouse 
Alexa Fluor 594 was used at a final concentration of 1:400.  Fluorescence detected from (i) 
D2l-YFP, (ii) Alexa Fluor 594 bound to 6F12/1E5, (iii) Hoescht stain are shown.  To 
demonstrate expression of transfected Gα protein a parallel immunocytochemistry 
experiment was performed using rabbit polyclonal anti-peptide antisera against the 
corresponding C-terminal decapeptide sequences of Gαi1/2 or Gαo1 (iv).  Scale marker 
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Figure 5.33: The conformation-selective antibody 6F12/1E5 does not show selectivity 
for the constitutively active mutant Gln
227Leu Gαs 
 
HEK293T cells were grown on poly-D-lysine coated coverslips.  These cells were co-
transfected with cDNA of the D2l-YFP fusion protein and either Gly
226Ala Gαs inactive 
variant (A), Gln
227Leu Gαs active variant (B), or the active variant Gln
204Leu Gαi1 (C).  As 
a control HEK293T cells were co-transfected with cDNA of the D2l-YFP fusion protein 
and pcDNA3 (D). Immunocytochemistry was performed as in section 2.10.5.  Nuclear 
staining was performed using Hoescht stain.  The conformation selective antibody 
6F12/1E5 was used at a final dilution of 1:200.  The fluorescently labelled secondary 
antibody anti-mouse Alexa Fluor 594 was used at a final concentration of 1:400.  
Fluorescence detected from (i) D2l-YFP, (ii) Alexa Fluor 594 bound to 6F12/1E5, (iii) 
Hoescht stain are shown.  To demonstrate expression of transfected Gα protein a parallel 
immunocytochemistry experiment was performed using rabbit polyclonal anti-peptide 
antisera raised against the corresponding C-terminal decapeptide sequences of Gαi1/2 or 
Gαs (iv).  Scale marker represents 10 µM.  
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Figure 5.34:  The conformation-selective antibody 6B12/1E5 does not show selectivity 
for the constitutively active mutant Q
209L Gαq 
 
HEK293T cells were grown on poly-D-lysine coated coverslips.  These cells were co-
transfected with cDNA of the D2l-YFP fusion protein and either Gly
208Ala Gαq inactive 
variant (A), Gln
209Leu Gαq active variant (B), or the active variant Gln
204Leu Gαi1 (C).  As 
a control HEK293T cells were co-transfected with cDNA of the D2l-YFP fusion protein 
and pcDNA3 (D). Immunocytochemistry was performed as in section 2.10.5.  Nuclear 
staining was performed using Hoescht stain.  The conformation selective antibody 
6F12/1E5 was used at a final dilution of 1:200.  The fluorescently labelled secondary 
antibody anti-mouse Alexa Fluor 594 was used at a final concentration of 1:400.  
Fluorescence detected from (i) D2l-YFP, (ii) Alexa Fluor 594 bound to 6F12/1E5, (iii) 
Hoescht stain are shown.  To demonstrate expression of transfected Gα protein a parallel 
immunocytochemistry experiment was performed using rabbit polyclonal anti-peptide 
antisera raised against the corresponding C-terminal decapeptide sequences of Gαi1/2 or 
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Figure 5.35:  The conformation-selective antibody 6F12/1E5 does not show selectivity 
for the constitutively active mutant R
178C Gαi2  
 
HEK293T cells were grown on poly-D-lysine coated coverslips.  These cells were co-
transfected with cDNA of the D2l-YFP fusion protein and either Gln
204Leu Gαi2 active 
variant (A), Arg
178Cys Gαi2 active variant (B), or the wild type Gαi2 (C).  As a control 
HEK293T cells were co-transfected with cDNA of the D2l-YFP fusion protein and 
pcDNA3 (D). Immunocytochemistry was performed as in section 2.10.5.  Nuclear staining 
was performed using Hoescht stain.  The non-conformation selective antibody 6F12/1E5 
was used at a final dilution of 1:200.  The fluorescently labelled secondary antibody anti-
mouse Alexa Fluor 594 was used at a final concentration of 1:400.  Fluorescence detected 
from (i) D2l-YFP, (ii) Alexa Fluor 594 bound to 6F12/1E5, (iii) Hoescht stain are shown.  
To demonstrate expression of transfected Gα protein a parallel immunocytochemistry 
experiment was performed using the rabbit polyclonal anti-peptide antiserum raised against 
the corresponding C-terminal decapeptide sequences of Gαi1/2 (iv).  Scale marker 
represents 10 µM. J. Robert Lane, 2007    Chapter 5 
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Figure 5.35 




- is a substitute for and mimic of the γ phosphate of GTP  
 




the magnesium ion and other active site residues. 
 
B)  Model of the active site of Gαi1 at the transition state of the phosphorolysis 
reaction, based on the structure of the GDP.AlF4
- complex.  The phosphorous 
atom of a trigonal ‘PO3’ group was centred on the aluminium ion of the AlF4
- with 
the planes of the PO3 group co-incident with that of AlF4
-.  The PO3 group was 
rotated to achieve a O-Mg distance similar to that observed for the F30-Mg contact 
in the AlF
4- complex.  This model is otherwise identical to the GDP.AlF4
- complex 
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HEK293T cells were grown on poly-D-lysine coated coverslips.  These cells were co-
transfected with cDNA of the D2l-YFP fusion protein and either wild type Gαi2 (A and B), 
or the active variant Gln
205Leu Gαi2 (C).  As a control HEK293T cells were co-transfected 
with cDNA of the D2l-YFP fusion protein and pcDNA3 (D).  Cells transfected with cDNA 
of wild type Gαi2 were incubated with (A) or without (B) the addition of AlF4
- (10 µM 
AlCl3 + 10 mM NaF).   Immunocytochemistry was performed as in section 2.10.5.  
Nuclear staining was performed using Hoescht stain.  The conformation selective antibody 
6F12/1E5 was used at a final dilution of 1:200.  The fluorescently labelled secondary 
antibody anti-mouse Alexa Fluor 594 was used at a final concentration of 1:400.  
Fluorescence detected from (i) D2l-YFP, (ii) Alexa Fluor 594 bound to 6F12/1E5, (iii) 
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Figure 5.38:  The conformation-selective antibody 6F12/1E5 recognises the agonist 
induced complex Gαi2.GTPγS  
 
HEK293T cells were grown on poly-D-lysine coated coverslips.  These cells were co-
transfected with cDNA of the D2l-YFP fusion protein and either wild type Gαi1 (A and B), 
or the active variant Gln
205Leu Gαi1 (C).  As a control HEK293T cells were co-transfected 
with cDNA of the D2l-YFP fusion protein and pcDNA3 (D).  Cells transfected with cDNA 
of wild type Gαi1 were incubated with (A) or without (B) the addition of dopamine D2 
receptor agonist nor-apomorphine (1 µM).  Immunocytochemistry was performed as in 
section 2.5.10.  Nuclear staining was performed using Hoescht stain.  The conformation 
selective antibody 6F12/1E5 was used at a final dilution of 1:200.  The fluorescently 
labelled secondary antibody anti-mouse Alexa Fluor 594 was used at a final concentration 
of 1:400.  Fluorescence detected from (i) D2l-YFP, (ii) Alexa Fluor 594 bound to 
6F12/1E5, (iii) Hoescht stain are shown.  To demonstrate expression of transfected Gα 
protein a parallel immunocytochemistry experiment was performed using rabbit polyclonal 
anti-peptide antiserum against the C-terminal decapeptide sequence of Gαi1/2 (iv).  Scale 









5.3  Discussion 
 
Characterisation of antisera raised against the C-terminal ten amino acids of Gαt, Gαq and 
Gαs revealed the successful generation of antisera selective for each G-protein α subunit.  
Indeed, the antisera characterised in this study compared favourably with antisera for 
Gαi1/2, Gαq  and Gαs previously generated in-house against the same decapeptide antigens 
(Milligan, 1994).  The selectivity of each antiserum towards the G protein α subunit 
against which it was raised was demonstrated using Western blotting.  To achieve this, the 
relevant G protein α subunit was expressed in an essentially null background for the G 
protein α subunit of interest.  As demonstrated in previous work, expression of Gαi1, Gαi2, 
and Gαi3, and Gαo1 in E coli allowed the characterisation of antisera raised against the C-
terminal tail of Gαt (Milligan, 1994).  Three out of four antisera eluates tested showed 
selectivity towards Gαi1/2 but not Gαi3 or Gαo1.  The C-terminal ten amino acids of Gαt, 
Gαi1 and Gαi2 differ only by one amino acid change whereas the sequences of the 
equivalent regions of Gαi3 and Gαo1 differ from that of Gαt by two and four amino acid 
residues respectively.  This would indicate that the substitution of these amino acids has a 
significant effect on the structure of the decapeptide.  As discussed in section 5.1, the C-
terminal of G protein α subunits has been implicated as an important region for the 
selective interaction with receptors (Slessareva et al., 2003; Wess, 1998).  It is possible 
then that the selectivity demonstrated by the antisera towards Gαi1/2 and not Gαi3 or Gαo1 is 
due to the same difference in structure of the ten C-terminal amino acids that forms the 
basis of receptor-G protein selectivity as demonstrated for dopamine D2-like receptors in 
chapter 4.  Conversely, however, in the case of the dopamine D3 selectivity towards the 
Gαo1 subunit over other members of the Gαi/o family was observed.  Furthermore, whilst 
Slessareva et al identified the C-terminal of Gα subunits as being an important region for J. Robert Lane, 2007    Chapter 5 
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receptor coupling specificity, it was observed that different receptors interacted with 
different amino acids within this region (Slessareva et al., 2003).  Interestingly one 
antiserum eluate raised against the decapeptide corresponding to the C-terminal ten amino 
acids of Gαt recognised Gαi1, Gαi2, Gαi3 and Gαo1.  This suggests that within the structure 
of peptides corresponding to the C-terminal tail of these Gα subunits there must be 
elements which are conserved, and that these are the structural elements forming the 
epitope for this antiserum.  It is tempting to speculate that these conserved structural 
elements are those recognised by more promiscuous receptors, for example D2l which 
interacts functionally with all members of the Gαi/o family (Chapter 3).   
 
The expression of Gαq in the Gαq/11 null EF88 cell line demonstrated the selectivity of 
antisera raised against the C-terminal ten amino acids of Gαq.  Prolonged treatment of 
HEK293T cells with cholera toxin to knockdown levels of endogenous Gαs allowed the 
characterisation of antisera raised against the C-terminal of Gαs.  This characterisation 
revealed antisera which are selective against Gαs.  The use of antisera raised against the C-
terminal ten amino acids in a [
35S] GTPγS assay with an immunoprecipitation step has 
been well documented (Milligan, 2003).  This immunocapture step allows the [
35S] GTPγS 
bound G protein α subunit of interest to be isolated and enriched, improving the signal 
window between basal and agonist stimulated conditions.  All antisera generated for this 
project against Gα subunit C-terminal decapeptides showed a similar efficiency in the 
immunoprecipitation of the [
35S] GTPγS bound form of the relevant G α subunit in 
comparison to previously-characterised in-house antisera.  The majority of published 
reports using a [
35S]GTPγS assay with immunocapture step have used heterologous cell 
systems.  However, this approach has been usefully applied to membranes from native 
tissues. Indeed, this approach has been used in hippocampal and cortical membranes from 
wild-type mice and both muscarinic M1 and M3 acetylcholine receptor knockout mice to 
demonstrate the predominant role of the M1 receptor in these locations and to explore the J. Robert Lane, 2007    Chapter 5 
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extent of M1 receptor reserve (Porter et al., 2002).  As described in chapters 3 and 4, many 
receptors can couple to multiple G protein α subunit subtypes.  [
35S] GTPγS binding with 
an immunocapture step could be a suitable assay with which to investigate receptor-G 
protein coupling specificity.  By performing a [
35S] GTPγS assay including pulldown of 
different G protein α subunits, this would allow analysis of the agonist stimulation over 
basal observed for each.  This could allow dissection of the G-protein coupling specificity 
for each receptor.  However, this method could lead to potentially erroneous conclusions.  
Consideration must be given towards the variation of relative efficiencies of 
immunoprecipitation between different antisera. For example using this method, it was 
shown that the muscarinic M3 receptor activates Gαi1 and Gαq/11, with comparable signal 
seen for each G protein α subunit.  However, there is a widespread appreciation that the 
M3 receptor couples preferentially to Gαq, so the above result is unlikely to reflect 
effective selection of both these GPCRs (Akam et al., 2001; Milligan, 2003).  The titre of 
antisera used in an immunocapture step is likely to be high.  My results demonstrated cross 
reactivity of antisera with G protein α subunits other than the ones which they were raised 
against, namely, an antisera raised against the C-terminal tail of Gαo1 showed cross 
reactivity with Gαi3.  Conclusions about receptor-G protein selectivity, especially between 
G-proteins of high sequence homology reached when using this methodology should be 
viewed with caution.  Antisera raised against the C-terminal tail of Gα subunits have been 
used to investigate receptor-G protein coupling specificity (Milligan, 1994; Newman-
Tancredi et al., 1999; Newman-Tancredi et al., 2002).  Due to the importance of the C-
terminal region of Gα subunits for receptor coupling, antisera raised against this region are 
able to functionally un-couple the receptor and a specific G protein.  Indeed, experiments 
using antisera raised against Gαi/o and Gαq/11 in this manner, showed selective coupling of 
D2l receptors to Gαi/o, and coupling of D3 to Gαi/o and to a lesser extent Gαq/11(Newman-
Tancredi et al., 1999).  However, as with the immunocapture assay, the relative affinity of 
different antisera for the relevant G protein and their cross reactivity at high titres are both J. Robert Lane, 2007    Chapter 5 
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potential caveats of this approach.  The polyclonal anti-Gαi1/2 antiserum raised against the 
C-terminal ten amino acids of Gαt (1319 glycine) has been used throughout this chapter 
and in both chapters 3 and 4. 
 
Assays using radiolabelled markers, such as [
35S] GTPγS binding to measure nucleotide 
exchange or [γ-
32P]GTP to measure GTPase activity have been used extensively to  
measure receptor mediated G protein activation (Milligan, 2003; Ward and Milligan, 
2005).  However, the expense associated with the use of radiolabelled markers, especially 
in an industrial setting makes these approaches increasingly unattractive.  Other 
approaches such as monitoring calcium mobilisation or intracellular cAMP levels have 
been utilised in high-throughput screening assays (Wise et al., 2002).  However, guanine 
nucleotide exchange is a very early event in the signal transduction cascade, and is an 
attractive event to monitor because it is less subject to amplification or regulation by other 
cellular processes than the more distal events described above.  It can thus provide 
excellent measures of the basic pharmacological characteristics and the relative efficacy of 
a series of compounds at a GPCR that might often be compromised when using reporter 
gene analyses, for example.   The premise of this study then, was to develop an alternative 
non-radioactive assay equivalent to the [
35S] GTPγS assay.  The approach used in this 
study was the generation of antibodies that selectively recognise the active (GTP bound 
conformation) of G α subunits.   Accordingly, an immunisation programme was initiated 
in which recombinant Gαi1 was loaded with GTPγS and used to immunise mice. Antibody 
producing plasma cells from these animals were used to generate hybridomas. 1824 
hybridoma clones were generated and screened.  Initial screens employed FMAT 
technology to identify clones with the appropriate characteristics.  From these screens three 
hybridoma clones were identified that produce antibodies with the desired selective 
recognition of the active (GTP bound) form of Gαi1.  All three hybridoma clones produced 
antibody which showed a higher signal for conditions in which HEK293T cells expressing J. Robert Lane, 2007    Chapter 5 
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wild type Gαi1 had been preloaded with GTPγS (and therefore in the activated 
conformation) than was seen for the same cells preloaded with GDPβS.  Furthermore, all 
three antibodies displayed marked selectivity for the condition in which HEK293T cells 
were transfected with the constitutively active Gln
204Leu Gαi1 mutant which mimics the 
active state.  Subsequent FMAT experiments using purified antibodies confirmed these 
results.  Furthermore, all three antibodies failed to interact significantly with the 
constitutively inactive Gly
203Ala Gαi1, a mutant that is unable to exchange guanine 
nucleotide and therefore unable to adopt the active state. To confirm the selectivity of these 
three antibodies for activated Gαi1 a series of immunocytochemistry-based experiments 
was performed.  Again, all three antibodies showed selectivity towards the active 
Gln
204Leu Gαi1 variant and showed little interaction with the inactive Gly
203Ala Gαi1 
variant.  Furthermore, the antibodies showed no interaction with wild type Gαi1 in an un-
stimulated condition.  Without receptor mediated stimulation the majority of expressed 
Gαi1 will be in the inactive, GDP bound conformation.  The large difference in signal 
observed for this condition and that of the active Gln
204Leu Gαi1 is significant since it 
demonstrates the apparent high selectivity of the antibodies for the GTP bound versus GDP 
bound conformation.  This high selectivity makes them potentially useful reagents to form 
the basis of an assay to monitor receptor mediated G protein activation. 
 
In an effort to characterise these antibodies further, Western blots were performed on 
lysates of E coli transformed to express the α subunits of Gαi1, Gαi2, Gαi3 and Gαo1. 
Perhaps unsurprisingly, these conformational selective antibodies were unable to recognise 
denatured protein.  The majority of hybridoma generated by the immunisation programme, 
when screened using the FMAT assay, produced antibody selective towards conditions in 
which Gαi1 was expressed, but showed no selectivity between the activated and inactive 
conformation of Gαi1.  Two of these antibodies were also characterised in Western blots 
and showed selectivity towards the Gαi1 over the other Gαi/o subunits.  Given the high J. Robert Lane, 2007    Chapter 5 
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sequence homology of Gαi1 with Gαi2 and Gαi3 (88% and 94% respectively, see Figure 
5.1) this indicates that the epitope recognised by these antibodies is within regions of 
relative dissimilarity between these three G protein α subunits.  Efforts to determine the 
epitope recognised by the conformation selective antibodies using an overlapping set of 
peptides corresponding to the sequence of Gαi1 were unsuccessful.  This again is not 
surprising given the conformation dependent nature of their selectivity. It is likely that the 
epitope recognised is three dimensional and could include residues from disparate regions 
of the amino acid sequence. 
 
Without knowledge of the epitope recognised by the three conformational selective 
antibodies the information they can give about the conformational changes associated with 
the activation of Gαi1 is limited.  The structures of both the inactive (GDP bound) and 
active (GTP bound) conformations of Gαi1 have been elucidated and this has provided 
information concerning the conformational changes occurring upon nucleotide exchange 
and, indeed, the mechanism of GTP hydrolysis (Coleman and Sprang, 1998; Kleuss et al., 
1994; Mixon et al., 1995; Wall et al., 1998). Upon GTP hydrolysis switch I and switch II 
segments become disordered and linker II connecting the Ras and alpha helical domains 
moves, altering the structures of potential effector and beta gamma binding regions.  
Contacts between the alpha helical and Ras domains are weakened, possibly facilitating the 
release of guanosine diphosphate (GDP). The amino and carboxyl termini, which contain 
receptor and beta gamma binding determinants, are disordered in the complex with GTP, 
but are organised into a compact microdomain on GTP hydrolysis (Mixon et al., 1995).  
This work highlighted the importance of the residues Arg
178 and Gln
204 for stabilisation of 
the transition state reached during GTP hydrolysis.  It is significant that the three antisera 
showed selectivity towards the constitutively active variant Gln
204Leu.  This indicates that 
the structure of this active mutant must be analogous to that of the active (GTPγS bound) 
form of Gαi1.  A functional study that found that an equivalent mutation in Gαt (Gln
200Leu) J. Robert Lane, 2007    Chapter 5 
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exhibited compromised GTPase activity, but instead of simply being locked in a GTP 
bound state 35-45% of the protein was were in a GDP-Pi bound state (Majumdar et al., 
2006).  It was concluded that the mutation reveals Gα subunit states that occur subsequent 
to GTP hydrolysis but are still capable of fully stimulating effector activity.  It could be 
extrapolated then that the structure of this Gln
204Leu mutant has a structure highly similar 
to that of the GTP bound form.  This is confirmed by the results from the antibody studies 
in this chapter.  Consequently, despite the limitations of not knowing their epitope, the 
three antibodies can give useful information concerning the conformation of Gαi1.  
Similarly, the mutation of residue Gly
203 to an Ala has been shown to prevent nucleotide 
exchange thus this variant is unable to adopt the active state (Mixon et al., 1995).  The lack 
of interaction of the three conformation selective antibodies with this mutant is consistent 
with this observation.   
 
Alterations in the conformation of Gα subunits associated with their activation and the 
concomitant exchange of GDP for GTP have been detected previously by the incorporation 
of fluorescence resonance energy competent transfer sensors into the α subunit and the βγ 
complex (Frank et al., 2005).  However, this approach requires substantial modifications to 
the polypeptides.  Use of the conformation selective antibodies generated in this study 
allow study on the native Gα subunit and consequently has a significant advantage over the 
FRET approach.  Various residues have been identified as important in the G protein both 
for the mechanism of receptor catalysed activation of heterotrimeric G proteins and as 
described above the mechanism of GTP hydrolysis.  It would be interesting to see if the 
conformational selective antibodies show affinity for these various mutants.  An obvious 
example was the Arg
178Cys variant, which has, like the Gln
204Leu mutation, been shown to 
produce a constitutively active state (Majumdar et al., 2006).  Indeed, as for the Gln
204Leu 
mutation it has been hypothesised that the Arg
178Cys mutation stabilises a conformational 
state subsequent to GTP hydrolysis with a structure that still allows full stimulation of J. Robert Lane, 2007    Chapter 5 
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effector activity.  However, work described in this chapter suggests that the conformation 
selective antibodies do not interact with this mutant, suggesting that its structure is 
significantly different from that of the Gln
204Leu mutant.  This may relate to the different 
roles of these arginine and glutamine residues in the mechanism of GTP hydrolysis.  Gln
204 
stabilises and orients the hydrolytic water in the trigonal-bipyrimidal transition state 
(Figure 5.38)  Arg
178 stabilises the negative charge at the equatorial oxygen atoms of the 
pentacoordinate γ phosphate intermediate (Coleman et al., 1994).  A recent study identified 
amino acids involved in the binding of GRK2 with a mutagenesis strategy in a background 
of three different activated forms Gαq.  Interestingly it was shown that the Gαq mutations 




183Cys.  This is consistent with the Gln
209Leu and Arg
183Cys having a 
different structure (Day et al., 2004). 
 
Similarly, mutation of Gly
42 to a Val diminishes the GTPase activity of Gαi1 due to the 
steric bulk of Val pushing Gln
204 into a catalytically incompetent conformation (Raw et al., 
1997).  Again, it would be interesting to see if the antibodies have a high affinity for this 
constitutively active variant. 
 
In a similar vein, use of the above mutants or wild type Gαi1complexed with various non-
hydrolysable analogues of GTP has allowed the elucidation of structures thought to be 
snapshots of transition states involved in GTP hydrolysis (Berghuis et al., 1996; Raw et al., 
1997).  For example the Gly
203Ala Gαi1 mutant complexed with GTPγS was thought to 
give a structure that was hypothesised to be similar, but not identical to the transient 
ternary complex of Gαi1 catalysed GTP hydrolysis (Berghuis et al., 1996).  It would be 
interesting to probe this structure with the conformation selective antibodies.   
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A key experiment was to test these antibodies in a condition in which AlF4
- was added to 
cells expressing a wild type GDP-bound G protein.  AlF4
- is a substitute for, and can mimic 
the γ phosphate of GTP, promoting an active conformation.  However it was argued that, 
the geometry and coordination of the GDP.AlF4
- complex, the structural changes within the 
catalytic site and the guanine nucleotide exchange kinetics indicate that GDP.AlF4
- is not a 
GTP analogue but rather mimics the trigonal-bipyrimidal species presumed to appear at or 
near the transition state of the GTP hydrolysis reaction (Coleman et al., 1994).  Our results 
showed that the antibodies recognised the complex Gαi1.GDP.AlF4, confirming that this 
complex has a conformation equivalent or highly similar to the active GTP bound 
conformation of Gαi1. In conclusion then, the conformation selective antibodies could be a 
useful tool in determining changes in Gαi1 structure associated with nucleotide exchange 
and GTP hydrolysis.  Furthermore, A variety of human tumors have been associated with 
mutations of either the switch II glutamine (corresponding to Gαi1 Q
204) or the arginine 
finger (corresponding to Gαi1 R
178) both in Gαi and Gαs (Bourne, 1987; Landis et al., 1989; 
Weinstein and Shenker, 1993).  It follows then, that these conformation selective 
antibodies could be useful in the screening of potentially cancerous tissue for these 
mutations. 
  
The characterisation of the conformation selective antibodies was further investigated with 
regard to their selectivity towards the active (GTP bound) conformations of other Gα 
subunits. Specific binding was also observed for the GlnÆLeu active mutants of Gαi2 and 
Gαo1.  However, the antibodies showed affinity for neither the equivalent wild type G α 
subunits when expressed in an un-stimulated condition or the equivalent GlyÆAla 
constitutively inactive mutants.  Furthermore, the antibodies did not recognise equivalent 
active mutants of Gαq and Gαs.  Considering the high sequence homology of Gαi1, Gαi2, 
Gαi3 and Gαo1 (Figure 5.1) it could be expected that they have a similar overall structure.   
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the active structures of all Gαi/o family α subunits.  The sequence homology of Gαi1 with 
Gαq and Gαs is considerably lower (44% and 55% respectively).  Consequently it is less 
likely that these conformation selective antibodies would recognise the active 
conformations of these Gα subunits, since the structure of these G α subunits is likely to 
be significantly different from that of Gαi1. 
 
A key role of RGS (Regulators of G protein Signalling) proteins is binding to the G-protein 
Gα-subunit and acting as GTPase-activating proteins (GAPs), thereby rapidly terminating 
G protein-coupled receptor (GPCR) signalling.  In 1997, Tesmer and colleagues reported a 
2.8 Ǻ resolution crystal structure of the RGS protein, RGS4, complexed with Gαi1-Mg
2+-
GDP-AlF4
- (Tesmer et al., 1997a).  As described above this complex the GDP.AlF4
- 
mimics the transition state of GTP during its hydrolysis to GDP, inducing the conformation 
of Gαi1 thought to be stabilized by RGS-binding.  The contacts of RGS4 with Gαi1 on the 
surface of Gαi1 are formed by residues in the three Switch regions of Gαi1: residues 179–
185
 in Switch I, residues 204–213 in Switch II, and residues 235–237 in Switch III. Of 
these regions, Switch I of Gαi1 interacts with three-fourths of the RGS4-binding pocket.   
Two surface residues of Switch I (Thr
182 and Gly
183) appear to be essential for high-affinity 
Gα–RGS interaction (Fu et al., 2004; Tesmer et al., 1997a).  Peptides corresponding to this 
region have been shown to inhibit RGS function (Roof et al., 2006).  Since the 
conformation-selective antibodies also recognize the Gαi1.GDP.AlF4
- complex it would be 
interesting to see if these antibodies recognise a similar region to RGS4.  As for early 
experiments using antisera raised against the C-terminal tail of Gα subunits to ablate the 
functional interaction between receptor and G protein, the conformation-selective 
antibodies could block the action of RGS proteins.  This would not only give information 
about the epitope that is recognised by the antibodies, but highlights further possibilities of 
their use. 
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The ultimate aim of this study was the production of reagents suitable for, and the design 
of, a high throughput assay to monitor receptor mediated G protein activation.  To this end 
then, the most important experiment was a demonstration of whether the antibodies could 
recognise agonist-induced receptor-meditated activation of G α subunits.  The design of 
the immunocytochemistry-based experiments described in this chapter provided a good 
basis for this experiment.  The co-transfection of cDNA of wild type Gαi1 with the D2l-
eYFP fusion protein allowed easy identification of successfully transfected cells.  These 
transfected cells were exposed to the dopaminergic agonist nor-apomorphine in the 
presence of 10 µM GTPγS to lock activated Gαi1 in the active conformation.  D2l couples 
to Gαi1, Gαi2, Gαi3 and Gαo1 and has a wide and well characterised pharmacology, making 
it ideal for these preliminary experiments.  In these conditions the conformation-selective 
antibodies identified Gαi2 only in samples stimulated by agonist.  These data indicate that 
the conformation selective antibodies described herein may be useful reagents with which 
to develop a non-radioactive assay for G protein activation by agonist ligands.  However, 
an obvious extension to this experiment would be to include a condition in which the 
action of nor-apomorphine is blocked using a D2l antagonist or inverse agonist such as 
spiperone.  This would be a futher demonstration that these antibodies would indeed be 
useful pharmacological tools. 
 
In two different studies, antibodies sensitive to the different conformation of GPCRs have 
been developed (Gupta et al., 2007; Mancia et al., 2007).  In the first study antibodies 
directed against the mid portion of the N-terminus were shown to have enhanced 
recognition of active state receptors(Gupta et al., 2007).  This technique was applied to 
Gαi-coupled, µ-opioid, δ-opioid, CB1 cannabinoid, α2A-adrenergic as well
 as Gαs-(β2-
adrenergic) and G q-coupled (AT1 angiotensin) receptors.  It was shown that these 
antibodies accurately differentiate ligands with varying
 efficacies and can be used
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investigate the extent and duration of activation of endogenous
 receptors.  Indeed, it was 
found that peripheral morphine administration led
 to a time-dependent increase in antibody 
binding in the striatum
 and prefrontal cortex with a peak at about 30 min.  This study then 
demonstrates the utility of conformation selective antibodies for the monitoring of receptor 
pharmacology.  Similarly conformation selective antibodies against the 5-HT2C serotonin 
receptor were generated using a hybridoma generation strategy similar to the one described 
in this chapter.  Monoclonal antibodies specific to 5-HT2c were generated by immunising 
mice with 5-HT2c expressed and purified in E coli.  As in this study, antibodies of various 
specificities were generated including two that are specific to the 5-HT (agonist) bound 
form as compared to the ketanserin (inverse agonist) bound form. 
 
However, the above studies would require a different antibody for each receptor.  Since 
there are only 16 known G protein α subunits, antibodies recognising the active 
conformation of G protein α subunits could be used to study the interaction between 
numerous GPCRs and one G protein.  This makes them a more powerful and useful tool.  
Indeed, the fact that the antibodies characterised in this assay recognise the active form of 
all members of the Gαi1 family make them an even more versatile tool. It would, therefore, 
be interesting to examine if the antibodies selective for the active conformation of Gαi1 
could be used to investigate the extent and duration of activation of endogenous
 G proteins. 
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6  General discussion 
 
Receptor efficacy, that is how strongly a ligand activates a receptor, was thought to be 
independent of the system used and the response measured.  However, this concept has 
been challenged by the recognition of inverse agonists – compounds with negative efficacy 
– and the recognition that distinct signalling pathways mediated by the same receptor do 
not show the same pattern of agonist dependence (Perez and Karnik, 2005; Urban et al., 
2006a).  This second observation has been given various names such as protean agonism or 
agonist directed trafficking of receptor stimulus.  The possibility that agonists could 
selectively activate different G proteins was one possible explanation for this phenomenon, 
although evidence for this hypothesis was indirect (Berg et al., 1998).  In the present study 
I investigated the activation of different members of the Gαi/o family by different agonists 
at the dopamine D2l receptor. The majority of D2 agonists tested activated all Gαi/o 
subunits, although as a general pattern most agonists tended to activate Gαo1 better than 
Gαi1-3.  However, S-(-)-3PPP and p-tyramine were only able to activate Gαo1.  Subsequent 
experiments using both [
35S] GTPγS binding and the monitoring of high affinity agonist 
binding showed that in contrast to its action as an agonist at Gαo1, S-(-)-3PPP was an 
inverse agonist/antagonist at Gαi1, Gαi2, Gαi3.  This clearly establishes S-(-)-3PPP as a 
protean agonist.  The use of receptor-G protein fusion proteins ensured that the ratio of 
receptor to G protein was constant and that the receptor and G protein had the same 
cellular localisation.    This study then provides direct evidence that different agonists at 
the same receptor can induce differential G protein coupling.  S-(-)-3PPP  was shown to 
have differential effects on pre- and post-synaptic functions in vivo (Arnt et al., 1983).  
However, in 1983, the existence of five different dopamine receptor subtypes was not yet 
known, so a repetition of this work with receptor knock out models and/or improved 
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in chapter 5, which are selective against the active conformation of Gαi/o would perhaps be 
useful tools to visualise pre- and postsynaptic Gαi/o activation. Furthermore distinct effector 
mechanisms have been proposed for Gαi and Gαo signalling, with inhibition of voltage 
gated Ca
2+ and activation of GIRK channels respectively (Sowell et al., 1997; Valenzuela 
et al., 1997).  It would be interesting therefore, to investigate the action of S-(-)-3PPP by 
physiological studies in a D2 regulated neuronal system.  Aripiprazole, an atypical 
antipsychotic, has been shown to display a pattern of differential efficacy through D2 
mediated signalling pathways, that is startlingly similar to that of S-(-)-3PPP.  As for S-(-)-
3PPP, aripiprazole has been shown to have partial agonist and antagonist activity functions 
at the D2 receptor depending on the end point studied (Urban et al., 2006b).  Furthermore, 
this drug has also been shown to be an antagonist at the post-synaptic principal and an 
agonist at pre-synaptic densities (Kikuchi et al., 1995).  This suggests that functionally 
selective ligands or protean agonists may provide a new area for the development of novel 
therapeutics for psychoses and other disorders.  However, the actions of aripiprazole have 
been proposed to originate solely from its partial agonist properties, and indeed other 
partial agonists at the dopamine D2 receptor such as bifeprunox and, interestingly, the 
principle metabolite of clozapine - N-desmethyl-clozapine - have been shown to have 
antipsychotic properties (Lieberman, 2004; Millan et al., 2007). Consequently it would be 
interesting to conduct an equivalent study to the one performed in chapter 3 using 
aripiprazole and these other D2 partial agonists. 
 
The demonstration of S-(-)-3PPP as a protean agonist conforms with a growing body of 
evidence that the efficacy of a ligand at one receptor and for one signalling pathway cannot 
be extrapolated to other signalling pathways at the same receptor.  Drug screening 
programmes often use heterologous expression systems to monitor the action of ligands at 
a certain receptor with the expectation that the efficacy detected in this system is consistent J. Robert Lane, 2007    Chapter 6 
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with that observed in vivo.  However, as shown by the actions of S-(-)-3PPP at the D2l 
receptor, efficacy can be pathway, and therefore cell or tissue specific. 
 
The study comparing the coupling specificities of the D2 and D3 receptors showed that 
whilst the D2 receptor could promiscuously couple to Gαi1, Gαi2, Gαi3 and Gαo1, the D3 
receptor coupled only to Gαo1.  Furthermore, the exchange of a twelve amino acid section 
at the c-terminus of the third intracellular loop of the D3 receptor with an equivalent region 
of the D2 receptor gave a chimeric D3/D2 receptor that gained a D2-like ability to couple to 
all four Gαi/o subunits.  However, the order of potency observed for dopamine at the D2 
and chimeric D3/2 receptor coupled to the different Gα subunits was distinct.  At the D2 
receptor the order of potency was as follows Gαo1 > Gαi1 ≥ Gαi3 = Gαi2 whereas for the 
chimeric D3/2 receptor the order was Gαi3 = Gαo1 > Gαi2 = Gαi1.  This difference suggests 
that other regions within D2 are important for G protein coupling, particularly to Gαi1 and 
Gαi2.  There is evidence to suggest that this is the case, and the N-terminus of the third 
intracellular loop has been implicated as a particularly important region.  A recent study by 
Nanoff et al. used a peptide derived from this region to activate both Gαi1 and Gαo1 directly 
(Nanoff et al., 2006).  Similarly a previous study constructed reciprocal chimeric D2/D3 
receptors with fusion points near the center of the third intracellular loop. Both of the 
D2/D3 receptor chimeras were able to effectively inhibit adenylate cyclase activity to 
almost the same extent as that seen with the D2 receptor whereas the D3 receptor was 
without effect (Lachowicz and Sibley, 1997). These results suggest that the D2 receptor 
possesses two independent domains for G-protein coupling and inhibition of adenylate 
cyclase activity.  A logical future experiment then would be to investigate other regions 
within the D2 receptor that direct its coupling to Gαi1, Gαi2 and Gαi3 with particular focus 
on the N-terminal region of the second intracellular loop.  It would also be of interest to 
attempt to define the residues within the twelve amino acid section of the third intracellular 
loop that are important for coupling to each of the Gαi/o subunits.  Work by Slessareva et al. J. Robert Lane, 2007    Chapter 6 
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demonstrated that multiple and distinct regions of both the receptor and the G protein can 
direct G protein coupling (Slessareva et al., 2003).  Furthermore it was shown, for the 
receptors and G proteins investigated in their study, that although regions such as the c-
terminus of the G protein are universally important for receptor G protein coupling the 
individual residues involved differed for each receptor-G protein pair.  It would be 
interesting to perform a similar study with the D2 and D3 receptors as models.     
 
From both the investigation into the coupling specificity of the D2 and D3 receptors, and 
the study of agonist-directed coupling at the D2l receptor, it could be concluded that the 
Gαo1 subunit is more promiscuous in its ability to couple to both dopamine receptor 
subtypes, in conformations stabilised by all agonists tested.  An investigation into the 
molecular basis of this coupling specificity would be worthwhile.  In both the agonist 
directed trafficking study and the investigation of the G protein coupling specificities of 
the D2 and D3 receptors I have described two models with which the molecular basis of 
Gαo1 coupling could be explored.  Firstly, Gαo1 couples to the D2l receptor even when this 
receptor is bound to S-(-)-3PPP.  In contrast Gαi1, Gαi2 and Gαi3 do not. Consequently, a 
study using mutagenesis or chimeric G proteins, in which regions of Gαo1 are exchanged 
with equivalent regions of Gαi1, Gαi2 and Gαi3 could lead to the identification of important 
regions within Gαo1 and the other Gαi subunits which govern their coupling specificity.  
Similarly the promiscuous coupling of Gαo1 to both D2 and D3 in comparison to the 
selective coupling of Gαi1, 2, and 3 to D2 provides another model with which to investigate 
this coupling specificity.  Again chimeric G proteins could be useful to define the 
molecular basis of this difference.  A simple extension of this study could be the use of 
chimeric Gαi/Gαq subunits described by Kostenis and Milligan (Kostenis et al., 2005).  
Chimeric G proteins in which the C-terminal 5 amino acids of Gαq are replaced by those of 
Gαi1/2 or Gαo1 allow Gαi coupled receptors to couple to this chimeric G protein and hence 
activate PLC-β (Kostenis et al., 1997).  It could be predicted then that whilst D2 could J. Robert Lane, 2007    Chapter 6 
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couple to a chimeric G protein in which the last five amino acids of Gαq had been replaced 
by Gαi1 or Gαo1, D3 would perhaps only couple to the Gαq/Gαo1 chimera.  Furthermore, this 
could determine whether replacement of this region would be sufficient for the coupling of 
D3 to Gαo1 or whether other regions of Gαo1 are also required. 
 
It is worth mentioning that the two models described above differ by the mode in which 
receptor-G protein coupling is determined.  The basis of agonist directed trafficking or 
protean agonism is that the different agonists stabilise different receptor conformations, 
which in turn differentially couple to downstream signalling pathways (Kenakin, 2001). 
Accordingly, for the model making use of differential coupling of the D2 receptor to Gαi/o 
subunits the orientation or availability of regions within the receptor provides the basis of 
G protein coupling specificity.  For example, ligands such as dopamine and NPA which 
promote the coupling of the D2 receptor to all four Gαi/o subunits, must stabilise a 
conformation of the receptor in which regions of the receptor that are essential for the 
interactions between receptor and Gαi1,2 and 3 to occur are available.  However, S-(-)-3PPP 
must stabilise a conformation in which these critical regions are obscured and so 
preventing coupling to Gαi1, Gαi2, and Gαi3.   For coupling of the D2 receptor to Gαo1, these 
regions must be not be necessary, or can exist in various orientations.  Biophysical studies 
akin to those performed by Ghanouni et al. could provide information about the different 
conformations of the receptor stabilised by an agonist such as NPA in comparison with the 
protean agonist S-(-)-3PPP (Ghanouni et al., 2001; Swaminath et al., 2004).  Kendall et al. 
demonstrated that the substitution of the entire insert region of the D2l receptor with an 
equivalent length, yet non-homologous, protein sequence resulted in a receptor which was 
indistinguishable from the wild type receptor (Kendall and Senogles, 2006).  It is likely 
that this region has an effect on the overall conformation of the receptor and is another 
example of how changing the conformation of a receptor can alter G protein coupling 
specificity.   In contrast, the ability of D2 to couple to Gαi1, 2, 3 and Gαo1,  but D3 to only J. Robert Lane, 2007    Chapter 6 
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couple to Gαo1 is most likely determined by regions within the D2 receptor that are not 
present in the D3 receptor.  Studies using chimeric D3 receptors, which contain regions of 
D2, and which gain a D2 like ability to couple to Gαi1, 2 and 3 (this study) or downstream 
effectors support this theory (Filteau et al., 1999; Lachowicz and Sibley, 1997; Robinson 
and Caron, 1996; Robinson et al., 1994). 
 
Receptor-G protein fusion proteins proved useful tools in both of the above investigations.  
Their use ensured a 1:1 ratio of receptor to G protein.  Therefore, they allowed the analysis 
and comparison of both efficacy and potency of different ligands at the same receptor and 
the same ligand at different receptors.  Furthermore, they eliminated factors such as 
receptor reserve which may hamper such investigations (Hildebrandt, 2006; Milligan et al., 
2004).  They also eliminate membrane compartmentalization as a reason why one 
particular G protein is activated and the other is not.  A recent study demonstrating agonist 
directed trafficking at the thromboxane A2 receptor is a further example of their utility 
(Zhang et al., 2006)  It is interesting to note the higher potency of dopamine observed at 
the D2l receptor in cell lines where Gαi2 or Gαo1 was expressed from the inducible Flp-In 
locus as compared to that observed for the equivalent D2-Gα subunit fusion proteins.  This 
difference indicates the presence of receptor reserve.  Both the dopamine receptor-G 
protein fusion proteins and the cell lines in which dopamine receptor is constitutively 
expressed and the expression of pertussis toxin resistant Gα subunits can be induced from 
the Flp-In locus could be useful tools to investigate this phenomenon.  Performing agonist 
dose-response experiments in the presence of increasing concentrations of an irreversible 
D2 antagonist, such as N-(p-isothiocyanatophenethyl)spiperone (NIPS), it could be 
expected that different results would be obtained for fusion proteins and the Flp-In stable 
cell line.  In the case of the fusion protein I would expect a decrease in Emax but no change 
in potency with increasing concentrations of the irreversible inhibitor.  However, for the 
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potency but no change in Emax with increasing concentrations of irreversible inhibitor until 
a ratio of G protein to receptor-not-bound-to-irreversible-inhibitor of 1:1 is reached and 
there is no longer spare receptor.  After this point it could be expected that, as for the 
fusion protein, a decrease in Emax but no change in potency with increasing concentrations 
of the irreversible inhibitor would be observed.  In the characterisation of the Flp-In stable 
cell lines, it was shown that the amount of G protein expressed could be controlled by 
treating cells with variable amounts of tetracycline.  It would be interesting then to monitor 
the effect that increasing amounts of G protein could have on the potency and efficacy of 
agonists at the constitutively expressed D2l receptor.  For example, would an increase in G 
protein effectively cause a decrease in receptor reserve and therefore a decrease in 
potency? 
 
The majority of agonists used in this study, including the endogenous ligand dopamine, 
showed a higher potency at the D3 receptor coupled to Gαo1 than the D2l receptor coupled 
to Gαo1. There is increasingly strong evidence that the D3 receptor represents an attractive 
target for antipsychotic agents.  It is interesting then, that S-(-)-3PPP, a prototypical 
antipsychotic drug has both a higher potency and efficacy at the D3 receptor.  It follows 
then, that future studies using aripiprazole and other partial agonists should be extended to 
include their action at the D3 receptor.  
 
In all species, the D3 receptor is generally less abundant than the D2 receptor but with a 
high concentration in the limbic region of the striatum, in a post-synaptic location.  The D3 
receptor is also thought to have a role as an autoreceptor and is expressed by dopaminergic 
neurons of the substantia nigra (Joyce and Millan, 2005). Furthermore, there is anatomical 
and functional evidence that dopamine D2 and D3 receptors are co-localized in specific 
populations of cerebral neurones, both post-synaptically and pre-synaptically (Joyce, 2001; 
Segal et al., 1997).  The existence of D2/D3 heterodimers has been demonstrated in vitro J. Robert Lane, 2007    Chapter 6 
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(Maggio et al., 2003).  It is likely that these heterodimers represent another target for 
therapeutic intervention.  It would worthwhile, to investigate the pharmacology and G 
protein coupling specificities of these hetero-oligomers, taking into account the differences 
in both the pharmacology and G protein coupling specificities of these two dopamine 
receptor subtypes.  This could be investigated using functional complementation of two 
non-functional receptor-G protein fusion proteins.  However, another approach would be to 
make use of the stable cell lines generated in this study in which pertussis toxin insensitive 
variant Gα subunits are expressed from the inducible Flp-In locus (Figure 6.1A).  A single 
stable cell line could express both the D2 and D3 receptors, with tetracycline controlled 
expression of Gα subunit.  Although the pharmacology of the D2 and D3 receptors are 
similar, both D2 and D3 selective agonists and antagonists have recently been described. 
For example, the selective D3 receptor antagonists SB277,011 and the  
exceptionally potent S33084 have been thoroughly characterized in vitro and in vivo (Joyce 
and Millan, 2005; Millan et al., 2000; Stemp et al., 2000).  The use of S33084 and 
SB277,011, then, in parallel with the preferential D2 versus D3 receptor antagonists 
L741,626 and S23199, is currently the best approach  for pharmacological identification of 
the roles of D3 versus D2 receptors in functional models (Chaperon et al., 2003; Millan et 
al., 2007).  Using these D3 selective antagonists and agonists with the inducible cell lines 
described above the pharmacology and G protein coupling specificity of the D2/D3 
heterodimer could be dissected.  Furthermore, these studies could be extended to 
experimental models in which either expression of the D2 or D3 receptor can be induced 
from the Flp-In locus and the other dopamine receptor subtype and a pertussis toxin 
insensitive mutant Gαi/o subunit can be constitutively expressed (Figure 6.1B).  Using this 
system the pharmacology and coupling specificity of the D2/D3 heterodimer could easily be 
compared with that of D2 or D3 homodimers.  Both of the above systems would have the 
added advantage of receptor and G proteins expressed as separate polypeptides, instead of 
the useful, but inherently artificial, receptor-G protein fusion proteins used in the J. Robert Lane, 2007    Chapter 6 
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dimerscreen™ method.  Two obvious questions to be answered in this study would be does 
the D2/D3 heterodimer gain a D3-like high affinity (and therefore potency) for dopamine, 
and can this heterodimer couple to Gαi1-3 and Gαo1?      It is perhaps of note that 
heterodimerisation has been shown to cause a switch in G protein coupling specificity 
whereupon a Gαi/o coupled GPCR (CB1) gains coupling to Gαs upon dimerisation with the 
dopamine D2 receptor (Kearn et al., 2005).  These studies could be extended to characterise 
the action of S-(-)-3PPP, aripiprazole and other D2 partial agonists at the D2/D3 
heterodimer. 
 
The characterisation of antisera raised against decapeptides corresponding to the C-
terminal tail of Gαt, Gαs and Gαq was described.  I demonstrated their selectivity towards 
the G protein against which they were raised and their utility in a [
35S] GTPγS assay with 
an immunocapture step, making these antisera useful and highly selective tools for 
investigations into GPCR research.  The final part of chapter 5 describes the successful 
generation and characterisation of antibodies selective against the active (GTP bound) 
conformation of Gα subunits.  The ultimate aim of this project was to use these antibodies 
in an assay, equivalent to the [
35S] GTPγS assay, which would monitor receptor-mediated 
G protein activation. To this end, perhaps the most significant result was that these 
antibodies selectively recognised the GTPγS.Gαi1 complex formed following the activation 
of the dopamine D2l receptor by the agonist nor-apomorphine.  This shows that, not only 
can the antibodies recognise the constitutively active Gαi/o subunit variants but can also 
recognise the activated form of the wild-type Gα subunit and are, therefore, potentially 
useful tools with which to develop a functional assay.  Although, immunocytochemistry 
has been a useful technique with which to characterise these antibodies it is certainly not a 
high-throughput process.  The next stage, then, would be to attempt to develop a high-
throughput assay using these antibodies.  Given the success of the immunocytochemical 
experiments, an assay based on this methodology would be perhaps the most successful.  J. Robert Lane, 2007    Chapter 6 
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The ArrayScan® HCS Reader (Cellomics Inc., Thermo-Fisher, Waltham, MA, USA) is an 
automated fluorescence microscopic imaging system designed for high content screening 
and high content analysis.  This perhaps would be a suitable format with which to design 
an assay.  Sovago et al. describe autoradiographic mapping of dopamine-D2/D3 receptor 
stimulated [
35S] GTPγS binding in the human brain (Sovago et al., 2005).  It would of 
interest to see if these antibodies would provide an alternative to this useful technique.   
 
The demonstration that the antibodies could recognise one constitutively active mutant of 
Gαi2 (Q
205L) but not another (R
179C) suggests that, although their epitope was not 
determined, these conformation-selective antibodies could provide interesting information 
about the structural changes occurring upon G protein activation.  Furthermore, since the 
antibodies, like RGS proteins and effectors, interact with the active form of the G-protein, 
it would be worthwhile to see if these antibodies can interfere with these interactions.   
 
The work by Mancia et al. demonstrated that, simply immunising mice with purified 
serotonin receptor and by following a hybridoma generation procedure equivalent to the 
one used in this study, antibodies selective to the agonist-bound conformation of the 
receptor can be generated (Mancia et al., 2007).  One of the unsolved, and perhaps 
unknowable, questions from the immunisation procedure used to generate the active Gαi/o 
selective antibodies is whether preincubation of the G protein with GTPγS was necessary 
or even useful.  Although GTPγS binds Gα subunits with a high affinity and is non-
hydrolysable, this binding is not irreversible.   Perhaps then, the success of the antibody 
generation programme was due simply to the number of hybridoma generated and the 
design of a robust screen that allowed selection of antibodies with the desired 
characteristics.  In the introduction to this body of work, I described the current 
understanding of the conformational changes undergone by both receptor and G protein 
following receptor activation by an agonist.  Antibodies have been generated that are J. Robert Lane, 2007    Chapter 6 
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selective against the active (agonist bound) form of the receptor (Gupta et al., 2007; 
Mancia et al., 2007) and the active (GTP bound) form of Gαi/o subunits (this study).  With 
the design of the correct screen and the use of a suitable antigen and antibody production 
using the generation of hybridoma, antibodies selective against other events in the GPCR-
G protein cycle could be generated. 
 
One aspect of GPCR function that could be investigated is dimerisation / oligomerisation.  
Although many different techniques have been used to demonstrate the quaternary 
structure of GPCRs, antibodies specific for a receptor homo or hetero-oligomer would be a 
useful tool and a direct demonstration of this higher order structure.  A technique described 
in a recent paper by Guo et al. (2005) provides a route by which this could be achieved.  In 
this paper the heterodimer interface in the dopamine D2s receptor was mapped over the 
entire length of TM IV by cross-linking substituted cysteines (Figure 6.2 A).  Using this 
method it was demonstrated that the rearrangement of the dimer interface is a critical 
component of receptor activation.   The TM IV dimer interface in the inverse-agonist 
bound conformation is consistent with the dimer of the inactive form of rhodopsin 
modelled with constraints from atomic force microscopy (Fotiadis et al., 2003).  
Crosslinking of another set of a different set of cysteines in TM IV effectively locks the 
receptor in an active state (Guo et al., 2005).  Therefore, the paper demonstrates the 
stabilisation of a D2s homo-dimer by cysteine cross-linking.  Furthermore, both the inactive 
and active conformations can be stabilised by cysteine-cross linking.  If these two species 
could be purified they would represent two different antigens.  Unfortunately, a negative 
condition with which to screen generated antibodies, where homo-dimerisation is 
prevented, does not exist.  However, as described in chapter 1 the D2 and D3 receptors are 
highly homologous, particularly within the transmembrane domains.  It is likely then that 
equivalent cysteine linkages can be made between D2 and D3 receptors in a hetero-dimer.  
If this was the case a screen could be designed in which the positive condition would be D2 J. Robert Lane, 2007    Chapter 6 
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and D3 receptors expressed in the same cell and the negative condition would be a mixture 
of cells expressing either D2 or D3 receptors only (Figure 6.2 C + D).  D2/D3 heterodimers 
have been demonstrated in vitro (Maggio et al., 2003), and it has been suggested that they 
may represent important therapeutic targets for the treatment of schizophrenia (Joyce and 
Millan, 2005).  Antibodies selective against a D2/D3 heterodimer would be useful in the 
visualisation of this species in native tissue. 
 
Historically, and as demonstrated in this study, antibodies selective against individual Gα 
subunits have been important tools with which to investigate receptor-G protein coupling 
(Milligan, 1994).  However, the generation of antibodies selective against the active 
conformation of both GPCRs (Gupta et al., 2007; Mancia et al., 2007) and G α subunits 




















Two possible methods for investigation of D2/D3 heterodimers taking advantage of the 
Flp-In TREx expression system 
 
A)  In this model both the D2 and D3 receptors are constitutively expressed and the 
pertussis toxin resistant variant of either Gαi1, 2, 3 or o1 is expressed from the inducible Flp-
In locus.  Using this model then the pharmacology and G protein coupling specificity of 
the D2/D3 heterodimer can be dissected using the D2 and D3 selective antagonists shown in 
the presence of each Gαi/o subtype. 
 
B) An alternative model, which still takes advantage of the Flp-In TREx system, is 
described where the D2 receptor and the pertussis toxin resistant variant of either Gαi1, 2, 3 
or o1 are constitutively expressed and D3 is expressed from the inducible Flp-In locus.  
Using this model the pharmacology and G protein coupling of the D2 homodimer can be 
compared with that easily compared with that of the D2/D3 heterodimer, simply by 






















An illustration of potential dimer interface rearrangements following receptor 
activation and the potential use of these cysteine cross-linked and stabilized 
conformations as antigens with which to generate antibodies selective against D2/D3 
heterodimers 
 
The entire homodimer interface of the D2 receptor was mapped over the entire length of 
TM IV.  In the inactive (inverse agonist) bound conformation cysteine linkages were made 
between one set of cysteine residues (yellow, A).  However in the agonist bound 
conformation another set of cysteine residues were linked (red).  This suggests that a 
conformational change at the TM IV interface is part of receptor activation.  Given the 
high homology of D2 and D3 receptors it is likely that similar rearrangements may occur in 
a D2/D3 heterodimer.  These cysteine linked species then could be used as antigens for the 
generation of antibodies specific to this heterodimer (Taken from Guo et al., 2005).  
 
An effective screen for antibodies with the correct selectivity would be needed, with both 
negative and positive conditions.  Expression of either D2 or D3 in a heterologous cell line 
would generate only D2 or D3 homodimers, these then would be negative conditions (B). 
Co-expression of D2 and D3 within the same cell would generate D2/D3 heterodimers, as 

















Sequence and residue number of peptides from Pepset™ corresponding to sequence 
of human Gαi1 (supplied by Mimotopes Ltd. Aus) 
   
Peptide  
Corresponding residues of human 
Gαi1 
   Peptide Sequence  First residue   Last residue 
1       H- MGCTLSAEDKAAVERSGSG -NH2  1 16 
2  Biotin- SGSGLSAEDKAAVERSKMID -NH2  5 20 
3  Biotin- SGSGDKAAVERSKMIDRNLR -NH2  9 24 
4  Biotin- SGSGVERSKMIDRNLREDGE -NH2  13 28 
5  Biotin- SGSGKMIDRNLREDGEKAAR -NH2  17 32 
6  Biotin- SGSGRNLREDGEKAAREVKL -NH2  21 36 
7  Biotin- SGSGEDGEKAAREVKLLLLG -NH2  25 40 
8  Biotin- SGSGKAAREVKLLLLGAGES -NH2  29 44 
9  Biotin- SGSGEVKLLLLGAGESGKST -NH2  33 48 
10  Biotin- SGSGLLLGAGESGKSTIVKQ -NH2  37 52 
11  Biotin- SGSGAGESGKSTIVKQMKII -NH2  41 56 
12  Biotin- SGSGGKSTIVKQMKIIHEAG -NH2  45 60 
13  Biotin- SGSGIVKQMKIIHEAGYSEE -NH2  49 64 
14  Biotin- SGSGMKIIHEAGYSEEECKQ -NH2  53 68 
15  Biotin- SGSGHEAGYSEEECKQYKAV -NH2  57 72 
16  Biotin- SGSGYSEEECKQYKAVVYSN -NH2  61 76 
17  Biotin- SGSGECKQYKAVVYSNTIQS -NH2  65 80 
18  Biotin- SGSGYKAVVYSNTIQSIIAI -NH2  69 84 
19  Biotin- SGSGVYSNTIQSIIAIIRAM -NH2  73 88 
20  Biotin- SGSGTIQSIIAIIRAMGRLK -NH2  77 92 
21  Biotin- SGSGIIAIIRAMGRLKIDFG -NH2  81 96 
22  Biotin- SGSGIRAMGRLKIDFGDSAR -NH2  85 100 
23  Biotin- SGSGGRLKIDFGDSARADDA -NH2  89 104 
24  Biotin- SGSGIDFGDSARADDARQLF -NH2  93 108 
25  Biotin- SGSGDSARADDARQLFVLAG -NH2  97 112 
26  Biotin- SGSGADDARQLFVLAGAAEE -NH2  101 116 
27  Biotin- SGSGRQLFVLAGAAEEGFMT -NH2  105 120 
28  Biotin- SGSGVLAGAAEEGFMTAELA -NH2  109 124 
29  Biotin- SGSGAAEEGFMTAELAGVIK -NH2  113 128 
30  Biotin- SGSGGFMTAELAGVIKRLWK -NH2  117 132 
31  Biotin- SGSGAELAGVIKRLWKDSGV -NH2  121 136 
32  Biotin- SGSGGVIKRLWKDSGVQACF -NH2  125 140 
33  Biotin- SGSGRLWKDSGVQACFNRSR -NH2  129 144 
34  Biotin- SGSGDSGVQACFNRSREYQL -NH2  133 148 
35  Biotin- SGSGQACFNRSREYQLNDSA -NH2  137 152 
36  Biotin- SGSGNRSREYQLNDSAAYYL -NH2  141 156 
37  Biotin- SGSGEYQLNDSAAYYLNDLD -NH2  145 160 
38  Biotin- SGSGNDSAAYYLNDLDRIAQ -NH2  149 164 
39  Biotin- SGSGAYYLNDLDRIAQPNYI -NH2  153 168 J. Robert Lane, 2007     
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40  Biotin- SGSGNDLDRIAQPNYIPTQQ -NH2  157 172 
41  Biotin- SGSGRIAQPNYIPTQQDVLR -NH2  161 176 
42  Biotin- SGSGPNYIPTQQDVLRTRVK -NH2  165 180 
43  Biotin- SGSGPTQQDVLRTRVKTTGI -NH2  169 184 
44  Biotin- SGSGDVLRTRVKTTGIVETH -NH2  173 188 
45  Biotin- SGSGTRVKTTGIVETHFTFK -NH2  177 192 
46  Biotin- SGSGTTGIVETHFTFKDLHF -NH2  181 196 
47  Biotin- SGSGVETHFTFKDLHFKMFD -NH2  185 200 
48  Biotin- SGSGFTFKDLHFKMFDVGGQ -NH2  189 204 
49  Biotin- SGSGDLHFKMFDVGGQRSER -NH2  193 208 
50  Biotin- SGSGKMFDVGGQRSERKKWI -NH2  197 212 
51  Biotin- SGSGVGGQRSERKKWIHCFE -NH2  201 216 
52  Biotin- SGSGRSERKKWIHCFEGVTA -NH2  205 220 
53  Biotin- SGSGKKWIHCFEGVTAIIFC -NH2  209 224 
54  Biotin- SGSGHCFEGVTAIIFCVALS -NH2  213 228 
55  Biotin- SGSGGVTAIIFCVALSDYDL -NH2  217 232 
56  Biotin- SGSGIIFCVALSDYDLVLAE -NH2  221 236 
57  Biotin- SGSGVALSDYDLVLAEDEEM -NH2  225 240 
58  Biotin- SGSGDYDLVLAEDEEMNRMH -NH2  229 244 
59  Biotin- SGSGVLAEDEEMNRMHESMK -NH2  233 248 
60  Biotin- SGSGDEEMNRMHESMKLFDS -NH2  237 252 
61  Biotin- SGSGNRMHESMKLFDSICNN -NH2  241 256 
62  Biotin- SGSGESMKLFDSICNNKWFT -NH2  245 260 
63  Biotin- SGSGLFDSICNNKWFTDTSI -NH2  249 264 
64  Biotin- SGSGICNNKWFTDTSIILFL -NH2  253 268 
65  Biotin- SGSGKWFTDTSIILFLNKKD -NH2  257 272 
66  Biotin- SGSGDTSIILFLNKKDLFEE -NH2  261 276 
67  Biotin- SGSGILFLNKKDLFEEKIKK -NH2  265 280 
68  Biotin- SGSGNKKDLFEEKIKKSPLT -NH2  269 284 
69  Biotin- SGSGLFEEKIKKSPLTICYP -NH2  273 288 
70  Biotin- SGSGKIKKSPLTICYPEYAG -NH2  277 292 
71  Biotin- SGSGSPLTICYPEYAGSNTY -NH2  281 296 
72  Biotin- SGSGICYPEYAGSNTYEEAA -NH2  285 300 
73  Biotin- SGSGEYAGSNTYEEAAAYIQ -NH2  289 304 
74  Biotin- SGSGSNTYEEAAAYIQCQFE -NH2  293 308 
75  Biotin- SGSGEEAAAYIQCQFEDLNK -NH2  297 312 
76  Biotin- SGSGAYIQCQFEDLNKRKDT -NH2  301 316 
77  Biotin- SGSGCQFEDLNKRKDTKEIY -NH2  305 320 
78  Biotin- SGSGDLNKRKDTKEIYTHFT -NH2  309 324 
79  Biotin- SGSGRKDTKEIYTHFTCATD -NH2  313 328 
80  Biotin- SGSGKEIYTHFTCATDTKNV -NH2  317 332 
81  Biotin- SGSGTHFTCATDTKNVQFVF -NH2  321 336 
82  Biotin- SGSGCATDTKNVQFVFDAVT -NH2  325 340 
83  Biotin- SGSGTKNVQFVFDAVTDVII -NH2  329 344 
84  Biotin- SGSGQFVFDAVTDVIIKNNL -NH2  333 348 
85  Biotin- SGSGDAVTDVIIKNNLKDCG -NH2  337 352 
86  Biotin- SGSGVTDVIIKNNLKDCGLF -OH  339 354 
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Additional Material 
The following paper is based on work performed as part of this thesis 
 
 